<SEC-DOCUMENT>0001731122-21-000261.txt : 20210216
<SEC-HEADER>0001731122-21-000261.hdr.sgml : 20210216
<ACCEPTANCE-DATETIME>20210216163358
ACCESSION NUMBER:		0001731122-21-000261
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		43
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210216
DATE AS OF CHANGE:		20210216

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ANAVEX LIFE SCIENCES CORP.
		CENTRAL INDEX KEY:			0001314052
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				208365999
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37606
		FILM NUMBER:		21639446

	BUSINESS ADDRESS:	
		STREET 1:		51 W 52ND STREET,
		STREET 2:		7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019-6163
		BUSINESS PHONE:		800-689-3939

	MAIL ADDRESS:	
		STREET 1:		51 W 52ND STREET,
		STREET 2:		7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019-6163

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Thrifty Printing Inc.
		DATE OF NAME CHANGE:	20050111
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>e2415_10q.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:avxl="http://anavex.com/20201231">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02B_US%2DGAAP%2D2020_currency -->
<!-- Field: Set; Name: xdx; ID: xdx_033_avxl_anavex.com_20201231 -->
<!-- Field: Set; Name: xdx; ID: xdx_044_20201001_20201231 -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DEntityCentralIndexKey_0001314052 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05D_edei%2D%2DCurrentFiscalYearEndDate_09/30 -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DDocumentFiscalYearFocus_2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_05F_edei%2D%2DDocumentFiscalPeriodFocus_Q1 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
  <ix:hidden>
    <ix:nonNumeric contextRef="From2020-10-01to2020-12-31" name="dei:EntityCentralIndexKey">0001314052</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-10-01to2020-12-31" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-10-01to2020-12-31" format="ixt:datemonthday" name="dei:CurrentFiscalYearEndDate">09/30</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-10-01to2020-12-31" name="dei:DocumentFiscalYearFocus">2021</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-10-01to2020-12-31" name="dei:DocumentFiscalPeriodFocus">Q1</ix:nonNumeric>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-10-012020-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0235" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" contextRef="From2020-10-012020-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0242" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" contextRef="From2020-10-01to2020-12-31" id="xdx2ixbrl0243" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2020-10-012020-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0249" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-10-012020-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0254" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-10-012020-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0256" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-10-012020-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0259" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-10-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0260" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2019-10-012019-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0280" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" contextRef="From2019-10-012019-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0287" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" contextRef="From2019-10-012019-12-31" id="xdx2ixbrl0288" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2019-10-012019-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0292" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2019-10-012019-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0294" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-10-012019-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0297" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-10-012019-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0298" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" contextRef="From2020-10-012020-12-31_custom_PurchaseWarrantsMember" id="xdx2ixbrl0408" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
    </ix:hidden>
  <ix:references>
    <link:schemaRef xlink:href="avxl-20201231.xsd" xlink:type="simple" />
    </ix:references>
  <ix:resources>
    <xbrli:context id="From2020-10-01to2020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-02-12">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-02-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012019-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012019-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012019-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012019-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-012017-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2017-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012020-12-31_currency_AUD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012019-12-31_currency_AUD">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-06-06</xbrli:startDate>
        <xbrli:endDate>2019-06-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012020-12-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012019-12-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012020-12-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:EquityOfferingSalesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:CantorFitzgeraldAndCoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-09-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:EquityOfferingSalesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:CantorFitzgeraldAndCoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_custom_PurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-09-30_custom_PurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_PurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012020-12-31_custom_PurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_PurchaseWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_PurchaseWarrants1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrants1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_PurchaseWarrants2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrants2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_StockOptionPlan2015Member_custom_OptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:OptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_StockOptionPlan2015Member_custom_OptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:OptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012020-12-31_custom_StockOptionPlan2019Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2019Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_StockOptionPlan2019Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2019Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_StockOptionPlan2019Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2019Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012020-09-30_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-09-30_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012020-12-31_custom_StockOptionPlan2015Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012020-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012019-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-10-012020-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-10-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-012019-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-01</xbrli:startDate>
        <xbrli:endDate>2019-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-02-11_us-gaap_SubsequentEventMember_custom_MichaelJFoxFoundationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avxl:MichaelJFoxFoundationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-02-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-02-11_us-gaap_SubsequentEventMember_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-02-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-02-11_us-gaap_SubsequentEventMember_custom_SalesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001314052</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:SalesAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-02-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    </ix:resources>
  </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 16pt Times New Roman, Times, Serif"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 16pt Times New Roman, Times, Serif"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 16pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 12pt Times New Roman, Times, Serif"><b>FORM
<span id="xdx_901_edei--DocumentType_c20201001__20201231_zRYYXxgsaZkk"><ix:nonNumeric contextRef="From2020-10-01to2020-12-31" name="dei:DocumentType">10-Q</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 31.5pt"><span style="font: 10pt Times New Roman, Times, Serif">(Mark
One)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90A_edei--DocumentQuarterlyReport_c20201001__20201231_zvAQZgAAStL4"><ix:nonNumeric contextRef="From2020-10-01to2020-12-31" format="ixt:booleantrue" name="dei:DocumentQuarterlyReport">&#9746;</ix:nonNumeric></span>
<b>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE&#160;ACT&#160;OF 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">For
the quarterly period ended: <b><span style="text-decoration: underline"><span id="xdx_901_edei--DocumentPeriodEndDate_c20201001__20201231_zyzjBZQIgkpj"><ix:nonNumeric contextRef="From2020-10-01to2020-12-31" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">December 31, 2020</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_900_edei--DocumentTransitionReport_c20201001__20201231_zDvZWY9z31Ga"><ix:nonNumeric contextRef="From2020-10-01to2020-12-31" format="ixt:booleanfalse" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span>
<b>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE&#160;ACT&#160;OF 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">For
the transition period from _____to _____</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Commission
File Number: <span style="text-decoration: underline"><span id="xdx_90A_edei--EntityFileNumber_c20201001__20201231_z4706l6H9u68"><ix:nonNumeric contextRef="From2020-10-01to2020-12-31" name="dei:EntityFileNumber">001-37606</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 14pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_904_edei--EntityRegistrantName_c20201001__20201231_zDa1VFZ6aw5j"><ix:nonNumeric contextRef="From2020-10-01to2020-12-31" name="dei:EntityRegistrantName">ANAVEX LIFE SCIENCES CORP.</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_90E_edei--EntityIncorporationStateCountryCode_c20201001__20201231_zUpCMnWVkhE5"><ix:nonNumeric contextRef="From2020-10-01to2020-12-31" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></span></b></span></td>
    <td style="width: 50%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_907_edei--EntityTaxIdentificationNumber_c20201001__20201231_zIQjUlebf9a5"><ix:nonNumeric contextRef="From2020-10-01to2020-12-31" name="dei:EntityTaxIdentificationNumber">98-0608404</ix:nonNumeric></span></span></b></span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(State or other jurisdiction
    of</span></td>
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(IRS Employer</span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">incorporation or
    organization)</span></td>
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Identification No.)</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_90B_edei--EntityAddressAddressLine1_c20201001__20201231_zfd5dhQKahV4"><ix:nonNumeric contextRef="From2020-10-01to2020-12-31" name="dei:EntityAddressAddressLine1">51 West 52nd Street</ix:nonNumeric></span>, <span id="xdx_90E_edei--EntityAddressAddressLine2_c20201001__20201231_zhPYzXVg87F6"><ix:nonNumeric contextRef="From2020-10-01to2020-12-31" name="dei:EntityAddressAddressLine2">7th Floor</ix:nonNumeric></span>, <span id="xdx_905_edei--EntityAddressCityOrTown_c20201001__20201231_zU0sjEq7OPHa"><ix:nonNumeric contextRef="From2020-10-01to2020-12-31" name="dei:EntityAddressCityOrTown">New York</ix:nonNumeric></span>, <span id="xdx_90D_edei--EntityAddressStateOrProvince_c20201001__20201231_zKfcImU0Zco6"><ix:nonNumeric contextRef="From2020-10-01to2020-12-31" name="dei:EntityAddressStateOrProvince">NY</ix:nonNumeric></span> <span id="xdx_902_edei--EntityAddressCountry_c20201001__20201231_zbl6YJPMrXfd"><ix:nonNumeric contextRef="From2020-10-01to2020-12-31" name="dei:EntityAddressCountry">US</ix:nonNumeric></span>A <span id="xdx_90A_edei--EntityAddressPostalZipCode_c20201001__20201231_zrKjfKMcCl07"><ix:nonNumeric contextRef="From2020-10-01to2020-12-31" name="dei:EntityAddressPostalZipCode">10019</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Address
of principal executive offices) (Zip Code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">1-<span id="xdx_900_edei--CityAreaCode_c20201001__20201231_zpiCrmjOVx6i"><ix:nonNumeric contextRef="From2020-10-01to2020-12-31" name="dei:CityAreaCode">844</ix:nonNumeric></span>-<span id="xdx_90C_edei--LocalPhoneNumber_c20201001__20201231_zTvUWbAAxWvb"><ix:nonNumeric contextRef="From2020-10-01to2020-12-31" name="dei:LocalPhoneNumber">689-3939</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Registrant&#8217;s
telephone number, including area code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">N/A</span></b><br />
(Former name, former address and former fiscal year, if changed since last report)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Securities
Registered Pursuant to Section&#160;12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Title
    of Each Class</span></td>
    <td style="vertical-align: top; padding-bottom: 1.5pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Trading
    Symbol</span></td>
    <td style="vertical-align: top; padding-bottom: 1.5pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Name
    of Each Exchange on Which Registered</span></td></tr>
<tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="width: 32%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90F_edei--Security12bTitle_c20201001__20201231_zNfCUS64dEz1"><ix:nonNumeric contextRef="From2020-10-01to2020-12-31" name="dei:Security12bTitle">Common Stock Par Value $0.001</ix:nonNumeric></span></span></td>
    <td style="width: 1%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 32%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90B_edei--TradingSymbol_c20201001__20201231_z67WLd3rTrce"><ix:nonNumeric contextRef="From2020-10-01to2020-12-31" name="dei:TradingSymbol">AVXL</ix:nonNumeric></span></span></td>
    <td style="width: 1%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 34%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_906_edei--SecurityExchangeName_c20201001__20201231_z18FymvFfIf6"><ix:nonNumeric contextRef="From2020-10-01to2020-12-31" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span>
    Stock Market LLC</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#9746;
<span id="xdx_903_edei--EntityCurrentReportingStatus_c20201001__20201231_zetX6C7YLXKh"><ix:nonNumeric contextRef="From2020-10-01to2020-12-31" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span> &#9744; No</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant
to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that
the registrant was required to submit such files).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#9746;
<span id="xdx_90A_edei--EntityInteractiveDataCurrent_c20201001__20201231_zjmTFUxu2Mri"><ix:nonNumeric contextRef="From2020-10-01to2020-12-31" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> &#9744; No</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;
&#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 25%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Large
    accelerated filer</span></td>
    <td style="width: 25%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#9744;</span></td>
    <td style="width: 25%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Accelerated Filer</span></td>
    <td style="width: 25%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#9744;</span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_902_edei--EntityFilerCategory_c20201001__20201231_zxHx27kqLSQi"><ix:nonNumeric contextRef="From2020-10-01to2020-12-31" name="dei:EntityFilerCategory">Non-accelerated Filer</ix:nonNumeric></span></span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#9746;</span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Smaller reporting
    company</span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90D_edei--EntitySmallBusiness_c20201001__20201231_zp9wLhxT080d"><ix:nonNumeric contextRef="From2020-10-01to2020-12-31" format="ixt:booleantrue" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Emerging growth
    company</span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_edei--EntityEmergingGrowthCompany_c20201001__20201231_zRm97Hwi485l"><ix:nonNumeric contextRef="From2020-10-01to2020-12-31" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#9744;
Yes &#9746; <span id="xdx_904_edei--EntityShellCompany_c20201001__20201231_zvVtZUI6d3fl"><ix:nonNumeric contextRef="From2020-10-01to2020-12-31" format="ixt:booleanfalse" name="dei:EntityShellCompany">No</ix:nonNumeric></span></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
the number of shares outstanding of each of the issuer&#8217;s classes of common stock, as of the latest practicable date: <span style="background-color: White"><span id="xdx_909_edei--EntityCommonStockSharesOutstanding_iI_c20210212_zUGp6t8iinY2" title="Entity Common Stock, Shares Outstanding"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2021-02-12" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">69,487,852</ix:nonFraction></span>
shares of common stock outstanding as of February 12, 2021.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 00 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>TABLE
OF CONTENTS </b></span></p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>



<table cellpadding="0" cellspacing="0" style="width: 100%">
<tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; text-transform: uppercase">
    <td style="text-align: left; padding-top: 12pt; padding-bottom: 0pt; padding-left: 0in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; padding-top: 12pt; padding-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">Page</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; text-transform: uppercase; background-color: rgb(204,238,255)">
    <td style="width: 90%; text-align: left; padding-top: 12pt; padding-bottom: 0pt; padding-left: 0in"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#PARTI">PART I - FINANCIAL INFORMATION</a></span></td>
    <td style="width: 10%; text-align: right; padding-top: 12pt; padding-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">3</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; text-transform: uppercase; background-color: White">
    <td style="text-align: left; padding-top: 12pt; padding-bottom: 0pt; padding-left: 0in"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#item1">Item 1. FINANCIAL STATEMENTS</a></span></td>
    <td style="text-align: right; padding-top: 12pt; padding-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">3</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; text-transform: uppercase; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 12pt; padding-bottom: 0pt; padding-left: 0in"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#item2">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</a></span></td>
    <td style="text-align: right; padding-top: 12pt; padding-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">16</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; text-transform: uppercase; background-color: White">
    <td style="text-align: left; padding-top: 12pt; padding-bottom: 0pt; padding-left: 0in"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#item3">Item 3. Quantitative and Qualitative Disclosures about Market Risks.</a></span></td>
    <td style="text-align: right; padding-top: 12pt; padding-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">30</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; text-transform: uppercase; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 12pt; padding-bottom: 0pt; padding-left: 0in"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#item4">Item 4. Controls and Procedures.</a></span></td>
    <td style="text-align: right; padding-top: 12pt; padding-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">30</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; text-transform: uppercase; background-color: White">
    <td style="text-align: left; padding-top: 12pt; padding-bottom: 0pt; padding-left: 0in"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#PARTII">PART II &#8211; OTHER INFORMATION</a></span></td>
    <td style="text-align: right; padding-top: 12pt; padding-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">31</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; text-transform: uppercase; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 12pt; padding-bottom: 0pt; padding-left: 0in"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#LEGAL">Item 1. Legal Proceedings.</a></span></td>
    <td style="text-align: right; padding-top: 12pt; padding-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">31</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; text-transform: uppercase; background-color: White">
    <td style="text-align: left; padding-top: 12pt; padding-bottom: 0pt; padding-left: 0in"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#RISK">Item 1A. Risk Factors.</a></span></td>
    <td style="text-align: right; padding-top: 12pt; padding-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">31</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; text-transform: uppercase; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 12pt; padding-bottom: 0pt; padding-left: 0in"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#UNREGISTERED">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.</a></span></td>
    <td style="text-align: right; padding-top: 12pt; padding-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">31</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; text-transform: uppercase; background-color: White">
    <td style="text-align: left; padding-top: 12pt; padding-bottom: 0pt; padding-left: 0in"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#DEFAULTS">Item 3. Defaults Upon Senior Securities.</a></span></td>
    <td style="text-align: right; padding-top: 12pt; padding-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">31</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; text-transform: uppercase; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 12pt; padding-bottom: 0pt; padding-left: 0in"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#MINE">Item 4. Mine Safety Disclosures</a></span></td>
    <td style="text-align: right; padding-top: 12pt; padding-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">31</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; text-transform: uppercase; background-color: White">
    <td style="text-align: left; padding-top: 12pt; padding-bottom: 0pt; padding-left: 0in"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#OTHER">Item 5. Other Information.</a></span></td>
    <td style="text-align: right; padding-top: 12pt; padding-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">31</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; text-transform: uppercase; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-top: 12pt; padding-bottom: 0pt; padding-left: 0in"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#EXHIBITS">Item 6. Exhibits.</a></span></td>
    <td style="text-align: right; padding-top: 12pt; padding-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">32</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: bottom; text-transform: uppercase; background-color: White">
    <td style="text-align: left; padding-top: 12pt; padding-bottom: 0pt; padding-left: 0in"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#SIGNATURES">SIGNATURES</a></span></td>
    <td style="text-align: right; padding-top: 12pt; padding-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif">33</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 00 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-transform: uppercase; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="PARTI"></span>PART
I - FINANCIAL INFORMATION</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-transform: uppercase; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-transform: uppercase; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="item1"></span>Item
1. FINANCIAL STATEMENTS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>ANAVEX
LIFE SCIENCES CORP.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">INTERIM
CONDENSED CONSOLIDATED BALANCE SHEETS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">December
31, 2020 and September 30, 2020&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_306_111_zE1WGlEivi88" summary="xdx: Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_49C_20201231_zT8KTHw4CzIe" style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_498_20200930_zxgKn0jyemag" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>December
    31,</b></span></td><td style="font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>September
    30,</b></span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2020</b></span></td><td style="font-weight: bold; padding-bottom: 1pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2020</b></span></td></tr>
<tr style="vertical-align: bottom; background-color: WHITE">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Unaudited)</span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_407_eus-gaap--AssetsAbstract_iB_zxXoqG7KDrgh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font: 10pt Times New Roman, Times, Serif">Assets</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40C_eus-gaap--AssetsCurrentAbstract_i01B_zoP0oblOdaP7" style="vertical-align: bottom; background-color: White">
    <td><span style="font: 10pt Times New Roman, Times, Serif">Current</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-style: italic"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-style: italic; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-style: italic; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-style: italic; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40E_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maAzOr9_zwpW9s3Bnx9a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 45%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Cash and
    cash equivalents</span></td><td style="width: 1%; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 10%; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">47,357,599</ix:nonFraction></span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 10%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,249,018</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_401_eus-gaap--IncomeTaxesReceivable_i02I_maAzOr9_zoeGsJ5NpYd5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Incentive and tax receivables</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncomeTaxesReceivable" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,577,807</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncomeTaxesReceivable" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,849,340</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_400_eus-gaap--PrepaidExpenseCurrent_i02I_pp0p0_maAzOr9_zqmVXCXw7275" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Prepaid expenses and
    deposits</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">398,840</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">443,839</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40F_eus-gaap--Assets_i01TI_pp0p0_mtAzOr9_z1ZZmRksvwO7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Total
    Assets</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">54,334,246</ix:nonFraction></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">34,542,197</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40C_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Liabilities and Stockholders'
    Equity</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_409_eus-gaap--LiabilitiesCurrentAbstract_i01B" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Current Liabilities</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_402_eus-gaap--AccountsPayableCurrent_i02I_pp0p0_maLCzByZ_z5dtom2f0nF4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Accounts payable</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,216,948</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,989,054</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_407_eus-gaap--AccruedLiabilitiesCurrent_i02I_pp0p0_maLCzByZ_zcgj2YYKElGi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Accrued
    liabilities</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,816,521</ix:nonFraction></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,316,574</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_401_eus-gaap--LiabilitiesCurrent_i02TI_pp0p0_mtLCzByZ_maLASEzbgu_z0xNfsEaO5Uf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Total
    Liabilities</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,033,469</ix:nonFraction></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,305,628</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_407_eus-gaap--CommitmentsAndContingencies_i01I_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Commitments and Contingencies
    - Note 5</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40A_eus-gaap--PreferredStockValue_i01I_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Capital stock</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Authorized:</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_c20201231_zEVV1W48TdR5" title="Preferred stock, shares authorized"><span id="xdx_908_eus-gaap--PreferredStockSharesAuthorized_iI_c20200930_zN9g1lZdrwTh" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000,000</ix:nonFraction></ix:nonFraction></span></span>&#160;preferred
    stock, par value $<span id="xdx_90D_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20201231_zzRF7scOe0Fk" title="Preferred stock, par value"><span id="xdx_903_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20200930_z9mRSUzVIX26" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span>&#160;per share</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--PreferredStockValue_iI_pp0p0_d0_maSEzeI6_c20201231_zyja6JRp5xXj" title="Capital stock Authorized: 10,000,000 preferred stock, par value $0.001 per share" style="display: none; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2020-12-31" format="ixt:zerodash" decimals="0" scale="0" sign="-" unitRef="USD">-</ix:nonFraction><span style="font: 10pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="display: none; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 11pt Calibri, Helvetica, Sans-Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--PreferredStockValue_iI_pp0p0_d0_maSEzeI6_c20200930_zRQJgEmnQ8Gc" title="Capital stock Authorized: 10,000,000 preferred stock, par value $0.001 per share" style="font: 11pt Calibri, Helvetica, Sans-Serif; display: none; text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2020-09-30" format="ixt:zerodash" decimals="0" scale="0" sign="-" unitRef="USD">-</ix:nonFraction><span style="font: 10pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_iI_c20201231_z5hVWjzBngq9" title="Common stock, shares authorized"><span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_iI_c20200930_zuYzSu9CmpM3" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000,000</ix:nonFraction></ix:nonFraction></span></span>&#160;common
    stock, par value $<span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20201231_zh8JLSVLaQQf" title="Common stock, par value"><span id="xdx_908_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20200930_zYUYkoqft515" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span>&#160;per share</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Issued and outstanding:</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt TimesNew Roman, Times, Serif"><span id="xdx_90C_eus-gaap--CommonStockSharesIssued_iI_c20201231_z9hJ4U8dt0Q9" title="Common stock, shares issued"><span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_iI_c20201231_zBmUiKbMP9b9" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">66,962,957</ix:nonFraction></ix:nonFraction></span></span>&#160;common shares</span></p>
                                 <p style="margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">(September 30, 2020 -&#160;<span id="xdx_904_eus-gaap--CommonStockSharesIssued_iI_c20200930_zcTWfMS4CQge" title="Common stock, shares issued"><span id="xdx_90D_eus-gaap--CommonStockSharesOutstanding_iI_c20200930_zfiiOvSxKCn1" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">62,045,198</ix:nonFraction></ix:nonFraction></span></span>)</span></p></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--CommonStockValue_iI_pp0p0_maSEzeI6_c20201231_zPgIMpZli3j1" title="Capital stock Authorized: 100,000,000 common shares, par value $0.001 per share Issued and outstanding: 60,082,291 common shares (September 30, 2019 - 52,650,251)" style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">66,964</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--CommonStockValue_iI_pp0p0_maSEzeI6_c20200930_zLDiJaAmNuUd" title="Capital stock Authorized: 100,000,000 common shares, par value $0.001 per share Issued and outstanding: 60,082,291 common shares (September 30, 2019 - 52,650,251)" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">62,047</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40A_eus-gaap--AdditionalPaidInCapitalCommonStock_iI_pp0p0_maSEzeI6_zJ5xtBC0rQDf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Additional paid-in
    capital</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">213,766,108</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">186,851,752</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_404_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_pp0p0_maSEzeI6_zFlmUIgWi7Ri" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Accumulated
    deficit</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">167,532,295</ix:nonFraction></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">159,677,230</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_40A_eus-gaap--StockholdersEquity_iTI_pp0p0_mtSEzeI6_maLASEzbgu_znHLqigSgUvb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Total
    Stockholders' Equity</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">46,300,777</ix:nonFraction></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">27,236,569</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40C_eus-gaap--LiabilitiesAndStockholdersEquity_iTI_pp0p0_mtLASEzbgu_zPgMPJmyUMo6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Total
    Liabilities and Stockholders' Equity</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">54,334,246</ix:nonFraction></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">34,542,197</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 00 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<b>ANAVEX
LIFE SCIENCES CORP</b>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">INTERIM
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">For
the three months ended December 31, 2020 and 2019</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">(Unaudited)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_302_113_zSrSDdtKP2A5" summary="xdx: Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_499_20201001__20201231_zUouZzkNH1Yk" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_499_20191001__20191231_z9dVpLaJOQsh" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Three
    months ended December 31,</b></span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2020</b></span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2019</b></span></td></tr>
<tr id="xdx_40E_eus-gaap--OperatingExpensesAbstract_iB_z4TSVV2HEul" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Operating expenses</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40F_eus-gaap--GeneralAndAdministrativeExpense_i01_maCzeuU_zi8T5oYYxvtd" style="vertical-align: bottom; background-color: White">
    <td style="width: 45%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">General
    and administrative</span></td><td style="width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 10%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2020-10-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,470,656</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 10%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2019-10-012019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,352,035</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_407_eus-gaap--ResearchAndDevelopmentExpense_i01_maCzeuU_zTItxnmhAotd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Research
    and development</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2020-10-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,925,519</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2019-10-012019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,348,668</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40D_eus-gaap--OperatingExpenses_iNT_di_mtCzeuU_msCz3eS_zBxfyxMoOP81" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Total operating expenses</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2020-10-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,396,175</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2019-10-012019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,700,703</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_401_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zhPYNKVImGh6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Other income (expenses)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_401_ecustom--NonOperatingIncomeFromGrant_i01_d0_maCzron_zNe4ySraGoH6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Grant income</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrant" contextRef="From2020-10-01to2020-12-31" format="ixt:zerodash" decimals="0" sign="-" unitRef="USD">-</ix:nonFraction><span style="font: 10pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrant" contextRef="From2019-10-012019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">74,944</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40E_ecustom--ResearchAndDevelopmentIncentiveIncome_i01_maCzron_zTeIf3J7LU75" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Research and development
    incentive income</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="avxl:ResearchAndDevelopmentIncentiveIncome" contextRef="From2020-10-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,269,316</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="avxl:ResearchAndDevelopmentIncentiveIncome" contextRef="From2019-10-012019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">943,215</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_407_eus-gaap--InterestIncomeExpenseNet_i01_maCzron_z8kdS7I01BD8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Interest (expense)
    income, net</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2020-10-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,559</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2019-10-012019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46,720</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40D_eus-gaap--ForeignCurrencyTransactionGainLossBeforeTax_i01_maCzron_z2E75CPFu5oc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Foreign
    exchange gain, net</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2020-10-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">332,634</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" contextRef="From2019-10-012019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">53,113</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_403_eus-gaap--NonoperatingIncomeExpense_iT_mtCzron_maCz3eS_zWRgUXXfgpSa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Total
    other income, net</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2020-10-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,600,391</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2019-10-012019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,117,992</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40F_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_mtCz3eS_maCzNTF_zpdq7V3IrTDe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Net loss before provision
    for income taxes</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2020-10-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,795,784</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2019-10-012019-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,582,711</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_405_eus-gaap--CurrentIncomeTaxExpenseBenefit_iN_di_msCzNTF_zeOjlflM1ezg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Income
    tax expense, current</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2020-10-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">59,281</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="From2019-10-012019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,214</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40C_eus-gaap--NetIncomeLoss_iT_mtCzNTF_zZ1GfLaxCuH6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Net
    loss and comprehensive loss</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-10-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,855,065</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-10-012019-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,591,925</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_409_eus-gaap--EarningsPerShareBasicAndDilutedAbstract_iB_ziFsi1uTzMRd" style="vertical-align: bottom; background-color: White">
    <td><span style="font: 10pt Times New Roman, Times, Serif">Net Loss per share</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40B_eus-gaap--EarningsPerShareBasicAndDiluted_i01_zFL6pZEmN818" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Basic
    and diluted</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2020-10-01to2020-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.12</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2019-10-012019-12-31" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.12</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40F_eus-gaap--WeightedAverageNumberOfSharesOutstandingAbstract_iB_zYn3SRgQ1ej2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font: 10pt Times New Roman, Times, Serif">Weighted average number of shares outstanding</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40A_eus-gaap--WeightedAverageNumberOfShareOutstandingBasicAndDiluted_i01_znJsllCVRBh6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Basic
    and diluted</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="From2020-10-01to2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">64,295,143</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="From2019-10-012019-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">54,773,685</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 00 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<b>ANAVEX
LIFE SCIENCES CORP.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">INTERIM
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">For
the three months ended December 31, 2020 and 2019</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_307_112_zIg5wiyytd0h" summary="xdx: Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" id="xdx_499_20201001__20201231_zgHS7ZD81Bc" style="text-align: right; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" id="xdx_49D_20191001__20191231_z5xU5V1X2GB6" style="text-align: right; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2020</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2019</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_400_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_iB_zd7UByyOFg49" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Cash Flows used in
    Operating Activities</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_402_eus-gaap--NetIncomeLoss_i01_maCzQK1_z7sqUxqsOXf" style="vertical-align: bottom; background-color: White">
    <td style="width: 45%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Net loss</span></td><td style="width: 1%; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 10%; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-10-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,855,065</ix:nonFraction></span></td><td style="width: 1%; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 10%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-10-012019-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,591,925</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_402_eus-gaap--AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zepa9qoidVC8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Adjustments to reconcile
    net loss to net cash used in operations:</span></td><td style="color: red; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="color: red; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="color: red; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="color: red; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="color: red"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="color: red; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="color: red; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="color: red; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_404_eus-gaap--ShareBasedCompensation_i02_maCzQK1_znE7TNnD5KM8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Stock-based compensation</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-10-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">939,314</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2019-10-012019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,264,424</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_409_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i01B_zcNv1sZWxcLa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Changes in non-cash
    working capital balances related to operations:</span></td><td style="color: red; font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="color: red; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="color: red; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="color: red; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="color: red"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="color: red; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="color: red; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="color: red; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_406_eus-gaap--IncreaseDecreaseInIncomeTaxesReceivable_i02N_di_msCzQK1_zyoEAGz81dfl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Incentive and tax receivables</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" contextRef="From2020-10-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,728,467</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" contextRef="From2019-10-012019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,087,927</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_40B_eus-gaap--IncreaseDecreaseInPrepaidExpense_i02N_di_msCzQK1_zDW7NHT6KU69" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Prepaid expenses and
    deposits</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2020-10-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">44,999</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="From2019-10-012019-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">266,026</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_408_eus-gaap--IncreaseDecreaseInAccountsPayable_i02_maCzQK1_z7QHCpTFLVkh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Accounts payable</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2020-10-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">227,894</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"></span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right">(<span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2019-10-012019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">395,834</ix:nonFraction></span></td><td style="text-align: left">)<span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_402_eus-gaap--IncreaseDecreaseInAccruedLiabilities_i02_maCzQK1_zEIqrbMFzPRc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Accrued
    liabilities</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2020-10-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">499,947</ix:nonFraction></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2019-10-012019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">820,077</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"></span></td></tr>
<tr id="xdx_404_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iT_mtCzQK1_maCzR0V_zSnAE2cwsIw4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Net cash used in operating
    activities</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2020-10-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,871,378</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2019-10-012019-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,725,159</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_401_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_iB_ziO5AQDqDRo3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Cash Flows provided
    by Financing Activities</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_403_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_maCzrgX_zGGK8dXTjPWg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font: 10pt Times New Roman, Times, Serif">Issuance of common shares</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2020-10-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,243,419</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2019-10-012019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,997,952</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40A_eus-gaap--PaymentsOfFinancingCosts_i01N_di0_msCzrgX_zTHW0C05LVA2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Share
    issue costs</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:PaymentsOfFinancingCosts" contextRef="From2020-10-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">263,460</ix:nonFraction></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PaymentsOfFinancingCosts" contextRef="From2019-10-012019-12-31" format="ixt:zerodash" decimals="0" unitRef="USD">-</ix:nonFraction><span style="font: 10pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_408_eus-gaap--NetCashProvidedByUsedInFinancingActivities_iT_mtCzrgX_maCzR0V_znixC8dYqZ1b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Net cash provided by
    financing activities</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2020-10-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,979,959</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2019-10-012019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,997,952</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_409_eus-gaap--CashAndCashEquivalentsPeriodIncreaseDecrease_iT_mtCzR0V_zfc4pYdPglg4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Increase in cash and
    cash equivalents during the period</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" contextRef="From2020-10-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,108,581</ix:nonFraction></span></td><td style="font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" contextRef="From2019-10-012019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,272,793</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--Cash_iS_zwietqooOmu" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Cash
    and cash equivalents, beginning of period</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,249,018</ix:nonFraction></span></td><td style="padding-bottom: 1pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,185,630</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_40C_eus-gaap--Cash_iE_zqUz1NZKNsAl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Cash
    and cash equivalents, end of period</span></td><td style="font-weight: bold; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">47,357,599</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,458,423</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 00 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>ANAVEX
LIFE SCIENCES CORP.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">INTERIM
CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">For
the three months ended December 31, 2020 and 2019&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<table cellpadding="0" cellspacing="0" id="xdx_305_114_z1yqvvOdMt93" summary="xdx: Statement - INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS&apos; EQUITY (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zIvNfBFsmEGi" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zvLKQb84UNyc" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_4BA_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zsedKmXGJ2hf" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_4B9_zdBxuKYo1hX3" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="11" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Common
    Stock</b></span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Additional</b></span></td><td><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Paid-in</b></span></td><td><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Accumulated</b></span></td><td><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Shares</b></span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Par
    Value</b></span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Capital</b></span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Deficit</b></span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Total</b></span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_43A_c20201001__20201231_eus-gaap--StockholdersEquity_iS_zeFJ8JnLoWYc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%"><span style="font: 10pt Times New Roman, Times, Serif">Balance, October 1, 2020</span></td><td style="width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--SharesOutstanding_iS_pii_c20201001__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zMjgGwLSpBf3" title="Balance beginning, shares" style="width: 9%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">62,045,198</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">62,047</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">186,851,752</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">159,677,230</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,236,569</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Shares issued under
    2019 purchase agreement</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_407_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zeL3i1l1zJY5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;Purchase shares</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pii_c20201001__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zlx2Ln1eyQfb" title="Purchase shares, shares" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2020-10-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,346,288</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-10-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,346</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-10-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,458,056</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0235">&#8212;</span>&#160;&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-10-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,461,402</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_407_ecustom--CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2_pp0p0_zCWZLng33oq7" style="vertical-align: bottom; background-color: White">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;Commitment shares</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_ecustom--CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2_pii_c20201001__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z9qo9sYQ38ki" title="Commitment shares, shares" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" contextRef="From2020-10-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">56,642</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" contextRef="From2020-10-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">56</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" contextRef="From2020-10-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">56</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0242">&#8212;</span>&#160;&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0243">&#8212;</span>&#160;&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_404_eus-gaap--StockIssuedDuringPeriodValueOther_zgr0JsW8hpre" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Shares issued under
    Sales Agreement, net of shares issue costs</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesOther_c20201001__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zaPx8GDv8WL8" title="Shares issued under Sales Agreement, net of shares issue costs, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2020-10-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,514,829</ix:nonFraction><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2020-10-012020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,515</ix:nonFraction><span style="font: 10pt Times New Roman, Times, Serif"></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2020-10-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,517,042</ix:nonFraction><span style="font: 10pt Times New Roman, Times, Serif"></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0249">&#8212;</span>&#160;&#160;<span style="font: 10pt Times New Roman, Times, Serif"></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2020-10-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,518,557</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_407_eus-gaap--ShareBasedCompensation_zPmiJY7NXfhh" style="vertical-align: bottom; background-color: White">
    <td><span style="font: 10pt Times New Roman, Times, Serif">Share based compensation</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#8212;&#160;&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0254">&#8212;</span>&#160;&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-10-012020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">939,314</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0256">&#8212;</span>&#160;&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-10-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">939,314</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_405_eus-gaap--NetIncomeLoss_zWDrMCX4AYta" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Net
    loss</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#8212;&#160;&#160;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0259">&#8212;</span>&#160;&#160;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0260">&#8212;</span>&#160;&#160;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-10-012020-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,855,065</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-10-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,855,065</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)&#160;</span></td></tr>
<tr id="xdx_435_c20201001__20201231_eus-gaap--StockholdersEquity_iE_zWOHc2BIApvg" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Balance, December
    31, 2020</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--SharesOutstanding_iE_pii_c20201001__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zEejv0eBI9Sl" title="Balance ending, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">66,962,957</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">66,964</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">213,766,108</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">167,532,295</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46,300,777</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_435_c20191001__20191231_eus-gaap--StockholdersEquity_iS_ztKq39EW71tj" style="vertical-align: bottom; background-color: White">
    <td><span style="font: 10pt Times New Roman, Times, Serif">Balance, October 1, 2019</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--SharesOutstanding_iS_pii_c20191001__20191231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLDicFZRdj41" title="Balance beginning, shares" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2019-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">52,650,521</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,652</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">153,633,807</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">133,396,760</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,289,699</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Shares issued under
    2019 purchase agreement</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_409_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zLNSbNTyjix3" style="vertical-align: bottom; background-color: White">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;Purchase shares</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pii_c20191001__20191231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ze5fWY3nVO13" title="Purchase shares, shares" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2019-10-012019-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,394,160</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2019-10-012019-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,394</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2019-10-012019-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,993,558</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0280">&#8212;</span>&#160;&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2019-10-012019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,997,952</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_404_ecustom--CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2_pp0p0_zKN8PPLceZ4i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;Commitment shares</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_ecustom--CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2_pii_c20191001__20191231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWJg9smVcrMb" title="Commitment shares, shares" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" contextRef="From2019-10-012019-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">35,675</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" contextRef="From2019-10-012019-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">36</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" contextRef="From2019-10-012019-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">36</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0287">&#8212;</span>&#160;&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0288">&#8212;</span>&#160;&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_407_eus-gaap--ShareBasedCompensation_zV9L4fm8gEh3" style="vertical-align: bottom; background-color: White">
    <td><span style="font: 10pt Times New Roman, Times, Serif">Share based compensation</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#8212;&#160;&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0292">&#8212;</span>&#160;&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2019-10-012019-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,264,424</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0294">&#8212;</span>&#160;&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2019-10-012019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,264,424</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr id="xdx_405_eus-gaap--NetIncomeLoss_zwIdzxv25ira" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Net
    loss</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#8212;&#160;&#160;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0297">&#8212;</span>&#160;&#160;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0298">&#8212;</span>&#160;&#160;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-10-012019-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,591,925</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-10-012019-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,591,925</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
<tr id="xdx_43D_c20191001__20191231_eus-gaap--StockholdersEquity_iE_zqGetmhffDV5" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Balance, December
    31, 2019</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--SharesOutstanding_iE_pii_c20191001__20191231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWt3YskZcg5c" title="Balance ending, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">57,080,356</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">57,082</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">165,891,753</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">139,988,685</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,960,150</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 00 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-10-01to2020-12-31" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p id="xdx_806_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_z1q3wTYSqXTh" style="font: 10pt/115% Arial, Helvetica, Sans-Serif; margin: 0 0 0pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Note
1 &#9;&#160;&#160;&#160;&#160;&#160;<span style="text-decoration: underline"><span id="xdx_82F_zDtKOiXoQljc">Business Description and Basis of Presentation</span></span></span></p>

<p style="font: 10pt/115% Arial, Helvetica, Sans-Serif; margin: 0; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Business</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Anavex
Life Sciences Corp. (&#8220;Anavex&#8221; or the &#8220;Company&#8221;) is a clinical stage biopharmaceutical company engaged
in the development of differentiated therapeutics by applying precision medicine to central nervous system (&#8220;CNS&#8221;)
diseases with high unmet need. Anavex analyzes genomic data from clinical studies to identify biomarkers, which are used to select
patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. The
Company&#8217;s lead compound ANAVEX<sup>&#174;</sup>2-73 is being developed to treat Alzheimer&#8217;s disease, Parkinson&#8217;s
disease and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological
monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2 (&#8220;MECP2&#8221;).</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Basis
of Presentation</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">These
unaudited interim condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the
Securities and Exchange Commission (&#8220;SEC&#8221;) and accounting principles generally accepted in the United States of America
(&#8220;U.S. GAAP&#8221;) for interim reporting. Accordingly, certain information and note disclosures normally included in the
annual financial statements in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations.
In the opinion of management, the disclosures are adequate to make the information presented not misleading.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">These
accompanying unaudited interim condensed consolidated financial statements reflect all adjustments, consisting of normal recurring
adjustments, which in the opinion of management are necessary for fair presentation of the information contained herein. The consolidated
balance sheet as of September 30, 2020 was derived from the audited annual financial statements but does not include all disclosures
required by U.S. GAAP. The accompanying unaudited interim condensed consolidated financial statements should be read in conjunction
with the audited consolidated financial statements and notes thereto included in the Company&#8217;s annual report on Form 10-K
for the year ended September 30, 2020 filed with the SEC on December 28, 2020. The Company follows the same accounting policies
in the preparation of interim reports.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Operating
results for the three months ended December 31, 2020 are not necessarily indicative of the results that may be expected for the
year ending September 30, 2021.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Liquidity</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">All
of the Company&#8217;s potential drug compounds are in the clinical development stage and the Company cannot be certain that its
research and development efforts will be successful or, if successful, that its potential drug compounds will ever be approved
for sales to pharmaceutical companies or generate commercial revenues. To date, we have not generated any revenues from our operations.
The Company expects the business to continue to experience negative cash flows for the foreseeable future and cannot predict when,
if ever, our business might become profitable.</span></p>

<ix:exclude><p id="xdx_235_z1NsOEXt3RV3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 00 -->
    <div id="xdx_23D_zT1ezhBlT171" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_235_zd7YHFUUqJP8" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td id="xdx_238_zn7TTjzUIIod" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_230_zUfNR9AvJXY3" style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_237_z0kithyDWDke" style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_232_zaF1vv77MKka" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_238_z6inteV9PT72" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Note
1 &#9;&#160;&#160;&#160;&#160;&#160;<span style="text-decoration: underline">Business Description and Basis of Presentation</span> &#8211; (Continued)</span></p></ix:exclude>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company believes that its existing cash and cash equivalents, along with existing financial commitments from third parties, will
be sufficient to meet its cash commitments for at least two years after the date that these interim condensed consolidated financial
statements are issued. The process of drug development can be costly, and the timing and outcomes of clinical trials is uncertain.&#160;The
assumptions upon which the Company has based its estimates are routinely evaluated and may be subject to change.&#160;The actual
amount of the Company&#8217;s expenditures will vary depending upon a number of factors including but not limited to the design,
timing and duration of future clinical trials, the progress of the Company&#8217;s research and development programs and the level
of financial resources available. The Company has the ability to adjust its operating plan spending levels based on the timing
of future clinical trials.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Other
than our rights related to the 2019 Purchase Agreement and the Sales Agreement (each as defined below in Note 4), there can be
no assurance that additional financing will be available to us when needed or, if available, that it can be obtained on commercially
reasonable terms. If the Company is not able to obtain the additional financing on a timely basis, if and when it is needed, it
will be forced to delay or scale down some or all of its research and development activities.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
December 2019, a novel strain of coronavirus, COVID-19, was reported to have surfaced in Wuhan, China. In March 2020, the World
Health Organization (&#8220;WHO&#8221;) declared COVID-19 to be a global pandemic as a result of the rapid spread of the virus
beyond its point of origin.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
global outbreak of COVID-19 continues to rapidly evolve as of the date these interim condensed consolidated financial statements
are issued. As such, it is uncertain as to the full magnitude that the outbreak will have on the Company&#8217;s financial condition
and future results of operations. Management is actively monitoring the global situation on its business, including on its clinical
trials and operations and financial condition. The effects of COVID-19 did not have a material impact on the Company&#8217;s result
of operations or financial condition for the period ended December 31, 2020. However, given the daily evolution of the COVID-19
situation, and the global responses to curb its spread, the Company is not able to estimate the effects COVID-19 may have on its
future results of operations or financial condition.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify; color: gray"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Use
of Estimates</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify; color: gray"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and
expenses in the reporting period. The Company regularly evaluates estimates and assumptions related to accounting for research
and development costs, valuation and recoverability of deferred tax assets, asset impairment, stock-based compensation, and loss
contingencies. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors
that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the
carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources.
The actual results experienced by the Company may differ materially and adversely from the Company&#8217;s estimates. To the extent
there are material differences between the estimates and the actual results, future results of operations will be affected.</span></p>
<ix:exclude><p id="xdx_23C_zFDSVx3Nlwgj" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 00 -->
    <div id="xdx_23B_zxZtuedWUlOf" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_23E_zDihK79jPd34" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td><td id="xdx_237_zdpDBmatNIm5" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23F_zuTmMMwQ1mMk" style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_239_zUMLdWKoOxHi" style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_235_z5oW61s3RKWd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_233_zUXtV6AMA3J4" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Note
1 &#9;&#160;&#160;&#160;&#160;&#160;<span style="text-decoration: underline">Business Description and Basis of Presentation</span> &#8211; (Continued)</span></p></ix:exclude>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Principles
of Consolidation</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">These
consolidated financial statements include the accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex
Australia Pty Limited. (&#8220;Anavex Australia&#8221;), a company incorporated under the laws of Australia, Anavex Germany GmbH,
a company incorporated under the laws of Germany, and Anavex Canada Ltd., a company incorporated under the laws of the Province
of Ontario, Canada. All inter-company transactions and balances have been eliminated.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Fair
Value Measurements</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
fair value hierarchy under GAAP is based on three levels of inputs, of which the first two are considered observable and the last
unobservable, that may be used to measure fair value which are the following:</span></p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Level
1 - &#160;&#160;quoted prices (unadjusted) in active markets for identical assets or liabilities;</span></p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Level
2 - observable inputs other than Level 1, quoted prices for similar assets or liabilities in active markets, quoted prices for
identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable
or whose significant value drivers are observable; and</span></p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Level
3 - &#160;&#160;assets and liabilities whose significant value drivers are unobservable by little or no market activity and that
are significant to the fair value of the assets or liabilities.</span></p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
book value of cash and cash equivalents and accounts payable and accrued liabilities approximate their fair values due to the
short-term maturity of those instruments.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">At
December 31, 2020 and September 30, 2020, the Company did not have any Level 3 assets or liabilities.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Basic
and Diluted Loss per Share</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Basic
income/(loss) per common share is computed by dividing net income/(loss) available to common stockholders by the weighted average
number of common shares outstanding during the period. Diluted income/(loss) per common share is computed by dividing net income/(loss)
available to common stockholders by the sum of (1) the weighted-average number of common shares outstanding during the period,
(2) the dilutive effect of the assumed exercise of options and warrants using the treasury stock method and (3) the dilutive effect
of other potentially dilutive securities. For purposes of the diluted net loss per share calculation, options and warrants are
potentially dilutive securities and are excluded from the calculation of diluted net loss per share because their effect would
be anti-dilutive.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
of December 31, 2020, loss per share excludes <span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pii_c20201001__20201231_z2hbCbPRj5I5" title="Loss per share for potentially dilutive common shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2020-10-01to2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,801,266</ix:nonFraction></span> (September 30, 2020 &#8211; <span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pii_c20191001__20200930_z5wMgNEZYDLk" title="Loss per share for potentially dilutive common shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2019-10-012020-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,576,266</ix:nonFraction></span>) potentially dilutive common shares
related to outstanding options and warrants, as their effect was anti-dilutive.</span></p>

<ix:exclude><p id="xdx_23C_zsAb56T7XML" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 00 -->
    <div id="xdx_23B_zAiucDssPkWh" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_234_zvQzA0C8Uo5h" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td><td id="xdx_232_zjsqtjGF3Fb3" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23E_z6VRwFkV9419" style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_235_zETYaaFAPMOl" style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_237_zFUQKXvHXoHh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-10-01to2020-12-31" escape="true" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"><p id="xdx_80F_eus-gaap--NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_zawa9YYWxJRc" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">Note
2&#9;&#160;&#160;&#160;&#160;&#160;<span style="text-decoration: underline"><span id="xdx_826_zF0lfF6c7mYi">Recent Accounting Pronouncements</span></span></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2020-10-01to2020-12-31" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zB6lChZMEpAj" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Recent
Accounting Pronouncements Not Yet Adopted</i></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company does not expect the adoption of recently issued accounting pronouncements to have a significant impact on its results
of operations, financial position or cash flow.</span></p>



<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2020-10-01to2020-12-31" escape="true" name="avxl:OtherIncomeDisclosureTextBlock"><p id="xdx_80E_ecustom--OtherIncomeDisclosureTextBlock_zEeMucGadMU" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">Note
3&#9;&#160;&#160;&#160;&#160;&#160;<span style="text-decoration: underline"><span id="xdx_826_zGYW3F5d6vO2">Other Income</span> </span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Grant
Income</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">During
the year ended September 30, 2017, the Company was awarded grant funding in the amount of $<span id="xdx_904_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20161001__20170930_zAYd3rsxJrU5" title="Grant income"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrant" contextRef="From2016-10-012017-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">597,886</ix:nonFraction></span>. The grant was received in
equal quarterly installments over a period of two years ending during the year ended September 30, 2020, in exchange for a commitment
to complete clinical testing for a therapeutic drug candidate for the treatment of Rett syndrome.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
grant income was deferred when received and amortized to other income as the related research and development expenditures were
incurred. The Company recognized $<span id="xdx_90E_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20191001__20191231_zoQoFvKawjja" title="Grant income"><ix:nonFraction name="avxl:NonOperatingIncomeFromGrant" contextRef="From2019-10-012019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">74,944</ix:nonFraction></span> of this grant on its statement of operations within grant income during the three-month
period ended December 31, 2019.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Research
and development incentive income</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Research
and development incentive income represents the receipt by the Company&#8217;s Australian subsidiary, of the Australian research
and development incentive credit, (the &#8220;ATO R&amp;D Credit&#8221;).</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">During
the three months ended December 31, 2020, the Company recorded research and development incentive income of $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20201001__20201231_zxnVKxfSO0Kf" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2020-10-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,269,316</ix:nonFraction></span> (AUD <span id="xdx_909_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20201001__20201231__srt--CurrencyAxis__currency--AUD_z2lnXGvYJpM8" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2020-10-012020-12-31_currency_AUD" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,735,962</ix:nonFraction></span>)
(2019: $<span id="xdx_90A_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20191001__20191231_pp0p0" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2019-10-012019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">943,215</ix:nonFraction></span> (AUD <span id="xdx_902_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20191001__20191231__srt--CurrencyAxis__currency--AUD_pp0p0" title="Research and development incentive income"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" contextRef="From2019-10-012019-12-31_currency_AUD" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,345,000</ix:nonFraction></span>)) in respect of the ATO R&amp;D Credit for eligible research and development expenses incurred
during the period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:exclude><!-- Field: Page; Sequence: 00 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-10-01to2020-12-31" escape="true" name="avxl:EquityOfferingAgreementsTextBlock"><p id="xdx_80A_ecustom--EquityOfferingAgreementsTextBlock_zB5zLH6eluZ1" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Note
4&#9;&#160;&#160;&#160;&#160;&#160;<span style="text-decoration: underline"><span id="xdx_828_zMuukJ5RA2ac">Equity Offering Agreements</span></span> </span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">2019
Purchase Agreement</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
June 7, 2019, the Company entered into a $<span id="xdx_90D_ecustom--ValueOfSharesObligatedToPurchase_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pp0p0"><ix:nonFraction name="avxl:ValueOfSharesObligatedToPurchase" contextRef="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,000,000</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">purchase agreement (the &#8220;2019 Purchase
Agreement&#8221;) with Lincoln Park, as amended on July 1, 2020 , pursuant to which the Company had the right to sell and issue
to Lincoln Park, and Lincoln Park was obligated to purchase, up to $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pp0p0_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z9m79178NJbl"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,000,000</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">in value of its shares of common stock
from time to time from June 12, 2019, the date a prospectus supplement under which shares of common stock issuable under the 2019
Purchase Agreement was filed with the SEC, until such date as the Company directed Lincoln Park to purchase the $50,000,000 aggregate
commitment, or July 1, 2022.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
consideration for entering into the 2019 Purchase Agreement, the Company issued to Lincoln Park <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pii" title="Number of share issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">324,383</ix:nonFraction></span> shares of common stock
as a commitment fee and agreed to issue up to <span id="xdx_90D_ecustom--NumberOfSharesObligatedToPurchaseProrataBasic_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pii" title="Pro rata basic number of shares obligated to purchase"><ix:nonFraction name="avxl:NumberOfSharesObligatedToPurchaseProrataBasic" contextRef="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">162,191</ix:nonFraction></span> shares pro rata, when and if, Lincoln Park purchased at the Company&#8217;s
discretion the $50,000,000 aggregate commitment.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the three months ended December 31, 2020, the Company issued to Lincoln Park an aggregate of <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pii_c20201001__20201231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zrJr9MScFf6i" title="Number of share issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2020-10-012020-12-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,402,930</ix:nonFraction></span> (2019 &#8211; <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pii_c20191001__20191231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z7dEUyxfYHRf" title="Number of share issued"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2019-10-012019-12-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,429,835</ix:nonFraction></span>)
shares of common stock under the 2019 Purchase Agreement, including <span id="xdx_904_ecustom--StockIssuedDuringPeriodSharesNewIssues4_pii_c20201001__20201231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zTxlBsFnslhi" title="Number of shares issued for aggregate purchase price"><ix:nonFraction name="avxl:StockIssuedDuringPeriodSharesNewIssues4" contextRef="From2020-10-012020-12-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,346,288</ix:nonFraction></span> (2019: <span id="xdx_901_ecustom--StockIssuedDuringPeriodSharesNewIssues4_pii_c20191001__20191231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zbrComGf8ARd" title="Number of shares issued for aggregate purchase price"><ix:nonFraction name="avxl:StockIssuedDuringPeriodSharesNewIssues4" contextRef="From2019-10-012019-12-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,394,160</ix:nonFraction></span>) shares of common stock for an
aggregate purchase price of $<span id="xdx_903_ecustom--StockIssuedDuringPeriodValueNewIssues3_c20201001__20201231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pp0p0" title="Number of shares issued for aggregate purchase price, value"><ix:nonFraction name="avxl:StockIssuedDuringPeriodValueNewIssues3" contextRef="From2020-10-012020-12-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">17,461,402</ix:nonFraction></span> (2019: $<span id="xdx_907_ecustom--StockIssuedDuringPeriodValueNewIssues3_pp0p0_c20191001__20191231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z8cCkKGRDvb8" title="Number of shares issued for aggregate purchase price, value"><ix:nonFraction name="avxl:StockIssuedDuringPeriodValueNewIssues3" contextRef="From2019-10-012019-12-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,997,952</ix:nonFraction></span>) and <span id="xdx_90C_ecustom--StockIssuedDuringPeriodSharesNewIssues3_c20201001__20201231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pii" title="Number of shares issued for commitment"><ix:nonFraction name="avxl:StockIssuedDuringPeriodSharesNewIssues3" contextRef="From2020-10-012020-12-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">56,642</ix:nonFraction></span> (2019: <span id="xdx_903_ecustom--StockIssuedDuringPeriodSharesNewIssues3_pii_c20191001__20191231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zSrUgxwg1tqe" title="Number of shares issued for commitment"><ix:nonFraction name="avxl:StockIssuedDuringPeriodSharesNewIssues3" contextRef="From2019-10-012019-12-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">35,675</ix:nonFraction></span>) commitment shares. At December 31, 2020,
an amount of $<span id="xdx_902_ecustom--StockIssuedDuringPeriodValueNewIssues4_c20201001__20201231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pp0p0" title="Amount of shares remain available"><ix:nonFraction name="avxl:StockIssuedDuringPeriodValueNewIssues4" contextRef="From2020-10-012020-12-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,649,794</ix:nonFraction></span> (September 30, 2020: $<span id="xdx_905_ecustom--StockIssuedDuringPeriodValueNewIssues4_pp0p0_c20191001__20191231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zqBUCxvbdDaf" title="Amount of shares remain available"><ix:nonFraction name="avxl:StockIssuedDuringPeriodValueNewIssues4" contextRef="From2019-10-012019-12-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">24,111,197</ix:nonFraction></span>) remained available under the 2019 Purchase Agreement.</span></p>

<ix:exclude><p id="xdx_23C_zYgA0bXjV8R3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 00 -->
    <div id="xdx_23C_zfpZyGW3l75h" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_231_zdOGrh6SQmcf" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td><td id="xdx_238_zlRtrWWrSmLf" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_238_z9zBpy1ekCT9" style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_23A_zUXSereH5Z4f" style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_231_zBuGd8JppKp6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_232_zbfRmArM6a3g" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">Note
4&#9;&#160;&#160;&#160;&#160;&#160;<span style="text-decoration: underline">Equity Offering Agreements </span>&#8211; (Continued)</span></p></ix:exclude>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Sales
Agreement</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company entered into a Controlled Equity Offering Sales Agreement on July 6, 2018, which was amended and restated on May 1, 2020
(the &#8220;Sales Agreement&#8221;) with Cantor Fitzgerald&#160;&amp; Co. and SVB Leerink LLC (together the &#8220;Sales Agents&#8221;),
pursuant to which the Company may offer and sell shares of common stock registered under an effective registration statement from
time to time through the Sales Agents (the &#8220;Offering&#8221;).&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Upon
delivery of a placement notice based on the Company&#8217;s instructions and subject to the terms and conditions of the Sales
Agreement, the Sales Agents may sell the Shares by methods deemed to be an &#8220;at the market offering&#8221; offering, in negotiated
transactions at market prices prevailing at the time of sale or at prices related to such prevailing market prices, or by any
other method permitted by law, including negotiated transactions, subject to the prior written consent of the Company. The Company
is not obligated to make any sales of Shares under the Sales Agreement. The Company or Sales Agents may suspend or terminate the
offering of Shares upon notice to the other party, subject to certain conditions.&#160; The Sales Agents will act as agent on
a commercially reasonable efforts basis consistent with their normal trading and sales practices and applicable state and federal
law, rules&#160;and regulations and the rules&#160;of Nasdaq.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company has agreed to pay the Sales Agents commissions for their services of up to <span id="xdx_90B_ecustom--PercentageOfGrossProceedsFromSales_c20201001__20201231__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pii" title="Percentage of gross proceeds from sales"><ix:nonFraction name="avxl:PercentageOfGrossProceedsFromSales" contextRef="From2020-10-012020-12-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.0</ix:nonFraction>%</span> of the gross proceeds from the sale of
the Shares pursuant to the Sales Agreement.&#160; The Company also agreed to provide the Sales Agents with customary indemnification
and contribution rights. During the three months ended December 31, 2020, <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pii_c20201001__20201231__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_z4yBKQ40fH16" title="Share issued for offering, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2020-10-012020-12-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,514,829</ix:nonFraction></span> shares were sold pursuant to the Offering
for gross proceeds of $<span id="xdx_909_ecustom--GrossProceedsFromSaleOfCommonStock_c20201001__20201231__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zLFv1c37d7a7" title="Gross proceeds from sale of common stock"><ix:nonFraction name="avxl:GrossProceedsFromSaleOfCommonStock" contextRef="From2020-10-012020-12-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,782,017</ix:nonFraction></span> (net proceeds of $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pii_c20201001__20201231__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_z75SIQjjvBAb" title="Proceed from offering"><span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20201001__20201231__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zQbabuPih1Q1"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2020-10-012020-12-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2020-10-012020-12-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,518,557</ix:nonFraction></ix:nonFraction></span></span> after deducting offering expenses). At December 31, 2020, an amount
of $<span id="xdx_907_ecustom--StockIssuedDuringPeriodValueNewIssues4_pp0p0_c20201001__20201231__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zeYGDf5g3cR9" title="Amount of shares remain available"><ix:nonFraction name="avxl:StockIssuedDuringPeriodValueNewIssues4" contextRef="From2020-10-012020-12-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">33,718,084</ix:nonFraction></span> (September 30, 2020: $<span id="xdx_909_ecustom--StockIssuedDuringPeriodValueNewIssues4_pp0p0_c20191001__20200930__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zfkOGPWM23Wc" title="Amount of shares remain available"><ix:nonFraction name="avxl:StockIssuedDuringPeriodValueNewIssues4" contextRef="From2019-10-012020-09-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">42,500,100</ix:nonFraction></span>) remained registered under the Company&#8217;s effective shelf registration
statement and available to be offered and sold in the Offering.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2020-10-01to2020-12-31" escape="true" name="us-gaap:CommitmentsDisclosureTextBlock"><p id="xdx_80E_eus-gaap--CommitmentsDisclosureTextBlock_zbvqLma7Cab1" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">Note
5 &#9;&#160;&#160;&#160;&#160;&#160;<span style="text-decoration: underline"><span id="xdx_822_zEzYUFIn54D4">Commitments</span> </span></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.75pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">a)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">Leases
                                         </span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; color: gray"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">During
the three months ended December 31, 2020, the Company incurred office lease expense of $<span id="xdx_901_eus-gaap--LeaseAndRentalExpense_c20201001__20201231_pp0p0" title="Lease expense"><ix:nonFraction name="us-gaap:LeaseAndRentalExpense" contextRef="From2020-10-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">68,387</ix:nonFraction></span> (2019: $<span id="xdx_900_eus-gaap--LeaseAndRentalExpense_c20191001__20191231_pp0p0" title="Lease expense"><ix:nonFraction name="us-gaap:LeaseAndRentalExpense" contextRef="From2019-10-012019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,054</ix:nonFraction></span>).</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.75pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">b)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">Litigation</span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; color: gray"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">The
Company is subject to claims and legal proceedings that arise in the ordinary course of business. Such matters are inherently
uncertain, and there can be no guarantee that the outcome of any such matter will be decided favorably to the Company or that
the resolution of any such matter will not have a material adverse effect upon the Company's consolidated financial statements.
The Company does not believe that any of such pending claims and legal proceedings will have a material adverse effect on its
consolidated financial statements.</span></p>

<ix:exclude><p id="xdx_23F_zy2JBHaI0Hn4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<ix:exclude><!-- Field: Page; Sequence: 00 -->
    <div id="xdx_23A_zvuYop1GB5Ql" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_239_zns3J78UhVk6" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td><td id="xdx_239_zICVcwU8kdmg" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23A_z4Sd8tVzpiYc" style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_236_zrb9WpO96r7f" style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_235_z7Og6HgKZLw" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_233_zWR7eDAawXQ1" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">Note
5&#9;&#160;&#160;&#160;&#160;&#160;<span style="text-decoration: underline">Commitments </span>&#8211; (Continued)</span></p></ix:exclude>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; color: gray"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.75pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">c)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">Share
                                         Purchase Warrants</span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 58.5pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">A
summary of the status of the Company&#8217;s outstanding share purchase warrants is presented below:</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"></p>

<ix:nonNumeric contextRef="From2020-10-01to2020-12-31" escape="true" name="us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_zkUdaD0EO4L5" summary="xdx: Disclosure - Commitments (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: left"><span id="xdx_8B4_zAas41cfHNY6" style="display: none">Schedule of exercisable share purchase warrants outstanding</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Number
    of Shares</b></span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted</b></span></p>
                                                           <p style="margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Average</b></span></p>
                                                           <p style="margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exercise
                                         Price</b></span></p>
                                                           <p style="margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>($)</b></span></p></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 26%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Balance,
                                         September 30, 2019</span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pii_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zgpKvn2g3U29" title="Share Purchase Warrants Balance, at beginning" style="width: 26%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2019-09-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_z12EXHH5wlql" title="Weighted Average Exercise Price Balance, at beginning" style="width: 26%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2019-09-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.19</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Granted</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_pii_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zD4KMttUzjs2" title="Share Purchase Warrants Granted" style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" contextRef="From2019-10-012020-09-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">150,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_pii_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zOIcTJGf6Eg3" title="Weighted Average Exercise Price Granted" style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" contextRef="From2019-10-012020-09-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.17</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Balance, September
                                                                                                                                 30, 2020 and December 31, 2020</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pii_c20201001__20201231__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zEoc0LS7ftif" title="Share Purchase Warrants Balance, at beginning" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2020-09-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20201001__20201231__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zCNxEAjaibJi" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-09-30_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.88</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="display: none; padding-bottom: 1pt; text-align: left">&#160;</td><td style="display: none; padding-bottom: 1pt; text-align: left"><p style="display: none; margin-top: 0; margin-bottom: 0">Granted&#160;</p></td><td style="display: none; padding-bottom: 1pt; text-align: left">&#160;</td><td style="display: none; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; display: none; text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_pii_d0_c20201001__20201231__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zPapjFg1Zze4" title="Share Purchase Warrants Granted" style="border-bottom: Black 1pt solid; display: none; text-align: right"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" contextRef="From2020-10-012020-12-31_custom_PurchaseWarrantsMember" format="ixt:zerodash" decimals="INF" sign="-" unitRef="Shares">-</ix:nonFraction></td><td style="display: none; padding-bottom: 1pt; text-align: left">&#160;</td><td style="display: none; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; display: none; text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_pii_c20201001__20201231__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zLx7EkHnlDtc" style="border-bottom: Black 1pt solid; display: none; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0408">-</span></td><td style="display: none; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="display: none; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="display: none; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif; display: none">Balance, September
                                                                                                                                 30, 2020 And December 31, 2020</span></td><td style="display: none; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="display: none; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pii_c20201001__20201231__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zEh7QVXxtRz6" title="Share Purchase Warrants Balance, at ending" style="border-bottom: Black 2.5pt double; display: none; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif; display: none"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2020-12-31_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500,000</ix:nonFraction></span></td><td style="display: none; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="display: none; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20201001__20201231__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zfXdqFEMA4Cj" title="Weighted Average Exercise Price Balance, at ending" style="border-bottom: Black 2.5pt double; display: none; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif; display: none"><ix:nonFraction name="avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_custom_PurchaseWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.88</ix:nonFraction></span></td><td style="display: none; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif; display: none">&#160;</span></td></tr>
</table>


</ix:nonNumeric><p id="xdx_8A1_zAUdHTujm65e" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>



<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0pt 58.5pt; text-align: justify; text-indent: -0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">At
December 31, 2020, the Company had share purchase warrants outstanding as follows:</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify; text-indent: -0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"></p>

<ix:nonNumeric contextRef="From2020-10-01to2020-12-31" escape="true" name="avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_z3rcRMOw98h7" summary="xdx: Disclosure - Commitments (Details 1)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: left"><span id="xdx_8B8_zNseOy8SObC" style="display: none">Schedule of share purchase warrants outstanding</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Number</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Exercise
    Price</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Expiry
    Date</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20201231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pii" title="Number" style="width: 10%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2020-12-31_custom_PurchaseWarrants1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20201231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pii" title="Exercise Price" style="width: 10%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_custom_PurchaseWarrants1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.19</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 45%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20201231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zES9VgNb277" title="Expiry date"><ix:nonNumeric contextRef="AsOf2020-12-31_custom_PurchaseWarrants1Member" format="ixt:datemonthdayyearen" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">June 30, 2021</ix:nonNumeric></span></span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20201231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pii" title="Number" style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2020-12-31_custom_PurchaseWarrants2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">150,000</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20201231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pii" title="Exercise Price" style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_custom_PurchaseWarrants2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.17</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20201231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_zuKfmMumvdFi"><ix:nonNumeric contextRef="AsOf2020-12-31_custom_PurchaseWarrants2Member" format="ixt:datemonthdayyearen" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">May 6, 2024</ix:nonNumeric></span></span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20201231_pii" title="Number" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">500,000</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>


</ix:nonNumeric><p id="xdx_8A1_zQfAD7HHKkCj" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.75pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">d)</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Stock&#8211;based
                                         Compensation Plan</span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">2015
Stock Option Plan</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>



<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
September 18, 2015, the Company&#8217;s board of directors approved a 2015 Omnibus Incentive Plan (the &#8220;2015 Plan&#8221;),
which provided for the grant of stock options and restricted stock awards to directors, officers, employees and consultants of
the Company.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
maximum number of our common shares reserved for issue under the plan was <span id="xdx_900_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_c20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" title="Maximum number of common shares reserved for future issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2020-12-31_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,050,553</ix:nonFraction></span> shares, subject to adjustment in the event
of a change of the Company&#8217;s capitalization. At December 31, 2020, <span id="xdx_90E_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pii_c20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--OptionsMember_z5QYNkLiWrwa" title="Maximum number of common shares reserved for future issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2020-12-31_custom_StockOptionPlan2015Member_custom_OptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">146,371</ix:nonFraction></span> (September 30, 2020: <span id="xdx_909_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pii_c20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--OptionsMember_zvfECJ0lQCmj" title="Maximum number of common shares reserved for future issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2020-09-30_custom_StockOptionPlan2015Member_custom_OptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">146,371</ix:nonFraction></span>) options remain
available for issue under the 2015 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:exclude><!-- Field: Page; Sequence: 00 -->
    <div id="xdx_23B_z0uB31vva6tl" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_237_zWy9PTfwHt8h" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td><td id="xdx_239_zHVR2TSOGHJc" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_237_zVzRvhxiNaxf" style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_235_zQ1ONQHy9Wic" style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23E_zkeD4dvAJko5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_237_z2jEkMfEshM6" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">Note
5&#9;&#160;&#160;&#160;&#160;&#160;<span style="text-decoration: underline">Commitments </span>&#8211; (Continued)</span></p></ix:exclude>

<ix:exclude><p id="xdx_239_zA3pc9sRkDPl" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<ix:exclude><table cellpadding="0" cellspacing="0" id="xdx_231_za2Fh2pbNfal" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.75pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">d)</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Stock-based
                                         Compensation Plan &#8211; (Continued)</span></td></tr></table></ix:exclude>

<ix:exclude><p id="xdx_232_zzPe3tACFRS6" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">2019
Stock Option Plan</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
January 15, 2019, the Board approved the 2019 Omnibus Incentive Plan (the &#8220;2019 Plan&#8221;), which provides for the grant
of stock options and restricted stock awards to directors, officers, employees, consultants and advisors of the Company. Under
the terms of the 2019 Plan, <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20201001__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_pii" title="Additional shares of common stock available for issuance"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="From2020-10-012020-12-31_custom_StockOptionPlan2019Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,000,000</ix:nonFraction></span> additional shares of Common Stock are available for issuance under the 2019 Plan, in addition
to the shares available under the 2015 Plan. Any awards outstanding under the 2015 Plan or the Company&#8217;s 2007 Stock Option
Plan (the &#8220;2007 Plan&#8221;) will remain subject to and be paid under the 2015 Plan or the 2007 Plan, respectively, and
any shares subject to outstanding awards under the 2015 Plan or the 2007 Plan that subsequently cease to be subject to such awards
(other than by reason of settlement of the awards in shares) will automatically become available for issuance under the 2019 Plan.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
2019 Plan provides that it may be administered by the Board, or the Board may delegate such responsibility to a committee. <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20201001__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member" title="Description of grant option"><ix:nonNumeric contextRef="From2020-10-012020-12-31_custom_StockOptionPlan2019Member" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">The
exercise price will be determined by the board of directors at the time of grant shall be at least equal to the fair market
value on such date. If the grantee is a 10% stockholder on the grant date, then the exercise price shall not be less than
110% of fair market value of the Company&#8217;s shares of common stock on the grant date.</ix:nonNumeric></span> Stock options may be
granted under the 2019 Plan for an exercise period of up to ten <span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dtY_c20201001__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_z8HO18wFsTid" title="Expiration period" style="display: none"><ix:nonNumeric contextRef="From2020-10-012020-12-31_custom_StockOptionPlan2019Member" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">10</ix:nonNumeric></span> years from the date of grant of the option or such lesser
periods as may be determined by the board, subject to earlier termination in accordance with the terms of the 2019 Plan. At
December 31, 2020, <span id="xdx_902_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pii_c20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_ziByfxBYEcZ7" title="Maximum number of common shares reserved for future issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2020-12-31_custom_StockOptionPlan2019Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,936,665</ix:nonFraction></span> (September 30, 2020: <span id="xdx_90E_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pii_c20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_zyoJmtleP3n4" title="Maximum number of common shares reserved for future issuance"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="AsOf2020-09-30_custom_StockOptionPlan2019Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,161,665</ix:nonFraction></span>) options remain available for issue under the 2019
Plan.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">A
summary of the status of Company&#8217;s outstanding stock purchase options is presented below:</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"></p>

<ix:nonNumeric contextRef="From2020-10-01to2020-12-31" escape="true" name="us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_zQ83AOo3Wsk4" summary="xdx: Disclosure - Commitments (Details 2)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8B3_z30bCJkFbRQ2" style="display: none">Schedule of outstanding stock purchase options</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Number
    of Shares</b></span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted
    Average Exercise Price ($)</b></span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted
    </b><br /><b>Average </b><br /><b>Grant Date </b><br /><b>Fair Value ($)</b></span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Aggregate
    </b><br /><b>intrinsic </b><br /><b>value ($)</b></span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 49%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Outstanding,
    September 30, 2019</span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zRluj2hFaNn4" title="Options Outstanding at beginning" style="width: 10%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2019-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,462,933</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zG1zRQRfJ9nk" title="Weighted Average Exercise Price Outstanding at beginning" style="width: 10%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2019-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.58</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 10%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zwrFMVqhACi4" title="Aggregate intrinsic value Outstanding at beginning" style="text-align: right; width: 10%"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2019-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,115,032</ix:nonFraction></span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Granted</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zYDhSO5E6rgj" title="Options Granted" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2019-10-012020-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,695,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" title="Weighted Average Exercise Price Granted" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2019-10-012020-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.96</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zTXoYceDOcA8" title="Weighted Average Grant Date Fair Value Granted" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2019-10-012020-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.27</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td></td><td></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Forfeited</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pii_di_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zdhsTfjeaaK6" title="Options Forfeited" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2019-10-012020-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">68,332</ix:nonFraction></span></td><td style="text-align: left">)</td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" title="Weighted Average Exercise Price Forfeited" style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2019-10-012020-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.01</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td></td><td></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Exercised</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pii_di_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zuBTOBMvg9v2" title="Option Exercised" style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2019-10-012020-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,335</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" title="Weighted Average Exercise Price Exercised" style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2019-10-012020-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.15</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td></td><td style="border-bottom: Black 1pt solid"></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Outstanding,
    September 30, 2020</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20201001__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z9VnCIB1mldj" title="Options Outstanding at beginning" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,076,266</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20201001__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zXiuyUGbwmEc" title="Weighted Average Exercise Price Outstanding at beginning" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.48</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20201001__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zbEd1Q1eVc0k" title="Aggregate intrinsic value Outstanding at beginning" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2020-09-30_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">14,982,581</ix:nonFraction></span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Granted</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_c20201001__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z0ppO71T5UY2" title="Options Granted" style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2020-10-012020-12-31_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,225,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20201001__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" title="Weighted Average Exercise Price Granted" style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2020-10-012020-12-31_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.49</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_c20201001__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zGWAAq1VABzk" title="Weighted Average Grant Date Fair Value Granted" style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2020-10-012020-12-31_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.16</ix:nonFraction></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td></td><td></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Outstanding,
    December 31, 2020</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pii_c20201001__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zHiaRYRbvUOg" title="Options Outstanding at ending" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-12-31_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,301,266</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20201001__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zcwxqrZBq3L9" title="Weighted Average Exercise Price Outstanding at ending" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.69</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20201001__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zvwDGiJXDNUl" title="Aggregate intrinsic value Outstanding at ending" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2020-12-31_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">21,622,986</ix:nonFraction></span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Exercisable,
    December 31, 2020</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zEKTySVmpVuk" title="Options Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2020-12-31_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,540,018</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zF0445Jcte8g" title="Weighted Average Exercise Price, Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.64</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zK6C3LbNdaJl" title="Aggregate intrinsic value Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2020-12-31_custom_StockOptionPlan2015Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">15,482,966</ix:nonFraction></span></td></tr>
</table>


</ix:nonNumeric><p id="xdx_8AD_z2TNSdglgbgl" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted market
price of the Company&#8217;s stock for the options that were in-the-money at December 31, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:exclude><!-- Field: Page; Sequence: 00 -->
    <div id="xdx_235_z79ONuwcWpRb" style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_23F_z9ORCJMgFtta" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td><td id="xdx_236_zBOfmtizLxak" style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23C_z9oMOHYuCtdk" style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p id="xdx_232_ziZlvqsdF2ol" style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23B_zF3Vwiz2HLWh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<ix:exclude><p id="xdx_23D_zIFa2Z8lHY0g" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">Note
5&#9;&#160;&#160;&#160;&#160;&#160;<span style="text-decoration: underline">Commitments </span>&#8211; (Continued)</span></p></ix:exclude>

<ix:exclude><p id="xdx_234_zOBQDH6Pwode" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<ix:exclude><table cellpadding="0" cellspacing="0" id="xdx_230_zdxqPyw0Fyg" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.75pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">d)</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Stock-based
                                         Compensation Plan &#8211; (Continued)</span></td></tr></table></ix:exclude>

<ix:exclude><p id="xdx_23A_zaoGonTYG6Y6" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></ix:exclude>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the three months ended December 31, 2020, the Company recognized stock-based compensation expense of $<span id="xdx_900_eus-gaap--ShareBasedCompensation_c20201001__20201231_pp0p0" title="Stock-based compensation expense"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-10-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">939,314</ix:nonFraction></span> (2019: $<span id="xdx_901_eus-gaap--ShareBasedCompensation_c20191001__20191231_pp0p0" title="Stock-based compensation expense"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2019-10-012019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,264,424</ix:nonFraction></span>)
in connection with the issuance and vesting &#9;of stock options and warrants in exchange for services. These amounts have been
included in general and &#9;administrative expenses and research and development expenses on the Company&#8217;s statement of
&#9;operations as follows:</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"></p>

<ix:nonNumeric contextRef="From2020-10-01to2020-12-31" escape="true" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zjfVdEfcVdmf" summary="xdx: Disclosure - Commitments (Details 3)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span id="xdx_8B7_zmRwDlcCoC2a" style="display: none">Schedule of general and administrative expenses and research and development expenses</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2020</b></span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2019</b></span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 45%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">General
    and administrative</span></td><td style="width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" title="Total share based compensation" style="width: 10%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-10-012020-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">422,823</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_c20191001__20191231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" title="Total share based compensation" style="width: 10%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2019-10-012019-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">481,101</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Research
    and development</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" title="Total share based compensation" style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-10-012020-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">516,491</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_c20191001__20191231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" title="Total share based compensation" style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2019-10-012019-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">783,323</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Total
    share based compensation</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20201231_pp0p0" title="Total share based compensation" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-10-01to2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">939,314</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_c20191001__20191231_pp0p0" title="Total share based compensation" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2019-10-012019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,264,424</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>


</ix:nonNumeric><p id="xdx_8AB_zXmajV4ska21" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0 63.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">An
amount of approximately $<span id="xdx_904_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pp0p0_c20201231_zALuO9cPrmV9" title="Remaining stock based compensation"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,185,000</ix:nonFraction></span> in stock-based compensation is expected to be recorded over the remaining term &#9;of such
options through fiscal 2023.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0 63.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0 63.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
fair value of each option award granted during the three months ended December 31, 2020 and 2019 is estimated on the date of grant
using the Black Scholes option pricing model based on the following weighted average assumptions:</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<ix:nonNumeric contextRef="From2020-10-01to2020-12-31" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zDvhjoWkbkja" summary="xdx: Disclosure - Commitments (Details 4)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8B4_z2vwROq8pDac" style="display: none">Schedule of weighted average assumptions for fair value of each option award</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2020</b></span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2019</b></span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 45%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Risk-free
    interest rate</span></td><td style="width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 10%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_c20201001__20201231_zyp1NGTe3ZM3" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2020-10-01to2020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.62</ix:nonFraction></span></span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">%</span></td><td style="width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 10%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_c20191001__20191231_zgNCsM05hm9h" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2019-10-012019-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.88</ix:nonFraction></span></span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">%</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Expected life of options
    (years)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20201001__20201231_zEP40vMBknfa" title="Expected life of options (years)"><ix:nonNumeric contextRef="From2020-10-01to2020-12-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.59</ix:nonNumeric></span></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20191001__20191231_zfuRzahAtwHj" title="Expected life of options (years)"><ix:nonNumeric contextRef="From2019-10-012019-12-31" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.21</ix:nonNumeric></span></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Annualized volatility</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_c20201001__20201231_zFoqecu8LOl7" title="Annualized volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2020-10-01to2020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">96.16</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">%</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_c20191001__20191231_zZdeGvsA4Mz6" title="Annualized volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2019-10-012019-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">101.60</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">%</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Dividend rate</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_dp_c20201001__20201231_zgZNCxhfwSMb" title="Dividend rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2020-10-01to2020-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">%</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_dp_c20191001__20191231_z3Ix7rYAIo07" title="Dividend rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2019-10-012019-12-31" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></span></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">%</span></td></tr>
</table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0 63.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2020-10-01to2020-12-31" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_805_eus-gaap--SubsequentEventsTextBlock_znyQNgALn8Lg" style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt"><span style="font: 10pt Times New Roman, Times, Serif">Note
6&#9;&#160;&#160;&#160;&#160;&#160;<span id="xdx_829_z7Yfmp9MvN7d"><span style="text-decoration: underline">Subsequent Events</span></span></span></p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">Subsequent to December 31,
2020;</p>

<p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 11pt/106% Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.55pt"></td><td style="width: 18pt"><span style="font-size: 10pt">a)</span></td><td style="text-align: justify"><span style="font-size: 10pt">the Company received $<span id="xdx_904_ecustom--GrantReceived_c20210101__20210211__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MichaelJFoxFoundationMember_z5NUEPoSiFO4" title="Grant received"><ix:nonFraction name="avxl:GrantReceived" contextRef="From2021-01-012021-02-11_us-gaap_SubsequentEventMember_custom_MichaelJFoxFoundationMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">497,931</ix:nonFraction></span> of a $<span id="xdx_903_ecustom--TotalGrant_c20210101__20210211__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MichaelJFoxFoundationMember_zcV8a2sHcyTa" title="Total grant"><ix:nonFraction name="avxl:TotalGrant" contextRef="From2021-01-012021-02-11_us-gaap_SubsequentEventMember_custom_MichaelJFoxFoundationMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">995,862</ix:nonFraction></span> research grant awarded
by the Michael J. Fox Foundation for Parkinson's Research. The grant will be used to fund a clinical trial in the Company's lead
compound, ANAVEX<sup>&#174;</sup>2-73 for the treatment of Parkinson's disease.</span></td></tr></table>

<p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 0 60.55pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 11pt/106% Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.55pt"></td><td style="width: 18pt"><span style="font-size: 10pt">b)</span></td><td style="text-align: justify"><span style="font-size: 10pt">the Company issued  <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pii_c20210101__20210211__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zt5c7WpwRRk3" title="Share issued for offering, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-01-012021-02-11_us-gaap_SubsequentEventMember_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">683,279</ix:nonFraction></span> shares
of common stock under the 2019 Purchase Agreement, including <span id="xdx_90A_ecustom--StockIssuedDuringPeriodSharesNewIssues4_pii_c20210101__20210211__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zUhmnfm0ZkW1" title="Number of shares issued for aggregate purchase price"><ix:nonFraction name="avxl:StockIssuedDuringPeriodSharesNewIssues4" contextRef="From2021-01-012021-02-11_us-gaap_SubsequentEventMember_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">661,708</ix:nonFraction></span> shares of common stock for an aggregate purchase price of
$<span id="xdx_901_ecustom--StockIssuedDuringPeriodValueNewIssues3_pii_c20210101__20210211__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z53G7fcR0Ogf" title="Number of shares issued for aggregate purchase price"><ix:nonFraction name="avxl:StockIssuedDuringPeriodValueNewIssues3" contextRef="From2021-01-012021-02-11_us-gaap_SubsequentEventMember_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,649,782</ix:nonFraction></span> and <span id="xdx_90F_ecustom--StockIssuedDuringPeriodSharesNewIssues3_pii_c20210101__20210211__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z6XLmh18eVl6" title="Number of shares issued for commitment"><ix:nonFraction name="avxl:StockIssuedDuringPeriodSharesNewIssues3" contextRef="From2021-01-012021-02-11_us-gaap_SubsequentEventMember_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">21,571</ix:nonFraction></span> commitment shares.</span></td></tr></table>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 0 36pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 11pt/106% Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.55pt"></td><td style="width: 18pt"><span style="font-size: 10pt">c)</span></td><td style="text-align: justify"><span style="font-size: 10pt">an aggregate of <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pii_c20210101__20210211__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zZo2FTuhEqV" title="Share issued for offering, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-01-012021-02-11_us-gaap_SubsequentEventMember_custom_SalesAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,841,616</ix:nonFraction></span> shares were sold under the Sales Agreement
for gross proceeds of $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0p0_c20210101__20210211__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_ztYP7YQD4mVe" title="Gross sale proceeds"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2021-01-012021-02-11_us-gaap_SubsequentEventMember_custom_SalesAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">25,893,861</ix:nonFraction></span>.</span></td></tr></table>

</ix:nonNumeric><p id="xdx_815_z47ymWc48ii1" style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>



<!-- Field: Page; Sequence: 00 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-transform: uppercase; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="item2"></span>Item
2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-transform: uppercase; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Forward-Looking
Statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">This
Quarterly Report on Form 10-Q includes forward-looking statements. All statements other than statements of historical facts contained
in this Quarterly Report on Form 10-Q, including statements regarding our anticipated future clinical and regulatory milestone
events, future financial position, business strategy and plans and objectives of management for future operations, are forward-looking
statements. The words &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221;
&#8220;intend,&#8221; &#8220;expect&#8221; &#8220;should,&#8221; &#8220;forecast,&#8221; &#8220;could,&#8221; &#8220;suggest,&#8221;
&#8220;plan&#8221; and similar expressions, as they relate to us, are intended to identify forward-looking statements. Such forward-looking
statements include, without limitation, statements regarding:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">volatility
                                         in our stock and in the markets in general;</span></td></tr>                                                                                                                                                     <tr style="vertical-align: top">
<td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
                                         ability to successfully conduct clinical and preclinical trials for our product candidates;</span></td></tr>
</table>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
                                         ability to raise additional capital on favorable terms and the impact of such activities
                                         on our stockholders and stock price;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
                                         impact of the COVID-19 outbreak and its effect on us;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
                                         ability to generate any revenue or to continue as a going concern;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
                                         ability to execute our research and development plan on time and on budget;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
                                         products ability to demonstrate efficacy or an acceptable safety profile of our product
                                         candidates;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
                                         ability to obtain the support of qualified scientific collaborators;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
                                         ability, whether alone or with commercial partners, to successfully commercialize any
                                         of our product candidates that may be approved for sale;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
                                         ability to identify and obtain additional product candidates;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
                                         reliance on third parties in non-clinical and clinical studies;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
                                         ability to defend against product liability claims;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
                                         ability to safeguard against security breaches;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
                                         ability to obtain and maintain sufficient intellectual property protection for our product
                                         candidates;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
                                         ability to comply with our intellectual property licensing agreements;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
                                         ability to defend against claims of intellectual property infringement;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
                                         ability to comply with the maintenance requirements of the government patent agencies;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
                                         ability to protect our intellectual property rights throughout the world;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">competition;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
                                         anticipated start dates, durations and completion dates of our ongoing and future clinical
                                         studies;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
                                         anticipated designs of our future clinical studies;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
                                         anticipated future regulatory submissions and our ability to receive regulatory approvals
                                         to develop and market our product candidates, including any orphan drug or fast track
                                         designations; and </span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 20.65pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
                                         anticipated future cash position. </span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
have based these forward-looking statements largely on our current expectations and projections about future events, including
the responses we expect from the U.S. Food and Drug Administration, (&#8220;FDA&#8221;), and other regulatory authorities and
financial trends that we believe may affect our financial condition, results of operations, business strategy, preclinical and
clinical trials, and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions
including without limitation the risks described in &#8220;Risk Factors&#8221; in Part I, Item 1A of our Annual Report on Form
10-K filed with the Securities and Exchange Commission on December 28, 2020. These risks are not exhaustive. Other sections of
this Quarterly Report on Form 10-Q include additional factors which could adversely impact our business and financial performance.
Moreover, we operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time and it
is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or
the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained
in any forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. We cannot
assure you that the events and circumstances reflected in the forward-looking statements will be achieved or occur and actual
results could differ materially from those projected in the forward-looking statements. Except as required by applicable laws
including the securities laws of the United States, we assume no obligation to update or supplement forward-looking statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 00 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
used in this Quarterly Report on Form 10-Q, the terms &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; and &#8220;Anavex&#8221;
mean Anavex Life Sciences Corp., unless the context clearly requires otherwise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our
Current Business</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Anavex
Life Sciences Corp. is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by
applying precision medicine to central nervous system (&#8220;CNS&#8221;) diseases with high unmet need. We analyze genomic data
from clinical studies to identify biomarkers, which we use to select patients that will receive the therapeutic benefit for the
treatment of neurodegenerative and neurodevelopmental diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our
lead compound, ANAVEX<sup>&#174;</sup>2-73, is being developed to treat Alzheimer&#8217;s disease, Parkinson&#8217;s disease and
potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological
monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2 (&#8220;MECP2&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
currently have two core programs and two seed programs. Our core programs are at various stages of clinical and preclinical development,
in neurodegenerative and neurodevelopmental diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">The
following table summarizes key information about our programs:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 9pt Sans-Serif; margin: 0; color: Red"><span style="font: 10pt Times New Roman, Times, Serif"><img src="image_001.jpg" alt="" style="width: 670px; height: 300px" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Anavex
has a portfolio of compounds varying in sigma-1 receptor (S1R) binding activities. The SIGMAR1 gene encodes the S1R protein, which
is an intracellular chaperone protein with important roles in cellular communication. S1R is also involved in transcriptional
regulation at the nuclear envelope and restores homeostasis and stimulates recovery of cell function when activated. In order
to validate the ability of our compounds to activate quantitatively the S1R, we performed, in collaboration with Stanford University,
a quantitative Positron Emission Tomography (PET) imaging scan in mice, which demonstrated a dose-dependent ANAVEX<sup>&#174;</sup>2-73
target engagement or receptor occupancy (RO) with S1R in the brain.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 00 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 9pt Sans-Serif; margin: 0; text-align: justify; color: Red"><span style="font: 10pt Times New Roman, Times, Serif"><img src="image_002.jpg" alt="" style="width: 670px; height: 300px" /></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Cellular
Homeostasis</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Many
diseases are possibly directly caused by chronic homeostatic imbalances or cellular stress of brain cells. In pediatric diseases
like Rett syndrome or infantile spasms, the chronic cellular stress is possibly caused by the presence of a constant genetic mutation.
In neurodegenerative diseases, such as Alzheimer&#8217;s and Parkinson&#8217;s diseases, chronic cellular stress is possibly caused
by age-correlated buildup of cellular insult and hence chronic cellular stress. Specifically, defects in homeostasis of protein
or ribonucleic acid (&#8220;RNA&#8221;) lead to the death of neurons and dysfunction of the nervous system. The spreading of protein
aggregates resulting in a proteinopathy, a characteristic finding in Alzheimer&#8217;s and Parkinson&#8217;s diseases that results
from disorders of protein synthesis, trafficking, folding, processing or degradation in cells. The clearance of macromolecules
in the brain is particularly susceptible to imbalances that result in aggregation and degeneration in nerve cells. For example,
Alzheimer&#8217;s disease pathology is characterized by the presence of amyloid plaques, neurofibrillary tangles, which are aggregates
of hyperphosphorylated Tau protein that are a marker of other diseases known as tauopathies as well as inflammation of microglia.
With the SIGMAR1 activation through SIGMAR1 agonists like ANAVEX<sup>&#174;</sup>2-73, our approach is to restore cellular balance,
i.e. homeostasis. Therapies that correct defects in cellular homeostasis might have the potential to halt or delay neurodevelopmental
and neurodegenerative disease progression.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>ANAVEX</i></b><sup>&#174;</sup><b><i>2-73-specific
Biomarkers</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">A
full genomic analysis of Alzheimer&#8217;s disease (AD) patients treated with ANAVEX<sup>&#174;</sup>2-73 resulted in the identification
of actionable genetic variants. A significant impact of the genomic biomarkers SIGMAR1, the direct target of ANAVEX<sup>&#174;</sup>2-73
and COMT, a gene involved in memory function, on the drug response level was identified, leading to an early ANAVEX<sup>&#174;</sup>2-73-specific
biomarker hypothesis. It is expected that <i>excluding</i> patients with these two identified biomarker variants (approximately
10%-20% of the population) in prospective studies would identify approximately 80%-90% patients that would display clinically
significant improved functional and cognitive scores.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 00 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
consistency between the identified DNA and RNA data related to ANAVEX<sup>&#174;</sup>2-73, which are considered independent of
AD pathology, as well as multiple endpoints and time-points, provides support for precision medicine clinical development of ANAVEX<sup>&#174;</sup>2-73
by using genetic biomarkers identified within the study population itself to target patients who are most likely to respond to
ANAVEX<sup>&#174;</sup>2-73 treatment in AD as well as indications like Parkinson&#8217;s disease dementia (PDD) or Rett syndrome
(RTT) in which ANAVEX<sup>&#174;</sup>2-73 is currently studied.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Clinical
Studies Overview</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Alzheimer&#8217;s
Disease</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
November 2016, we completed a Phase 2a clinical trial, consisting of PART A and PART B, which lasted a total of 57 weeks, for
ANAVEX<sup>&#174;</sup>2-73 in mild-to-moderate Alzheimer&#8217;s patients. This open-label randomized trial met both primary and
secondary endpoints and was designed to assess the safety and exploratory efficacy of ANAVEX<sup>&#174;</sup>2-73 in 32 patients.
ANAVEX<sup>&#174;</sup>2-73 targets sigma-1 and muscarinic receptors, which have been shown in preclinical studies to reduce stress
levels in the brain believed to restore cellular homeostasis and to reverse the pathological hallmarks observed in Alzheimer&#8217;s
disease. The Phase 2a trial demonstrated positive pharmacokinetic (PK) and pharmacodynamic (PD) data, which established a concentration-effect
relationship between ANAVEX<sup>&#174;</sup>2-73 and study measurements. These measures obtained from all patients who participated
in the entire 57 weeks include exploratory cognitive and functional scores as well as biomarker signals of brain activity. Additionally,
the study appears to show that ANAVEX<sup>&#174;</sup>2-73 activity is enhanced by its active metabolite (ANAVEX19-144), which
also targets the sigma-1 receptor and has a half-life approximately twice as long as the parent molecule.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Two
consecutive trial extensions for the Phase 2a trial have allowed participants who completed the 52-week PART B of the study to
continue taking ANAVEX<sup>&#174;</sup>2-73, providing an opportunity to gather extended safety data for a cumulative time period
of five years. In August 2020, patients completing these Phase 2a trial extensions were granted continued access to treatment
with ANAVEX<sup>&#174;</sup>2-73 through the Australian Government Department of Health &#8211; Therapeutic Goods Administration
(TGA) compassionate use Special Access Scheme.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">A
larger Phase 2b/3 double-blind, placebo-controlled study of ANAVEX<sup>&#174;</sup>2-73 in Alzheimer&#8217;s disease
commenced in August 2018. The Phase 2b/3 study will enroll approximately 450 patients for 48 weeks, randomized 1:1:1 to two
different ANAVEX<sup>&#174;</sup>2-73 doses or placebo. The trial commenced in Australia; and additional regions have been
added in the United Kingdom, The Netherlands, Germany and Canada. The ANAVEX<sup>&#174;</sup>2-73 Phase 2b/3 study design
incorporates genomic precision medicine biomarkers identified in the ANAVEX<sup>&#174;</sup>2-73 Phase 2a study. Primary and
secondary endpoints will assess safety and both cognitive and functional efficacy, measured through Alzheimer&#8217;s Disease
Assessment Scale &#8211; Cognition (ADAS-Cog), ADCS-ADL and Clinical Dementia Rating &#8211; Sum of Boxes for cognition and
function (CDR-SB).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;In
October 2019, we initiated a long-term open label extension study of ANAVEX<sup>&#174;</sup>2-73, entitled the ATTENTION-AD study,
for patients who have completed the 48-week Phase 2b/3 placebo-controlled trial referenced above. This study is expected to last
two years and will give patients the opportunity to continue their treatment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span><i>Rett Syndrome </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
February 2016, we presented positive preclinical data for ANAVEX<sup>&#174;</sup>2-73 in Rett syndrome, a rare neurodevelopmental
disease. The study was funded by the International Rett Syndrome Foundation (&#8220;Rettsyndrome.org&#8221;). In January 2017,
we were awarded a financial grant from Rettsyndrome.org of a minimum of $0.6 million to cover some of the costs of a multicenter
Phase 2 clinical trial of ANAVEX<sup>&#174;</sup>2-73 for the treatment of Rett syndrome. This award was received in quarterly
instalments which commenced during fiscal 2018.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
March 2019, we commenced the first Phase 2 clinical trial in a planned Rett syndrome program of ANAVEX<sup>&#174;</sup>2-73
for the treatment of Rett syndrome. The studies are being conducted in a range of patient age demographics and geographic
regions</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">and utilize a convenient oral liquid once-daily
formulation of ANAVEX<sup>&#174;</sup>2-73.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 00 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
first Phase 2 study, which took place in the United States, was completed in December 2020. This trial was a randomized
double-blind, placebo-controlled safety, tolerability, pharmacokinetic and efficacy study of oral liquid
ANAVEX<sup>&#174;</sup>2-73 formulation in 25 adult female patients with Rett syndrome over a 7-week treatment period
including ANAVEX<sup>&#174;</sup>2-73-specific genomic precision medicine biomarkers. The primary endpoint of the trial was
safety. The dosing of 5 mg ANAVEX<sup>&#174;</sup>2-73 was well-tolerated and demonstrated dose-proportional PK
(pharmacokinetics). All secondary efficacy endpoints of the trial showed statistically significant and clinically meaningful,
drug exposure-dependent response in the Rett Syndrome Behaviour Questionnaire (RSBQ) Total scores, when compared to placebo,
in the ITT cohort (all participants, p = 0.048). 66.7% of ANAVEX<sup>&#174;</sup>2-73 treated subjects showed a statistically
significant improvement in drug exposure-dependent RSBQ response as compared to 10% of the subjects on placebo in the ITT
cohort (all participants, p = 0.011). ANAVEX<sup>&#174;</sup>2-73 treatment resulted in a sustained improvement in Clinical
Global Impression Improvement (CGI-I) scores throughout the 7-week study, when compared to placebo in the ITT cohort (all
participants, p = 0.014). 86.7% of ANAVEX<sup>&#174;</sup>2-73 treated subjects showed a statistically significant CGI-I
response, defined as sustained improvement to treatment, as compared to 40% of the subjects on placebo in the ITT cohort (all
participants, p = 0.014). Consistent with previous ANAVEX<sup>&#174;</sup>2-73 clinical trials, patients carrying the common
form of the SIGMAR1 gene treated with ANAVEX<sup>&#174;</sup>2-73 experienced stronger improvements in the prespecified
efficacy endpoints.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
second Phase 2 study of ANAVEX<sup>&#174;</sup>2-73 for the treatment of Rett syndrome, called the AVATAR study, commenced in
June 2019. This study is taking place in Australia and the United Kingdom using a higher dose than the U.S. based Phase 2 study
for Rett syndrome. The study will evaluate the safety and efficacy of ANAVEX<sup>&#174;</sup>2-73 in approximately 33 patients
over a 7-week treatment period including ANAVEX<sup>&#174;</sup>2-73 specific precision medicine biomarkers. All patients who
participate in the study will be eligible to receive ANAVEX<sup>&#174;</sup>2-73 under a voluntary open label extension protocol.&#160;</span></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
July 2020, we commenced the third study of ANAVEX<sup>&#174;</sup>2-73 for the treatment of Rett syndrome, called the
EXCELLENCE study. This Phase 2/3 study in pediatric patients with Rett syndrome will evaluate the safety and efficacy of
ANAVEX<sup>&#174;</sup>2-73 in at least 69 pediatric patients, aged 5 to 18, over a 12-week treatment period incorporating
ANAVEX<sup>&#174;</sup>2-73 specific precision medicine biomarkers. All patients who participate in the study will be
eligible to receive ANAVEX<sup>&#174;</sup>2-73 under a voluntary open label extension protocol.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Parkinson&#8217;s
Disease</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
September 2016, we presented positive preclinical data for ANAVEX<sup>&#174;</sup>2-73 in an animal model of
Parkinson&#8217;s disease, which demonstrated significant improvements on  behavioral, histopathological, and
neuroinflammatory endpoints. The study was funded by the Michael J. Fox Foundation. Additional data  announced in October
2017 indicates that ANAVEX<sup>&#174;</sup>2-73 induces
robust neurorestoration in experimental parkinsonism. The encouraging results we have gathered in this model, coupled with
the favorable profile of this compound in the Alzheimer&#8217;s disease trial, support the notion that
ANAVEX<sup>&#174;</sup>2-73 is a promising clinical candidate drug for Parkinson&#8217;s disease dementia.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
October 2020, we completed a double-blind, randomized, placebo-controlled proof-of-concept Phase 2 trial with ANAVEX<sup>&#174;</sup>2-73
in Parkinson&#8217;s Disease Dementia (PDD), to study the effect of the compound on both the cognitive and motor impairment of
Parkinson&#8217;s disease. The Phase 2 study enrolled approximately 132 patients for 14 weeks, randomized 1:1:1 to two different
ANAVEX<sup>&#174;</sup>2-73 doses, 30mg and 50mg, or placebo. The ANAVEX<sup>&#174;</sup>2-73 Phase 2 PDD study design incorporated
genomic precision medicine biomarkers identified in the ANAVEX<sup>&#174;</sup>2-73 Phase 2a Alzheimer&#8217;s disease study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Within
this study  ANAVEX<sup>&#174;</sup>2-73 was safe and well tolerated in oral doses up to 50mg once daily. The
results show clinically meaningful, dose-dependent, and statistically significant improvements in the Cognitive Drug Research
(CDR) computerized assessment system analysis. The study confirmed the precision medicine approach of targeting SIGMAR1 as a
genetic biomarker in response to ANAVEX<sup>&#174;</sup>2-73.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 00 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
August 2020, we announced a financial commitment by Shake It Up Australia Foundation for Parkinson&#8217;s Research to fund up
to 50% of the costs of an Australian clinical study to develop ANAVEX<sup>&#174;</sup>2-73 for the disease modifying treatment
of Parkinson&#8217;s disease. The financial commitment would be made through private placement purchases of our common stock at
200% of the fair market value on the purchase date and will be contingent upon the completion of certain clinical trial milestones
relating to the proposed clinical trial. The proposed clinical trial will use a convenient, once-daily oral ANAVEX<sup>&#174;</sup>2-73
formulation to confirm the potential disease modifying features of ANAVEX<sup>&#174;</sup>2-73 in an animal
model of Parkinson&#8217;s disease. Safety and efficacy will be investigated in an appropriately powered placebo-controlled clinical
study of Parkinson&#8217;s disease patients over at least 48-weeks including ANAVEX<sup>&#174;</sup>2-73-specific precision medicine
biomarkers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
January 2021, we announced we were awarded a research grant of $1.0 million from&#160;The Michael J. Fox Foundation for
Parkinson&#8217;s Research&#160;(MJFF) to develop ANAVEX<sup>&#174;</sup>2-73 for the treatment of Parkinson&#8217;s disease.
The award will explore utilization of PET imaging biomarkers to enable measurement of target engagement and pathway
activation of the sigma-1 receptor (SIGMAR1) with clinically relevant doses in people with Parkinson&#8217;s
disease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Frontotemporal
Dementia</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
July 2020, we commenced the First-in-Human Phase 1 clinical trial of ANAVEX<sup>&#174;</sup>3-71, which was previously granted
orphan drug designation for the treatment of Frontotemporal Dementia (FTD) by the FDA. ANAVEX<sup>&#174;</sup>3-71 is an orally
administered small molecule targeting sigma-1 and M1 muscarinic receptors that is designed to be beneficial for neurodegenerative
diseases. In preclinical studies, <span style="background-color: white">ANAVEX<sup>&#174;</sup>3-71 demonstrated disease-modifying
activity against the major hallmarks of Alzheimer&#8217;s disease in transgenic (3xTg-AD) mice, including cognitive deficits,
amyloid and tau pathologies, as well as beneficial effects on mitochondrial dysfunction and neuroinflammation.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">The
Phase 1 clinical trial will be a prospective double-blind, randomized, placebo-controlled study. A total of at least 36 healthy
male and female subjects will be included. Single escalating doses of ANAVEX<sup>&#174;</sup>3-71 will be administered in order
to evaluate the safety, tolerability, and pharmacokinetics (PK) of ANAVEX<sup>&#174;</sup>3-71 and the effects of food and gender
on its PK in healthy volunteers. This study is expected to be followed by longer duration dosing including patients with FTD or
other dementia indications with unmet medical need, incorporating exploratory efficacy and disease biomarker measures<span style="color: #1F1F1F">.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Our
Pipeline</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our
research and development pipeline includes ANAVEX<sup>&#174;</sup>2-73 currently in three different clinical study indications,
and several other compounds in different stages of clinical and pre-clinical study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our
proprietary SIGMACEPTOR&#8482; Discovery Platform produced small molecule drug candidates with unique modes of action, based on
our understanding of sigma receptors. Sigma receptors may be targets for therapeutics to combat many human diseases, both of neurodegenerative
nature, including Alzheimer&#8217;s disease, as well as of neurodevelopmental nature, like Rett syndrome. When bound by the appropriate
ligands, sigma receptors influence the functioning of multiple biochemical signals that are involved in the pathogenesis (origin
or development) of disease. Multiple viruses including SARS-CoV-2 (COVID-19) induce cellular stress by intrinsic mitochondrial
apoptosis and other related cellular processes, in order to ensure survival and replication. Hence, it is possible that S1R could
play a role in modulating the cellular response to viral infection and ameliorate pathogenesis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Compounds
that have been subjects of our research include the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">ANAVEX<sup>&#174;</sup>2-73
<i>(blarcamesine)</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">ANAVEX<sup>&#174;</sup>2-73
may offer a disease-modifying approach in neurodegenerative and neurodevelopmental diseases by activation of sigma-1 receptors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
Rett syndrome, administration of ANAVEX<sup>&#174;</sup>2-73 resulted in both significant and dose related improvements in an array
of behavioral paradigms in the MECP2 HET Rett syndrome disease model. In addition, in a further experiment sponsored by Rettsyndrome.org,
ANAVEX<sup>&#174;</sup>2-73 was evaluated in automatic visual response and respiration tests in 7-month old mice, an age at which
advanced pathology is evident. Vehicle-treated MECP2 mice demonstrated fewer automatic visual responses than wild-type mice. Treatment
with ANAVEX<sup>&#174;</sup>2-73 for four weeks significantly increased the automatic visual response in the MECP2 Rett syndrome
disease mouse. Additionally, chronic oral dosing daily for 6.5 weeks of ANAVEX<sup>&#174;</sup>2-73 starting at ~5.5 weeks of age
was conducted in the MECP2 HET Rett syndrome disease mouse model assessed the different aspects of muscular coordination, balance,
motor learning and muscular strengths, some of the core deficits observed in Rett syndrome. Administration of ANAVEX<sup>&#174;</sup>2-73
resulted in both significant and dose related improvements in an array of these behavioral paradigms in the MECP2 HET Rett syndrome
disease model.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 00 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
March 2019, we commenced the first Phase 2 clinical trial in a planned Rett syndrome program of ANAVEX<sup>&#174;</sup>2-73 for
the treatment of Rett syndrome. This study, which took place in the United States, was completed in December 2020, however two
other clinical trials in Rett syndrome, the AVATAR study and the EXCELLENCE study, are still underway. The studies are being conducted
in a range of patient age demographics and geographic regions, as more fully described above under <i>Clinical Studies Overview
&#8211; Rett Syndrome</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
May 2016 and June 2016, the FDA granted Orphan Drug Designation to ANAVEX<sup>&#174;</sup>2-73 for the treatment of Rett syndrome
and infantile spasms, respectively. In November 2019, the FDA granted to ANAVEX<sup>&#174;</sup>2-73 the Rare Pediatric Disease
(RPD) designation for the treatment of Rett syndrome. The RPD designation provides priority review by the FDA to encourage the
development of treatments for rare pediatric diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Further,
in February 2020, the FDA granted Fast Track designation for the ANAVEX<sup>&#174;</sup>2-73 clinical development program for the
treatment of Rett syndrome. The FDA Fast Track program is designed to facilitate and expedite the development and review of new
drugs to address unmet medical needs in the treatment of serious and life-threatening conditions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">For
Parkinson&#8217;s disease, data demonstrates significant improvements and restoration of function in a disease modifying animal
model of Parkinson&#8217;s disease. Significant improvements were seen on all measures tested: behavioral, histopathological,
and neuroinflammatory endpoints. In October 2020, we completed a double-blind, randomized, placebo-controlled proof-of-concept
Phase 2 trial with ANAVEX<sup>&#174;</sup>2-73 in Parkinson&#8217;s Disease Dementia (PDD), to study the effect of the compound
on both the cognitive and motor impairment of Parkinson&#8217;s disease. The Phase 2 study enrolled approximately 132 patients
for 14 weeks, randomized 1:1:1 to two different ANAVEX<sup>&#174;</sup>2-73 doses, 30mg and 50mg, or placebo. The ANAVEX<sup>&#174;</sup>2-73
Phase 2 PDD study design incorporated genomic precision medicine biomarkers identified in the ANAVEX<sup>&#174;</sup>2-73 Phase
2a Alzheimer&#8217;s disease study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
study found that ANAVEX<sup>&#174;</sup>2-73 was safe and well tolerated in oral doses up to 50mg once daily. The results show
clinically meaningful, dose-dependent, and statistically significant improvements in the Cognitive Drug Research (CDR) computerized
assessment system analysis. We anticipate conducting further clinical trials of ANAVEX<sup>&#174;</sup>2-73 in Parkinson&#8217;s
disease dementia after submitting the results of the study to the FDA to obtain regulatory guidance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
Alzheimer&#8217;s disease (AD) animal models, ANAVEX<sup>&#174;</sup>2-73 has shown pharmacological, histological and behavioral
evidence as a potential neuroprotective, anti-amnesic, anti-convulsive and anti-depressive therapeutic agent, due to its potent
affinity to sigma-1 receptors and moderate affinities to M1-4 type muscarinic receptors. In addition, ANAVEX<sup>&#174;</sup>2-73
has shown a potential dual mechanism which may impact amyloid, tau pathology and inflammation. In a transgenic AD animal model
Tg2576, ANAVEX<sup>&#174;</sup>2-73 induced a statistically significant neuroprotective effect against the development of oxidative
stress in the mouse brain, as well as significantly increased the expression of functional and synaptic plasticity markers that
is apparently amyloid-beta independent. It also statistically alleviated the learning and memory deficits developed over time
in the animals, regardless of sex, both in terms of spatial working memory and long-term spatial reference memory.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Based
on the results of pre-clinical testing, we initiated and completed a Phase 1 single ascending dose (SAD) clinical trial of ANAVEX<sup>&#174;</sup>2-73.
In this Phase 1 SAD trial, the maximum tolerated single dose was defined per protocol as 55-60 mg. This dose is above the equivalent
dose shown to have positive effects in mouse models of AD. There were no significant changes in laboratory or electrocardiogram
(ECG) parameters. ANAVEX<sup>&#174;</sup>2-73 was well tolerated below the 55-60 mg dose with only mild adverse events in some
subjects. Observed adverse events at doses above the maximum tolerated single dose included headache and dizziness, which were
moderate in severity and reversible. These side effects are often seen with drugs that target CNS conditions, including AD.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 00 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
December 2014, a Phase 2a clinical trial was initiated for ANAVEX<sup>&#174;</sup>2-73, for the treatment of Alzheimer&#8217;s
disease. The open-label randomized trial was designed to assess the safety and exploratory efficacy of ANAVEX<sup>&#174;</sup>2-73
in 32 patients with mild-to-moderate Alzheimer&#8217;s disease. ANAVEX<sup>&#174;</sup>2-73 is an orally available drug candidate
that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential
to halt and/or reverse the course of Alzheimer&#8217;s. The Phase 2a study met both primary and secondary objectives of the study.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">In
July 2018, we presented the results of a genomic DNA and RNA evaluation of the participants in the Phase 2a study. More than 33,000
genes were analyzed using unbiased, data driven, machine learning, artificial intelligence (AI) system for analyzing DNA &amp;
RNA data in patients exposed to ANAVEX<sup>&#174;</sup>2-73. The analysis identified genetic variants that impacted response to
ANAVEX<sup>&#174;</sup>2-73, among them variants related to the Sigma-1 receptor (SIGMAR1), the target for ANAVEX<sup>&#174;</sup>2-73.
Results showed that study participants with the common SIGMAR1 wild type gene variant, which is about 80 percent of the population
worldwide, demonstrated improved cognitive (MMSE) and the functional (ADCS-ADL) scores. The results from this evaluation have
been used to establish a precision medicine approach in subsequent clinical trials, since these signatures can now be applied
to neurological indications tested in clinical studies with ANAVEX<sup>&#174;</sup>2-73 including Alzheimer&#8217;s disease, Parkinson&#8217;s
disease dementia and Rett syndrome.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">ANAVEX<sup>&#174;</sup>2-73
data presented met prerequisite information in order to progress into a Phase 2b/3 placebo-controlled study. On July 2, 2018,
the Human Research Ethics Committee in Australia approved the initiation of our Phase 2b/3, double-blind, randomized, placebo-controlled
48-week safety and efficacy trial of ANAVEX<sup>&#174;</sup>2-73 for the treatment of early Alzheimer&#8217;s disease. Clinical
trial sites in Canada, the United Kingdom, the Netherlands and Germany were also added. This Phase 2b/3 study design incorporates
inclusion of genomic precision medicine biomarkers identified in the ANAVEX<sup>&#174;</sup>2-73 Phase 2a study. The Phase 2b/3
study, which is expected to enroll approximately 450 patients, randomized 1:1:1 to either two different ANAVEX<sup>&#174;</sup>2-73
doses or placebo, commenced in October 2018.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Preclinical
data also validates ANAVEX<sup>&#174;</sup>2-73 as a prospective platform drug for other neurodegenerative diseases beyond Alzheimer&#8217;s
disease, Parkinson&#8217;s disease or Rett syndrome, more specifically, epilepsy, infantile spasms, Fragile X syndrome, Angelman
syndrome, multiple sclerosis and, more recently, tuberous sclerosis complex (TSC). ANAVEX<sup>&#174;</sup>2-73 demonstrated significant
improvements in all of these indications in the respective preclinical animal models.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
a study sponsored by the Foundation for Angelman Syndrome, ANAVEX<sup>&#174;</sup>2-73 was assessed in a mouse model for the development
of audiogenic seizures. The results indicated that ANAVEX<sup>&#174;</sup>2-73 administration significantly reduced audiogenic-induced
seizures. In a study sponsored by FRAXA Research Foundation regarding Fragile X syndrome, data demonstrated that ANAVEX<sup>&#174;</sup>2-73
restored hippocampal brain-derived neurotrophic factor (BDNF) expression to normal levels. BDNF under-expression has been observed
in many neurodevelopmental and neurodegenerative pathologies. BDNF signaling promotes maturation of both excitatory and inhibitory
synapses. ANAVEX<sup>&#174;</sup>2-73 normalization of BDNF expression could be a contributing factor for the positive data observed
in both neurodevelopmental and neurodegenerative disorders like Angelman and Fragile X syndromes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Preclinical
data presented also indicates that ANAVEX<sup>&#174;</sup>2-73 demonstrates protective effects of mitochondrial enzyme complexes
during pathological conditions, which, if impaired, are believed to play a role in the pathogenesis of neurodegenerative and neurodevelopmental
diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Preclinical
data on ANAVEX<sup>&#174;</sup>2-73 related to multiple sclerosis indicates that ANAVEX<sup>&#174;</sup>2-73 may promote remyelination
in multiple sclerosis disease. Further, data also demonstrates that ANAVEX<sup>&#174;</sup>2-73 provides protection for oligodendrocytes
(&#8220;OL&#8217;s&#8221;) and oligodendrocyte precursor cells (&#8220;OPC&#8217;s&#8221;), as well as central nervous system
neurons in addition to helping repair by increasing OPC proliferation and maturation in tissue culture.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
March 2018, we presented preclinical data of ANAVEX<sup>&#174;</sup>2-73 in a genetic mouse model of tuberous sclerosis complex
(&#8220;TSC&#8221;). TSC is a rare genetic disorder characterized by the growth of numerous benign tumors in many parts of the
body with a high incidence of seizures. The new preclinical data demonstrates that treatment with ANAVEX<sup>&#174;</sup>2-73 significantly
increases survival and reduces seizures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 00 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>ANAVEX<sup>&#174;</sup>3-71</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">ANAVEX<sup>&#174;</sup>3-71
is a clinical drug candidate with a novel mechanism of action via sigma-1 receptor activation and M1 muscarinic allosteric modulation,
which has been shown to enhance neuroprotection and cognition in Alzheimer&#8217;s disease models. ANAVEX<sup>&#174;</sup>3-71
is a CNS-penetrable potential disease modifying treatment for cognitive impairments. It is highly effective in very small doses
against the major Alzheimer&#8217;s hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies,
and also has beneficial effects on inflammation and mitochondrial dysfunctions. ANAVEX<sup>&#174;</sup>3-71 indicates extensive
therapeutic advantages in Alzheimer&#8217;s and other protein-aggregation-related diseases given its ability to enhance neuroprotection
and cognition via sigma-1 receptor activation and M1 muscarinic allosteric modulation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">A
preclinical study examined the response of ANAVEX<sup>&#174;</sup>3-71 in aged transgenic animal models and showed a significant
reduction in the rate of cognitive deficit, amyloid beta pathology and inflammation with the administration of ANAVEX 3-71. In
April 2016, the FDA granted Orphan Drug Designation to ANAVEX<sup>&#174;</sup>3-71 for the treatment of Frontotemporal dementia
(FTD).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
pathological conditions ANAVEX<sup>&#174;</sup>3-71 demonstrated the formation of new synapses between neurons (synaptogenesis)
without causing an abnormal increase in the number of astrocytes. In neurodegenerative diseases such as Alzheimer&#8217;s and
Parkinson&#8217;s disease, synaptogenesis is believed to be impaired. Additional preclinical data presented also indicates that
in addition to reducing oxidative stress, ANAVEX<sup>&#174;</sup>3-71 demonstrates protective effects of mitochondrial enzyme complexes
during pathological conditions, which, if impaired, are believed to play a role in the pathogenesis of neurodegenerative and neurodevelopmental
diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
July 2020, we commenced the first Phase 1 clinical trial of ANAVEX<sup>&#174;</sup>3-71, with focus on the treatment of Frontotemporal
Dementia (FTD) and <span style="background-color: white">other dementia indications with unmet medical need</span>. The study
is more fully described above under <i>Clinical Studies Overview &#8211; Frontotemporal Dementia</i>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>ANAVEX<sup>&#174;</sup>1-41</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">ANAVEX<sup>&#174;</sup>1-41
is a sigma-1 receptor agonist. Pre-clinical tests revealed significant neuroprotective benefits (i.e., protects nerve cells from
degeneration or death) through the modulation of endoplasmic reticulum, mitochondrial and oxidative stress, which damages and
impairs cell viability. In addition, in animal models, ANAVEX<sup>&#174;</sup>1-41 prevented the expression of caspase-3, an enzyme
that plays a key role in apoptosis (programmed cell death) and loss of cells in the hippocampus, the part of the brain that regulates
learning, emotion and memory. These activities involve both muscarinic and sigma-1 receptor systems through a novel mechanism
of action.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Preclinical
data presented also indicates that ANAVEX<sup>&#174;</sup>1-41 demonstrates protective effects of mitochondrial enzyme complexes
during pathological conditions, which, if impaired, are believed to play a role in the pathogenesis of neurodegenerative and neurodevelopmental
diseases.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>ANAVEX<sup>&#174;</sup>1066</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">ANAVEX<sup>&#174;</sup>1066,
a mixed sigma-1/sigma-2 ligand is designed for the potential treatment of neuropathic and visceral pain. ANAVEX<sup>&#174;</sup>1066
was tested in two preclinical models of neuropathic and visceral pain that have been extensively validated in rats. In the chronic
constriction injury model of neuropathic pain, a single oral administration of ANAVEX<sup>&#174;</sup>1066 dose-dependently restored
the nociceptive threshold in the affected paw to normal levels while leaving the contralateral healthy paw unchanged. Efficacy
was rapid and remained significant for two hours. In a model of visceral pain, chronic colonic hypersensitivity was induced by
injection of an inflammatory agent directly into the colon and a single oral administration of ANAVEX<sup>&#174;</sup>1066 returned
the nociceptive threshold to control levels in a dose-dependent manner. Companion studies in rats demonstrated the lack of any
effects on normal gastrointestinal transit with ANAVEX<sup>&#174;</sup>1066 and a favorable safety profile in a battery of behavioral
measures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 00 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>ANAVEX<sup>&#174;</sup>1037
</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">ANAVEX<sup>&#174;</sup>1037
is designed for the treatment of prostate and pancreatic cancer. It is a low molecular weight, synthetic compound exhibiting high
affinity for sigma-1 receptors at nanomolar levels and moderate affinity for sigma-2 receptors and sodium channels at micromolar
levels. In advanced pre-clinical studies, this compound revealed antitumor potential. It has also been shown to selectively kill
human cancer cells without affecting normal/healthy cells and also to significantly suppress tumor growth in immune-deficient
mice models. Scientific publications highlight the possibility that these ligands may stop tumor growth and induce selective cell
death in various tumor cell lines. Sigma receptors are highly expressed in different tumor cell types. Binding by appropriate
sigma-1 and/or sigma-2 ligands can induce selective apoptosis. In addition, through tumor cell membrane reorganization and interactions
with ion channels, our drug candidates may play an important role in inhibiting the processes of metastasis (spreading of cancer
cells from the original site to other parts of the body), angiogenesis (the formation of new blood vessels) and tumor cell proliferation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our
compounds are in the clinical and pre-clinical testing stages of development, and there is no guarantee that the activity demonstrated
in pre-clinical models will be shown in human testing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
continue to identify and initiate discussions with potential strategic and commercial partners to most effectively advance our
programs and realize maximum shareholder value. Further, we may acquire or develop new intellectual property and assign, license,
or otherwise transfer our intellectual property to further our goals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Our
Target Indications</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
have developed compounds with potential application to two broad categories and several specific indications. including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Central
Nervous System Diseases</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>



<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Alzheimer&#8217;s
    disease &#8211; In 2020, an estimated 5.8 million Americans were suffering from Alzheimer&#8217;s disease. The Alzheimer&#8217;s
    Association<sup>&#174; </sup>estimates that by 2050, this number will rise to nearly 14 million Americans. Medications on the
    market today treat only the symptoms of Alzheimer&#8217;s disease and do not have the ability to stop its onset or its progression.
    There is an urgent and unmet need for both a disease modifying cure for Alzheimer&#8217;s disease as well as for better symptomatic
    treatments.</span></td></tr>

</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>



<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Parkinson&#8217;s
    disease &#8211; Parkinson&#8217;s disease is a progressive disease of the nervous system marked by tremors, muscular rigidity,
    and slow, imprecise movement. It is associated with degeneration of the basal ganglia of the brain and a deficiency of the
    neurotransmitter dopamine. Parkinson&#8217;s disease afflicts more than 10 million people worldwide, typically middle-aged
    and elderly people. The Parkinson&#8217;s disease market is expected to expand to $3.2 billion by 2021, according to business
    intelligence provider GBI Research.</span></td></tr>

</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Rett syndrome &#8211;
    Rett syndrome is a rare X-linked genetic neurological and developmental disorder that affects the way the brain develops,
    including protein transcription, which is altered and as a result leads to severe disruptions in neuronal homeostasis. It
    is considered a rare, progressive neurodevelopmental disorder and is caused by a single mutation in the MECP2 gene. Because
    males have a different chromosome combination from females, boys who have the genetic MECP2 mutation are affected in devastating
    ways. Most of them die before birth or in early infancy. For females who survive infancy, Rett syndrome leads to severe impairments,
    affecting nearly every aspect of the child&#8217;s life; severe mental retardation, their ability to speak, walk and eat,
    sleeping problems, seizures and even the ability to breathe easily. Rett syndrome affects approximately 1 in every 10,000-15,000
    females.</span></td></tr>

</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Depression &#8211;
    Depression is a major cause of morbidity worldwide according to the World Health Organization. Pharmaceutical treatment for
    depression is dominated by blockbuster brands, with the leading nine brands historically accounting for approximately 75%
    of total sales. However, the dominance of the leading brands is waning, largely due to the effects of patent expiration and
    generic competition.</span></td></tr>

</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Epilepsy &#8211;
    Epilepsy is a common chronic neurological disorder characterized by recurrent unprovoked seizures. These seizures are transient
    signs and/or symptoms of abnormal, excessive or synchronous neuronal activity in the brain. According to the Centers for Disease
    Control and Prevention, in 2015 epilepsy affected 3.4 million Americans. Today, epilepsy is often controlled, but not cured,
    with medication that is categorized as older traditional anti-epileptic drugs and second generation anti-epileptic drugs.
    Because epilepsy afflicts sufferers in different ways, there is a need for drugs used in combination with both traditional
    anti-epileptic drugs and second generation anti-epileptic drugs.</span></td></tr>

</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Neuropathic Pain
    &#8211; We define neuralgia, or neuropathic pain, as pain that is not related to activation of pain receptor cells in any
    part of the body. Neuralgia is more difficult to treat than some other types of pain because it does not respond well to normal
    pain medications. Special medications have become more specific to neuralgia and typically fall under the category of membrane
    stabilizing drugs or antidepressants.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 00 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Cancer</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Malignant Melanoma
    &#8211; Predominantly a skin cancer, malignant melanoma can also occur in melanocytes found in the bowel and the eye. Malignant
    melanoma accounts for 75% of all deaths associated with skin cancer. The treatment includes surgical removal of the tumor,
    adjuvant treatment, chemo and immunotherapy, or radiation therapy. According to IMS Health the worldwide malignant melanoma
    market is expected to grow to $4.4 billion by 2022.</span></td></tr>

</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Prostate Cancer
    &#8211; Specific to men, prostate cancer is a form of cancer that develops in the prostate, a gland in the male reproductive
    system. The cancer cells may metastasize from the prostate to other parts of the body, particularly the bones and lymph nodes.
    Drug therapeutics for prostate cancer are expected to increase to nearly $13.5 billion in 2024 according to Datamonitor Healthcare.</span></td></tr>

</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 24px"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 24px"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Pancreatic Cancer
    &#8211; Pancreatic cancer is a malignant neoplasm of the pancreas. In the United States, approximately 55,000 new cases of
    pancreatic cancer will be diagnosed this year and approximately 44,000 patients will die as a result of their cancer, according
    to the American Cancer Society. Sales predictions by GBI Research forecast that the market for the pharmaceutical treatment
    of pancreatic cancer in the United States and five largest European countries will increase to $2.9 billion by 2021.</span></td></tr>

</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Patents,
Trademarks and Intellectual Property </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
hold ownership or exclusive rights to ten U.S. patents, thirteen U.S. patent applications, and various PCT or ex-U.S. patent applications
relating to our drug candidates, methods associated therewith, and to our research programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
own one issued U.S. patent entitled &#8220;ANAVEX<sup>&#174;</sup>2-73 and certain anticholinesterase inhibitors composition and
method for neuroprotection&#8221; claims a composition of matter of ANAVEX<sup>&#174;</sup>2-73 directed to a novel and synergistic
neuroprotective compound combined with donepezil and other cholinesterase inhibitors. This patent is expected to expire in June
2034, absent any patent term extension for regulatory delays. We own two issued U.S. patents each with claims directed to crystalline
forms of ANAVEX<sup>&#174;</sup>2-73. The first of these two patents claims crystalline forms of ANAVEX<sup>&#174;</sup>2-73,
dosage forms and compositions containing crystalline ANAVEX<sup>&#174;</sup>2-73, and methods of treatment for Alzheimer&#8217;s
disease using them. This patent is expected to expire in July 2036, absent any patent term extension for regulatory delays. The
second of these two patents claims pharmaceutical compositions containing a crystalline form of ANAVEX<sup>&#174;</sup>2-73, and
methods of treatment for Alzheimer&#8217;s disease using the compositions. This patent is expected to expire in June 2037, absent
any patent term extension for regulatory delays. We also own two issued U.S. patents on seizure treatment. The first of these
two patents claims methods and dosage forms for treating seizures, the dosage forms containing a low-dose anti-epilepsy drug combined
with either: (i) ANAVEX<sup>&#174;</sup>2-73 and its active metabolite ANAVEX<sup>&#174;</sup>19-144; or (ii) ANAVEX<sup>&#174;</sup>19-144.
The second of these two patents further defines the seizure treatment being co-timely or coordinated administration of anti-epilepsy
drugs and (i) ANAVEX 19-144<sup>&#174;</sup> or (ii) ANAVEX 19-144<sup>&#174;</sup> with ANAVEX 2-73<sup>&#174;</sup>. Both patents
are expected to expire in October 2035, absent any patent term extension for regulatory delays. We also own an issued U.S. patent
that claims methods for treating a neurodevelopmental disorder or multiple sclerosis by administering ANAVEX<sup>&#174;</sup>2-73,
ANAVEX<sup>&#174;</sup>19-144, and/or ANAVEX<sup>&#174;</sup>1-41, another sigma receptor ligand similar to ANAVEX<sup>&#174;</sup>2-73.
This patent is expected to expire in January 2037, absent any patent term extension for regulatory delays. In addition, we own
one issued U.S. Patent with claims directed to methods of treating melanoma with a compound related to ANAVEX<sup>&#174;</sup>2-73.
This patent is expected to expire in February 2030, absent any patent term extension for regulatory delays.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 00 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
also own one issued patent with claims directed to methods for treating or preventing pain with ANAVEX<sup>&#174;</sup>1066. This
patent is expected to expire in November 2036, absent any patent term extension for regulatory delays.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">For
ANAVEX<sup>&#174;</sup>2-73, ANAVEX<sup>&#174;</sup>19-144, ANAVEX<sup>&#174;</sup>1-41, and ANAVEX<sup>&#174;</sup>1066, we also
have granted or pending applications in Australia, Canada, China, Europe, Japan, and Hong Kong, and are expected to expire after
2035.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">With
regard to ANAVEX<sup>&#174;</sup>3-71, we own exclusive rights to two issued U.S. patents with claims respectively directed to
the ANAVEX<sup>&#174;</sup>3-71 compound and methods of treating various diseases including Alzheimer&#8217;s with the same. These
patents are expected to expire in April 2030, and January 2030, respectively, absent any patent term extension for regulatory
delays. We also own exclusive rights to related patents or applications that are granted or pending in Australia, Canada, China,
Europe, Japan, Korea, New Zealand, Russia, and South Africa, and are expected to expire in January 2030.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
also own other patent applications directed to enantiomers, crystals, formulations, uses, and patient selection methods that may
provide additional protection for one or more of our product candidates.&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
regard patents and other intellectual property rights as corporate assets. Accordingly, we attempt to optimize the value of intellectual
property in developing our business strategy including the selective development, protection, and exploitation of our intellectual
property rights. In addition to filings made with intellectual property authorities, we protect our intellectual property and
confidential information by means of carefully considered processes of communication and the sharing of information, and by the
use of confidentiality and non-disclosure agreements and provisions for the same in contractor&#8217;s agreements. While no agreement
offers absolute protection, such agreements provide some form of recourse in the event of disclosure, or anticipated disclosure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our
intellectual property position, like that of many biomedical companies, is uncertain and involves complex legal and technical
questions for which important legal principles are unresolved. For more information regarding challenges to our existing or future
patents, see &#8220;Risk Factors&#8221; &#8221; in Part I, Item 1A of our Annual Report on Form 10-K filed with the Securities
and Exchange Commission on December 28, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Financial
Highlights</i></b></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Operating
expenses for the first quarter of fiscal 2021 were $9.4 million, compared to $7.7 million for the comparable quarter in fiscal
2020. The operating expenses include an aggregate of $0.9 million, as compared to $1.3 million in the first quarter of fiscal
2020, in non-cash charges related to the issuance and vesting of stock options. Our research and development expenses for the
first quarter of fiscal 2021 were $7.9 million, an increase of $1.6 million, or approximately 25% over the comparable period in
fiscal 2020. The increase is attributable to the continued advancement of our ongoing clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Net
loss for the first quarter of fiscal 2021 was $7.9 million, or $0.12 per share, as compared to $6.6 million, or $0.12 per share
in the comparative quarter of fiscal 2020.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 00 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Results
of Operations</i></b></span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Revenue</i></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">We
are in the development stage and have not earned any revenues since our inception and we do not anticipate earning any revenues
until we can establish an alliance with other companies to develop, co-develop, license, acquire or market our products.</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><b>Three
months ended December 31, 2020 compared to three months ended December 31, 2019.</b></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Operating
Expenses</i></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Total
operating expenses for the first quarter of fiscal 2021 were $9.4 million, which represents an increase of $1.7 million from the
comparable quarter of fiscal 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Research
and development expenses for the first quarter of fiscal 2021 were $7.9 million, as compared to $6.3 million fiscal 2020, an increase
of $1.6 million. The increase is attributable to the continued advancement of our ongoing clinical trials, most notably, the continued
enrollment of our Phase 2b/3 Alzheimer&#8217;s disease trial and expansion of this trial internationally, continued advancement
of our multi-regional Phase 2/3 clinical program for the treatment of Rett syndrome, and commencement of the first in human Phase
1 clinical trial of ANAVEX<sup>&#174;</sup>3-71 during the second half of fiscal 2020 with focus on the treatment of Frontotemporal
Dementia (FTD) and other dementia indications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the quarter our general and administrative expenses were $1.5 million as compared to $1.4 million in the comparable quarter of
fiscal 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Other
income</i></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
net amount of other income for the first quarter of fiscal 2021 was $1.6 million as compared to $1.1 million for the comparable
quarter of fiscal 2020. The increase in other income is attributable to an increase in Australian research and development incentive
income in connection with the increase in eligible clinical activities in Australia over the comparable period. Foreign exchange
gains during the period were related to the fluctuations in the Australian dollar against the US dollar and its related impact
on Incentive and tax receivables during the period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Liquidity
and Capital Resources</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Working
Capital</i></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">December
    31, 2020</span></td><td style="font-weight: bold; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">September
    30, 2020</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 45%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Current
    Assets</span></td><td style="width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 10%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">54,334,246</span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 10%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">34,542,197</span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Current
    Liabilities</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">8,033,469</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">7,305,628</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Working
    Capital</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">46,300,777</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">27,236,569</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><br />
At December 31, 2020, we had $47.4 million in cash and cash equivalents, an increase of $18.1 million from September 30, 2020.
During the quarter ended December 31, 2020, we received $26.0 million from the issuance of shares of common stock under the 2019
Purchase Agreement and the Sales Agreement, as more fully described below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Cash
Flows</i></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Three
    months ended December 31,</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2020</span></td><td style="font-weight: bold"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2019</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 45%; text-align: justify; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">Net
    cash flows used in operating activities</span></td><td style="width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 10%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(7,871,378</span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td><td style="width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="width: 10%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(5,725,159</span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">Net
    cash flows from financing activities</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">25,979,959</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">10,997,952</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 5.4pt"><span style="font: 10pt Times New Roman, Times, Serif">Increase
    in cash and cash equivalents</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">18,108,581</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">5,272,793</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 00 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Cash
flow used in operating activities</i></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Net
cash used in operating activities for the first quarter of fiscal 2021 was $7.9 million, compared to $5.7 million during the comparable
quarter of fiscal 2020. The principal reason for this increase in net cash used from operating activities in the current period
is due to an increase in research and development expenses and an increase in research and development incentive income receivable,
as compared to the first fiscal quarter of 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Cash
flow provided by financing activities</i></span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Cash
provided by financing activities for the three months ended December 31, 2020 was $26.0 million, attributable to cash received
from the issuance of common shares at various market prices under the 2019 Purchase Agreement and the Sales Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Cash
provided by financing activities for the three months ended December 31, 2019 was $11.0 million, attributable to cash received
from the issuance of common shares at various market prices under the 2019 Purchase Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Other
Financing</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Purchase
Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
June 7, 2019, we entered into a Purchase Agreement (the &#8220;2019 Purchase Agreement&#8221;) with Lincoln Park Capital Fund,
LLC (&#8220;Lincoln Park&#8221;), as amended on July 1, 2020, pursuant to which Lincoln Park committed to purchase up to $50,000,000
of our common stock. Concurrently with the execution of the 2019 Purchase Agreement in 2019, we issued 324,383 shares of our common
stock to Lincoln Park as a fee for its commitment to purchase shares of our common stock under the 2019 Purchase Agreement and
became obligated to issue up to 162,191 shares pro rata, when and if Lincoln Park purchased, at our discretion, the $50,000,000 aggregate commitment.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">At
December 31, 2020, approximately $6.6 million in shares of our common stock remained available for purchase by Lincoln Park under
the 2019 Purchase Agreement, and as of the date of this Quarterly Report on Form 10-Q, no shares of our common stock remain available for purchase by Lincoln Park under the 2019 Purchase Agreement.</span></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Controlled
Equity Offering Sales Agreement</b></span></p>

<p style="font: 10pt/115% Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
May 1, 2020, we entered into an Amended and Restated&#160;Sales Agreement (the &#8220;Sales Agreement&#8221;) with Cantor Fitzgerald
&amp; Co. and SVB Leerink LLC (the &#8220;Sales Agents&#8221;), pursuant to which we may offer and sell shares of common stock registered under an effective registration statement from time to time through the Sales Agents (the &#8220;At-the-Market Offering&#8221;).&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Upon
delivery of a placement notice based on our instructions and subject to the terms and conditions of the Sales Agreement, the Sales
Agents may sell shares of common stock by methods deemed to be an &#8220;at the market offering&#8221;, in negotiated transactions
at market prices prevailing at the time of sale or at prices related to such prevailing market prices, or by any other method
permitted by law, including negotiated transactions, subject to our prior written consent. We are not obligated to make any sales
of shares under the Sales Agreement. We or the Sales Agents may suspend or terminate the At-the-Market Offering upon notice to
the other party, subject to certain conditions. The Sales Agents will act as agents on a commercially reasonable efforts basis
consistent with their normal trading and sales practices and applicable state and federal law, rules&#160;and regulations and
the rules&#160;of Nasdaq.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 00 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
have agreed to pay the Sales Agents commissions for their services of 3.0% of the gross proceeds from the sale of the Shares pursuant
to the Sales Agreement. We have also agreed to provide the Sales Agents with customary indemnification and contribution rights.
At December 31, 2020, an amount of $33.7 million remained registered under the Company&#8217;s effective shelf registration
statement and available to be offered and sold under the Sales Agreement, and immediately prior to the filing of this Quarterly Report on Form 10-Q,
an amount of $7.8 million remained  registered under the Company&#8217;s effective shelf registration statement and available
to be offered and sold under the Sales Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Off-Balance
Sheet Arrangements</span></p>

<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">We
have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial
condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital
resources that are material to our stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>CRITICAL
ACCOUNTING POLICIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">We
prepare our interim condensed consolidated financial statements in accordance with accounting principles generally accepted in
the United States of America, and make estimates and assumptions that affect our reported amounts of assets, liabilities, revenue
and expenses, and the related disclosures of contingent liabilities. We base our estimates on historical experience and other
assumptions that we believe are reasonable in the circumstances. Actual results may differ from these estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">There
have been no significant changes in the critical accounting policies and estimates described in our Annual Report on Form 10-K
for the year ended September 30, 2020 as filed with the SEC on December 28, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>RECENT
ACCOUNTING PRONOUNCEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">Please
refer to Note 2 &#8220;Recent Accounting Pronouncements&#8221; in notes to our Interim Condensed Consolidated Financial Statements
included in this Form 10-Q.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-transform: uppercase; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="item3"></span>Item
3. Quantitative and Qualitative Disclosures about Market Risks.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-transform: uppercase; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Not
applicable</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-transform: uppercase; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="item4"></span>Item
4. Controls and Procedures.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-transform: uppercase; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Disclosure
Controls and Procedures </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
maintain disclosure controls and procedures that are designed to provide reasonable assurance that material information required
to be disclosed in our periodic reports filed under the Exchange Act is recorded, processed, summarized, and reported within the
time periods specified in the SEC&#8217;s rules and forms and to provide reasonable assurance that such information is accumulated
and communicated to our management, our chief executive officer and our principal financial officer, to allow timely decisions
regarding required disclosure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
carried out an evaluation, under the supervision and with the participation of our management, including our principal executive
officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures,
as defined in Rule 13a 15(e) under the Exchange Act, as of the end of the period covered by this Quarterly Report on Form 10-Q.
Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls
and procedures were effective as of December 31, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 00 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Changes
in Internal Control over Financial Reporting</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the quarter ended December 31, 2020, there were no changes in our internal control over financial reporting identified in management&#8217;s
evaluation pursuant to Rules 13a 15(d) or 15d 15(d) of the Exchange Act that materially affected, or are reasonably likely to
materially affect, our internal controls over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-transform: uppercase; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="PARTII"></span>PART
II &#8211; OTHER INFORMATION</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-transform: uppercase; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-transform: uppercase; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="LEGAL"></span>Item
1. Legal Proceedings.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-transform: uppercase; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
know of no material pending legal proceedings, other than ordinary routine litigation incidental to our business, to which our
Company or our subsidiary is a party or of which any of their property is subject. There are no proceedings in which any of our
directors, officers or affiliates, or any registered or beneficial stockholder holding more than 5% of our shares, is an adverse
party or has a material interest adverse to our or our subsidiary&#8217;s interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-transform: uppercase; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="RISK"></span>Item
1A. Risk Factors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">There
have been no material changes to the risk factors discussed in &#8220;Risk Factors&#8221; in Part I, Item 1A of our Annual Report
on Form 10-K for the fiscal year ended September 30, 2020 filed with the SEC on December 28, 2020 except for the following new
risks:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Our
stock price has recently been volatile and may be volatile in the future.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our
stock price has recently been volatile and may be volatile in the future. For example, on February 1, 2021, the price of our common
stock closed at $6.53 per share while on February 9, 2021, the price of our common stock closed at $14.99 per share without disclosure
of news or other developments by us. On February 4, 2021, the opening price of our common stock was $19.94 and the intra-day sales
price of our common stock fluctuated between a reported low sale price of $13.80 and a reported high sales price of $28.70, closing
at $14.91. Our volume on this day was 116,590,800, which was a substantial increase from the volume of 18,086,230 and 3,161,525
on the two days immediately preceding February 4, 2021. We may incur rapid and substantial increases or decreases in our stock
price in the foreseeable future that are do not coincide in timing with the disclosure of news or developments by us. The stock
market in general, and the market for biotechnology and pharmaceutical companies in particular, has experienced extreme volatility
that has often been unrelated to the operating performance of particular companies. The market price for our common stock may
be influenced by many factors, including the following:</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt TimesNewRomanPSStd-Regular; width: 100%; margin-top: 10pt; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">announcements
                                         of new data, clinical trial results or those of companies that are perceived to be similar
                                         to us;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt TimesNewRomanPSStd-Regular; width: 100%; margin-top: 10pt; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">announcements
                                         related to any delays in any preclinical or clinical trials related to our products;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt TimesNewRomanPSStd-Regular; width: 100%; margin-top: 10pt; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">announcements
                                         related to our products&#8217; ability to demonstrate efficacy or an acceptable safety
                                         profile of our product candidates or similar announcements by companies that are perceived
                                         to be similar to us;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt TimesNewRomanPSStd-Regular; width: 100%; margin-top: 10pt; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
                                         ability to meet or exceed expectations of analysts or investors;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt TimesNewRomanPSStd-Regular; width: 100%; margin-top: 10pt; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">news
                                         that the number of patients required for clinical trials for our drug candidates may
                                         be larger than we anticipate, enrollment in these clinical trials may be slower than
                                         we anticipate, participants may drop out of these clinical trials at a higher rate than
                                         we anticipate or the duration of these clinical trials may be longer than we anticipate;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt TimesNewRomanPSStd-Regular; width: 100%; margin-top: 10pt; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">actions
                                         taken by regulatory agencies with respect to our product candidates or the progress of
                                         our clinical studies, including with respect to any fast track or orphan drug designations;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt TimesNewRomanPSStd-Regular; width: 100%; margin-top: 10pt; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">announcements
                                         of significant acquisitions, strategic partnerships, joint ventures or capital commitments
                                         by us, our strategic collaboration partners or our competitors;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt TimesNewRomanPSStd-Regular; width: 100%; margin-top: 10pt; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">grants
                                         awarded to us or companies that are perceived to be similar to us from outside entities;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt TimesNewRomanPSStd-Regular; width: 100%; margin-top: 10pt; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">variations
                                         in our financial results or those of companies that are perceived to be similar to us;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt TimesNewRomanPSStd-Regular; width: 100%; margin-top: 10pt; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">trading
                                         volume of our common stock;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt TimesNewRomanPSStd-Regular; width: 100%; margin-top: 10pt; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">developments
                                         concerning our collaborations or partners;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt TimesNewRomanPSStd-Regular; width: 100%; margin-top: 10pt; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
                                         impact of the COVID-19 outbreak and its effect on us;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt TimesNewRomanPSStd-Regular; width: 100%; margin-top: 10pt; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the
                                         perception of the biotechnology or pharmaceutical industries by the public, legislatures,
                                         regulators and the investment community;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt TimesNewRomanPSStd-Regular; width: 100%; margin-top: 10pt; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">developments
                                         or disputes concerning intellectual property rights;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt TimesNewRomanPSStd-Regular; width: 100%; margin-top: 10pt; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">significant
                                         lawsuits, including patent or stockholder litigation;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt TimesNewRomanPSStd-Regular; width: 100%; margin-top: 10pt; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our
                                         ability or inability to raise additional capital and the terms on which we raise it;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt TimesNewRomanPSStd-Regular; width: 100%; margin-top: 10pt; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">sales
                                         of our common stock by us or our stockholders;</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt TimesNewRomanPSStd-Regular; width: 100%; margin-top: 10pt; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">declines
                                         in the market prices of stocks generally or of companies that are perceived to be similar
                                         to us; and</span></td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt/12pt TimesNewRomanPSStd-Regular; width: 100%; margin-top: 10pt; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">general
                                         economic, industry and market conditions.</span></td></tr></table>

<p style="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
addition, companies trading in the stock market in general, and The Nasdaq Capital Market in particular, have experienced extreme
price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies.
These broad market and industry factors may seriously harm the market price of our common stock, regardless of our operating performance.
In the past, following periods of volatility in the market, securities class-action litigation has often been instituted against
companies. Such litigation, if instituted against us, could result in substantial costs and diversion of management&#8217;s attention
and resources, which could materially and adversely affect our business, financial condition, results of operations and growth
prospects. There can be no guarantee that our stock price will remain at current prices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Our
common stock may become the target of a &#8220;short squeeze.&#8221;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
the past several weeks prior to the filing of this Quarterly Report on Form 10-Q, securities of certain companies have
increasingly experienced significant and extreme volatility in stock price due to short sellers of shares of common stock,
known as a &#8220;short squeeze.&#8221; These short squeezes have caused extreme volatility in those companies and in the
market and have led to the price per share of those companies to trade at a significantly inflated rate that is disconnected
from the underlying value of the company. Many investors who have purchased shares in those companies at an inflated rate
face the risk of losing a significant portion of their original investment as the price per share has declined steadily as
interest in those stocks have abated. There can be no assurance that we will not, in the future be, a target of a short
squeeze, and you may lose a significant portion or all of your investment if you purchase our shares at a rate that is
significantly disconnected from our underlying value.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
addition to the information set forth in this Form 10-Q, you should carefully review and consider the risk factors discussed in
&#8220;Risk Factors&#8221; in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended September 30, 2020 filed
with the SEC on December 28, 2020. These risks could materially and adversely affect our business, financial condition and results
of operations. The risks described in herein and in our Form 10-K are not the only risks we face. Our operations could also be
affected by additional factors that are not presently known to us or by factors that we currently consider immaterial to our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-transform: uppercase; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="UNREGISTERED"></span>Item
2. Unregistered Sales of Equity Securities and Use of Proceeds.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-transform: uppercase; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the period covered by this Quarterly Report on Form 10-Q, we have not sold any equity securities that were not registered under
the Securities Act of 1933 that were not previously reported in a Current Report on Form 8-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-transform: uppercase; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="DEFAULTS"></span>Item
3. Defaults Upon Senior Securities.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-transform: uppercase; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-transform: uppercase; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="MINE"></span>Item
4. Mine Safety Disclosures</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-transform: uppercase; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-transform: uppercase; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="OTHER"></span>Item
5. Other Information.</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-transform: uppercase; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
described in Note 4 to our Interim Condensed Consolidated Financial Statements included in this Form 10-Q, we previously entered
into the Sales Agreement, pursuant to which the Company may offer and sell shares of common stock registered under an effective
registration statement from time to time through the Sales Agents. We expect to file a prospectus supplement with the SEC on February
16, 2021 in connection with the offer and sale of up to $50 million of shares of common stock pursuant to the Sales Agreement,
and a legal opinion of Snell &amp; Wilmer L.L.P. relating to the validity of the Shares to be offered pursuant to the Sales Agreement
is filed as Exhibit 5.1 to this Form 10-Q.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 00 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-transform: uppercase; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="EXHIBITS"></span>Item
6. Exhibits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="border: Black 1pt solid; width: 12%; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exhibit
    </b><br />
    <b>Number </b></span></td>
    <td style="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; width: 88%; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><br />
    <b>Description</b></span></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>(3)
    </b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Articles
    of Incorporation and Bylaws </b></span></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000161577419007324/s118023_ex3-1.htm">3.1</a></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000161577419007324/s118023_ex3-1.htm">Articles
    of Incorporation (incorporated by reference to Exhibit 3.1 to our Quarterly Report on Form 10-Q for the quarter ended March
    31, 2019 filed on May 9, 2019)</a></span></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000108503707002199/exhibit3_1.htm">3.2</a></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000108503707002199/exhibit3_1.htm">Bylaws
    (incorporated by reference to our Current Report on Form 8-K filed on September 28, 2007)</a></span></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000108503707000198/form8kexh99_1.htm">3.3</a></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="http://www.sec.gov/Archives/edgar/data/1314052/000108503707000198/form8kexh99_1.htm">Articles
    of Merger filed with the Secretary of State of Nevada on January 10, 2007 and which is effective January 25, 2007 (incorporated
    by reference to our Current Report on Form 8-K filed on January 25, 2007)</a></span></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">(5)</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">Opinion
    re Legality</span></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><a href="e2415_ex5-1.htm"><span style="font: 10pt Times New Roman, Times, Serif">5.1*</span></a></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><a href="e2415_ex5-1.htm"><span style="font: 10pt Times New Roman, Times, Serif">Opinion
    by Snell &amp; Wilmer L.L.P.</span></a></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">(23)</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">Consents
    of Experts and Counsel</span></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><a href="e2415_ex5-1.htm"><span style="font: 10pt Times New Roman, Times, Serif">23.1*</span></a></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><a href="e2415_ex5-1.htm"><span style="font: 10pt Times New Roman, Times, Serif">Consent
    of Snell &amp; Wilmer L.L.P. (contained in Exhibit 5.1)</span></a></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>(31)
    </b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Rule
    13a-14(a)/15(d)-14(a)Certifications</b></span></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="e2415_ex31-1.htm">31.1*</a></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="e2415_ex31-1.htm">Certification
    of Christopher Missling, PhD.</a></span></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="e2415_ex31-2.htm">31.2*</a></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="e2415_ex31-2.htm">Certification
    of Sandra Boenisch</a></span></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>(32)
    </b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Section
    1350 Certifications</b></span></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="e2415_ex32-1.htm">32.1*</a></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><a href="e2415_ex32-1.htm">Certification
    of Christopher Missling, PhD and Sandra Boenisch.</a></span></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>(101)</b></span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>XBRL</b></span></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">101.INS*</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">XBRL
    INSTANCE DOCUMENT</span></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">101.SCH*</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">XBRL
    TAXONOMY EXTENSION SCHEMA</span></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">101.CAL*</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">XBRL
    TAXONOMY EXTENSION CALCULATION LINKBASE</span></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">101.DEF*</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">XBRL
    TAXONOMY EXTENSION DEFINITION LINKBASE</span></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">101.LAB*</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">XBRL
    TAXONOMY EXTENSION LABEL LINKBASE</span></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">101.PRE*</span></td>
    <td style="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><span style="font: 10pt Times New Roman, Times, Serif">XBRL
    TAXONOMY EXTENSION PRESENTATION LINKBASE</span></td></tr>
</table>
<p style="font: 11pt/115% Times New Roman, Times, Serif; margin: 0 0 0pt"><span style="font: 10pt Times New Roman, Times, Serif">*
Filed herewith.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 00 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-transform: uppercase; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="SIGNATURES"></span>SIGNATURES</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0; text-transform: uppercase; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>ANAVEX
LIFE SCIENCES CORP. &#8239;</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 50%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">/s/Christopher
                                         Missling, PhD</span></p>
                                                                                <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Christopher
    Missling, PhD</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Chief
    Executive Officer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">(Principal
    Executive Officer)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Date:
    February <span style="background-color: White">16, 2</span>021</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font: 10pt Times New Roman, Times, Serif">/s/Sandra
    Boenisch</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Sandra
    Boenisch, CPA, CGA</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Principal
    Financial Officer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">(Principal
    Financial and Accounting Officer)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Date:
    February <span style="background-color: White">16, 2</span>021</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<!-- Field: Page; Sequence: 00 -->
    <div style="border-bottom: Black 2pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- 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 -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>e2415_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 2in"><B>Exhibit 5.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0; text-indent: 2in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 2in"><B></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 50%"><P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Snell &amp; Wilmer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>____________</B></FONT>
<FONT STYLE="font-size: 10pt; text-transform: uppercase">L.L.P. </FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif"><B>____________</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase">Law
Offices</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">50 West Liberty Street<BR>
Suite 510<BR>
Reno, NV 89501</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">775.785.5440</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">775.785.5441 (Fax)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">www.swlaw.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P></TD>
    <TD STYLE="width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: right">Albuquerque</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: right">boise</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: right">Denver</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: right">Las Vegas</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: right">Los Angeles</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: right">Los Cabos</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: right">Orange County</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: right">Phoenix</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: right">PORTLAND</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: right">RENO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: right">Salt Lake City</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: right">SAN DIEGO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: right">SEATTLE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: right">Tucson</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: right">Washington DC</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 2in"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 50pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">February 16, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Anavex Life Sciences Corp.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">51 West 52<SUP>nd</SUP> Street, 7<SUP>th</SUP>
Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">New York, New York 10019-6163</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">Re:</TD><TD STYLE="text-align: justify">Prospectus Supplement &ndash; Cantor and Leerink</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have acted as your
counsel in connection with the Registration Statement on Form&nbsp;S-3 (File No. 333-232550) filed with the Securities and Exchange
Commission on July 3, 2019 under the Securities Act of 1933, as amended, (the &ldquo;Securities Act&rdquo;), and declared effective
on July 15, 2019 (the &ldquo;Registration Statement&rdquo;), and the related prospectus supplement filed pursuant to Rule 424(b)(5)
of the Securities Act dated February 16, 2021 (the &ldquo;Prospectus Supplement&rdquo;) relating to the registration of up to $50,000,000
of shares of the Company&rsquo;s common stock, par value $0.001 per share (the &ldquo;Shares&rdquo;), which may be sold and issued
to Cantor Fitzgerald &amp; Co. and SVB Leerink LLC (collectively, the &ldquo;Sales Agents&rdquo;) pursuant to an amended and restated
sales agreement between the Sales Agents and Anavex Life Sciences Corp. (the &ldquo;Company&rdquo;) dated as of May 1, 2020 (the
&ldquo; Sales Agreement&rdquo;). Capitalized terms used in this letter which are not otherwise defined shall have the meanings
given to such terms in the Prospectus Supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You have requested
our opinion as to the matters set forth below in connection with the Prospectus Supplement. For purposes of rendering this opinion,
we have examined the Registration Statement, the Prospectus Supplement, the Sales Agreement, the Company&rsquo;s articles of incorporation,
as amended, and bylaws, as amended, and the corporate action of the Company that provides for the issuance of the Shares, and we
have made such other investigation as we have deemed appropriate. We have examined and relied upon certificates of public officials
and, as to certain matters of fact that are material to our opinion, we have also relied on certificates made by officers of the
Company. In rendering our opinion, in addition to the assumptions that are customary in opinion letters of this kind, we have assumed
the genuineness of signatures on the documents we have examined, the conformity to authentic original documents of all documents
submitted to us as copies, and that the Company will have sufficient authorized and unissued shares of common stock available with
respect to any of the Shares issued after the date of this letter. We have not verified any of these assumptions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Snell &amp; Wilmer is a member of LEX MUNDI,
The Leading Association of Independent Law Firms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">&nbsp;</DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Snell &amp; Wilmer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase">__________</FONT>
<FONT STYLE="text-transform: uppercase">L.L.P. <FONT STYLE="font-family: Times New Roman, Times, Serif">__________</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Anavex Life Sciences Corp.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">February 16, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Page 2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This opinion is rendered
as of the date of this letter and is limited to matters of Nevada corporate law, including applicable provisions of the Nevada
Constitution and reported judicial decisions interpreting those laws. We express no opinion as to the laws of any other state,
the federal law of the United States, or the effect of any applicable federal or state securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based upon and subject
to the foregoing, it is our opinion that the Shares are duly authorized for issuance by the Company and, when issued and paid for
as described in the Prospectus Supplement and Sales Agreement, will be validly issued, fully paid, and nonassessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We consent to the
filing of this opinion as an exhibit to the Prospectus Supplement and to the reference to this firm under the caption &ldquo;Legal
Matters&rdquo;. In giving our consent we do not admit that we are in the category of persons whose consent is required under Section
7 of the Securities Act or the rules and regulations under such act.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 3in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0; width: 60%">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 40%">Very truly yours,</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0 0 1pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding-top: 0; padding-right: 0; padding-left: 0; text-indent: 0">/s/ <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Snell &amp; Wilmer L.L.P.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">Snell &amp; Wilmer <FONT STYLE="font-size: 10pt">L.L.P.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>e2415_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-right: 0; margin-left: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Exhibit
31.1</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>CERTIFICATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">I,
Christopher Missling, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.
I have reviewed this Quarterly Report on Form 10-Q for the three months ended December 31, 2020 of Anavex Life Sciences Corp.
(the &ldquo;registrant&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect
to the period covered by this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all
material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
presented in this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a&ndash;15(e) and 15d&ndash;15(e)) and internal control over financial reporting (as defined
in Exchange Act Rules 13a&ndash;15(f) and 15d&ndash;15(f)) for the registrant and have:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 30.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(a)
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by
others within those entities, particularly during the period in which this report is being prepared;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 30.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 30.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(b)
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed
under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 30.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 30.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(c)
evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on
such evaluation; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 30.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 30.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(d)
disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the
registrant&rsquo;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the
registrant&rsquo;s internal control over financial reporting; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 30.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5.
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons
performing the equivalent functions):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 30.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(a)
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 30.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 30.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(b)
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 30.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date:
February <FONT STYLE="background-color: White">16, 2</FONT>021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>/s/Christopher
Missling, PhD </U><BR>
Christopher Missling, PhD<BR>
Chief Executive Officer, President and Secretary<BR>
(Principal Executive Officer)</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
<!-- Field: Page; Sequence: 00 -->
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>e2415_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-right: 0; margin-left: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Exhibit
31.2</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-right: 0; margin-left: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>CERTIFICATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">I,
Sandra Boenisch, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.
I have reviewed this Quarterly Report on Form 10-Q for the three months ended December 31, 2020 of Anavex Life Sciences Corp.
(the &ldquo;registrant&rdquo;);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect
to the period covered by this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all
material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
presented in this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a&ndash;15(e) and 15d&ndash;15(e)) and internal control over financial reporting (as defined
in Exchange Act Rules 13a&ndash;15(f) and 15d&ndash;15(f)) for the registrant and have:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 30.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(a)
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by
others within those entities, particularly during the period in which this report is being prepared;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 30.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 30.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(b)
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed
under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 30.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 30.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(c)
evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on
such evaluation; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 30.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 30.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(d)
disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the
registrant&rsquo;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the
registrant&rsquo;s internal control over financial reporting; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 30.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5.
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons
performing the equivalent functions):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 30.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(a)
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 30.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 30.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(b)
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt 30.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date:
February <FONT STYLE="background-color: White">16, 2</FONT>021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>/s/Sandra
Boenisch</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Sandra
Boenisch, CPA, CGA</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 219.75pt; text-indent: -219.75pt; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Principal
Financial Officer, Treasurer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Principal
Financial and Accounting Officer)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 00 -->
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>e2415_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Exhibit
32.1</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">CERTIFICATION
PURSUANT TO<BR>
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO<BR>
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
connection with the Quarterly Report of Anavex Life Sciences Corp. (the &ldquo;Company&rdquo;) on Form 10-Q for the three months
ended December 31, 2020 as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), the
undersigned, in the capacities and on the date indicated below, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of our knowledge:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(1)
the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 30.6pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(2)
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Dated: February
    <FONT STYLE="background-color: White">16,</FONT> 2021</FONT></TD>
    <TD STYLE="width: 50%; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/<U>s/Christopher
    Missling, PhD </U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Christopher Missling,
    PhD</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;Chief Executive
    Officer, President, Secretary</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Principal
        Executive Officer)</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>/s/Sandra Boenisch</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Sandra Boenisch,
    CPA, CGA</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Principal Financial
    Officer, Treasurer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Principal Financial
    and Accounting Officer)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. &sect; 1350, and is not being
filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference
into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language
in such filing. A signed original of this written statement required by Section 906, or other document authenticating, acknowledging,
or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required
by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange
Commission or its staff upon request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 00 -->
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>avxl-20201231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.6b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 8KlZs7xRiXgen8uCandcSaOGycPtxJFz2Zkhv2p7fclKfyIgyFsMGCevl7VWcZYF -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:avxl="http://anavex.com/20201231" elementFormDefault="qualified" targetNamespace="http://anavex.com/20201231">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://anavex.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets" id="InterimCondensedConsolidatedBalanceSheets">
	  <link:definition>00000002 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical" id="InterimCondensedConsolidatedBalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations" id="InterimCondensedConsolidatedStatementsOfOperations">
	  <link:definition>00000004 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" id="InterimCondensedConsolidatedStatementsOfCashFlows">
	  <link:definition>00000005 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" id="InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity">
	  <link:definition>00000006 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" id="BusinessDescriptionAndBasisOfPresentation">
	  <link:definition>00000007 - Disclosure - Business Description and Basis of Presentation</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/RecentAccountingPronouncements" id="RecentAccountingPronouncements">
	  <link:definition>00000008 - Disclosure - Recent Accounting Pronouncements</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/OtherIncome" id="OtherIncome">
	  <link:definition>00000009 - Disclosure - Other Income</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/EquityOfferingAgreements" id="EquityOfferingAgreements">
	  <link:definition>00000010 - Disclosure - Equity Offering Agreements</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/Commitments" id="Commitments">
	  <link:definition>00000011 - Disclosure - Commitments</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/SubsequentEvents" id="SubsequentEvents">
	  <link:definition>00000012 - Disclosure - Subsequent Events</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/RecentAccountingPronouncementsPolicies" id="RecentAccountingPronouncementsPolicies">
	  <link:definition>00000013 - Disclosure - Recent Accounting Pronouncements (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsTables" id="CommitmentsTables">
	  <link:definition>00000014 - Disclosure - Commitments (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationDetailsNarrative" id="BusinessDescriptionAndBasisOfPresentationDetailsNarrative">
	  <link:definition>00000015 - Disclosure - Business Description and Basis of Presentation (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/OtherIncomeDetailsNarrative" id="OtherIncomeDetailsNarrative">
	  <link:definition>00000016 - Disclosure - Other Income (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative" id="EquityOfferingAgreementsDetailsNarrative">
	  <link:definition>00000017 - Disclosure - Equity Offering Agreements (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsDetails" id="CommitmentsDetails">
	  <link:definition>00000018 - Disclosure - Commitments (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsDetails1" id="CommitmentsDetails1">
	  <link:definition>00000019 - Disclosure - Commitments (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsDetails2" id="CommitmentsDetails2">
	  <link:definition>00000020 - Disclosure - Commitments (Details 2)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsDetails3" id="CommitmentsDetails3">
	  <link:definition>00000021 - Disclosure - Commitments (Details 3)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsDetails4" id="CommitmentsDetails4">
	  <link:definition>00000022 - Disclosure - Commitments (Details 4)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/CommitmentsDetailsNarrative" id="CommitmentsDetailsNarrative">
	  <link:definition>00000023 - Disclosure - Commitments (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://anavex.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
	  <link:definition>00000024 - Disclosure - Subsequent Events (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="avxl-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="avxl-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="avxl-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="avxl-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" />
    <import namespace="http://xbrl.sec.gov/currency/2020-01-31" schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd" />
    <import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" />
    <element id="avxl_PurchaseAgreement1Member" name="PurchaseAgreement1Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_LincolnParkCapitalFundLLCMember" name="LincolnParkCapitalFundLLCMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_EquityOfferingSalesAgreementMember" name="EquityOfferingSalesAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CantorFitzgeraldAndCoMember" name="CantorFitzgeraldAndCoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PurchaseWarrantsMember" name="PurchaseWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PurchaseWarrants1Member" name="PurchaseWarrants1Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PurchaseWarrants2Member" name="PurchaseWarrants2Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockOptionPlan2015Member" name="StockOptionPlan2015Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OptionsMember" name="OptionsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockOptionPlan2019Member" name="StockOptionPlan2019Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_MichaelJFoxFoundationMember" name="MichaelJFoxFoundationMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_SalesAgreementMember" name="SalesAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_NonOperatingIncomeFromGrant" name="NonOperatingIncomeFromGrant" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ResearchAndDevelopmentIncentiveIncome" name="ResearchAndDevelopmentIncentiveIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" name="CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" name="CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_DisclosureOtherIncomeAbstract" name="DisclosureOtherIncomeAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_OtherIncomeDisclosureTextBlock" name="OtherIncomeDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_DisclosureEquityOfferingAgreementsAbstract" name="DisclosureEquityOfferingAgreementsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_EquityOfferingAgreementsTextBlock" name="EquityOfferingAgreementsTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" name="ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ValueOfSharesObligatedToPurchase" name="ValueOfSharesObligatedToPurchase" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_NumberOfSharesObligatedToPurchaseProrataBasic" name="NumberOfSharesObligatedToPurchaseProrataBasic" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockIssuedDuringPeriodSharesNewIssues4" name="StockIssuedDuringPeriodSharesNewIssues4" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockIssuedDuringPeriodValueNewIssues3" name="StockIssuedDuringPeriodValueNewIssues3" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockIssuedDuringPeriodSharesNewIssues3" name="StockIssuedDuringPeriodSharesNewIssues3" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_StockIssuedDuringPeriodValueNewIssues4" name="StockIssuedDuringPeriodValueNewIssues4" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_PercentageOfGrossProceedsFromSales" name="PercentageOfGrossProceedsFromSales" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_GrossProceedsFromSaleOfCommonStock" name="GrossProceedsFromSaleOfCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_GrantReceived" name="GrantReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="avxl_TotalGrant" name="TotalGrant" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>avxl-20201231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.6b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://anavex.com/role/Cover" xlink:href="avxl-20201231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets" xlink:href="avxl-20201231.xsd#InterimCondensedConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:href="avxl-20201231.xsd#InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations" xlink:href="avxl-20201231.xsd#InterimCondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" xlink:href="avxl-20201231.xsd#InterimCondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:href="avxl-20201231.xsd#InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" xlink:href="avxl-20201231.xsd#BusinessDescriptionAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/RecentAccountingPronouncements" xlink:href="avxl-20201231.xsd#RecentAccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncome" xlink:href="avxl-20201231.xsd#OtherIncome" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferingAgreements" xlink:href="avxl-20201231.xsd#EquityOfferingAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/Commitments" xlink:href="avxl-20201231.xsd#Commitments" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/SubsequentEvents" xlink:href="avxl-20201231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/RecentAccountingPronouncementsPolicies" xlink:href="avxl-20201231.xsd#RecentAccountingPronouncementsPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsTables" xlink:href="avxl-20201231.xsd#CommitmentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationDetailsNarrative" xlink:href="avxl-20201231.xsd#BusinessDescriptionAndBasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:href="avxl-20201231.xsd#OtherIncomeDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative" xlink:href="avxl-20201231.xsd#EquityOfferingAgreementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetails" xlink:href="avxl-20201231.xsd#CommitmentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetails1" xlink:href="avxl-20201231.xsd#CommitmentsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetails2" xlink:href="avxl-20201231.xsd#CommitmentsDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetails3" xlink:href="avxl-20201231.xsd#CommitmentsDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetails4" xlink:href="avxl-20201231.xsd#CommitmentsDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetailsNarrative" xlink:href="avxl-20201231.xsd#CommitmentsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/SubsequentEventsDetailsNarrative" xlink:href="avxl-20201231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets" xlink:title="00000002 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="loc_us-gaapIncomeTaxesReceivable" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapIncomeTaxesReceivable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_NonOperatingIncomeFromGrant" xlink:label="loc_avxlNonOperatingIncomeFromGrant" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_avxlNonOperatingIncomeFromGrant" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_ResearchAndDevelopmentIncentiveIncome" xlink:label="loc_avxlResearchAndDevelopmentIncentiveIncome" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_avxlResearchAndDevelopmentIncentiveIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" xlink:title="00000005 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInIncomeTaxesReceivable" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInIncomeTaxesReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaapPaymentsOfFinancingCosts" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsOfFinancingCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:title="00000006 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS&apos; EQUITY (Unaudited)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" xlink:title="00000007 - Disclosure - Business Description and Basis of Presentation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/RecentAccountingPronouncements" xlink:title="00000008 - Disclosure - Recent Accounting Pronouncements" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncome" xlink:title="00000009 - Disclosure - Other Income" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferingAgreements" xlink:title="00000010 - Disclosure - Equity Offering Agreements" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/Commitments" xlink:title="00000011 - Disclosure - Commitments" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/SubsequentEvents" xlink:title="00000012 - Disclosure - Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/RecentAccountingPronouncementsPolicies" xlink:title="00000013 - Disclosure - Recent Accounting Pronouncements (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsTables" xlink:title="00000014 - Disclosure - Commitments (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationDetailsNarrative" xlink:title="00000015 - Disclosure - Business Description and Basis of Presentation (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:title="00000016 - Disclosure - Other Income (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative" xlink:title="00000017 - Disclosure - Equity Offering Agreements (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetails" xlink:title="00000018 - Disclosure - Commitments (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetails1" xlink:title="00000019 - Disclosure - Commitments (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetails2" xlink:title="00000020 - Disclosure - Commitments (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetails3" xlink:title="00000021 - Disclosure - Commitments (Details 3)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetails4" xlink:title="00000022 - Disclosure - Commitments (Details 4)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetailsNarrative" xlink:title="00000023 - Disclosure - Commitments (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://anavex.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000024 - Disclosure - Subsequent Events (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>avxl-20201231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.6b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://anavex.com/role/Cover" xlink:href="avxl-20201231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets" xlink:href="avxl-20201231.xsd#InterimCondensedConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:href="avxl-20201231.xsd#InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations" xlink:href="avxl-20201231.xsd#InterimCondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" xlink:href="avxl-20201231.xsd#InterimCondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:href="avxl-20201231.xsd#InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" xlink:href="avxl-20201231.xsd#BusinessDescriptionAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/RecentAccountingPronouncements" xlink:href="avxl-20201231.xsd#RecentAccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncome" xlink:href="avxl-20201231.xsd#OtherIncome" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferingAgreements" xlink:href="avxl-20201231.xsd#EquityOfferingAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/Commitments" xlink:href="avxl-20201231.xsd#Commitments" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/SubsequentEvents" xlink:href="avxl-20201231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/RecentAccountingPronouncementsPolicies" xlink:href="avxl-20201231.xsd#RecentAccountingPronouncementsPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsTables" xlink:href="avxl-20201231.xsd#CommitmentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationDetailsNarrative" xlink:href="avxl-20201231.xsd#BusinessDescriptionAndBasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:href="avxl-20201231.xsd#OtherIncomeDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative" xlink:href="avxl-20201231.xsd#EquityOfferingAgreementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetails" xlink:href="avxl-20201231.xsd#CommitmentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetails1" xlink:href="avxl-20201231.xsd#CommitmentsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetails2" xlink:href="avxl-20201231.xsd#CommitmentsDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetails3" xlink:href="avxl-20201231.xsd#CommitmentsDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetails4" xlink:href="avxl-20201231.xsd#CommitmentsDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetailsNarrative" xlink:href="avxl-20201231.xsd#CommitmentsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/SubsequentEventsDetailsNarrative" xlink:href="avxl-20201231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets" xlink:title="00000002 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" xlink:title="00000005 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:title="00000006 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS&apos; EQUITY (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" xlink:label="loc_avxlCommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlCommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" xlink:label="loc_avxlCommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlCommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_50" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" xlink:title="00000007 - Disclosure - Business Description and Basis of Presentation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/RecentAccountingPronouncements" xlink:title="00000008 - Disclosure - Recent Accounting Pronouncements" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncome" xlink:title="00000009 - Disclosure - Other Income" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferingAgreements" xlink:title="00000010 - Disclosure - Equity Offering Agreements" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/Commitments" xlink:title="00000011 - Disclosure - Commitments" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/SubsequentEvents" xlink:title="00000012 - Disclosure - Subsequent Events" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/RecentAccountingPronouncementsPolicies" xlink:title="00000013 - Disclosure - Recent Accounting Pronouncements (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsTables" xlink:title="00000014 - Disclosure - Commitments (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationDetailsNarrative" xlink:title="00000015 - Disclosure - Business Description and Basis of Presentation (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:title="00000016 - Disclosure - Other Income (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srtCurrencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtCurrencyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AUD" xlink:label="loc_currencyAUD_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyAUD_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_NonOperatingIncomeFromGrant" xlink:label="loc_avxlNonOperatingIncomeFromGrant_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlNonOperatingIncomeFromGrant_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_60" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative" xlink:title="00000017 - Disclosure - Equity Offering Agreements (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_PurchaseAgreement1Member" xlink:label="loc_avxlPurchaseAgreement1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlPurchaseAgreement1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_EquityOfferingSalesAgreementMember" xlink:label="loc_avxlEquityOfferingSalesAgreementMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlEquityOfferingSalesAgreementMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_LincolnParkCapitalFundLLCMember" xlink:label="loc_avxlLincolnParkCapitalFundLLCMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlLincolnParkCapitalFundLLCMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_CantorFitzgeraldAndCoMember" xlink:label="loc_avxlCantorFitzgeraldAndCoMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlCantorFitzgeraldAndCoMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_ValueOfSharesObligatedToPurchase" xlink:label="loc_avxlValueOfSharesObligatedToPurchase_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlValueOfSharesObligatedToPurchase_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_NumberOfSharesObligatedToPurchaseProrataBasic" xlink:label="loc_avxlNumberOfSharesObligatedToPurchaseProrataBasic_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlNumberOfSharesObligatedToPurchaseProrataBasic_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues4" xlink:label="loc_avxlStockIssuedDuringPeriodSharesNewIssues4_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodSharesNewIssues4_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_StockIssuedDuringPeriodValueNewIssues3" xlink:label="loc_avxlStockIssuedDuringPeriodValueNewIssues3_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodValueNewIssues3_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues3" xlink:label="loc_avxlStockIssuedDuringPeriodSharesNewIssues3_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodSharesNewIssues3_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_StockIssuedDuringPeriodValueNewIssues4" xlink:label="loc_avxlStockIssuedDuringPeriodValueNewIssues4_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodValueNewIssues4_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_PercentageOfGrossProceedsFromSales" xlink:label="loc_avxlPercentageOfGrossProceedsFromSales_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlPercentageOfGrossProceedsFromSales_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_GrossProceedsFromSaleOfCommonStock" xlink:label="loc_avxlGrossProceedsFromSaleOfCommonStock_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlGrossProceedsFromSaleOfCommonStock_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_60" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetails" xlink:title="00000018 - Disclosure - Commitments (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_PurchaseWarrantsMember" xlink:label="loc_avxlPurchaseWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_60" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetails1" xlink:title="00000019 - Disclosure - Commitments (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_PurchaseWarrants1Member" xlink:label="loc_avxlPurchaseWarrants1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrants1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_PurchaseWarrants2Member" xlink:label="loc_avxlPurchaseWarrants2Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrants2Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_40" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetails2" xlink:title="00000020 - Disclosure - Commitments (Details 2)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_StockOptionPlan2015Member" xlink:label="loc_avxlStockOptionPlan2015Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2015Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_60" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_60" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_60" xlink:type="arc" order="15" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetails3" xlink:title="00000021 - Disclosure - Commitments (Details 3)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapLossContingenciesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetails4" xlink:title="00000022 - Disclosure - Commitments (Details 4)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetailsNarrative" xlink:title="00000023 - Disclosure - Commitments (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_StockOptionPlan2015Member" xlink:label="loc_avxlStockOptionPlan2015Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2015Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_StockOptionPlan2019Member" xlink:label="loc_avxlStockOptionPlan2019Member_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2019Member_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_OptionsMember" xlink:label="loc_avxlOptionsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlOptionsMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaapLeaseAndRentalExpense_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapLeaseAndRentalExpense_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_100" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensation_100" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_100" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://anavex.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000024 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_MichaelJFoxFoundationMember" xlink:label="loc_avxlMichaelJFoxFoundationMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_avxlMichaelJFoxFoundationMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_PurchaseAgreement1Member" xlink:label="loc_avxlPurchaseAgreement1Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlPurchaseAgreement1Member_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_SalesAgreementMember" xlink:label="loc_avxlSalesAgreementMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlSalesAgreementMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_LincolnParkCapitalFundLLCMember" xlink:label="loc_avxlLincolnParkCapitalFundLLCMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlLincolnParkCapitalFundLLCMember_10" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_GrantReceived" xlink:label="loc_avxlGrantReceived_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_avxlGrantReceived_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_TotalGrant" xlink:label="loc_avxlTotalGrant_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_avxlTotalGrant_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues4" xlink:label="loc_avxlStockIssuedDuringPeriodSharesNewIssues4_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodSharesNewIssues4_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_StockIssuedDuringPeriodValueNewIssues3" xlink:label="loc_avxlStockIssuedDuringPeriodValueNewIssues3_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodValueNewIssues3_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues3" xlink:label="loc_avxlStockIssuedDuringPeriodSharesNewIssues3_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodSharesNewIssues3_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_40" xlink:type="arc" order="6" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>avxl-20201231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.6b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CurrencyAxis" xlink:label="srt_CurrencyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CurrencyAxis" xlink:to="srt_CurrencyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CurrencyAxis_lbl" xml:lang="en-US">Currency [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AUD" xlink:label="currency_AUD" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_AUD" xlink:to="currency_AUD_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_AUD_lbl" xml:lang="en-US">Australia, Dollars</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_PurchaseAgreement1Member" xlink:label="avxl_PurchaseAgreement1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseAgreement1Member" xlink:to="avxl_PurchaseAgreement1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PurchaseAgreement1Member_lbl" xml:lang="en-US">2019 Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_LincolnParkCapitalFundLLCMember" xlink:label="avxl_LincolnParkCapitalFundLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_LincolnParkCapitalFundLLCMember" xlink:to="avxl_LincolnParkCapitalFundLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_LincolnParkCapitalFundLLCMember_lbl" xml:lang="en-US">Lincoln Park Capital Fund, LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_EquityOfferingSalesAgreementMember" xlink:label="avxl_EquityOfferingSalesAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EquityOfferingSalesAgreementMember" xlink:to="avxl_EquityOfferingSalesAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_EquityOfferingSalesAgreementMember_lbl" xml:lang="en-US">Equity Offering Sales Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_CantorFitzgeraldAndCoMember" xlink:label="avxl_CantorFitzgeraldAndCoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CantorFitzgeraldAndCoMember" xlink:to="avxl_CantorFitzgeraldAndCoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CantorFitzgeraldAndCoMember_lbl" xml:lang="en-US">Cantor Fitzgerald &amp;amp; Co [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_PurchaseWarrantsMember" xlink:label="avxl_PurchaseWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseWarrantsMember" xlink:to="avxl_PurchaseWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PurchaseWarrantsMember_lbl" xml:lang="en-US">Purchase Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_PurchaseWarrants1Member" xlink:label="avxl_PurchaseWarrants1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseWarrants1Member" xlink:to="avxl_PurchaseWarrants1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PurchaseWarrants1Member_lbl" xml:lang="en-US">Purchase Warrants 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_PurchaseWarrants2Member" xlink:label="avxl_PurchaseWarrants2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseWarrants2Member" xlink:to="avxl_PurchaseWarrants2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PurchaseWarrants2Member_lbl" xml:lang="en-US">Purchase Warrants 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_StockOptionPlan2015Member" xlink:label="avxl_StockOptionPlan2015Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockOptionPlan2015Member" xlink:to="avxl_StockOptionPlan2015Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockOptionPlan2015Member_lbl" xml:lang="en-US">2015 Omnibus Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_OptionsMember" xlink:label="avxl_OptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OptionsMember" xlink:to="avxl_OptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OptionsMember_lbl" xml:lang="en-US">Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_StockOptionPlan2019Member" xlink:label="avxl_StockOptionPlan2019Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockOptionPlan2019Member" xlink:to="avxl_StockOptionPlan2019Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockOptionPlan2019Member_lbl" xml:lang="en-US">2019 Omnibus Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_MichaelJFoxFoundationMember" xlink:label="avxl_MichaelJFoxFoundationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_MichaelJFoxFoundationMember" xlink:to="avxl_MichaelJFoxFoundationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_MichaelJFoxFoundationMember_lbl" xml:lang="en-US">Michael J Fox Foundation [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_SalesAgreementMember" xlink:label="avxl_SalesAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_SalesAgreementMember" xlink:to="avxl_SalesAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_SalesAgreementMember_lbl" xml:lang="en-US">Sales Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="us-gaap_IncomeTaxesReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesReceivable" xlink:to="us-gaap_IncomeTaxesReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesReceivable_lbl" xml:lang="en-US">Incentive and tax receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses and deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Stockholders' Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies - Note 5</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Capital stock Authorized: 10,000,000 preferred stock, par value $0.001 per share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Capital stock Authorized: 100,000,000 common shares, par value $0.001 per share Issued and outstanding: 60,082,291 common shares (September 30, 2019 - 52,650,251)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Stockholders' Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Stockholders' Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expenses)</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_NonOperatingIncomeFromGrant" xlink:label="avxl_NonOperatingIncomeFromGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NonOperatingIncomeFromGrant" xlink:to="avxl_NonOperatingIncomeFromGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_NonOperatingIncomeFromGrant_lbl" xml:lang="en-US">Grant income</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_ResearchAndDevelopmentIncentiveIncome" xlink:label="avxl_ResearchAndDevelopmentIncentiveIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ResearchAndDevelopmentIncentiveIncome" xlink:to="avxl_ResearchAndDevelopmentIncentiveIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ResearchAndDevelopmentIncentiveIncome_lbl" xml:lang="en-US">Research and development incentive income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US">Interest (expense) income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US">Foreign exchange gain, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Net loss before provision for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax expense, current</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss and comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xml:lang="en-US">Net Loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">Weighted average number of shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Cash Flows used in Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operations:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in non-cash working capital balances related to operations:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_lbl" xml:lang="en-US">Incentive and tax receivables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Prepaid expenses and deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US">Cash Flows provided by Financing Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Issuance of common shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xml:lang="en-US">Share issue costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Increase in cash and cash equivalents during the period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_Cash_2_lbl" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance beginning, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">&#160;&#160;Purchase shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Purchase shares, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" xlink:label="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" xlink:to="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2_lbl" xml:lang="en-US">&#160;&#160;Commitment shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" xlink:label="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" xlink:to="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2_lbl" xml:lang="en-US">Commitment shares, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Shares issued under Sales Agreement, net of shares issue costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Shares issued under Sales Agreement, net of shares issue costs, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Share based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance ending, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Business Description and Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="us-gaap_AccountingChangesAndErrorCorrectionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract_lbl" xml:lang="en-US">Accounting Changes and Error Corrections [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_DisclosureOtherIncomeAbstract" xlink:label="avxl_DisclosureOtherIncomeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_DisclosureOtherIncomeAbstract" xlink:to="avxl_DisclosureOtherIncomeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_DisclosureOtherIncomeAbstract_lbl" xml:lang="en-US">Other Income</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_OtherIncomeDisclosureTextBlock" xlink:label="avxl_OtherIncomeDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OtherIncomeDisclosureTextBlock" xlink:to="avxl_OtherIncomeDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_OtherIncomeDisclosureTextBlock_lbl" xml:lang="en-US">Other Income</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_DisclosureEquityOfferingAgreementsAbstract" xlink:label="avxl_DisclosureEquityOfferingAgreementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_DisclosureEquityOfferingAgreementsAbstract" xlink:to="avxl_DisclosureEquityOfferingAgreementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_DisclosureEquityOfferingAgreementsAbstract_lbl" xml:lang="en-US">Equity Offering Agreements</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_EquityOfferingAgreementsTextBlock" xlink:label="avxl_EquityOfferingAgreementsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EquityOfferingAgreementsTextBlock" xlink:to="avxl_EquityOfferingAgreementsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_EquityOfferingAgreementsTextBlock_lbl" xml:lang="en-US">Equity Offering Agreements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="us-gaap_CommitmentsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsDisclosureTextBlock" xlink:to="us-gaap_CommitmentsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_lbl" xml:lang="en-US">Commitments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements Not Yet Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of exercisable share purchase warrants outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" xlink:label="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" xlink:to="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_lbl" xml:lang="en-US">Schedule of share purchase warrants outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock_lbl" xml:lang="en-US">Schedule of outstanding stock purchase options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule of general and administrative expenses and research and development expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of weighted average assumptions for fair value of each option award</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Loss per share for potentially dilutive common shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_lbl" xml:lang="en-US">Research and development incentive income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_ValueOfSharesObligatedToPurchase" xlink:label="avxl_ValueOfSharesObligatedToPurchase" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ValueOfSharesObligatedToPurchase" xlink:to="avxl_ValueOfSharesObligatedToPurchase_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ValueOfSharesObligatedToPurchase_lbl" xml:lang="en-US">Total number of shares obligated to purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Share issued for offering, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_NumberOfSharesObligatedToPurchaseProrataBasic" xlink:label="avxl_NumberOfSharesObligatedToPurchaseProrataBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NumberOfSharesObligatedToPurchaseProrataBasic" xlink:to="avxl_NumberOfSharesObligatedToPurchaseProrataBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_NumberOfSharesObligatedToPurchaseProrataBasic_lbl" xml:lang="en-US">Pro rata basic number of shares obligated to purchase</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues4" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues4" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodSharesNewIssues4" xlink:to="avxl_StockIssuedDuringPeriodSharesNewIssues4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues4_lbl" xml:lang="en-US">Number of shares issued for aggregate purchase price</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_StockIssuedDuringPeriodValueNewIssues3" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodValueNewIssues3" xlink:to="avxl_StockIssuedDuringPeriodValueNewIssues3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues3_lbl" xml:lang="en-US">Number of shares issued for aggregate purchase price, value</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues3" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodSharesNewIssues3" xlink:to="avxl_StockIssuedDuringPeriodSharesNewIssues3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues3_lbl" xml:lang="en-US">Number of shares issued for commitment</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_StockIssuedDuringPeriodValueNewIssues4" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues4" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodValueNewIssues4" xlink:to="avxl_StockIssuedDuringPeriodValueNewIssues4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues4_lbl" xml:lang="en-US">Amount of shares remain available</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_PercentageOfGrossProceedsFromSales" xlink:label="avxl_PercentageOfGrossProceedsFromSales" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PercentageOfGrossProceedsFromSales" xlink:to="avxl_PercentageOfGrossProceedsFromSales_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_PercentageOfGrossProceedsFromSales_lbl" xml:lang="en-US">Percentage of gross proceeds from sales</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_GrossProceedsFromSaleOfCommonStock" xlink:label="avxl_GrossProceedsFromSaleOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_GrossProceedsFromSaleOfCommonStock" xlink:to="avxl_GrossProceedsFromSaleOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_GrossProceedsFromSaleOfCommonStock_lbl" xml:lang="en-US">Gross proceeds from sale of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Proceed from offering</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Share Purchase Warrants Balance, at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Balance, at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_lbl" xml:lang="en-US">Share Purchase Warrants Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" xlink:to="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xml:lang="en-US">Share Purchase Warrants Balance, at ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price Balance, at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Number</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xml:lang="en-US">Expiry date</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Options Outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value Outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Options Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Grant Date Fair Value Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Options Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Option Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Options Outstanding at ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price Outstanding at ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Aggregate intrinsic value Outstanding at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Options Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Aggregate intrinsic value Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US">Loss Contingencies [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Total share based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected life of options (years)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Annualized volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xml:lang="en-US">Lease expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Maximum number of common shares reserved for future issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US">Additional shares of common stock available for issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xml:lang="en-US">Description of grant option</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Expiration period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_3_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Remaining stock based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_GrantReceived" xlink:label="avxl_GrantReceived" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_GrantReceived" xlink:to="avxl_GrantReceived_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_GrantReceived_lbl" xml:lang="en-US">Grant received</link:label>
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_TotalGrant" xlink:label="avxl_TotalGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_TotalGrant" xlink:to="avxl_TotalGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_TotalGrant_lbl" xml:lang="en-US">Total grant</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodValueNewIssues3" xlink:to="avxl_StockIssuedDuringPeriodValueNewIssues3_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues3_2_lbl" xml:lang="en-US">Number of shares issued for aggregate purchase price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_3_lbl" xml:lang="en-US">Gross sale proceeds</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" xlink:to="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2_doc" xml:lang="en-US">Commitment shares issued shares underterms of purchase agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" xlink:to="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2_doc" xml:lang="en-US">Commitment shares Issued value Underterms of purchase agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ValueOfSharesObligatedToPurchase" xlink:to="avxl_ValueOfSharesObligatedToPurchase_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_ValueOfSharesObligatedToPurchase_doc" xml:lang="en-US">Information related to value of shares obligated to purchase initially.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseAgreement1Member" xlink:to="avxl_PurchaseAgreement1Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_PurchaseAgreement1Member_doc" xml:lang="en-US">Represents the information pertaining to purchase agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_LincolnParkCapitalFundLLCMember" xlink:to="avxl_LincolnParkCapitalFundLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_LincolnParkCapitalFundLLCMember_doc" xml:lang="en-US">Information related to type of legal entity.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PercentageOfGrossProceedsFromSales" xlink:to="avxl_PercentageOfGrossProceedsFromSales_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_PercentageOfGrossProceedsFromSales_doc" xml:lang="en-US">Represents information related to percentage of gross proceeds from sales.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_NumberOfSharesObligatedToPurchaseProrataBasic" xlink:to="avxl_NumberOfSharesObligatedToPurchaseProrataBasic_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_NumberOfSharesObligatedToPurchaseProrataBasic_doc" xml:lang="en-US">Information related to number of shares obligated to purchase prorata basic.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodSharesNewIssues4" xlink:to="avxl_StockIssuedDuringPeriodSharesNewIssues4_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues4_doc" xml:lang="en-US">Number of new stock issued during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodValueNewIssues3" xlink:to="avxl_StockIssuedDuringPeriodValueNewIssues3_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues3_doc" xml:lang="en-US">Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodSharesNewIssues3" xlink:to="avxl_StockIssuedDuringPeriodSharesNewIssues3_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_StockIssuedDuringPeriodSharesNewIssues3_doc" xml:lang="en-US">Number of new stock issued during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockIssuedDuringPeriodValueNewIssues4" xlink:to="avxl_StockIssuedDuringPeriodValueNewIssues4_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_StockIssuedDuringPeriodValueNewIssues4_doc" xml:lang="en-US">Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EquityOfferingSalesAgreementMember" xlink:to="avxl_EquityOfferingSalesAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_EquityOfferingSalesAgreementMember_doc" xml:lang="en-US">Represents information related to equity offering sales agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_CantorFitzgeraldAndCoMember" xlink:to="avxl_CantorFitzgeraldAndCoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_CantorFitzgeraldAndCoMember_doc" xml:lang="en-US">Represents information related to cantor fitzgerald and co.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_PurchaseWarrantsMember" xlink:to="avxl_PurchaseWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_PurchaseWarrantsMember_doc" xml:lang="en-US">Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_doc" xml:lang="en-US">Information related to share based compensation arrangement by share based payment award equity instruments other than options outstanding weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockOptionPlan2015Member" xlink:to="avxl_StockOptionPlan2015Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_StockOptionPlan2015Member_doc" xml:lang="en-US">Information related to type of plan.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_StockOptionPlan2019Member" xlink:to="avxl_StockOptionPlan2019Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="avxl_StockOptionPlan2019Member_doc" xml:lang="en-US">Represents the information pertaining to stock option.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:to="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Income Taxes Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfFinancingCosts_2_lbl" xml:lang="en-US">Payments of Financing Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_2_lbl" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_3_lbl" xml:lang="en-US">Cash</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_OtherIncomeDisclosureTextBlock" xlink:to="avxl_OtherIncomeDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_OtherIncomeDisclosureTextBlock_2_lbl" xml:lang="en-US">OtherIncomeDisclosureTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_EquityOfferingAgreementsTextBlock" xlink:to="avxl_EquityOfferingAgreementsTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_EquityOfferingAgreementsTextBlock_2_lbl" xml:lang="en-US">EquityOfferingAgreementsTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_2_lbl" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Compensation Earned</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:to="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_4_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>avxl-20201231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.6b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://anavex.com/role/Cover" xlink:href="avxl-20201231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets" xlink:href="avxl-20201231.xsd#InterimCondensedConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:href="avxl-20201231.xsd#InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations" xlink:href="avxl-20201231.xsd#InterimCondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" xlink:href="avxl-20201231.xsd#InterimCondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:href="avxl-20201231.xsd#InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" xlink:href="avxl-20201231.xsd#BusinessDescriptionAndBasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/RecentAccountingPronouncements" xlink:href="avxl-20201231.xsd#RecentAccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncome" xlink:href="avxl-20201231.xsd#OtherIncome" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferingAgreements" xlink:href="avxl-20201231.xsd#EquityOfferingAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/Commitments" xlink:href="avxl-20201231.xsd#Commitments" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/SubsequentEvents" xlink:href="avxl-20201231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/RecentAccountingPronouncementsPolicies" xlink:href="avxl-20201231.xsd#RecentAccountingPronouncementsPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsTables" xlink:href="avxl-20201231.xsd#CommitmentsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationDetailsNarrative" xlink:href="avxl-20201231.xsd#BusinessDescriptionAndBasisOfPresentationDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:href="avxl-20201231.xsd#OtherIncomeDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative" xlink:href="avxl-20201231.xsd#EquityOfferingAgreementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetails" xlink:href="avxl-20201231.xsd#CommitmentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetails1" xlink:href="avxl-20201231.xsd#CommitmentsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetails2" xlink:href="avxl-20201231.xsd#CommitmentsDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetails3" xlink:href="avxl-20201231.xsd#CommitmentsDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetails4" xlink:href="avxl-20201231.xsd#CommitmentsDetails4" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/CommitmentsDetailsNarrative" xlink:href="avxl-20201231.xsd#CommitmentsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://anavex.com/role/SubsequentEventsDetailsNarrative" xlink:href="avxl-20201231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets" xlink:title="00000002 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="loc_us-gaapIncomeTaxesReceivable" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapIncomeTaxesReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_NonOperatingIncomeFromGrant" xlink:label="loc_avxlNonOperatingIncomeFromGrant" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_avxlNonOperatingIncomeFromGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_ResearchAndDevelopmentIncentiveIncome" xlink:label="loc_avxlResearchAndDevelopmentIncentiveIncome" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_avxlResearchAndDevelopmentIncentiveIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaapCurrentIncomeTaxExpenseBenefit" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapCurrentIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows" xlink:title="00000005 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInIncomeTaxesReceivable" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInIncomeTaxesReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaapPaymentsOfFinancingCosts" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="loc_us-gaapPaymentsOfFinancingCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_2" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCash_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity" xlink:title="00000006 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS&apos; EQUITY (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" xlink:label="loc_avxlCommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlCommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" xlink:label="loc_avxlCommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlCommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation" xlink:title="00000007 - Disclosure - Business Description and Basis of Presentation">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/RecentAccountingPronouncements" xlink:title="00000008 - Disclosure - Recent Accounting Pronouncements">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="loc_us-gaapAccountingChangesAndErrorCorrectionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingChangesAndErrorCorrectionsAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncome" xlink:title="00000009 - Disclosure - Other Income">
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_DisclosureOtherIncomeAbstract" xlink:label="loc_avxlDisclosureOtherIncomeAbstract" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_OtherIncomeDisclosureTextBlock" xlink:label="loc_avxlOtherIncomeDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureOtherIncomeAbstract" xlink:to="loc_avxlOtherIncomeDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferingAgreements" xlink:title="00000010 - Disclosure - Equity Offering Agreements">
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_DisclosureEquityOfferingAgreementsAbstract" xlink:label="loc_avxlDisclosureEquityOfferingAgreementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_EquityOfferingAgreementsTextBlock" xlink:label="loc_avxlEquityOfferingAgreementsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureEquityOfferingAgreementsAbstract" xlink:to="loc_avxlEquityOfferingAgreementsTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/Commitments" xlink:title="00000011 - Disclosure - Commitments">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/SubsequentEvents" xlink:title="00000012 - Disclosure - Subsequent Events">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/RecentAccountingPronouncementsPolicies" xlink:title="00000013 - Disclosure - Recent Accounting Pronouncements (Policies)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="loc_us-gaapAccountingChangesAndErrorCorrectionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingChangesAndErrorCorrectionsAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsTables" xlink:title="00000014 - Disclosure - Commitments (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfOtherShareBasedCompensationActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" xlink:label="loc_avxlScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_avxlScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock" xlink:label="loc_us-gaapScheduleOfStockOptionsRollForwardTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfStockOptionsRollForwardTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationDetailsNarrative" xlink:title="00000015 - Disclosure - Business Description and Basis of Presentation (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/OtherIncomeDetailsNarrative" xlink:title="00000016 - Disclosure - Other Income (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_DisclosureOtherIncomeAbstract" xlink:label="loc_avxlDisclosureOtherIncomeAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureOtherIncomeAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srtCurrencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtCurrencyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currencyAllCurrenciesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtCurrencyAxis" xlink:to="loc_currencyAllCurrenciesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd#currency_AUD" xlink:label="loc_currencyAUD" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currencyAllCurrenciesDomain" xlink:to="loc_currencyAUD" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_NonOperatingIncomeFromGrant" xlink:label="loc_avxlNonOperatingIncomeFromGrant" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_avxlNonOperatingIncomeFromGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:label="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative" xlink:title="00000017 - Disclosure - Equity Offering Agreements (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_DisclosureEquityOfferingAgreementsAbstract" xlink:label="loc_avxlDisclosureEquityOfferingAgreementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avxlDisclosureEquityOfferingAgreementsAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_PurchaseAgreement1Member" xlink:label="loc_avxlPurchaseAgreement1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlPurchaseAgreement1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_EquityOfferingSalesAgreementMember" xlink:label="loc_avxlEquityOfferingSalesAgreementMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlEquityOfferingSalesAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_LincolnParkCapitalFundLLCMember" xlink:label="loc_avxlLincolnParkCapitalFundLLCMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlLincolnParkCapitalFundLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_CantorFitzgeraldAndCoMember" xlink:label="loc_avxlCantorFitzgeraldAndCoMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlCantorFitzgeraldAndCoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_ValueOfSharesObligatedToPurchase" xlink:label="loc_avxlValueOfSharesObligatedToPurchase" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlValueOfSharesObligatedToPurchase" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_NumberOfSharesObligatedToPurchaseProrataBasic" xlink:label="loc_avxlNumberOfSharesObligatedToPurchaseProrataBasic" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlNumberOfSharesObligatedToPurchaseProrataBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues4" xlink:label="loc_avxlStockIssuedDuringPeriodSharesNewIssues4" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodSharesNewIssues4" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_StockIssuedDuringPeriodValueNewIssues3" xlink:label="loc_avxlStockIssuedDuringPeriodValueNewIssues3" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodValueNewIssues3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues3" xlink:label="loc_avxlStockIssuedDuringPeriodSharesNewIssues3" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodSharesNewIssues3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_StockIssuedDuringPeriodValueNewIssues4" xlink:label="loc_avxlStockIssuedDuringPeriodValueNewIssues4" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodValueNewIssues4" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_PercentageOfGrossProceedsFromSales" xlink:label="loc_avxlPercentageOfGrossProceedsFromSales" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlPercentageOfGrossProceedsFromSales" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_GrossProceedsFromSaleOfCommonStock" xlink:label="loc_avxlGrossProceedsFromSaleOfCommonStock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_avxlGrossProceedsFromSaleOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetails" xlink:title="00000018 - Disclosure - Commitments (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_PurchaseWarrantsMember" xlink:label="loc_avxlPurchaseWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" xlink:label="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_avxlShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetails1" xlink:title="00000019 - Disclosure - Commitments (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_PurchaseWarrants1Member" xlink:label="loc_avxlPurchaseWarrants1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrants1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_PurchaseWarrants2Member" xlink:label="loc_avxlPurchaseWarrants2Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlPurchaseWarrants2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetails2" xlink:title="00000020 - Disclosure - Commitments (Details 2)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_StockOptionPlan2015Member" xlink:label="loc_avxlStockOptionPlan2015Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2015Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetails3" xlink:title="00000021 - Disclosure - Commitments (Details 3)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaapLossContingenciesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLossContingenciesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaapLossContingenciesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapLossContingenciesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLossContingenciesLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetails4" xlink:title="00000022 - Disclosure - Commitments (Details 4)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/CommitmentsDetailsNarrative" xlink:title="00000023 - Disclosure - Commitments (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_StockOptionPlan2015Member" xlink:label="loc_avxlStockOptionPlan2015Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2015Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_StockOptionPlan2019Member" xlink:label="loc_avxlStockOptionPlan2019Member" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_avxlStockOptionPlan2019Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_OptionsMember" xlink:label="loc_avxlOptionsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_avxlOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaapLeaseAndRentalExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapLeaseAndRentalExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://anavex.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000024 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_MichaelJFoxFoundationMember" xlink:label="loc_avxlMichaelJFoxFoundationMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_avxlMichaelJFoxFoundationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_PurchaseAgreement1Member" xlink:label="loc_avxlPurchaseAgreement1Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlPurchaseAgreement1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_SalesAgreementMember" xlink:label="loc_avxlSalesAgreementMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_avxlSalesAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_deiLegalEntityAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_LincolnParkCapitalFundLLCMember" xlink:label="loc_avxlLincolnParkCapitalFundLLCMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_avxlLincolnParkCapitalFundLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_GrantReceived" xlink:label="loc_avxlGrantReceived" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_avxlGrantReceived" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_TotalGrant" xlink:label="loc_avxlTotalGrant" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_avxlTotalGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues4" xlink:label="loc_avxlStockIssuedDuringPeriodSharesNewIssues4" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodSharesNewIssues4" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_StockIssuedDuringPeriodValueNewIssues3" xlink:label="loc_avxlStockIssuedDuringPeriodValueNewIssues3" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodValueNewIssues3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="avxl-20201231.xsd#avxl_StockIssuedDuringPeriodSharesNewIssues3" xlink:label="loc_avxlStockIssuedDuringPeriodSharesNewIssues3" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_avxlStockIssuedDuringPeriodSharesNewIssues3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!K0)V P$1  (1 0,1 ?_$ 2   0 !! ,! 0
M       &!0<("0$"! ,* 0$  00# 0$             !@0%!P@! @,)"A
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M>]W_ .1Q[G'"+4M1>57F8H]+H!*[=DJW9IFF[ >7^*:,%9>MUZSR.L8ZOQB
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MRJ91$$75KLD&E%Q+9RX.V:+F7E(_PQ%\HE(Q"QH]2/!4'"9'3=15$3$*<IC
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M>/1[T3!A_P"C@[^2RTZQ_&-U.DRUN=[LV<!I\1O[OW%8;C@YP\B][:3?'?\
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MAZ!0$R?\^4X\  @A^$1'O_@R5^,,,'3\P')_@5CZ%W2]%[/*K3\Q/^0;<?\
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M1I:="@-<>=,:$]22T_9@H>#)HM3VAY,-Y"[M$;,=R#)\8*C*-FX-B !@6BA
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M-U_P7>XG13_-R?%=VE4X:$E['+QL# 1CR8FYAVC'Q<6P0.X>/G;D>@DW11(
MB;IB/=$>!2EXB80 !$+Q@<!F=39FSP&G[=]WFK^3<@AC[I\CJT(IS4H:EU
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MY#8[F!YEW=UP>),A)DM\>YQ:14MFJ >4"DHY5V)]F/I G>M>QP#CQ "R4$4
M'CQX]R [HB/X<Z1_V=G!6'=='?9SI&LW:F:!W<\M*&WIS\M*KCUP.(S8FPPV
M>*8&BE1'*7$=@DRDT0/LQ](!QX6K8X=+N&X2<$'2#_4B'B#NE_0[V/[NK@EN
MB,7F<$8K0=-#L)VEP_$<OL]C8NHZWO$1H.Y98@5Y:0O]W\HGW8^D./2"U;&
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M\->VV*M*5_L]G28*<'U>M,]*2T),L%1*#IBZ;NG"Q6YU2!^QN" "J"G Q>/
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M<:TM)9N='O2.8:U:XC9W*Z/KMK$C2QD2EG4U .I=Q/4JH2%/,A*4*:D)]G,
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M&395H<]MD&W!>2T/IOA[V=Q790 G8I7C=)9BUO\ #RF.!IM-*2V4@$XV71#
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MF^;(,@Z>(-?*X;13:-O/3L=E:Z^ ?A'_ $/U\^=6])\T_P!T+<O?/8;\=J<
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MLC+?3.\PU'^]20#[1O:)]JG69^=S?F'_ -,GN[<AG=_>_5_=X_\ ]R5_A_\
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M-/EWZ9D_/E5?:?UD=T,IE-T<WT9'^:+GW;^07\E:K^L97Z5X' ?J5#D9I_\
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M'IJD15%#W5:[NQ030\>LYL\V'07C7UA=&\-\7.[(6$=V :C812NU8L(C]G8
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M!H(^X5TERN4GC,,]S.^(\K72/(/M@FBK67A4"81,(F$6MS[3I,BFE::!R@8
MV5'"''X!\06#/GS_ &C\TD?!2P8P]S)G8@[9R@03N^YM:#L]I;;]3=SH^)5Y
M*PT>W$S$=CW\8VCD/+SK4?J73,QN&4F(FON82/<0T.O+K*3*QVJ*H)D6ZAND
MKU8I]8NLEP[INGP$1(0_1, ?*_A3P=S'%[)7^-Q%S8VC["U%RY\Q:QKPX5$(
M!H >:HV^VMV^(W$K \-[>TER5M<2B:6AZ)F\2T4WNSM .SL]D<J^(Z>E?-HU
MC)*5M19*(D;&M7@5D239:Y$V=2HOY8 7C$8PR:,NG_4?" <BE\8$Q'B&<C@U
MF9=,NU)%=XX2B+IS;]UO-M/&39^-E]-WHNG%-T'?_>T75W$K#?3S<2+*]%D^
M9L+;HMCZ$W+K?QL6V[^4 Z#\.GOOPE6@T<GYY-Z(;8%"+95Y,83P$R%MZI*8
M,X0038J/!K (&,8RIN!R"9( (/$W>XW^3@5 =7,T3]8<#%GWSNAW7^-"/?#&
M;&N-KW3B]X( )K2G(K-'Q8Z?3L^H[?!Y!]C ULA<!"?Q?1R.+J;XV=R":T/)
MR+P):CAG4?.RC;:.NSLJV#498X-[B55$7KKP%H5--6K$Z\5WO%,.CWA#B/ .
M[ENCX08Z:RO\E%J/3;H,<=R5N_="K][=%";7\)VP<@]E5\O$V2"^M;.73N5$
ME^RL(,< K1N^YU1.X[K6U)V<GLJ-QNO2OJL-M?3]:KT<M*NX>,2F1D^OEWL8
M@U<2*312/BWS5LH@B](8A7*B)EAX@0!X".6'#\.;;)Z6DU5-E,798OQCH;<W
M/2"2Y>*=+1L;',8V,;6%[F%_)NN/)<LCK8PY]FF\?CY\ADC")G&R#"R%M2 )
M^F-0TEN[(6;6M-10T4WB>7:ZRTHYA4AK[:4*K;$HUF]>G14G4ZC'M))[(0QP
M:F2<,)$)!N@R4.)"KKK 4![@\);B^KYJO,Y:YPECXNS(PONF0,EHUUV;6".7
MI&&@'03%[1!(-CGRQ-YW*RW_ !DTGC[-F3;%+/:NEMA(6LHRW\9D?&(WGWW2
MQ"*225NW=W3^#2M!C-/R+Z+2FY&7K-8BCU@MJ7=SAY7HLFBEK<4Q-@Y1CHE^
MZ)(FFVI@$@)F*4G 1-WP"Q8C@[E<CB?IN[N;&PQ/T7XX^:ZJT1,%UXF06L!=
MTKIP6L80?Q9:XBJK\EQ%Q=C=NP]E;7V2OAD#;L-I'$Z24>+MNM]H?1FX(G $
MTJ>;LJK1V@[(^5<M%9.HQ[X)F(@H-L[?/5$[@_GX$]FA#5U\QCW3(S&5ADQ4
M37<G;I@80*82FX@%^L. ^:O[N^M7W.(@R$4]NVUB>Z3H[TW-E)=PLMI ""'Q
MLW]Z1S:. ;6E0J*\XM:<A:V=EGE'61BEDF>R**MC'!,+>9]RQ_=%S9B 61@F
MA.S8%1V6H))VR9E\;5I&RRL"M9XBE+N'9;+(0:*#M\#E(J<>:)2=NH]BHLW:
MK.2.%D@ P%XF(!K-C>#V2OK"*+QK%1ZGN;.2ZAQ\CRVZ,3(WN E=001/>&&:
M*)Y$DD9!;4$!5=WQ0Q-K=RB;'7TF-MI^@DN;>-KK8RUC9L<\[] ^5C7&A#7]
MS7E7I6TC:D;3KZH@C#K/]EP\%-UUXDZ,,6FQFDNM,>3=F1*+$\0GQ.]*)1ZH
MH"(=(! <77!#55MJG3VEFMBDO=06MK/;.W=UCF7;CN]+45C, H9!LHS=<??5
M7I;\3]+R:=S>I2)&V&"GEBN&2-:V=SH=KNC:-CMX$!G9?4<H*\M@U.>L0R\M
M,V6KLUR25GBF4*!)IS*2CFIS9X&2.U.WACQK=%1^D/5"X63$Q.Z/ 1#.F<X2
MG3.'FO\ /7UE%>B[OK:WMV-<Z6XDLI7V\A+Z&.-HE;5E2*@T*]['7L&1R[,9
M:XV[<9;>WE;*!%XLUMQ!XPSI*N$H=T?OMVH',L?=L7^[M+ ^KG+9R@V+=K'3
M]-H4CO:XNK1.]4]OMXK;:XMJ?7H:"7:+UB$;UIR05II9-\B1XJFGU/1'B;ZJ
M\#NH5P#UYP<TKKO4$62&4SMG'*X>-L;[X25<6MHT %HV #93V5IUQ ZP?$W3
M>N<KA+.6V9CX+LQPM,,)#& T&\XM+G4YS6M%EMK?:'(%=X6CVR7HFV:]6-@Z
MQJ%^ABLKN>?MC.2LE=C9UW7Y:M)P#!)HT:J.'K9D\(]5/(KQ:Y4VX"*8&R#<
M_P!FWP!C<\,AR6XU]"?'!3WU!0[IK7GV;.SSJ"R]9_BY$3_O#%D#_5XOD+(>
MB5;D)NM>/87M0Y@J0@09$!;6L3E<"9@U4>$334ACRK-16331.1H7K.*ZY11+
M^R_$R(9SJ*=6S3U^^ROK?)5:!0B[<\'V@&@_?5LN^MOQ4LY U][C7&G(VUC=
M]X-K_@4A5U?R-I3$5&$K&\W",BG)HN7)%7@+QLVP9QLHE .&7@YCJOW,-)$=
MF,0XI))&3 3"=3HEL3NIIU8A(T&SS.Z3S2RT/L5V_N*G/7!XJN[EL]JXCX%B
MTG[M6\B];K5W($T:*23IINQE&$6!HC).@D$6;Z0\,D&'BUHNH@4#O1?0[U'H
MG A1.T4X&'X@G]G]3#JPM[OQ/,!@(%#-+RGDYAV$'7 XJ1BLL]JP5_#L6BOM
M4;[J\6R=.\B,72[P%"OKJ2V1$UB7D*_ +6I^X=>-V4<X?MT'L>I%(D >@U.(
MIJ')T^@( (CPRP\7.H]P7TAPBS^N<!99,W]GB9KBW+I7N#9&-):=UVQVWE#M
MBR3PTZQG%35>NL-BLD^T?@[S(0Q2AMO'&7,>X!S02W>%1^$""/;6M04$?ZVF
M/Z10_6SXY]$P !T18ZG(X-WO;V"FU?1-IA>-YC&[OLMVIU"/]:)_2ACHHO@M
M]P+M2/X#/<3J$?ZT3^E#'11?!;[@2D?P&>XG4(_UHG]*&.BB^"WW E(_@,]Q
M.H1_K1/Z4,=%%\%ON!*1_ 9[B=0C_6B?TH8Z*+X+?<"4C^ SW$ZA'^M$_I0Q
MT47P6^X$I'\!GN)U"/\ 6B?TH8Z*+X+?<"4C^ SW$ZA'^M$_I0QT47P6^X$I
M'\!GN)U"/]:)_2ACHHO@M]P)2/X#/<3J$?ZT3^E#'11?!;[@2D?P&>XG4(_U
MHG]*&.BB^"WW E(_@,]Q.H1_K1/Z4,=%%\%ON!*1_ 9[B=0C_6B?TH8Z*+X+
M?<"4C^ SW$ZA'^M$_I0QT47P6^X$I'\!GN*152RSU'L,5:JE)N(&PPKHCN-E
M&(E(N@J4! 2& 2B19LX((IJI' 4U$S"4P" Y*-&ZGU%HC4=MJ71L\EKJ2V?O
M0OCH'%W.T@]R]CFU#V/!:YE:BM%:,_@<1J3"W.(S5I%=XN6(B2,[#N_"810A
M[3M:0012H6R3=7-37^87E-?QTCX)#;,@K133V2NE/T$9!N5XLD:P0(',916-
M7.(=:GQ%1HH8"GXE$AS_ $/XR=9/"=8#JG7>YNV7$&PR./-W; G=J)BT7$%?
M?P2.!V;3&ZK75HUSM/>&_!B_X9<>+:XM7&ZTK-9W4EM<$;0YL8<8I!S21UY>
M1XH1MJ!KF8?SO>X#W^]^#/G=9O9/4AM&F9Y/LN<07G[I]SF6W]XZ-Q#HPT M
M:[8!RNVN^_[BF<>!0X<"@'>[O#\(9*;)H8\%HVJ.W)#JN<&EPYR!VE,60?&_
M4_E<<F%F2ZA)/W#16&Z#-K]UF]_BCM*9L #@3]'_ +&3"PJP!S2:T[)5AN&L
MHY^ZS>KV IFSXB)0#AP#CWN =X.YDKM7.)Y2H_<,C;M#6^X%,& <>CQX]X1_
M4$,F%B2VC&D@'_ERJ-W) J  /:%#]PJ:,  !+W.\/ZX9,;%TC&AC7OW?\8]A
M6&Y+@=W><1[))4SCAXJ ' .'<#O?H@'\K);8F0D=V_D[)5AN^Z[@^]J%,F'\
MZ/>[H]X1_7R76 WB0_N@!^%MY_95@N&U!K79[*F;$H?%[GX,E=FR.H(:T'V!
M11R\%3M)V>R5,&G HD  #@)0'O!W^/?_ -#)C8@/(>X#>&SD4=N!6I)/NJ9,
M@#N=SN=SN=X.Z(\>YWN[DSL"*A]!O>T%'[A@(+B37VRIHRZ(=$![@?R?T,EE
MH^O=$-K[05CG:T5V*91O2+W4AZ!^ <#<.D' ![H"41#CQ*'#)?CGNB(<S9L4
M7O6!^WV5+452K$Z0=\.X8 [P#^@/P@/P9+&G>%595]<Y1,(F$3")A$PB81,(
MF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%K?^TW_ ,BU.[@C
M_P ),=W@$?\ Q!8._P ,^?/]H[;SW/!G&QV['R2?3\6QO+_-[E;8]3^5L7$.
M^<][&-^B)=KO])%]]:/T'#EJ<ZC59TV4.DJ@=1LJLW.=!=,R*Z!S)"0QD5T3
MB4Y!^*8HB @(".?'"T.H<69&63KNW>]NZ\,@>-X4VM<YOOA[/.OHK??1&1#6
M7S[2>-C@YH>UKJ.%""*CEJ KT-]PK$U_':Y=M9A>N)4Z0AWC BR":/G.%N=6
MR L37BGTP29BH5NND<W!9(QNYQ HAFW%\4<A:Z(BX<3V>0.FOHRX92G<FZ9?
MRW\#S45(8_<BF:32C7"AHL3Y?AZV^U1<ZMM+K',RPRO2MD)(<+5]H+!\>RK0
M00=W9R@;14JLV'<S"8V?6=C*#>I-.%MA+ :!G7L8LWC&0+H+GC*^LU[J)1ZO
MH\5B@ E*7CW0XY>]2<6L?GN).*UK8.S$S;/,.NC#=11B)D1;!W%L&L%'%T3M
MVM*&A&VJM^F=!WV.T;D])2_0UOTUF8V3QN>73/W7,:Z7>:*4!_!K[YVQ6ICK
M*@Q@;[$*,WBBMN"#\#6*)039#%3WC94S@H_&-UJ/$A0)W -W^YF);7-W+,#J
M+'R6-VQF:N6OB--T,W9Q*14M(!(!;R&M:+(MYA1/EM/Y!U_:B+%LD;+N&CW;
M\!B;2G-O$5KS54EIEYAJK79^.<L[/*.)V,F8U[ *.8U2C22C]@JTB)=\P<M5
M)!M*UY94%T5$!ZTRB9.BHF7I%&4Z&UQB]-:6RN%O[7+2NR-C/;OM)#$ZRD<^
M)PM[@QNBV36\VX^)[1O!PV%1C6>E,UJ+4EE=6LV(CM8KFWD\8#G1W@9',Q\L
M56;)(Y8VN:]KB&[I-0315,^VE%%(I<[><47B=*J:N:+&=E!9M+B=T="=;'[Z
M;5 RB0@0!!7BF'=[@9>V\4[V2\L+Z>WR,UW8:*&*C._O.9<0R]+%)5K6D-8
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M/=X@/]J4KW>(\1X_VO\ =XCG/K.]5^H_WMCJC:/Y'+L]D?R=/L2X[M%#87P
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M!4;9)7"-D$3 SZL'AI"1,0W .B!"%$/C<<RR,-QWCP$.$L-%YBWNX;.UM&W
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MHBTG;<161FM>EMWM=OPQ6USTG2"&(NW9*G?<UM!RE50TCS*BJ90-%W8@>?\
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M-%!%(@%*4H   ' ,^C-G9VF/M8[&QCCALH6-9'&QH:QC&BC6M:  UK0
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MFB^T1IR+FI*01:+;'!DRIJEK(U7UF9O9WPIST9"E0BXI2;\#E6"A),JXN4G
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MG1-9=I2DE+.Y^-C90'9(%)&IND'\<F]<%KUC2DG02B\0X5\%=)*(H*$7*?N
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M1,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PBU-?:?M'+@^DCHQCF411>7
M[EN@@Y5(HD4*VH9!4[9%4R)5R)B7CW^ CPX\,^7W]I#;S2LTA/%!-<]#/>2=
M$R-[P\M\5H'%OO0:D>S5;K]3R[M[>74$,MS':RS6\#6/?R UEV[7M&RM=M5@
MD3>FS%9=W(RU<5F&9K)$6B#AU8AZS:5I[""Y;,4(U9E')N5$"0;DS P+&,(H
ME*(#Q#AFE(XV\19\M<W>=Q-U?!N19<V\+K9S?%'0#HX(XI6,#]V& O@94G\7
M1O(%L=/PFT?'81V^)R,$5P+&6UN)!(TB<3%LDKG-<\@$S-$PIR/J1RJB1^U[
M\RK=2KCBHEEF%6):(U3QA$2QU+!6;2P0C7=7FS)$3.=A'M""5HLF8JZ =#HC
M^QERAL>,&N+'#8W3F1P[+RVQ,EV9S(R=QO+2\@9;.@E<15XCB:V)CN5@:*'8
M5<)N&>F9\YE,O:Y9MO<7DEI-&8Y(@([BWVB=@Y-XFI>#W+R37WQ7K)M%\5L$
M,.K'BE3+4I.I!"*S5T5?&1E++&6I=V:QBGXPZ:<C%ID33*4I"HB)>[QXY[P\
M6;AG0XMVF+HZ4CQDEJR+QB]\99TEU'>D^-5Z0$3PL#>81 Q^])"H8N'=E'&^
M<YIOT^S(LN&S>*6G1$1Q20 "*FX062.WJU)=0UJ J<TO9FC"NLR:G54<TZQR
M%@JCQ22MICQI9*=83BT<Y0,W,C+I)G8@F"J_[()#"(\1RW6&O3CL1B+/(:3>
MZ7$WTUQ;/,UV0&2S-N)&3L (G+W,W6EY[DD$<BN5QHV>66YD&I"8;^U;!<-Z
M&VC:X,C=&PM<VG1[H=4;HY0%Z3;6O*L9$Q*M35.WBV]T:**>+95)U)M[=&3$
M0U1D70-C*+)5)A..21Y>\4JH@/#CE4>+VK+S&8_%SX5SW6PR(E<R.8OGCO8I
M;>WCF=2KQ;1W,K&UV[KRT\JH;3AA@K6\GOK/*0-N)1:FA=$6,\5?')1C:T;T
M[XV.FI^4+1O5HO=VT;(.^=&?5MQ(P:<C4Y&!K9XIXBPKB](D(]S70CGC>.2?
MK$9L6)F@]<<XF174'O\ #*VWXVZV%\PY3$/DTFUUF^WM'PO8V!]A)'):O8]C
M \OC9'+&"YQ!$G(O(<)]'QXV.&QR4=OE-RYCGD;*T=*RZ:>E!;O%H+GD/J #
M5C1S!0V<N5RL%&CJ&^KKL8^'L\A88E^6)DADFB#])Z4($3F1,FO$LG,@LJ@!
M@$Z8J&*'Q1[D'SNNM6:@T-!H^]Q#1;VV3==,G,<Q?&',<UT>Z!M89))IV#\"
M25Q;044IP^DM/XK5%QJN+)Q^,75HV&=G21[CGAS7&9K?P9) QK92/?M: 5TF
M++(/:@G38?7SRMQJLPRGY<45+/+ ^F&#!>/1<,F\H"J$(BLFY4.NFCTA54,7
MB?HD*7/;4FJ,IE-#_4_36G;JQQTMRRYED:;F:.25C7LZ1D<N\V(N#W;S&4KL
M/,%Y8K2=IB=6.U?D,O;WMV83%$QA@B>V(O+VB1[-KRPDAI=[UNQ4O739[%;
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M$[Y[%\_.O92-=.&,A&Z HCZ/?M%#(NF+YG>[XZ:.VRY/C(N6SA$ITS!W2F*
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M^P.;YM'>%AV:^M<#K0S.D5P*[J^DJSU/C9>7-<E]E7EG:XYN5N*8#3Q44.4
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M>J>N?^43'K"ZA_9AONO_ #=/5BTW^TP[S#X=/XO+RX_](8W]4]<_\HF/6'U
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MX_&IL87CW.'#XLV(Y;I>*UY)R6<31V-\[/8VM5RBX.XR,=U>W+G4VF@%3V:
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M\U<.570G3*@0Q2BY(<I%%('[1^\/M?Z[O<URGV=O'7KF_/RKNI^J[4I]LUQ
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M[Y&,$C0XD;SB!N@,<=[D]T*KT[E$O.QY^+@=;W;46P$IC8VM=5,;'6[C(#6
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M$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$7' /P!^IA$X!^ /U,+FI3@'X
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M N6,C,59Q6.D?Y0M=0]T.;;R55#C^']QDL#)G8;DM=&)2ZW=(\2 0?E"7UW
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MJ2F$5HOLU?X#O+W_ 'JRG^-E@PBSFPB^:JR*"8JKJIHI%$H&45.5-,!.<J9
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M=)3:E4*K/LY:1K=8:R%T>3=@CHBT2%45>Q[I&OFKZ:#I[%KK(BX>HF.W(!A
MIC%*)%:#P]_^4)#]W._]FPBVZ_9U?:-/M&OHS2^[I=W(Z;D796U;M3Y5=X^U
M@^=J_P!2=*G%5PZI#I<XF4)\8\><PJ)\4A.0"+]/#)ZSDF;61CG;9^P?-T7;
M)\R72=,WC1PF59NZ:N4#'1<-UTC@8AR&$IBB @(AA%Z<(F$3")A$PB81,(F$
M3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB8
M1,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$7Y>
M/MJ%"%YHJ,!CE*(Z8B! #& .YYV6GN]T<(L :+OF3H&K7] K<C*0,C-[(:6F
M8L426%._)5_-1>M2,7"NW[9=_#3JX.5#$<MCH&ZLPE,H #PPBOG'\YE;4M9)
M27US'QL%5=ETN_ZT+446;&S1:-+C%:8RC;+(OI!9K(KJZ_\ !VXJ()I%!VS3
M/P,7N@14J(YR%63:2G9J)?6C85EU7#:FO+R7<QYZU=ZU"7E"5%M+M4#HNT G
M-?G5B'AT"$4!T1)R3XXG$2*+-^8:G56LJUK7L=<(A.+I^Q*W3)21D8D\O"/;
M9MBI;)K;YTZ:*%!<:XWKAFZBI (=982' H )@ BN ?FPUO(;!@=C.*[?JHXB
MJ+5*U.4JFR=36H=_59/)V8O%:M$).M5T@I%NG9?KD@Z*ZC%$RA2("<$SE(H&
MEO\ UMXW@-I*52SMMOU*A#1X&*82\,75_7L*\_I]8LKD5DALZ9X*M/$R#'$*
M9)PY:D4%<A3')A%['?-'#O:CM*E.Z\]?1=PU;4*C273A^R3>TFVQ%5HU4MLG
MP**A%Z[;V5/(95N004!9!LKPZ13X10:C;>I5.U/=*:NG=YV5N4'-0[NIR+ZN
M.=3I3;]5$L'L)FT<(&GX:UU=HD )>"@4ZZI0Z;@J'%$2*KT/=>M:I6-3.I6O
M6Z8V#I:8N,W5&S:2@V%&E).?EFLW"O; X.1Q813A)%L0ZC9N0@.@*!>M(43"
M!%*J?S)42$FH2S2S78ZS^(UU3*+-52,D*F?7^SF5=A';*4@+]#S#=V88&2EW
M(+IKIE7<((]($TTUNBJ4BJP<S]$,KJ6<='V?(/\ 4M9JJ,)KB0=5E?4A;I2J
MF]AX"P$1%[X]\#+.&;.U4S$!0Z1#DX\1 1(J=!<SM0=O=?VFS,;E1[S0HV3K
M@26E#UN+KUDIRM@+8F=9L5=MJ\FE(M7JK^0;NP5.JAU2J9A15 !(4BH.Q-_T
M^]:R2IT<KL.CBR4M*K+7U>=UPVHU@G=D3-XC2O4554)LAH5C+%;$!)#H]8V(
M)0*3N 18F=<E_74_Z<OZ^$6R3D$Y!K%S6V)*YW!.0KVAZ[(=7,S"8&;/[R_:
MF*9:K558Q?ZB AT7[XH"1L0>@F(KB'0(OUBUJM0-.KT+5*O%,X.N5V,9PT'#
MQZ0(LHV,CT"-F;-LGQ'HI(()@4.(B(\.(B(\1PBK>$3")A$PB81,(F$3")A$
MPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$
M3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"+3-]HK
MS::_T'N&I5:T\KVK]V2$OKYM.I6>[$C1E(]J,],L20K<7=9FE19)J-C+%_92
ME ZIOB_")%@ /VD^F0 1'[/[E]  #B(BG!!_+H6$3[RC3 B(!]G]R^CP#B/Q
M((. <>'$>-"#HAQ_#P[N$7 ?:4Z6'O<@'+V/'\!($?@$0#^X+OB!1PBX'[2K
M2P=_D Y>P[O1XB2! .(=T0_N"[H@'=PB[?>3Z8_Z/[E][_#^IP7'B'=X</,+
MO\.[P_!W<(AOM*-,% 1-]G]R^EZ( )N)('XO2'@''^T+N<1PBZ_>5:7'AP^S
M_P"7P>(<0X$@1X]WHB ?VA=T0'X._A%V'[2C3!1 #?9_<OI.(@!>DG!!TA'N
M  <:%W^.$0WVE&F"" '^S^Y?"B/<#I$@0$1[G> :%Q'^:#"(/VE&F Z7'[/[
ME]^* "(]7! '='@' 1H0 /$<(N!^TJTN' /N_P#E\XCPX!T(+CW>Z'<\POA#
MO?A^#"+G[R?3' QON_N7W@01 P]""X%$ XCQ_M"[@!\/Z>$7'WE.E^ #[@'+
MWP'O")8$ 'O!P 1H7='B.$78?M)M-=X?L_.7[^Q0?T!PBW4\BG-[J'F6UXE"
MTF A]8VVD-"MIW4+#P-NV@HX5C%:RU73:-(YO(UAVHH =:D@F9NX,*:Q"F$A
ME"+.[")A$PB81,(F$3B'X?AX?R?P?IX1./\ [/\ 1_E81,(F$3B'<[O?[WZ/
MZ6$3C\'PCA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"
M)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,
M(OS$_;6_PD]<?YFV?^-]EPBP3Y6H.$3MMAV=:RTXU8U- EF1;[#,8E+F+?87
M1:_3X";X,),%T7:SAR[ZKJ#@8K(1'@ <0(KK;(T7.P-2<,-5TY_=_ N9*3FJ
MA/UFKJ6921U[9-=U&T:^5=.R1CDB\$JE(E I'8 U.J57I% >F $5T+1%'*:]
M4/;M47BF.OM"79S9MG0^G*U#2$SL=];: M-EI*:<53HF8B:0D*<6S5*X(*G2
M=N0/T%B%PB]<+7JO%5:<DJ#$6F1!#3_+"YA9B"T73-A7IT68=;(\:/WM-E'$
MG%1IIA9D@5\[3<KJ""*0"8_2X 1?"C56ARE#/&76L0#56]\OVIZPI8W<!'Q\
MA5+O>=U[*@XVY$41:I&C9)K/-&"#TY!(;P(IT1'H%  (I%2-;U2GL]5:Z=5.
M)D+QKFT;W@-B3,?58:Z3,GL=+E]5N,A$LXY^0[*SC09AP@R8,E3B@9XR.8G
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MW= %>;: 7 #::[>PM:W:_P"+.I]2YC%:+L<8^TQ-QT0-Q(02XEP;[()#23L
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M22=$1F4%4$3K2+0C<K<XB!.BND?N=W@$NTMJZZSIPD$SV$W3KEET!39- T5
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M1-ZCY:-O>\+E*5:YO]>'N_*N6X'6KA7"BB\@=_:O!3)&=Q_2(LA:S]G1RO\
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M05\=8[ IJ$7J2KVB<9L&->9V6S,)-0QC#5;>A/3YR,'Q2!TT6-O@G)4C<>(
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MS%\1O:4&VA4:HAK38:Z-8KR*R-&MJJ*J4+&D4253@) Z:B9RM@,0Y#E 0$!
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M71Y=.8J?T;/]2KX1+T27<$&P5T#B)VYS=$@S4(!S FC*($#BH3N$=$#HFX&
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M9% ^Z(GCMY83#O20-C@+7'>W   *DC>:*<H)79]QEFVY$S:6CF;@;3N:$U
MY*5J?;53;.+VO LH.-K=AZZ$+9H):08P\BZ5&&LY6RTE6GR L5B(@1?I+ /Q
M50\($. !P'*B*75<F+CL8;6\\<8'L=-$S?+HGT)BV^]83M(Y">9>D4N7\29;
MV<8WXR[>--H:X<GL*C0[R]1R\;%0:4XDZBI3SKCH]I%++NT)$K<K,98K<&:K
M@Q#MDBD-TP%$Q0$! >(AEOMIM3F88_'-OV92%W3QUMVU?*UNX6DTVM,1=4<A
M VJEMGY>$%D0/+6G8)%#0>R-A[(7O=W+83"$:PCZ0?LHQ_&+MV0+,&;9ZO!
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M'0-C0CG7.OU*75D5FY2 1RW0<K@BFFNU*)S$5@M9;NN^V=%<G]*V;SC[3U]
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MG*Z_DIF2BDZG!0%/DII8E[1EG;\U9J+=1:"1HPR)"M'RLHQ!J E3(8YA'I"
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M^LU-VT=N?:/[W%#\>]K7#S_[8NR:W]G7;=YL?VG]C?F)UO@7@']J_A?5=/\
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M>;G[9ZGK?"/VKT\(L6[K[M/F+&\/?9\ \[N?CQ1Y@>#^?/F3YV#[T7BWQ?\
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#1?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!P0)S P$1  (1 0,1 ?_$ /T  0 !! ,! 0$
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M-\FJF(@9!TS7NW-YZE\S#A&G0+#M7S"[G.<$>2.XMSO.4NI]_P!>VM4('?\
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MM9UISVY=;(\NJH;_ .'C#B51.!FSZ_O3:NS'FZ=;[(C]J["UUI^Y:GJ-)T'
MT"0?6%&E6>2NBTJ_D+"C$*-(QN1H""K@Y@ #-_RL]#;7XZ<;+G0=R5@M2MDK
MROYB[)CXLLS"SH.*7M/DGLB_469]<@GTBR1&;JL^U=>KF4!PW\7N+$(H!B@!
MKP@O* V1RZ5Y][8Y?[PY/<?;5S?VGL2H36D=-[7U[\ %N,.OXM[J+CM"WIHE
M4+BE.2+JAM5IITBWDFX)'FU$3%17!4< FN*_$#F'9]T<"K9S,U+$/XO5/EL<
MI^%G)20?6JF62'MT_(;4U/5Z2^>1<=./WLW%[PU505IISW$C@T%THW>>"L($
M$#"BA^5]YD/'RM^:7HS7J!;O4M[Z_P")'"SAQNAU?ZDVLL#Q";VG8U=NLS;T
MI.90FR63C/H[9;F'1,LFF\F%8YJ9F1?M' ,WIORI-G<4-V^7]R)XI[EY-<C)
M#C%?(?0=HU1O3:FNY"MUSA3M&K):^V6WH29:IK]%FYURK!UV=;,3.7)W*4*"
M2*8K 3O <^._EO;ZUYYIEYMUJC(8GE_Z;V%O/E]Q.;I2D.N\+R=YC5RJ5K;<
M$XK*,@K)14+K)PUN,A%J*M$D2K7 QD#F-WP3 H^*TSR+T#S2YX[&D/*+C^94
M)O?E+4MT:=WLWV1P^C). J\7I+3U(38-VVX;1'WZ ?P%NI;]TF5--(H'."B/
MNA[Q@*GY2\!.7W.+<?(#E!89)_H/:G%(8.(\HNNEN<;)QD-?J8O#WV^;XV>U
MK,P[A%F?)*PL4J,XC'QC+,*6V6%5$BSD!P#<_KAE(;JU!J.U\B]%U^F;/7K5
M;M-JU;;"U#8?]EVQE8UNI/14/8&*L_"/3PTL"B;:09+B*J)2'[Q3")0 UE^;
MNPY[[39ZRXX<:N-E\VIQ@V:A++\QKMJ/=FG-3[@F:"V.+8G'^@/=IVRK?!9G
ML\@^%8["U%9VC!'6:,O#<+&5(!=NM\.M=\P-'Z:0Y!<:-Y<*U=+1DUKK7N@-
M<\K[)2&U5H<<$-%07K3_ (G;5C*1.1J\5 MO>])RLX=1R0'('ABH<# >WD!Q
MHVIOSF[PDB)>MF;\*N'L)8.1LC,2=H:RKO9?*B+;CKC0E1>PSN3=VEZVU)7I
M.8M:LF]3,@XE56/\*HND;H!:#S$:MM':MJNVM9WR=]9\\Z-,:V5K.G=S2NSN
M/<;(5Z8M46HE9Z[=V^W&T'?=40\98"(N4Y6L.991= A5B$2=IE3P#.C@/I3:
M?''A;QBT1NZ]FV9MO5&F:12;_=AD9&93FK)"1"#9\#:9F"DEIAC&" ,V[MT4
MKAR@W(JH ',8  RYP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M&E:N^>>^,A!:OH];H\;)2($%(LA)MJ['1Y))\5(>X59?Q%"D "@(%  P"\>
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M+W 'Z\+I#]'[M7X]:C^+W 'Z\+I#]'[M7X]:C^+W 'Z\+I#]'[M7X]:C^+W
M'Z\+I#]'[M7X]:C^+W 'Z\+I#]'[M7X]:C^+W 'Z\+I#]'[M7X]:C^+W 'Z\
M+I#]'[M7X]:C^+W 'Z\+I#]'[M7X]:C^+W 'Z\+I#]'[M7X]:C^+W 'Z\+I#
M]'[M7X]:C^+W 'Z\+I#]'[M7X]:C^+W 'Z\+I#]'[M7X]:C^+W 'Z\+I#]'[
MM7X]:C^+W 'Z\+I#]'[M7X]:C^+W 'Z\+I#]'[M7X]:C^+W 'Z\+I#]'[M7X
M]:C^+W 'Z\+I#]'[M7X]:C^+W 'Z\+I#]'[M7X]:C^+W 'Z\+I#]'[M7X]:C
M^+W 'Z\+I#]'[M7X]:C^+W 'Z\+I#]'[M7X]:C^+W 'Z\+I#]'[M7X]:C^+W
M 'Z\+I#]'[M7X]:C^+W 'Z\+I#]'[M7X]:C^+W 'Z\+I#]'[M7X]:C^+W 'Z
M\+I#]'[M7X]:C^+W 'Z\+I#]'[M7X]:C^+W 'Z\+I#]'[M7X]:C^+W 'Z\+I
M#]'[M7X]:C^+W 'Z\+I#]'[M7X]:C^+W +U?KDND/@-\-/R']K=/[$_[8/>W
M^UZH_/\ Y1/]@7P<]<^"'SG7_P#%?7?"Z_\ JO@?^L8!_/\ _,!_V[>9O^]/
MOW_6G:< Q$P!@# & , 8 P!@# & , 8 P!@# & , 8 P!G*5?%(#.7&GBF#]
MZ9U Z#_Y\/@<I5550_!#I@-4&#@8 P!@# & , 8 P!@# & , 8 P!@# & ,
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MM:U.3KR #-3_ $&?\%?_ (BN 0WF _[=O,W_ 'I]^_ZT[3@&(F , 8 P!@#
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M(M2<N-%)<$^7B69UGUC8]V?7AWHNVI4X-1Y>YI_>6MW)Y8=_:"D>D03QT_4
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MM^UG#X(RQXN:&LN]=AQ%;@XU9\0'C15V5),ZA?#%8O0IRIE,;NG[.OR,SF[
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M]W7U-YF;974H.Y)PCQ;Z>EM^-3*V*TO34T6[A^R,_?*D26<**JG*3Q%"@<3
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MVG=]L#'P=X7XXR7E>?.*]M(\JT\>/$W[;,RKFIZ%BY]U-3NXT).O.K29;M0
M >GI'V>G3L',?<B#G)I<RIFW%T/.<H!V^V.2*];<)>YG,95,T/\ 09_P5_\
MB*Y".Q#>8#_MV\S?]Z??O^M.TX!B)@# & , S@X/<4*)RGG=]+;/W+)Z.UUQ
MZX[VOD-<K=":V4VM./8:KW&ATT8&&J"5MI(.'SU]?$5 5._(1,B)NH#U[ ):
M?X?U/;=ZK6OO+HM.^>;]C7@)"=O4.TXS2FN)ZFH)3\%7HITC"QE_V:K+PCY[
M.HD7?**,T6:JB9#]>_W@ MBEP=YA.-?WC:K?C3N9QKK6TO;(*\7%O0YY>$KT
ME09 \5>TW;M)H<%6U)DDC(3#A$%&\8J42N5$A < XK<'^8+;4SS?#CC3NE'3
M4?7:_<'>R5-?V$M3)3[2@P<P-N3E3,@07JT@A*MA+))]YD3UA,#JE$Y0$"^F
MZ?*OYE:AW?4>/S/3UVV+L.W:.USOIM'TJK33M%A3[[4*_9WZDFNX023CVM'D
MI\L+*OG(H,DY5 Z13B IB<"A);@SLZD:,Y2;/VZRLFI+]Q;V=Q^UI9]-76GR
M43:9!QOR/V1+1DNNL_79J1#2*C=?E72 6RY)%"03524*0H"H!4>A>'6MK'Q]
M>\L^46]9+C]H-?9K[2VOC5#6+C<.UMO[/A:]&VRVQE*I)K70H&/JU!KLY'+2
M\S*331$CB2;-6Z:ZRA@3 B]@<&K-([JKFJ>'UL0YNQ5\UO&;=I-ETU79+X0-
M*2_*Y2E&>VZ"HXDI'3ESI4BS4:S;"3=';-CF052=+(.4%3@4%4^"',^];(O6
MGZAQ=WC8-H:P6CD=C46.US95K'1_?A%TYAU[3'"P*K",I=LR44:N''AH.4P
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M_P!+&MS[4]^],PM:LIW,C.C"+G'JBDY+FG^TKG!S+=S/PLN7_AX7H=<?#F?
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M=./$KC'TF[N#2OR]Z;<E+JBDZ<?QX>XR_H6XZGL!%!%!V1K(G*'B-1,)D5%
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MA3.VK\<3/24UY;Y+]!;'0<99(F<5!4WA"9?OIB=0W3IWB_-#J&5YW]MZ5F[
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M'@W5*S3QHJ?K(+V/FY95KI;BN5*GMZF=9_[^2J_]7VG:+;YF9_\ H,_X*_\
MQ%<@'<AO,!_V[>9O^]/OW_6G:< Q$P!@# & , 8!^@80'J B B'01^1[7RL
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M*&LW,>>=.<E=KPDJ<6_=S,\>Q6S<;4\=W)8CE<46VU&O@1\\0S=UW!1%( ,
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MVYNO4>ORLQ2R)7^JDXT15Z..0.F,TU)55#DZC>DWS/W,E22Z6_&O[0<,Z@8
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M;BN%%P+N^)U'  Z=  /3['RLD[2]AP><^2')/1X'3DN P!@# /6S*)CG /\
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MU;LQ7[S7WD:8PB/41'+?_G+]^ZU<JN!%.E3T!DOU+Z8_%G>!F?\ Z#/^"O\
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MO=?=EC(2?Y2.4OM5?'W'P2[\V0]VSL>Q7)\JHJK*OE3%,<W>$Y.^(E,!NP
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M\%?_ (BN2XB$-Y@/^W;S-_WI]^_ZT[3@&(F , 8 P!@# & , 8 P!@# & ,
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M%#F$QS\H-\&,8?28QMGV<1$?DB. 8FX P!@# & , 8 P!@# & , 8 P!@#
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M?\SUCW?3_G8!Y>>7^V_S"_WGM[_ZS[/@&)^ , 8 P!@# & , 8 P!@# & ,
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M\=2#E=Z^<N'CQTJ==RZ=+JN7#A901,=5==<ZBRRIS#U$QC"(^S@'EP!@# &
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8!EI_H>_X2_\ WZ\ Z^>7^V_S"_WG
MM[_ZS[/@&)^ , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MQ [7_!/ 'Y$/-'\T/E!\0.U_P3P!^1#S1_-#Y0?$#M?\$\ ?D0\T?S0^4'Q
M[7_!/ 'Y$/-'\T/E!\0.U_P3P!^1#S1_-#Y0?$#M?\$\ ?D0\T?S0^4'Q [7
M_!/ 'Y$/-'\T/E!\0.U_P3P!^1#S1_-#Y0?$#M?\$\ ?D0\T?S0^4'Q [7_!
M/ 'Y$/-'\T/E!\0.U_P3P!^1#S1_-#Y0?$#M?\$\ ?D0\T?S0^4'Q [7_!/
M'Y$/-'\T/E!\0.U_P3P!^1#S1_-#Y0?$#M?\$\ ?D0\T?S0^4'Q [7_!/ ,M
M/R(N9W]CW3\DKDKWOR2NOA_V';+\;O?EU=_P? ^#7C^L^#_"^#W?&]7_ (;N
M^%[O /[4F , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!
M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M$A6:*"JF4XIB84U4O=@!3"'=6(F8>PP=O3I@'KP!@# & , 8 P!@# & , 8
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M@# & , 8!"US^08C[GM?\D7 )K & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & :9O.KGKS7./M6E:_65'56C7NP)>P7:)X[5OD
MU:*Q<8?7DR_U!6&%&LE,V&C7*]M&_)(0\O8D(=TO'(&31*=MZWZTB!=SRRJ[
M4IO7M]V[%ZKI$&PFMK7Z%TEM9MQPJ''?8FP>/JAJ_*5]:Q5>$JM5EFL7&VI6
M3BF"SIFQ5F(R(9R*S<%7 J' V>X P#0GYMNT=Y0VRXVLZ3V1:JB?5_$#=W(B
MU-8S<3K1<=430%PI4;7=T1KABV>DY$V.B,XJ80_LYE?4:\^3?)F>OD#N6P'
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MDH7[Y/?YKP!XMD^DH7[Y/?YKP!XMD^DH7[Y/?YKP"'45L'P@9]6</X@PTCT
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MF("P+K )AZJ"'0  R'P!@# & , @U?Z1LON+)?7T7G-'2O"GQ_4*KE7B3F<
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MRH(J3:-FUQ6JY3YF%3@Y.6?NUXV)0:HRL6C!M9$[B+D1;'\,Q@(8ARB0X!T
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M'\/Y?+])[88NS)*L\W4HO_\ 267^/YQ?H(E68V62P,#+4:M*'")E0 &E\<&
MQ1=Q7>$!=5%L8!*(!V=.WKZ>S/=AYN\978QU# P(6>EU=O,G.2?"B498MNJY
MU=52B]O"'/#VHXORL_,Z_!2Q(I4][CDR2?NK^@F1L>P2@/>ULF<0]A"Z1)P'
MY0KLFW9DW>7J"3?Y5M__ !(?M/%^3TBO#,=/?9E_K,_ M5W+_P!)JZ5'L_\
M5K1450Z^T'CRC0<E-[6]=M1;AHV5<:\(WL3C_I7XD>.EZ/+_ .IV8_&SD?\
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MT1.V&EL;!8N/T?'/;96M5S]_K:\:C*F>.)-NV41D7$8DR5%0@%]O+VWER&Y
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MWO?9WWP$KV-#H!N_U[H]>T/0/0/:P"8]X4OMG._?AY]'@#WA2^V<[]^'GT>
M/>%+[9SOWX>?1X ]X4OMG._?AY]'@#WA2^V<[]^'GT> />%+[9SOWX>?1X!#
MUZ$24@XH_OC-E$S!N(E)+.RD ?##YTH'Z%#Y =@8!,>\*7VSG?OP\^CP![PI
M?;.=^_#SZ/ 'O"E]LYW[\//H\ >\*7VSG?OP\^CP![PI?;.=^_#SZ/ (=>&3
M^$$>E[XS7NH>4-W_ 'U= <!(\BO0;O=>AN_VAZ!Z![6 3'O"E]LYW[\//H\
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MF)J%2A[Y:Y!*P1HM:U2[!".[+!VJ=5]8 L5 RU?CUWK=ROW$E6R)U"B)2B(
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M^S[JMODEQ? I;NVK87NC'E*/2#F]RD3OL+O:&X  @=500!:G0[D1^<* 2JI
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M:-?WP_0X ^$L#]M&O[X?H< AE+#"#8&BOOFU\,D/(%.?OCT*8SV-$H#[GTF
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M,Y8*@W7M\U,M(M5BFZ),R9E5W[A%%) H&?\ ,?R3*?<Y[];*X!X*G_16M?\
M=^&_[.;8!4& , I6U6A&MMFI$6JDO/2ZYF-=K[50B;R8D (*AB^(<#$9QS)+
M^%=NCAX39 HF'J82$-)M:UFWI%B/3"5[4+TNBQ9C]=V?L_Q81^J[<?RVX5D_
M!/W8.%+,FW)]&+;75<FU50C6GVR;X1BN,GP7BUY*K55HI5U/3[I*8N4PDF26
ME2)F(U9M2'%5"OP"*O51C7X]0X]P@CXCA3JLL)E#=D#1M'GBSEJFJ.%[<%^"
MC=N1348Q3;C9LJ3;C:@W[G<E6Y/BTH]LS,5Z*Q<9.&GP;<8OFWRZYTX.;7/P
MBOECPYUKE0$O(,_])&WW#??7\=@$Y@# & , 8!Q/\Z;_ !1_<' (BN_R##?<
MQE];IX!,X P!@# & 0:O])&7W%DOKV+P"<P!@# & , 8!"5L>L#$=>W_ #!O
M_DPP";P!@# & , @EQ_]I(T/8]YI?Z\A\ G< 8 P!@# & 0M<_D&(^Y[;_)%
MP":P!@# & , QVY!<8-6<C*?9:U;X5C%S5EC(6%6V)!PE?+L*.AH2T0]L2B(
MVRR$4^>H1CM_#D*LAU%(R:A^A0,(& "[$EKO7\S/A:YBC4Z5M 1@0H622K,*
M^GPABN >%B0F'3)61",!V *@AXGA>)[KN][MP#BOKC7CJT*W=U0Z8YNB[=@T
M6MZ]7@UK0LTBG*3R+:JSZC$TLHWC7;=-5N05A*BH0IB !@ < FAKE?%N9J,%
M#"U-+_" S88MEZN:?]?"5]^S(^!X8R_OH .?6>GC>L!XG>[_ &X!$N-?4)W-
MRME=4BH.;'.L8V,G+ XK4,M-S,;#.TG\/'RLJHR,_D6,4^1(LV264.F@J0IR
M 4P . <G] HDI,R-BDZ54I&P2]=7I\M.OZW#/)F4J3HYE'-7D9-PR4>O:ZX4
M.)CL53F;'$1$2". >6+UGKB#KSVHPNOZ1$522CO>>1K$75(&/KS^(\-PC[UO
M85HP1C74=X3M4O@'2,EW53AW>AAZ@2\-4JK7&R3*O5FOP3-"(CJ^BTAH:.BV
MR,#$%<EB81)!BV023B(LKU8&[8 !% %C]PI>\;J!T/*33)"JFHC^HUA]2#QZ
M,2:FO("*<U4T4V\,6\8:O+-#Q QZ HD[B/@^&7NAT .@8!Z:U5:Q2X9I7*=7
M(&IUY@!P80-:AX^"AF0*G,JH#2+BV[5BV!10PF-W"%ZF$1'MP"0C8R-AV2$;
M$1[&*CFP'!LPC6B#%DW!54ZR@(-6R:2"0*+*&.;NE#J8PB/:(X!0T'IS458L
M9[A6M5ZXKUM5.^45M,'1ZQ$V-124[XR1SS;"+;R9SR(J&\<15ZK=X>_UZC@%
M=,XV.CCOE(^/9,5)1Z>2DCLVJ#8\C(J(-VJD@^,BF0SMZ=LT23%53O*"FD0H
MCT*  !3CG7E >V]EL%Y1J>[OT8S-'QMX<UF%7M\?'G(JF=BRLJK(\TT9G(N<
MHI)KE((','3M' .*>NM?(VB4O"-%IJ5UFX\(B:MZ=8A"6B7B@331",E+ 5B$
MM(1X))$+X*JQT^Z4 [O0 P#RP>J]85F(<P%;UQ0Z] O6RK)Y"0=0KT3$.V:[
MA5XLT<QK".;LUVRSM8ZIDSD$IE#F,(=X1' *O][8[WQ&8][V7ON+((T93U5#
MWQ&.*N9T6/%]X?K(LBN3"H"7>\,%!$W3KVX!3TOK^AV"Q0=OGJ349NVUCJ%:
MM$O6X:2L5> QS*F"#FWC):2B>\H83#ZNJGU,(CZ< J%&-CF[Y[)H,&2$E(I-
M$9"01:H)OGZ,>"X,$GKLB95W23('2O@E.8P)^(;N].\/4#VX P!@# & , 8
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MON8R^MT\ F< 8 P!@# (-7^DC+[BR7U[%X!.8 P!@# & , A*W_($1_U!O\
MY,, F\ 8 P!@# ()?^DD;]QI?Z\A\ G< 8 P!@# & 0M<_D&(^Y[7_)%P":P
M!@# & , T9<U.:+G6G+AC98GD1!T#6/!YUI4N_\ 3KF[5V%/N=#E'.C7[P,K
M6'[Y*5L!N/6I743<8WP2!_G3]0I>^<.A0*CON_\ <>F?,;W)L69V+8YGB+3Z
M[Q.U!MC6C]TDM3]3AO@NQ!J?(V!3$J8Q8Q>Q8V/A;4J*@H# RY7R@ 6+ZX!3
M\UR/N!> -+JUEW_)ZVVURAY8;XXQUG>$Q<X:OV?7-:2Y+[R2M5T@;)87+5BR
ME]6:"U])>\1Q-T1?-&"9>HB0! E]+\J;[.U3@EN^2V@-N@X#;^Q/+WY>-*Y8
MFUDI4YMAQ,&UOKW<RB\8NZA57\MN#7L,5H]14Z#&;!$.HE$ *!;'D+N+;=JI
MECW4SOG(,NK-P>9=I_CWKFCZ#M<S!722T+J%Q8=97=37+J!EZ_*,WNW-N5^P
M2#U=L];*/(9JS#Q!33 H@7MWO?+)Q4XDU#F+KA_RI;Q?'V]3%NV#Q]Y'7FU6
MS:.^->71\UH%CU>V:W&T6]^ZV.+\S"7UTW(],!Y9(K$I2)2KCH!2&U-0\L=]
M<%=>SU6V],WJ[;TG7&\+S(T2P'G:Y3&&SPB;#1Z]K2)"7@/AAJ34-8 D2E$I
MO$E)AT?WW.4ZXJ% #(*L:=>UGAW R'+C<NYM*UG4K*W7BQEJ.\YZERT%4$XX
M/>Z-O.PJ(NPLTW\'U$EGL=',7Y$$5'2#(4G/JZ*90*SXM<A3:TXR\6H?F7L]
MO5=[;.JY0B6&T'+*(V+:6KNP*H4AO:6+1JU0/L4M0EH5&>(5)(??I1<#%*81
M  +2<A=.JH<H^-FO-4;PY31.Q]J;<?[SV,V0Y+;AD*+4>/VFY.,M.Q&AM>.[
M6[J+*O;!M\S 4MFP,R!J1M..#(E#U0>Z!25RM4OK/S"= U6 N7+VK-=@;<V*
MTV=<=\V6S.^)^TJ]-:ON<Y5-'Z9C':CFBLMDL+D:,=5TD<SA718N#E$UG+Y9
M4R:P&Y; & , 8 P!@# & , 8 P!@# & , 8!I#\W.H:8:VOB]<[[1N/E9=6R
MYV^A6CDULWAFAS$N6OJ\QH<W8:]58BCMX62.E$6Z>0%JK*297+"'$W0B157?
MC)@9E^7*G0&_'!NSUGLBD[1J;*\6M!I8-?<9V/$VM-')C,'#V&;:DCHF%:(.
M&BZXJ*R)4 ]>,OU$1$G7 ,\< 8 P!@$=,?R3*?<Y[];*X!X*G_16L_\ =^&_
M[.;8!8&E6.*K.R.4DM*+&\!/8FOFZ#=J073^0?+Z<U\W:1<:S2$5GLD]=?P2
M2) [QE.H=G0PA+M3UG2M+Q)YF1>^6TU"<5\T_,DUT6XPC64IW.J/1%*K;/;:
MP,J\[<86IQ5R+:E).,'%/C-2:2<8\I23:35.? NY5X"4=R!KI<4DR6-PBJWA
MX8BI'+2EPK@2&&,;*DZHN9M\!"FD7A>Q0X BD/@)E$\HTC3,V_E/7]>26J23
MC:M*75#&M-OY8OE*]-4\ZZN?"$*0C\WHS,NS"S_+L!O\HFG.3YW9JOS/V057
MT1\/J?S/A<+*H)4, 8!!G_I*V^X;[Z_CL G, 8 P!@# .)_G#?XIOW!P"(KO
M\@PWW,9?6Z> 3. , 8 P!@$&K_21E]Q9+Z]B\ G, 8 P!@# & 0E;_D"(_Z@
MW_R88!-X P!@# & 02_])(W[C2_UY#X!.X P!@# & , A:Y_(,1]SVO^2+@$
MU@# & , 8!A[&\&>/7P7W97+I2XG9SOD%<MIW'95LOL#6IFV2*NTP7C7,(PF
M?>5)>,@ZE4BM(6&23]TTCX] !,=4#*& :VX5ZRHT1LJ#L<S:MLQ^W](:=T+L
ME'8[B*D0ME2T[1[+06;Z5&,BXLRTW;X:TN3RZO4"*N.AT2(]H"!;;1WELZ,T
MM!<?ZL[F+IN*N<;:7NBIZ^B]TJUJ\$<R>\]AM+];K_9U%ZXU&=OK5)H,0S?G
M HI1CER!BG6<*JF JBV<!--V2G\KJ#%R%GH51Y8A4YB>A*": K;+6.R:;68B
MN0^VM3MVD%ZO7+V5:I0$F=98CI TK!MW/A=XZ_B@>^\<):=8N/\ HG0E-V!>
M]6H<<K1JJZZROU80IDQ;&MHU.@LA%R\\SN=5L=4L+BPF>.5I3UB/$'+AP=4.
MX<0$ )EIQ4?3TOI>;W;O39&]W>CK]9-G5AK;(/6%5A)>ZR,$G7J=,VB!US1:
ME%2R^K&KJ2<0/\$F*,A(B[6%9=JS,@!<K0FAJQQUJ]DHE&EIY>C2>PKG?*K5
M)A9BO&:U:7J5-8Y>B4D&C%FLSHK&SO7SR.9KF7-'D?&;)'!JD@DD!;7E;Q2<
M<HAU*']MNQM4-=2WG^T1O"4^%UG9JM=;0P;)DJ3R^U?9M'NL/8$J'*%&3B$3
M)D1;RH).SD46;MS) 9 ZWK%HIU.BJ]<MCV#;-B8B\%]?+1"TVOS<R#AZX<MR
MNXF@UVJU9L#!LJ1N3U9BB)TT@,IWE!,80*/KVC:U [VV3R$6E)N<O.PJ50M<
M-TI=5BK%4>BT)Q8)9"N4Y%!D@Y9-;%:+0\E)0ZRJZCIT*(")4VZ)" 614X<R
M5DV/2K;MCD=N3<%'U=LX^X=9:EML?JR+KM>OK5.83J\A-V2G:]KEWND?0??U
M<\*UD) Y$5BH*N1=J()&*!FQ@# & , 8 P!@# & , 8 P!@# & , U'^;_#<
M@IC1]20T@?9TN@ZE+Q"R5!TCM^%TOMFY[%F=>3R.BU(&=F+=0U;C7:OL5!-_
M,U=E+-WDLU3*IX3M!JNV5 OOY=4GL>QZ6NETO3VVA7[UN_9-IU'5]A;-K.WK
M_KW6KM>,9? >X7:H3]L@32,9?H^>70B$Y614KD>Y;Q*J_B,C))@9\X P#5AY
MC,I?D'M+K6H=[[D@=^W>G7* XW<>]*N(.#<6S;H.XA9MN_<%AD&$H!=%:>:G
M2-8$90B4#ZJ[43,5W(N8]L(&/FL]T[]#?FM[Y:-T6B?L%Z\Q/>G"RZ:*;NH]
M'5##56KM2;*E(JQ5>E&CS2\%:6\CK>/MYY<SHSEPPG5&ZXG:G:E2 W@S'\D2
MOW.??6RORL M-,R=DB=/N7C5["P[DE"20B93UB056:RKN#39PRC=N1B*CEZ>
M372*BD4!.HJ8I2@(B 93.\LR]@[4U3(Q[_Y3,6GWECWJ=;ADSBX67T?O-7)0
MZ8QZI3FU%1XD\VUCV,G7\.UEVY7<3\S;=R"_>LQDI7:UI1*"DVWP4:MM4-4'
M#;3F_(KD@O,SL,_BR41:22V*O97A54EY2>KIG,>T.L55\H^F'K:9;O$ED@.)
M6Y^\90H&Z#J[])W9CO\ [;[Y1W'OG%U2SHN+9O++O9]V4X7;MV$J/%4I2C?D
MVXIW(U\OI=9*JKFYWY[A=G\WM9/0MGW,3*U?+OVY6%9?'&A;DG)322E;4NE_
M*TJU7RFZT3V7KV(0?3Y+M_U^LLVUNE>'(P(=/ _.]9OXB"^JY#[#S@X'>LW\
M1!?5<A]AX [UF_B(+ZKD/L/ (<YK%\(&W\!">+[S/O\ UM]W.YZ[']>O^9][
MO ;IT[.@]O:'3M F.]9OXB"^JY#[#P!WK-_$07U7(?8> .]9OXB"^JY#[#P!
MWK-_$07U7(?8> .]9OXB"^JY#[#P#\,:R]TW5""Z=!Z_YV_#V/;]3[, BH$]
MC]Y(CPV\)W CF@$[[M]WA*") *)@*S,4!$OIZ"(8!+=ZS?Q$%]5R'V'@#O6;
M^(@OJN0^P\ =ZS?Q$%]5R'V'@#O6;^(@OJN0^P\ =ZS?Q$%]5R'V'@$.H:Q>
M_P"S_@(3Q?>>0Z!ZV_ G<]=C.\(CZGU$WHZ!T]OM]L"8[UF_B(+ZKD/L/ '>
MLW\1!?5<A]AX [UF_B(+ZKD/L/ '>LW\1!?5<A]AX [UF_B(+ZKD/L/ '>LW
M\1!?54A]AX!#U\UB]XXKPD(3P_4&W=$[M]WQ#PP[3 5F)2B/M=1Z8!,=ZS?Q
M$%]5R'V'@#O6;^(@OJN0^P\ =ZS?Q$%]5R'V'@#O6;^(@OJN0^P\ =ZS?Q$%
M]5R'V'@$.L:P^_\ 'CX,+XOO1* 4/6GW<$OKD5WQ$?5.O7L+T#I[?4?1U F.
M]9OXB"^JY#[#P!WK-_$07U7(?8> .]9OXB"^JY#[#P!WK-_$07U7(?8> .]9
MOXB"^JY#[#P#] ]EZ]K>#$/9Z.WX#Z!_^HCU[< AJ\>QC!Q/<;P@$]0;=SON
MWX&$OAEZ=XH,Q[H]/DC@%5,Q?"F;U\C0BO?'N S5653%/H'=$QED43 ?KUZ@
M =/DX!Z\ 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M\4W[@X!$5W^08;[F,OK=/ )G & , 8 P"#5_I(R^XLE]>Q> 3F , 8 P!@#
M(2M_R!$?]0;_ .3# )O & , 8 P""7_I)&_<:7^O(? )W & , 8 P!@$+7/Y
M!B/N>U_R1< FL 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M!-X P!@# & 02_\ 22-^XTO]>0^ 3N , 8 P!@# (6N?R#$?<]K_ )(N 36
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M %MF_LO 'P+:?;VX_P!;9O[+P!\"VGV]N/\ 6V;^R\ ? MI]O;C_ %MF_LO
M'P+:?;VX_P!;9O[+P#J&B1QE2KC-7 5B)J)$5^%DYWR)JF3.H0IO6^H%.9(H
MB'H]R& =OP+:?;VX_P!;9O[+P!\"VGV]N/\ 6V;^R\ ? MI]O;C_ %MF_LO
M'P+:?;VX_P!;9O[+P!\"VGV]N/\ 6V;^R\ ? MI]O;C_ %MF_LO .I&B1S=%
M-!":N"2*1 333);9P"D(4  I2@+P>Z4H!V '8& 5'%Q:42@=!)W)O .H*HJ2
MDB[DURB)2E[A%GBJJA$P[O7N@/3J(C[. 2> , 8 P!@# & , 8 P!@# & ,
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MB2CBP:L6L2M#>NR.W3)ZE EMS&,M3,(]VU.V<M9)LW?LWB*J"Z2:J9B !>W
M& , 8!KYYD<F^0'&YZRM]4UIJZ?U&P?:NKP(VJ[RS3:^\-C[.OXU%+46BZI
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M$JR5(U-<^1$J[F-L34)(QD QMDZE)/)>2+%M91\Z0AT)9XFB @HF*0&<PAU
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M*Z0*MS&,!EY@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P
M!@# & 4/LVIN+YK;85&:.T(]U<Z/;*FV?N4CKMV+BQ0+^'1=N$4C$560;*/
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M=,5^1E*XAR#VOK>K:AC>3=3)%O&BL5=&] @DV\PA[E&7<1$6NI_#$744 J.
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M>$A(+A_FX"D*JH&<F , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P (=0$!] ]@_-P#B!"AT .O0!Z@'>,(!\H.O3LP#EZ< _ *
M#U]GM#TCV (]1Z!UZ!U$, !Z1^7_ '@P#]P!@# & , 8 P!@# & , 8 P!@#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M^\& ?N , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M0S<"JN2+@9F8 P!@# & , 8 P!@# /P?2'R_[PX!^X P#\#TC\O^\& ?N ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M 8 P!@# & , 8!Q-Z2?XP_\ Q#8!RP!@'63YY3_&_O8!V8 P!@# & , 8 P!
M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
0, 8 P!@# & , 8 P!@'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>e2415_10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:avxl="http://anavex.com/20201231"
  xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="avxl-20201231.xsd" xlink:type="simple"/>
    <context id="From2020-10-01to2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-02-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2021-02-12</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="From2019-10-012019-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="From2020-10-012020-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-10-012020-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-10-012020-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="AsOf2019-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="AsOf2019-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="From2019-10-012019-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-10-012019-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-10-012019-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2019-10-012020-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2016-10-012017-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
        </entity>
        <period>
            <startDate>2016-10-01</startDate>
            <endDate>2017-09-30</endDate>
        </period>
    </context>
    <context id="From2020-10-012020-12-31_currency_AUD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-10-012019-12-31_currency_AUD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:AUD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-06</startDate>
            <endDate>2019-06-07</endDate>
        </period>
    </context>
    <context id="From2020-10-012020-12-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-10-012019-12-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2020-10-012020-12-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:EquityOfferingSalesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:CantorFitzgeraldAndCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-10-012020-09-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:EquityOfferingSalesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:CantorFitzgeraldAndCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2019-09-30_custom_PurchaseWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="From2019-10-012020-09-30_custom_PurchaseWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-09-30_custom_PurchaseWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="From2020-10-012020-12-31_custom_PurchaseWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_PurchaseWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_PurchaseWarrants1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrants1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_PurchaseWarrants2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:PurchaseWarrants2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_StockOptionPlan2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_StockOptionPlan2015Member_custom_OptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:OptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_custom_StockOptionPlan2015Member_custom_OptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avxl:OptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="From2020-10-012020-12-31_custom_StockOptionPlan2019Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_StockOptionPlan2019Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-09-30_custom_StockOptionPlan2019Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="AsOf2019-09-30_custom_StockOptionPlan2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="From2019-10-012020-09-30_custom_StockOptionPlan2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-09-30_custom_StockOptionPlan2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="From2020-10-012020-12-31_custom_StockOptionPlan2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avxl:StockOptionPlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-10-012020-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-10-012019-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2020-10-012020-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2019-10-012019-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-02-11_us-gaap_SubsequentEventMember_custom_MichaelJFoxFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">avxl:MichaelJFoxFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-02-11</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-02-11_us-gaap_SubsequentEventMember_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:PurchaseAgreement1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">avxl:LincolnParkCapitalFundLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-02-11</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-02-11_us-gaap_SubsequentEventMember_custom_SalesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001314052</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">avxl:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-02-11</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2020-10-01to2020-12-31">0001314052</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2020-10-01to2020-12-31">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2020-10-01to2020-12-31">--09-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2020-10-01to2020-12-31">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="From2020-10-01to2020-12-31">Q1</dei:DocumentFiscalPeriodFocus>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-10-012020-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0235"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2
      contextRef="From2020-10-012020-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0242"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2
      contextRef="From2020-10-01to2020-12-31"
      id="xdx2ixbrl0243"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2020-10-012020-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0249"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-10-012020-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0254"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-10-012020-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0256"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-10-012020-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0259"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-10-012020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0260"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2019-10-012019-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0280"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2
      contextRef="From2019-10-012019-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0287"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2
      contextRef="From2019-10-012019-12-31"
      id="xdx2ixbrl0288"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2019-10-012019-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0292"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2019-10-012019-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0294"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-10-012019-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0297"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-10-012019-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0298"
      unitRef="USD"
      xsi:nil="true"/>
    <avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice
      contextRef="From2020-10-012020-12-31_custom_PurchaseWarrantsMember"
      id="xdx2ixbrl0408"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2020-10-01to2020-12-31">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2020-10-01to2020-12-31">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2020-10-01to2020-12-31">2020-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="From2020-10-01to2020-12-31">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2020-10-01to2020-12-31">001-37606</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2020-10-01to2020-12-31">ANAVEX LIFE SCIENCES CORP.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2020-10-01to2020-12-31">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2020-10-01to2020-12-31">98-0608404</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2020-10-01to2020-12-31">51 West 52nd Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2020-10-01to2020-12-31">7th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2020-10-01to2020-12-31">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2020-10-01to2020-12-31">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressCountry contextRef="From2020-10-01to2020-12-31">US</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode contextRef="From2020-10-01to2020-12-31">10019</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2020-10-01to2020-12-31">844</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2020-10-01to2020-12-31">689-3939</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2020-10-01to2020-12-31">Common Stock Par Value $0.001</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2020-10-01to2020-12-31">AVXL</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2020-10-01to2020-12-31">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="From2020-10-01to2020-12-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2020-10-01to2020-12-31">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2020-10-01to2020-12-31">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2020-10-01to2020-12-31">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2020-10-01to2020-12-31">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2020-10-01to2020-12-31">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2021-02-12" decimals="INF" unitRef="Shares">69487852</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">47357599</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">29249018</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:IncomeTaxesReceivable contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">6577807</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">4849340</us-gaap:IncomeTaxesReceivable>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">398840</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">443839</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:Assets contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">54334246</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">34542197</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">4216948</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">3989054</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">3816521</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">3316574</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">8033469</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">7305628</us-gaap:LiabilitiesCurrent>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2020-09-30" decimals="INF" unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2020-12-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2020-09-30"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockValue contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">-0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">-0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2020-09-30" decimals="INF" unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2020-12-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2020-09-30"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">66962957</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">66962957</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2020-09-30" decimals="INF" unitRef="Shares">62045198</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2020-09-30" decimals="INF" unitRef="Shares">62045198</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">66964</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">62047</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">213766108</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">186851752</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">-167532295</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">-159677230</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">46300777</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">27236569</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">54334246</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">34542197</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      unitRef="USD">1470656</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2019-10-012019-12-31"
      decimals="0"
      unitRef="USD">1352035</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      unitRef="USD">7925519</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2019-10-012019-12-31"
      decimals="0"
      unitRef="USD">6348668</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      unitRef="USD">9396175</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2019-10-012019-12-31"
      decimals="0"
      unitRef="USD">7700703</us-gaap:OperatingExpenses>
    <avxl:NonOperatingIncomeFromGrant
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      unitRef="USD">-0</avxl:NonOperatingIncomeFromGrant>
    <avxl:NonOperatingIncomeFromGrant
      contextRef="From2019-10-012019-12-31"
      decimals="0"
      unitRef="USD">74944</avxl:NonOperatingIncomeFromGrant>
    <avxl:ResearchAndDevelopmentIncentiveIncome
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      unitRef="USD">1269316</avxl:ResearchAndDevelopmentIncentiveIncome>
    <avxl:ResearchAndDevelopmentIncentiveIncome
      contextRef="From2019-10-012019-12-31"
      decimals="0"
      unitRef="USD">943215</avxl:ResearchAndDevelopmentIncentiveIncome>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      unitRef="USD">-1559</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2019-10-012019-12-31"
      decimals="0"
      unitRef="USD">46720</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      unitRef="USD">332634</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="From2019-10-012019-12-31"
      decimals="0"
      unitRef="USD">53113</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      unitRef="USD">1600391</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2019-10-012019-12-31"
      decimals="0"
      unitRef="USD">1117992</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      unitRef="USD">-7795784</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2019-10-012019-12-31"
      decimals="0"
      unitRef="USD">-6582711</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      unitRef="USD">59281</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="From2019-10-012019-12-31"
      decimals="0"
      unitRef="USD">9214</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      unitRef="USD">-7855065</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-10-012019-12-31"
      decimals="0"
      unitRef="USD">-6591925</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2020-10-01to2020-12-31"
      decimals="INF"
      unitRef="USDPShares">-0.12</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2019-10-012019-12-31"
      decimals="INF"
      unitRef="USDPShares">-0.12</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="From2020-10-01to2020-12-31"
      decimals="INF"
      unitRef="Shares">64295143</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="From2019-10-012019-12-31"
      decimals="INF"
      unitRef="Shares">54773685</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      unitRef="USD">-7855065</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-10-012019-12-31"
      decimals="0"
      unitRef="USD">-6591925</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      unitRef="USD">939314</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2019-10-012019-12-31"
      decimals="0"
      unitRef="USD">1264424</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      unitRef="USD">1728467</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="From2019-10-012019-12-31"
      decimals="0"
      unitRef="USD">1087927</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      unitRef="USD">-44999</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="From2019-10-012019-12-31"
      decimals="0"
      unitRef="USD">-266026</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      unitRef="USD">227894</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2019-10-012019-12-31"
      decimals="0"
      unitRef="USD">395834</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      unitRef="USD">499947</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2019-10-012019-12-31"
      decimals="0"
      unitRef="USD">820077</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      unitRef="USD">-7871378</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2019-10-012019-12-31"
      decimals="0"
      unitRef="USD">-5725159</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      unitRef="USD">26243419</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2019-10-012019-12-31"
      decimals="0"
      unitRef="USD">10997952</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      unitRef="USD">263460</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="From2019-10-012019-12-31"
      decimals="0"
      unitRef="USD">0</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      unitRef="USD">25979959</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2019-10-012019-12-31"
      decimals="0"
      unitRef="USD">10997952</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      unitRef="USD">18108581</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease
      contextRef="From2019-10-012019-12-31"
      decimals="0"
      unitRef="USD">5272793</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:Cash contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">29249018</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">22185630</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">47357599</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">27458423</us-gaap:Cash>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">62045198</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">62047</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">186851752</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-159677230</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-09-30" decimals="0" unitRef="USD">27236569</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2020-10-012020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">3346288</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-10-012020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">3346</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-10-012020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">17458056</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      unitRef="USD">17461402</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2
      contextRef="From2020-10-012020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">56642</avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2
      contextRef="From2020-10-012020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">56</avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2
      contextRef="From2020-10-012020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-56</avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2020-10-012020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1514829</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2020-10-012020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1515</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2020-10-012020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">8517042</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      unitRef="USD">8518557</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-10-012020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">939314</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      unitRef="USD">939314</us-gaap:ShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-10-012020-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-7855065</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      unitRef="USD">-7855065</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">66962957</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">66964</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">213766108</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-167532295</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">46300777</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2019-09-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">52650521</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">52652</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">153633807</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-133396760</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">20289699</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2019-10-012019-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">4394160</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2019-10-012019-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">4394</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2019-10-012019-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">10993558</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2019-10-012019-12-31"
      decimals="0"
      unitRef="USD">10997952</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2
      contextRef="From2019-10-012019-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">35675</avxl:CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2
      contextRef="From2019-10-012019-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">36</avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2>
    <avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2
      contextRef="From2019-10-012019-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-36</avxl:CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2>
    <us-gaap:ShareBasedCompensation
      contextRef="From2019-10-012019-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">1264424</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2019-10-012019-12-31"
      decimals="0"
      unitRef="USD">1264424</us-gaap:ShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-10-012019-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-6591925</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-10-012019-12-31"
      decimals="0"
      unitRef="USD">-6591925</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2019-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">57080356</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">57082</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">165891753</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-139988685</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">25960150</us-gaap:StockholdersEquity>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2020-10-01to2020-12-31">&lt;p id="xdx_806_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_z1q3wTYSqXTh" style="font: 10pt/115% Arial, Helvetica, Sans-Serif; margin: 0 0 0pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Note
1 	&#160;&#160;&#160;&#160;&#160;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_82F_zDtKOiXoQljc"&gt;Business Description and Basis of Presentation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/115% Arial, Helvetica, Sans-Serif; margin: 0; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Business&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Anavex
Life Sciences Corp. (&#x201c;Anavex&#x201d; or the &#x201c;Company&#x201d;) is a clinical stage biopharmaceutical company engaged
in the development of differentiated therapeutics by applying precision medicine to central nervous system (&#x201c;CNS&#x201d;)
diseases with high unmet need. Anavex analyzes genomic data from clinical studies to identify biomarkers, which are used to select
patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. The
Company&#x2019;s lead compound ANAVEX&lt;sup&gt;&#xae;&lt;/sup&gt;2-73 is being developed to treat Alzheimer&#x2019;s disease, Parkinson&#x2019;s
disease and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological
monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2 (&#x201c;MECP2&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Basis
of Presentation&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;These
unaudited interim condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the
Securities and Exchange Commission (&#x201c;SEC&#x201d;) and accounting principles generally accepted in the United States of America
(&#x201c;U.S. GAAP&#x201d;) for interim reporting. Accordingly, certain information and note disclosures normally included in the
annual financial statements in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations.
In the opinion of management, the disclosures are adequate to make the information presented not misleading.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;These
accompanying unaudited interim condensed consolidated financial statements reflect all adjustments, consisting of normal recurring
adjustments, which in the opinion of management are necessary for fair presentation of the information contained herein. The consolidated
balance sheet as of September 30, 2020 was derived from the audited annual financial statements but does not include all disclosures
required by U.S. GAAP. The accompanying unaudited interim condensed consolidated financial statements should be read in conjunction
with the audited consolidated financial statements and notes thereto included in the Company&#x2019;s annual report on Form 10-K
for the year ended September 30, 2020 filed with the SEC on December 28, 2020. The Company follows the same accounting policies
in the preparation of interim reports.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Operating
results for the three months ended December 31, 2020 are not necessarily indicative of the results that may be expected for the
year ending September 30, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Liquidity&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;All
of the Company&#x2019;s potential drug compounds are in the clinical development stage and the Company cannot be certain that its
research and development efforts will be successful or, if successful, that its potential drug compounds will ever be approved
for sales to pharmaceutical companies or generate commercial revenues. To date, we have not generated any revenues from our operations.
The Company expects the business to continue to experience negative cash flows for the foreseeable future and cannot predict when,
if ever, our business might become profitable.&lt;/span&gt;&lt;/p&gt;









&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company believes that its existing cash and cash equivalents, along with existing financial commitments from third parties, will
be sufficient to meet its cash commitments for at least two years after the date that these interim condensed consolidated financial
statements are issued. The process of drug development can be costly, and the timing and outcomes of clinical trials is uncertain.&#160;The
assumptions upon which the Company has based its estimates are routinely evaluated and may be subject to change.&#160;The actual
amount of the Company&#x2019;s expenditures will vary depending upon a number of factors including but not limited to the design,
timing and duration of future clinical trials, the progress of the Company&#x2019;s research and development programs and the level
of financial resources available. The Company has the ability to adjust its operating plan spending levels based on the timing
of future clinical trials.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Other
than our rights related to the 2019 Purchase Agreement and the Sales Agreement (each as defined below in Note 4), there can be
no assurance that additional financing will be available to us when needed or, if available, that it can be obtained on commercially
reasonable terms. If the Company is not able to obtain the additional financing on a timely basis, if and when it is needed, it
will be forced to delay or scale down some or all of its research and development activities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
December 2019, a novel strain of coronavirus, COVID-19, was reported to have surfaced in Wuhan, China. In March 2020, the World
Health Organization (&#x201c;WHO&#x201d;) declared COVID-19 to be a global pandemic as a result of the rapid spread of the virus
beyond its point of origin.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
global outbreak of COVID-19 continues to rapidly evolve as of the date these interim condensed consolidated financial statements
are issued. As such, it is uncertain as to the full magnitude that the outbreak will have on the Company&#x2019;s financial condition
and future results of operations. Management is actively monitoring the global situation on its business, including on its clinical
trials and operations and financial condition. The effects of COVID-19 did not have a material impact on the Company&#x2019;s result
of operations or financial condition for the period ended December 31, 2020. However, given the daily evolution of the COVID-19
situation, and the global responses to curb its spread, the Company is not able to estimate the effects COVID-19 may have on its
future results of operations or financial condition.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Use
of Estimates&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify; color: gray"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and
expenses in the reporting period. The Company regularly evaluates estimates and assumptions related to accounting for research
and development costs, valuation and recoverability of deferred tax assets, asset impairment, stock-based compensation, and loss
contingencies. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors
that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the
carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources.
The actual results experienced by the Company may differ materially and adversely from the Company&#x2019;s estimates. To the extent
there are material differences between the estimates and the actual results, future results of operations will be affected.&lt;/span&gt;&lt;/p&gt;








&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Principles
of Consolidation&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;These
consolidated financial statements include the accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex
Australia Pty Limited. (&#x201c;Anavex Australia&#x201d;), a company incorporated under the laws of Australia, Anavex Germany GmbH,
a company incorporated under the laws of Germany, and Anavex Canada Ltd., a company incorporated under the laws of the Province
of Ontario, Canada. All inter-company transactions and balances have been eliminated.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Fair
Value Measurements&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
fair value hierarchy under GAAP is based on three levels of inputs, of which the first two are considered observable and the last
unobservable, that may be used to measure fair value which are the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 9pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 9pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Level
1 - &#160;&#160;quoted prices (unadjusted) in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 9pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 9pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Level
2 - observable inputs other than Level 1, quoted prices for similar assets or liabilities in active markets, quoted prices for
identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable
or whose significant value drivers are observable; and&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 9pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 9pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Level
3 - &#160;&#160;assets and liabilities whose significant value drivers are unobservable by little or no market activity and that
are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 9pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
book value of cash and cash equivalents and accounts payable and accrued liabilities approximate their fair values due to the
short-term maturity of those instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;At
December 31, 2020 and September 30, 2020, the Company did not have any Level 3 assets or liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Basic
and Diluted Loss per Share&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Basic
income/(loss) per common share is computed by dividing net income/(loss) available to common stockholders by the weighted average
number of common shares outstanding during the period. Diluted income/(loss) per common share is computed by dividing net income/(loss)
available to common stockholders by the sum of (1) the weighted-average number of common shares outstanding during the period,
(2) the dilutive effect of the assumed exercise of options and warrants using the treasury stock method and (3) the dilutive effect
of other potentially dilutive securities. For purposes of the diluted net loss per share calculation, options and warrants are
potentially dilutive securities and are excluded from the calculation of diluted net loss per share because their effect would
be anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
of December 31, 2020, loss per share excludes &lt;span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pii_c20201001__20201231_z2hbCbPRj5I5" title="Loss per share for potentially dilutive common shares"&gt;11,801,266&lt;/span&gt; (September 30, 2020 &#x2013; &lt;span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pii_c20191001__20200930_z5wMgNEZYDLk" title="Loss per share for potentially dilutive common shares"&gt;10,576,266&lt;/span&gt;) potentially dilutive common shares
related to outstanding options and warrants, as their effect was anti-dilutive.&lt;/span&gt;&lt;/p&gt;







</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2020-10-01to2020-12-31"
      decimals="INF"
      unitRef="Shares">11801266</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2019-10-012020-09-30"
      decimals="INF"
      unitRef="Shares">10576266</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock contextRef="From2020-10-01to2020-12-31">&lt;p id="xdx_80F_eus-gaap--NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_zawa9YYWxJRc" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Note
2	&#160;&#160;&#160;&#160;&#160;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_826_zF0lfF6c7mYi"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zB6lChZMEpAj" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Recent
Accounting Pronouncements Not Yet Adopted&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company does not expect the adoption of recently issued accounting pronouncements to have a significant impact on its results
of operations, financial position or cash flow.&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2020-10-01to2020-12-31">&lt;p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zB6lChZMEpAj" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Recent
Accounting Pronouncements Not Yet Adopted&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company does not expect the adoption of recently issued accounting pronouncements to have a significant impact on its results
of operations, financial position or cash flow.&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <avxl:OtherIncomeDisclosureTextBlock contextRef="From2020-10-01to2020-12-31">&lt;p id="xdx_80E_ecustom--OtherIncomeDisclosureTextBlock_zEeMucGadMU" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Note
3	&#160;&#160;&#160;&#160;&#160;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_826_zGYW3F5d6vO2"&gt;Other Income&lt;/span&gt; &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Grant
Income&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;During
the year ended September 30, 2017, the Company was awarded grant funding in the amount of $&lt;span id="xdx_904_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20161001__20170930_zAYd3rsxJrU5" title="Grant income"&gt;597,886&lt;/span&gt;. The grant was received in
equal quarterly installments over a period of two years ending during the year ended September 30, 2020, in exchange for a commitment
to complete clinical testing for a therapeutic drug candidate for the treatment of Rett syndrome.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
grant income was deferred when received and amortized to other income as the related research and development expenditures were
incurred. The Company recognized $&lt;span id="xdx_90E_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20191001__20191231_zoQoFvKawjja" title="Grant income"&gt;74,944&lt;/span&gt; of this grant on its statement of operations within grant income during the three-month
period ended December 31, 2019.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Research
and development incentive income&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Research
and development incentive income represents the receipt by the Company&#x2019;s Australian subsidiary, of the Australian research
and development incentive credit, (the &#x201c;ATO R&amp;amp;D Credit&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;During
the three months ended December 31, 2020, the Company recorded research and development incentive income of $&lt;span id="xdx_90D_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20201001__20201231_zxnVKxfSO0Kf" title="Research and development incentive income"&gt;1,269,316&lt;/span&gt; (AUD &lt;span id="xdx_909_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20201001__20201231__srt--CurrencyAxis__currency--AUD_z2lnXGvYJpM8" title="Research and development incentive income"&gt;1,735,962&lt;/span&gt;)
(2019: $&lt;span id="xdx_90A_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20191001__20191231_pp0p0" title="Research and development incentive income"&gt;943,215&lt;/span&gt; (AUD &lt;span id="xdx_902_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20191001__20191231__srt--CurrencyAxis__currency--AUD_pp0p0" title="Research and development incentive income"&gt;1,345,000&lt;/span&gt;)) in respect of the ATO R&amp;amp;D Credit for eligible research and development expenses incurred
during the period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</avxl:OtherIncomeDisclosureTextBlock>
    <avxl:NonOperatingIncomeFromGrant
      contextRef="From2016-10-012017-09-30"
      decimals="0"
      unitRef="USD">597886</avxl:NonOperatingIncomeFromGrant>
    <avxl:NonOperatingIncomeFromGrant
      contextRef="From2019-10-012019-12-31"
      decimals="0"
      unitRef="USD">74944</avxl:NonOperatingIncomeFromGrant>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      unitRef="USD">1269316</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2020-10-012020-12-31_currency_AUD"
      decimals="0"
      unitRef="USD">1735962</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2019-10-012019-12-31"
      decimals="0"
      unitRef="USD">943215</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="From2019-10-012019-12-31_currency_AUD"
      decimals="0"
      unitRef="USD">1345000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <avxl:EquityOfferingAgreementsTextBlock contextRef="From2020-10-01to2020-12-31">&lt;p id="xdx_80A_ecustom--EquityOfferingAgreementsTextBlock_zB5zLH6eluZ1" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Note
4	&#160;&#160;&#160;&#160;&#160;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_828_zMuukJ5RA2ac"&gt;Equity Offering Agreements&lt;/span&gt;&lt;/span&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2019
Purchase Agreement&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
June 7, 2019, the Company entered into a $&lt;span id="xdx_90D_ecustom--ValueOfSharesObligatedToPurchase_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pp0p0"&gt;50,000,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;purchase agreement (the &#x201c;2019 Purchase
Agreement&#x201d;) with Lincoln Park, as amended on July 1, 2020 , pursuant to which the Company had the right to sell and issue
to Lincoln Park, and Lincoln Park was obligated to purchase, up to $&lt;span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pp0p0_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z9m79178NJbl"&gt;50,000,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;in value of its shares of common stock
from time to time from June 12, 2019, the date a prospectus supplement under which shares of common stock issuable under the 2019
Purchase Agreement was filed with the SEC, until such date as the Company directed Lincoln Park to purchase the $50,000,000 aggregate
commitment, or July 1, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
consideration for entering into the 2019 Purchase Agreement, the Company issued to Lincoln Park &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pii" title="Number of share issued"&gt;324,383&lt;/span&gt; shares of common stock
as a commitment fee and agreed to issue up to &lt;span id="xdx_90D_ecustom--NumberOfSharesObligatedToPurchaseProrataBasic_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pii" title="Pro rata basic number of shares obligated to purchase"&gt;162,191&lt;/span&gt; shares pro rata, when and if, Lincoln Park purchased at the Company&#x2019;s
discretion the $50,000,000 aggregate commitment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;During
the three months ended December 31, 2020, the Company issued to Lincoln Park an aggregate of &lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pii_c20201001__20201231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zrJr9MScFf6i" title="Number of share issued"&gt;3,402,930&lt;/span&gt; (2019 &#x2013; &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pii_c20191001__20191231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z7dEUyxfYHRf" title="Number of share issued"&gt;4,429,835&lt;/span&gt;)
shares of common stock under the 2019 Purchase Agreement, including &lt;span id="xdx_904_ecustom--StockIssuedDuringPeriodSharesNewIssues4_pii_c20201001__20201231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zTxlBsFnslhi" title="Number of shares issued for aggregate purchase price"&gt;3,346,288&lt;/span&gt; (2019: &lt;span id="xdx_901_ecustom--StockIssuedDuringPeriodSharesNewIssues4_pii_c20191001__20191231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zbrComGf8ARd" title="Number of shares issued for aggregate purchase price"&gt;4,394,160&lt;/span&gt;) shares of common stock for an
aggregate purchase price of $&lt;span id="xdx_903_ecustom--StockIssuedDuringPeriodValueNewIssues3_c20201001__20201231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pp0p0" title="Number of shares issued for aggregate purchase price, value"&gt;17,461,402&lt;/span&gt; (2019: $&lt;span id="xdx_907_ecustom--StockIssuedDuringPeriodValueNewIssues3_pp0p0_c20191001__20191231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z8cCkKGRDvb8" title="Number of shares issued for aggregate purchase price, value"&gt;10,997,952&lt;/span&gt;) and &lt;span id="xdx_90C_ecustom--StockIssuedDuringPeriodSharesNewIssues3_c20201001__20201231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pii" title="Number of shares issued for commitment"&gt;56,642&lt;/span&gt; (2019: &lt;span id="xdx_903_ecustom--StockIssuedDuringPeriodSharesNewIssues3_pii_c20191001__20191231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zSrUgxwg1tqe" title="Number of shares issued for commitment"&gt;35,675&lt;/span&gt;) commitment shares. At December 31, 2020,
an amount of $&lt;span id="xdx_902_ecustom--StockIssuedDuringPeriodValueNewIssues4_c20201001__20201231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pp0p0" title="Amount of shares remain available"&gt;6,649,794&lt;/span&gt; (September 30, 2020: $&lt;span id="xdx_905_ecustom--StockIssuedDuringPeriodValueNewIssues4_pp0p0_c20191001__20191231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zqBUCxvbdDaf" title="Amount of shares remain available"&gt;24,111,197&lt;/span&gt;) remained available under the 2019 Purchase Agreement.&lt;/span&gt;&lt;/p&gt;









&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Sales
Agreement&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company entered into a Controlled Equity Offering Sales Agreement on July 6, 2018, which was amended and restated on May 1, 2020
(the &#x201c;Sales Agreement&#x201d;) with Cantor Fitzgerald&#160;&amp;amp; Co. and SVB Leerink LLC (together the &#x201c;Sales Agents&#x201d;),
pursuant to which the Company may offer and sell shares of common stock registered under an effective registration statement from
time to time through the Sales Agents (the &#x201c;Offering&#x201d;).&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Upon
delivery of a placement notice based on the Company&#x2019;s instructions and subject to the terms and conditions of the Sales
Agreement, the Sales Agents may sell the Shares by methods deemed to be an &#x201c;at the market offering&#x201d; offering, in negotiated
transactions at market prices prevailing at the time of sale or at prices related to such prevailing market prices, or by any
other method permitted by law, including negotiated transactions, subject to the prior written consent of the Company. The Company
is not obligated to make any sales of Shares under the Sales Agreement. The Company or Sales Agents may suspend or terminate the
offering of Shares upon notice to the other party, subject to certain conditions.&#160; The Sales Agents will act as agent on
a commercially reasonable efforts basis consistent with their normal trading and sales practices and applicable state and federal
law, rules&#160;and regulations and the rules&#160;of Nasdaq.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company has agreed to pay the Sales Agents commissions for their services of up to &lt;span id="xdx_90B_ecustom--PercentageOfGrossProceedsFromSales_c20201001__20201231__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pii" title="Percentage of gross proceeds from sales"&gt;3.0%&lt;/span&gt; of the gross proceeds from the sale of
the Shares pursuant to the Sales Agreement.&#160; The Company also agreed to provide the Sales Agents with customary indemnification
and contribution rights. During the three months ended December 31, 2020, &lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pii_c20201001__20201231__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_z4yBKQ40fH16" title="Share issued for offering, shares"&gt;1,514,829&lt;/span&gt; shares were sold pursuant to the Offering
for gross proceeds of $&lt;span id="xdx_909_ecustom--GrossProceedsFromSaleOfCommonStock_c20201001__20201231__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zLFv1c37d7a7" title="Gross proceeds from sale of common stock"&gt;8,782,017&lt;/span&gt; (net proceeds of $&lt;span id="xdx_908_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pii_c20201001__20201231__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_z75SIQjjvBAb" title="Proceed from offering"&gt;&lt;span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20201001__20201231__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zQbabuPih1Q1"&gt;8,518,557&lt;/span&gt;&lt;/span&gt; after deducting offering expenses). At December 31, 2020, an amount
of $&lt;span id="xdx_907_ecustom--StockIssuedDuringPeriodValueNewIssues4_pp0p0_c20201001__20201231__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zeYGDf5g3cR9" title="Amount of shares remain available"&gt;33,718,084&lt;/span&gt; (September 30, 2020: $&lt;span id="xdx_909_ecustom--StockIssuedDuringPeriodValueNewIssues4_pp0p0_c20191001__20200930__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zfkOGPWM23Wc" title="Amount of shares remain available"&gt;42,500,100&lt;/span&gt;) remained registered under the Company&#x2019;s effective shelf registration
statement and available to be offered and sold in the Offering.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</avxl:EquityOfferingAgreementsTextBlock>
    <avxl:ValueOfSharesObligatedToPurchase
      contextRef="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="0"
      unitRef="USD">50000000</avxl:ValueOfSharesObligatedToPurchase>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="0"
      unitRef="USD">50000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">324383</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <avxl:NumberOfSharesObligatedToPurchaseProrataBasic
      contextRef="From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">162191</avxl:NumberOfSharesObligatedToPurchaseProrataBasic>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2020-10-012020-12-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">3402930</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2019-10-012019-12-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">4429835</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <avxl:StockIssuedDuringPeriodSharesNewIssues4
      contextRef="From2020-10-012020-12-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">3346288</avxl:StockIssuedDuringPeriodSharesNewIssues4>
    <avxl:StockIssuedDuringPeriodSharesNewIssues4
      contextRef="From2019-10-012019-12-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">4394160</avxl:StockIssuedDuringPeriodSharesNewIssues4>
    <avxl:StockIssuedDuringPeriodValueNewIssues3
      contextRef="From2020-10-012020-12-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="0"
      unitRef="USD">17461402</avxl:StockIssuedDuringPeriodValueNewIssues3>
    <avxl:StockIssuedDuringPeriodValueNewIssues3
      contextRef="From2019-10-012019-12-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="0"
      unitRef="USD">10997952</avxl:StockIssuedDuringPeriodValueNewIssues3>
    <avxl:StockIssuedDuringPeriodSharesNewIssues3
      contextRef="From2020-10-012020-12-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">56642</avxl:StockIssuedDuringPeriodSharesNewIssues3>
    <avxl:StockIssuedDuringPeriodSharesNewIssues3
      contextRef="From2019-10-012019-12-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">35675</avxl:StockIssuedDuringPeriodSharesNewIssues3>
    <avxl:StockIssuedDuringPeriodValueNewIssues4
      contextRef="From2020-10-012020-12-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="0"
      unitRef="USD">6649794</avxl:StockIssuedDuringPeriodValueNewIssues4>
    <avxl:StockIssuedDuringPeriodValueNewIssues4
      contextRef="From2019-10-012019-12-31_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="0"
      unitRef="USD">24111197</avxl:StockIssuedDuringPeriodValueNewIssues4>
    <avxl:PercentageOfGrossProceedsFromSales
      contextRef="From2020-10-012020-12-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember"
      decimals="INF"
      unitRef="Pure">0.030</avxl:PercentageOfGrossProceedsFromSales>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2020-10-012020-12-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember"
      decimals="INF"
      unitRef="Shares">1514829</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <avxl:GrossProceedsFromSaleOfCommonStock
      contextRef="From2020-10-012020-12-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember"
      decimals="0"
      unitRef="USD">8782017</avxl:GrossProceedsFromSaleOfCommonStock>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2020-10-012020-12-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember"
      decimals="0"
      unitRef="USD">8518557</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2020-10-012020-12-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember"
      decimals="0"
      unitRef="USD">8518557</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <avxl:StockIssuedDuringPeriodValueNewIssues4
      contextRef="From2020-10-012020-12-31_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember"
      decimals="0"
      unitRef="USD">33718084</avxl:StockIssuedDuringPeriodValueNewIssues4>
    <avxl:StockIssuedDuringPeriodValueNewIssues4
      contextRef="From2019-10-012020-09-30_custom_EquityOfferingSalesAgreementMember_custom_CantorFitzgeraldAndCoMember"
      decimals="0"
      unitRef="USD">42500100</avxl:StockIssuedDuringPeriodValueNewIssues4>
    <us-gaap:CommitmentsDisclosureTextBlock contextRef="From2020-10-01to2020-12-31">&lt;p id="xdx_80E_eus-gaap--CommitmentsDisclosureTextBlock_zbvqLma7Cab1" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Note
5 	&#160;&#160;&#160;&#160;&#160;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_822_zEzYUFIn54D4"&gt;Commitments&lt;/span&gt; &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 42.75pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;a)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Leases
                                         &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; color: gray"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;During
the three months ended December 31, 2020, the Company incurred office lease expense of $&lt;span id="xdx_901_eus-gaap--LeaseAndRentalExpense_c20201001__20201231_pp0p0" title="Lease expense"&gt;68,387&lt;/span&gt; (2019: $&lt;span id="xdx_900_eus-gaap--LeaseAndRentalExpense_c20191001__20191231_pp0p0" title="Lease expense"&gt;50,054&lt;/span&gt;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 42.75pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;b)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Litigation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; color: gray"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;The
Company is subject to claims and legal proceedings that arise in the ordinary course of business. Such matters are inherently
uncertain, and there can be no guarantee that the outcome of any such matter will be decided favorably to the Company or that
the resolution of any such matter will not have a material adverse effect upon the Company's consolidated financial statements.
The Company does not believe that any of such pending claims and legal proceedings will have a material adverse effect on its
consolidated financial statements.&lt;/span&gt;&lt;/p&gt;









&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; color: gray"&gt;&lt;span style="font: normal 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 42.75pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;c)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Share
                                         Purchase Warrants&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 58.5pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;A
summary of the status of the Company&#x2019;s outstanding share purchase warrants is presented below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"/&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_zkUdaD0EO4L5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span id="xdx_8B4_zAas41cfHNY6" style="display: none"&gt;Schedule of exercisable share purchase warrants outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Number
    of Shares&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
                                                           &lt;p style="margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
                                                           &lt;p style="margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Exercise
                                         Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
                                                           &lt;p style="margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;($)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 26%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Balance,
                                         September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pii_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zgpKvn2g3U29" style="width: 26%; text-align: right" title="Share Purchase Warrants Balance, at beginning"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;350,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_z12EXHH5wlql" style="width: 26%; text-align: right" title="Weighted Average Exercise Price Balance, at beginning"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;4.19&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_pii_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zD4KMttUzjs2" style="border-bottom: Black 1pt solid; text-align: right" title="Share Purchase Warrants Granted"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;150,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_pii_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zOIcTJGf6Eg3" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Granted"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;3.17&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Balance, September
                                                                                                                                 30, 2020 and December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pii_c20201001__20201231__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zEoc0LS7ftif" style="border-bottom: Black 2.5pt double; text-align: right" title="Share Purchase Warrants Balance, at beginning"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;500,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20201001__20201231__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zCNxEAjaibJi" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;3.88&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="display: none; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; text-align: left"&gt;&lt;p style="display: none; margin-top: 0; margin-bottom: 0"&gt;Granted&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_pii_d0_c20201001__20201231__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zPapjFg1Zze4" style="border-bottom: Black 1pt solid; display: none; text-align: right" title="Share Purchase Warrants Granted"&gt;-&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_pii_c20201001__20201231__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zLx7EkHnlDtc" style="border-bottom: Black 1pt solid; display: none; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0408"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="display: none; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;Balance, September
                                                                                                                                 30, 2020 And December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; display: none; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pii_c20201001__20201231__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zEh7QVXxtRz6" style="border-bottom: Black 2.5pt double; display: none; text-align: right" title="Share Purchase Warrants Balance, at ending"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;500,000&lt;/span&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; display: none; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20201001__20201231__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zfXdqFEMA4Cj" style="border-bottom: Black 2.5pt double; display: none; text-align: right" title="Weighted Average Exercise Price Balance, at ending"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;3.88&lt;/span&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p id="xdx_8A1_zAUdHTujm65e" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0pt 58.5pt; text-align: justify; text-indent: -0.8pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;At
December 31, 2020, the Company had share purchase warrants outstanding as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify; text-indent: -0.8pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"/&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_z3rcRMOw98h7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments (Details 1)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span id="xdx_8B8_zNseOy8SObC" style="display: none"&gt;Schedule of share purchase warrants outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Number&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Exercise
    Price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Expiry
    Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20201231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pii" style="width: 10%; text-align: right" title="Number"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;350,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20201231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pii" style="width: 10%; text-align: right" title="Exercise Price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;4.19&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 45%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20201231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zES9VgNb277" title="Expiry date"&gt;June 30, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20201231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pii" style="border-bottom: Black 1pt solid; text-align: right" title="Number"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;150,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20201231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pii" style="border-bottom: Black 1pt solid; text-align: right" title="Exercise Price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;3.17&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20201231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_zuKfmMumvdFi"&gt;May 6, 2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20201231_pii" style="border-bottom: Black 2.5pt double; text-align: right" title="Number"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;500,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p id="xdx_8A1_zQfAD7HHKkCj" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 42.75pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;d)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Stock&#x2013;based
                                         Compensation Plan&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2015
Stock Option Plan&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
September 18, 2015, the Company&#x2019;s board of directors approved a 2015 Omnibus Incentive Plan (the &#x201c;2015 Plan&#x201d;),
which provided for the grant of stock options and restricted stock awards to directors, officers, employees and consultants of
the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
maximum number of our common shares reserved for issue under the plan was &lt;span id="xdx_900_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_c20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" title="Maximum number of common shares reserved for future issuance"&gt;6,050,553&lt;/span&gt; shares, subject to adjustment in the event
of a change of the Company&#x2019;s capitalization. At December 31, 2020, &lt;span id="xdx_90E_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pii_c20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--OptionsMember_z5QYNkLiWrwa" title="Maximum number of common shares reserved for future issuance"&gt;146,371&lt;/span&gt; (September 30, 2020: &lt;span id="xdx_909_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pii_c20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--OptionsMember_zvfECJ0lQCmj" title="Maximum number of common shares reserved for future issuance"&gt;146,371&lt;/span&gt;) options remain
available for issue under the 2015 Plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;













&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2019
Stock Option Plan&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
January 15, 2019, the Board approved the 2019 Omnibus Incentive Plan (the &#x201c;2019 Plan&#x201d;), which provides for the grant
of stock options and restricted stock awards to directors, officers, employees, consultants and advisors of the Company. Under
the terms of the 2019 Plan, &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20201001__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_pii" title="Additional shares of common stock available for issuance"&gt;6,000,000&lt;/span&gt; additional shares of Common Stock are available for issuance under the 2019 Plan, in addition
to the shares available under the 2015 Plan. Any awards outstanding under the 2015 Plan or the Company&#x2019;s 2007 Stock Option
Plan (the &#x201c;2007 Plan&#x201d;) will remain subject to and be paid under the 2015 Plan or the 2007 Plan, respectively, and
any shares subject to outstanding awards under the 2015 Plan or the 2007 Plan that subsequently cease to be subject to such awards
(other than by reason of settlement of the awards in shares) will automatically become available for issuance under the 2019 Plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
2019 Plan provides that it may be administered by the Board, or the Board may delegate such responsibility to a committee. &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20201001__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member" title="Description of grant option"&gt;The
exercise price will be determined by the board of directors at the time of grant shall be at least equal to the fair market
value on such date. If the grantee is a 10% stockholder on the grant date, then the exercise price shall not be less than
110% of fair market value of the Company&#x2019;s shares of common stock on the grant date.&lt;/span&gt; Stock options may be
granted under the 2019 Plan for an exercise period of up to ten &lt;span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dtY_c20201001__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_z8HO18wFsTid" style="display: none" title="Expiration period"&gt;10&lt;/span&gt; years from the date of grant of the option or such lesser
periods as may be determined by the board, subject to earlier termination in accordance with the terms of the 2019 Plan. At
December 31, 2020, &lt;span id="xdx_902_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pii_c20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_ziByfxBYEcZ7" title="Maximum number of common shares reserved for future issuance"&gt;1,936,665&lt;/span&gt; (September 30, 2020: &lt;span id="xdx_90E_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pii_c20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_zyoJmtleP3n4" title="Maximum number of common shares reserved for future issuance"&gt;3,161,665&lt;/span&gt;) options remain available for issue under the 2019
Plan.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;A
summary of the status of Company&#x2019;s outstanding stock purchase options is presented below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"/&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_zQ83AOo3Wsk4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments (Details 2)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B3_z30bCJkFbRQ2" style="display: none"&gt;Schedule of outstanding stock purchase options&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Number
    of Shares&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted
    Average Exercise Price ($)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted
    &lt;/b&gt;&lt;br/&gt;&lt;b&gt;Average &lt;/b&gt;&lt;br/&gt;&lt;b&gt;Grant Date &lt;/b&gt;&lt;br/&gt;&lt;b&gt;Fair Value ($)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Aggregate
    &lt;/b&gt;&lt;br/&gt;&lt;b&gt;intrinsic &lt;/b&gt;&lt;br/&gt;&lt;b&gt;value ($)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 49%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding,
    September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zRluj2hFaNn4" style="width: 10%; text-align: right" title="Options Outstanding at beginning"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;8,462,933&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zG1zRQRfJ9nk" style="width: 10%; text-align: right" title="Weighted Average Exercise Price Outstanding at beginning"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;3.58&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zwrFMVqhACi4" style="text-align: right; width: 10%" title="Aggregate intrinsic value Outstanding at beginning"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;4,115,032&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zYDhSO5E6rgj" style="text-align: right" title="Options Granted"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,695,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" style="text-align: right" title="Weighted Average Exercise Price Granted"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2.96&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zTXoYceDOcA8" style="text-align: right" title="Weighted Average Grant Date Fair Value Granted"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2.27&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pii_di_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zdhsTfjeaaK6" style="text-align: right" title="Options Forfeited"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(68,332&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" style="text-align: right" title="Weighted Average Exercise Price Forfeited"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;3.01&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pii_di_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zuBTOBMvg9v2" style="border-bottom: Black 1pt solid; text-align: right" title="Option Exercised"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(13,335&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Exercised"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;3.15&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td/&gt;&lt;td style="border-bottom: Black 1pt solid"/&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding,
    September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20201001__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z9VnCIB1mldj" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding at beginning"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;10,076,266&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20201001__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zXiuyUGbwmEc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding at beginning"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;3.48&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20201001__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zbEd1Q1eVc0k" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value Outstanding at beginning"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;14,982,581&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_c20201001__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z0ppO71T5UY2" style="border-bottom: Black 1pt solid; text-align: right" title="Options Granted"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,225,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20201001__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Granted"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;5.49&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_c20201001__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zGWAAq1VABzk" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value Granted"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;4.16&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding,
    December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pii_c20201001__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zHiaRYRbvUOg" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding at ending"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;11,301,266&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20201001__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zcwxqrZBq3L9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding at ending"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;3.69&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20201001__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zvwDGiJXDNUl" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value Outstanding at ending"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;21,622,986&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Exercisable,
    December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zEKTySVmpVuk" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;7,540,018&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zF0445Jcte8g" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;3.64&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zK6C3LbNdaJl" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;15,482,966&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p id="xdx_8AD_z2TNSdglgbgl" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted market
price of the Company&#x2019;s stock for the options that were in-the-money at December 31, 2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;













&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;During
the three months ended December 31, 2020, the Company recognized stock-based compensation expense of $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensation_c20201001__20201231_pp0p0" title="Stock-based compensation expense"&gt;939,314&lt;/span&gt; (2019: $&lt;span id="xdx_901_eus-gaap--ShareBasedCompensation_c20191001__20191231_pp0p0" title="Stock-based compensation expense"&gt;1,264,424&lt;/span&gt;)
in connection with the issuance and vesting 	of stock options and warrants in exchange for services. These amounts have been
included in general and 	administrative expenses and research and development expenses on the Company&#x2019;s statement of
	operations as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"/&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zjfVdEfcVdmf" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments (Details 3)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span id="xdx_8B7_zmRwDlcCoC2a" style="display: none"&gt;Schedule of general and administrative expenses and research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 45%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;General
    and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 10%; text-align: right" title="Total share based compensation"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;422,823&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_c20191001__20191231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 10%; text-align: right" title="Total share based compensation"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;481,101&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Research
    and development&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;516,491&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_c20191001__20191231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;783,323&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Total
    share based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20201231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total share based compensation"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;939,314&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_c20191001__20191231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total share based compensation"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,264,424&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


&lt;p id="xdx_8AB_zXmajV4ska21" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0 63.8pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;An
amount of approximately $&lt;span id="xdx_904_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pp0p0_c20201231_zALuO9cPrmV9" title="Remaining stock based compensation"&gt;8,185,000&lt;/span&gt; in stock-based compensation is expected to be recorded over the remaining term 	of such
options through fiscal 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0 63.8pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0 63.8pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
fair value of each option award granted during the three months ended December 31, 2020 and 2019 is estimated on the date of grant
using the Black Scholes option pricing model based on the following weighted average assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zDvhjoWkbkja" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments (Details 4)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B4_z2vwROq8pDac" style="display: none"&gt;Schedule of weighted average assumptions for fair value of each option award&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 45%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Risk-free
    interest rate&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_c20201001__20201231_zyp1NGTe3ZM3" title="Risk-free interest rate"&gt;0.62&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_c20191001__20191231_zgNCsM05hm9h" title="Risk-free interest rate"&gt;1.88&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Expected life of options
    (years)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20201001__20201231_zEP40vMBknfa" title="Expected life of options (years)"&gt;5.59&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20191001__20191231_zfuRzahAtwHj" title="Expected life of options (years)"&gt;5.21&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Annualized volatility&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_c20201001__20201231_zFoqecu8LOl7" title="Annualized volatility"&gt;96.16&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_c20191001__20191231_zZdeGvsA4Mz6" title="Annualized volatility"&gt;101.60&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_dp_c20201001__20201231_zgZNCxhfwSMb" title="Dividend rate"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_dp_c20191001__20191231_z3Ix7rYAIo07" title="Dividend rate"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0 63.8pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;</us-gaap:CommitmentsDisclosureTextBlock>
    <us-gaap:LeaseAndRentalExpense
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      unitRef="USD">68387</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="From2019-10-012019-12-31"
      decimals="0"
      unitRef="USD">50054</us-gaap:LeaseAndRentalExpense>
    <us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock contextRef="From2020-10-01to2020-12-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_zkUdaD0EO4L5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments (Details)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span id="xdx_8B4_zAas41cfHNY6" style="display: none"&gt;Schedule of exercisable share purchase warrants outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Number
    of Shares&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
                                                           &lt;p style="margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
                                                           &lt;p style="margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Exercise
                                         Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
                                                           &lt;p style="margin-top: 0; margin-bottom: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;($)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 26%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Balance,
                                         September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pii_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zgpKvn2g3U29" style="width: 26%; text-align: right" title="Share Purchase Warrants Balance, at beginning"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;350,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_z12EXHH5wlql" style="width: 26%; text-align: right" title="Weighted Average Exercise Price Balance, at beginning"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;4.19&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_pii_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zD4KMttUzjs2" style="border-bottom: Black 1pt solid; text-align: right" title="Share Purchase Warrants Granted"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;150,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_pii_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zOIcTJGf6Eg3" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Granted"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;3.17&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Balance, September
                                                                                                                                 30, 2020 and December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pii_c20201001__20201231__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zEoc0LS7ftif" style="border-bottom: Black 2.5pt double; text-align: right" title="Share Purchase Warrants Balance, at beginning"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;500,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20201001__20201231__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zCNxEAjaibJi" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;3.88&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="display: none; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; text-align: left"&gt;&lt;p style="display: none; margin-top: 0; margin-bottom: 0"&gt;Granted&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_pii_d0_c20201001__20201231__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zPapjFg1Zze4" style="border-bottom: Black 1pt solid; display: none; text-align: right" title="Share Purchase Warrants Granted"&gt;-&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; display: none; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_pii_c20201001__20201231__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zLx7EkHnlDtc" style="border-bottom: Black 1pt solid; display: none; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0408"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="display: none; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;Balance, September
                                                                                                                                 30, 2020 And December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; display: none; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pii_c20201001__20201231__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zEh7QVXxtRz6" style="border-bottom: Black 2.5pt double; display: none; text-align: right" title="Share Purchase Warrants Balance, at ending"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;500,000&lt;/span&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; display: none; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20201001__20201231__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zfXdqFEMA4Cj" style="border-bottom: Black 2.5pt double; display: none; text-align: right" title="Weighted Average Exercise Price Balance, at ending"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;3.88&lt;/span&gt;&lt;/td&gt;&lt;td style="display: none; padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


</us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2019-09-30_custom_PurchaseWarrantsMember"
      decimals="INF"
      unitRef="Shares">350000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2019-09-30_custom_PurchaseWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">4.19</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod
      contextRef="From2019-10-012020-09-30_custom_PurchaseWarrantsMember"
      decimals="INF"
      unitRef="Shares">150000</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod>
    <avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice
      contextRef="From2019-10-012020-09-30_custom_PurchaseWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">3.17</avxl:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2020-09-30_custom_PurchaseWarrantsMember"
      decimals="INF"
      unitRef="Shares">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-09-30_custom_PurchaseWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">3.88</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod
      contextRef="From2020-10-012020-12-31_custom_PurchaseWarrantsMember"
      decimals="INF"
      unitRef="Shares">-0</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2020-12-31_custom_PurchaseWarrantsMember"
      decimals="INF"
      unitRef="Shares">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_custom_PurchaseWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">3.88</avxl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice>
    <avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock contextRef="From2020-10-01to2020-12-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_z3rcRMOw98h7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments (Details 1)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span id="xdx_8B8_zNseOy8SObC" style="display: none"&gt;Schedule of share purchase warrants outstanding&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Number&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Exercise
    Price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Expiry
    Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20201231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pii" style="width: 10%; text-align: right" title="Number"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;350,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20201231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pii" style="width: 10%; text-align: right" title="Exercise Price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;4.19&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 45%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20201231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zES9VgNb277" title="Expiry date"&gt;June 30, 2021&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20201231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pii" style="border-bottom: Black 1pt solid; text-align: right" title="Number"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;150,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20201231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pii" style="border-bottom: Black 1pt solid; text-align: right" title="Exercise Price"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;3.17&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20201231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_zuKfmMumvdFi"&gt;May 6, 2024&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20201231_pii" style="border-bottom: Black 2.5pt double; text-align: right" title="Number"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;500,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


</avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="AsOf2020-12-31_custom_PurchaseWarrants1Member"
      decimals="INF"
      unitRef="Shares">350000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_custom_PurchaseWarrants1Member"
      decimals="INF"
      unitRef="USDPShares">4.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate contextRef="AsOf2020-12-31_custom_PurchaseWarrants1Member">2021-06-30</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="AsOf2020-12-31_custom_PurchaseWarrants2Member"
      decimals="INF"
      unitRef="Shares">150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_custom_PurchaseWarrants2Member"
      decimals="INF"
      unitRef="USDPShares">3.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate contextRef="AsOf2020-12-31_custom_PurchaseWarrants2Member">2024-05-06</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2020-12-31_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">6050553</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2020-12-31_custom_StockOptionPlan2015Member_custom_OptionsMember"
      decimals="INF"
      unitRef="Shares">146371</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2020-09-30_custom_StockOptionPlan2015Member_custom_OptionsMember"
      decimals="INF"
      unitRef="Shares">146371</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="From2020-10-012020-12-31_custom_StockOptionPlan2019Member"
      decimals="INF"
      unitRef="Shares">6000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription contextRef="From2020-10-012020-12-31_custom_StockOptionPlan2019Member">The
exercise price will be determined by the board of directors at the time of grant shall be at least equal to the fair market
value on such date. If the grantee is a 10% stockholder on the grant date, then the exercise price shall not be less than
110% of fair market value of the Company&#x2019;s shares of common stock on the grant date.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="From2020-10-012020-12-31_custom_StockOptionPlan2019Member">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2020-12-31_custom_StockOptionPlan2019Member"
      decimals="INF"
      unitRef="Shares">1936665</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="AsOf2020-09-30_custom_StockOptionPlan2019Member"
      decimals="INF"
      unitRef="Shares">3161665</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock contextRef="From2020-10-01to2020-12-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_zQ83AOo3Wsk4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments (Details 2)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B3_z30bCJkFbRQ2" style="display: none"&gt;Schedule of outstanding stock purchase options&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Number
    of Shares&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted
    Average Exercise Price ($)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted
    &lt;/b&gt;&lt;br/&gt;&lt;b&gt;Average &lt;/b&gt;&lt;br/&gt;&lt;b&gt;Grant Date &lt;/b&gt;&lt;br/&gt;&lt;b&gt;Fair Value ($)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Aggregate
    &lt;/b&gt;&lt;br/&gt;&lt;b&gt;intrinsic &lt;/b&gt;&lt;br/&gt;&lt;b&gt;value ($)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 49%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding,
    September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zRluj2hFaNn4" style="width: 10%; text-align: right" title="Options Outstanding at beginning"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;8,462,933&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zG1zRQRfJ9nk" style="width: 10%; text-align: right" title="Weighted Average Exercise Price Outstanding at beginning"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;3.58&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zwrFMVqhACi4" style="text-align: right; width: 10%" title="Aggregate intrinsic value Outstanding at beginning"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;4,115,032&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zYDhSO5E6rgj" style="text-align: right" title="Options Granted"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,695,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" style="text-align: right" title="Weighted Average Exercise Price Granted"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2.96&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zTXoYceDOcA8" style="text-align: right" title="Weighted Average Grant Date Fair Value Granted"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2.27&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pii_di_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zdhsTfjeaaK6" style="text-align: right" title="Options Forfeited"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(68,332&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" style="text-align: right" title="Weighted Average Exercise Price Forfeited"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;3.01&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pii_di_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zuBTOBMvg9v2" style="border-bottom: Black 1pt solid; text-align: right" title="Option Exercised"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(13,335&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Exercised"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;3.15&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td/&gt;&lt;td style="border-bottom: Black 1pt solid"/&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding,
    September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20201001__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z9VnCIB1mldj" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding at beginning"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;10,076,266&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20201001__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zXiuyUGbwmEc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding at beginning"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;3.48&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20201001__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zbEd1Q1eVc0k" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value Outstanding at beginning"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;14,982,581&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_c20201001__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z0ppO71T5UY2" style="border-bottom: Black 1pt solid; text-align: right" title="Options Granted"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,225,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20201001__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Granted"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;5.49&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_c20201001__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zGWAAq1VABzk" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value Granted"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;4.16&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td/&gt;&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Outstanding,
    December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pii_c20201001__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zHiaRYRbvUOg" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding at ending"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;11,301,266&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20201001__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zcwxqrZBq3L9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding at ending"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;3.69&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20201001__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zvwDGiJXDNUl" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value Outstanding at ending"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;21,622,986&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Exercisable,
    December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zEKTySVmpVuk" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;7,540,018&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zF0445Jcte8g" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;3.64&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zK6C3LbNdaJl" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;15,482,966&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


</us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2019-09-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">8462933</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2019-09-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">3.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2019-09-30_custom_StockOptionPlan2015Member"
      decimals="0"
      unitRef="USD">4115032</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2019-10-012020-09-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">1695000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2019-10-012020-09-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">2.96</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2019-10-012020-09-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">2.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2019-10-012020-09-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">68332</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2019-10-012020-09-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">3.01</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2019-10-012020-09-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">13335</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2019-10-012020-09-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">3.15</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-09-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">10076266</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-09-30_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">3.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2020-09-30_custom_StockOptionPlan2015Member"
      decimals="0"
      unitRef="USD">14982581</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2020-10-012020-12-31_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">1225000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2020-10-012020-12-31_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">5.49</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2020-10-012020-12-31_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">4.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-12-31_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">11301266</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">3.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2020-12-31_custom_StockOptionPlan2015Member"
      decimals="0"
      unitRef="USD">21622986</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2020-12-31_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="Shares">7540018</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_custom_StockOptionPlan2015Member"
      decimals="INF"
      unitRef="USDPShares">3.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2020-12-31_custom_StockOptionPlan2015Member"
      decimals="0"
      unitRef="USD">15482966</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      unitRef="USD">939314</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2019-10-012019-12-31"
      decimals="0"
      unitRef="USD">1264424</us-gaap:ShareBasedCompensation>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="From2020-10-01to2020-12-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zjfVdEfcVdmf" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments (Details 3)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span id="xdx_8B7_zmRwDlcCoC2a" style="display: none"&gt;Schedule of general and administrative expenses and research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 45%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;General
    and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 10%; text-align: right" title="Total share based compensation"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;422,823&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_c20191001__20191231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 10%; text-align: right" title="Total share based compensation"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;481,101&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Research
    and development&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;516,491&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_c20191001__20191231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;783,323&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Total
    share based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20201231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total share based compensation"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;939,314&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_c20191001__20191231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total share based compensation"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,264,424&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;


</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2020-10-012020-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      unitRef="USD">422823</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2019-10-012019-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      unitRef="USD">481101</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2020-10-012020-12-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">516491</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2019-10-012019-12-31_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">783323</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2020-10-01to2020-12-31"
      decimals="0"
      unitRef="USD">939314</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2019-10-012019-12-31"
      decimals="0"
      unitRef="USD">1264424</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">8185000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2020-10-01to2020-12-31">&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zDvhjoWkbkja" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments (Details 4)"&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B4_z2vwROq8pDac" style="display: none"&gt;Schedule of weighted average assumptions for fair value of each option award&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 45%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Risk-free
    interest rate&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_c20201001__20201231_zyp1NGTe3ZM3" title="Risk-free interest rate"&gt;0.62&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_c20191001__20191231_zgNCsM05hm9h" title="Risk-free interest rate"&gt;1.88&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Expected life of options
    (years)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20201001__20201231_zEP40vMBknfa" title="Expected life of options (years)"&gt;5.59&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20191001__20191231_zfuRzahAtwHj" title="Expected life of options (years)"&gt;5.21&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Annualized volatility&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_c20201001__20201231_zFoqecu8LOl7" title="Annualized volatility"&gt;96.16&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_c20191001__20191231_zZdeGvsA4Mz6" title="Annualized volatility"&gt;101.60&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_dp_c20201001__20201231_zgZNCxhfwSMb" title="Dividend rate"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_dp_c20191001__20191231_z3Ix7rYAIo07" title="Dividend rate"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0 63.8pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2020-10-01to2020-12-31"
      decimals="INF"
      unitRef="Pure">0.0062</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2019-10-012019-12-31"
      decimals="INF"
      unitRef="Pure">0.0188</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2020-10-01to2020-12-31">P5Y7M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2019-10-012019-12-31">P5Y2M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2020-10-01to2020-12-31"
      decimals="INF"
      unitRef="Pure">0.9616</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2019-10-012019-12-31"
      decimals="INF"
      unitRef="Pure">1.0160</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2020-10-01to2020-12-31"
      decimals="INF"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2019-10-012019-12-31"
      decimals="INF"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2020-10-01to2020-12-31">&lt;p id="xdx_805_eus-gaap--SubsequentEventsTextBlock_znyQNgALn8Lg" style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Note
6	&#160;&#160;&#160;&#160;&#160;&lt;span id="xdx_829_z7Yfmp9MvN7d"&gt;&lt;span style="text-decoration: underline"&gt;Subsequent Events&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;Subsequent to December 31,
2020;&lt;/p&gt;

&lt;p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 11pt/106% Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 42.55pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font-size: 10pt"&gt;a)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;the Company received $&lt;span id="xdx_904_ecustom--GrantReceived_c20210101__20210211__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MichaelJFoxFoundationMember_z5NUEPoSiFO4" title="Grant received"&gt;497,931&lt;/span&gt; of a $&lt;span id="xdx_903_ecustom--TotalGrant_c20210101__20210211__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MichaelJFoxFoundationMember_zcV8a2sHcyTa" title="Total grant"&gt;995,862&lt;/span&gt; research grant awarded
by the Michael J. Fox Foundation for Parkinson's Research. The grant will be used to fund a clinical trial in the Company's lead
compound, ANAVEX&lt;sup&gt;&#xae;&lt;/sup&gt;2-73 for the treatment of Parkinson's disease.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 0 60.55pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 11pt/106% Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 42.55pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font-size: 10pt"&gt;b)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;the Company issued  &lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pii_c20210101__20210211__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zt5c7WpwRRk3" title="Share issued for offering, shares"&gt;683,279&lt;/span&gt; shares
of common stock under the 2019 Purchase Agreement, including &lt;span id="xdx_90A_ecustom--StockIssuedDuringPeriodSharesNewIssues4_pii_c20210101__20210211__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zUhmnfm0ZkW1" title="Number of shares issued for aggregate purchase price"&gt;661,708&lt;/span&gt; shares of common stock for an aggregate purchase price of
$&lt;span id="xdx_901_ecustom--StockIssuedDuringPeriodValueNewIssues3_pii_c20210101__20210211__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z53G7fcR0Ogf" title="Number of shares issued for aggregate purchase price"&gt;6,649,782&lt;/span&gt; and &lt;span id="xdx_90F_ecustom--StockIssuedDuringPeriodSharesNewIssues3_pii_c20210101__20210211__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z6XLmh18eVl6" title="Number of shares issued for commitment"&gt;21,571&lt;/span&gt; commitment shares.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 0 36pt"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 11pt/106% Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 42.55pt"/&gt;&lt;td style="width: 18pt"&gt;&lt;span style="font-size: 10pt"&gt;c)&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;an aggregate of &lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pii_c20210101__20210211__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zZo2FTuhEqV" title="Share issued for offering, shares"&gt;1,841,616&lt;/span&gt; shares were sold under the Sales Agreement
for gross proceeds of $&lt;span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0p0_c20210101__20210211__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_ztYP7YQD4mVe" title="Gross sale proceeds"&gt;25,893,861&lt;/span&gt;.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

</us-gaap:SubsequentEventsTextBlock>
    <avxl:GrantReceived
      contextRef="From2021-01-012021-02-11_us-gaap_SubsequentEventMember_custom_MichaelJFoxFoundationMember"
      decimals="0"
      unitRef="USD">497931</avxl:GrantReceived>
    <avxl:TotalGrant
      contextRef="From2021-01-012021-02-11_us-gaap_SubsequentEventMember_custom_MichaelJFoxFoundationMember"
      decimals="0"
      unitRef="USD">995862</avxl:TotalGrant>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-01-012021-02-11_us-gaap_SubsequentEventMember_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">683279</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <avxl:StockIssuedDuringPeriodSharesNewIssues4
      contextRef="From2021-01-012021-02-11_us-gaap_SubsequentEventMember_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">661708</avxl:StockIssuedDuringPeriodSharesNewIssues4>
    <avxl:StockIssuedDuringPeriodValueNewIssues3
      contextRef="From2021-01-012021-02-11_us-gaap_SubsequentEventMember_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="0"
      unitRef="USD">6649782</avxl:StockIssuedDuringPeriodValueNewIssues3>
    <avxl:StockIssuedDuringPeriodSharesNewIssues3
      contextRef="From2021-01-012021-02-11_us-gaap_SubsequentEventMember_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember"
      decimals="INF"
      unitRef="Shares">21571</avxl:StockIssuedDuringPeriodSharesNewIssues3>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-01-012021-02-11_us-gaap_SubsequentEventMember_custom_SalesAgreementMember"
      decimals="INF"
      unitRef="Shares">1841616</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2021-01-012021-02-11_us-gaap_SubsequentEventMember_custom_SalesAgreementMember"
      decimals="0"
      unitRef="USD">25893861</us-gaap:ProceedsFromIssuanceOfCommonStock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140141841242360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Feb. 12, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--09-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ANAVEX LIFE SCIENCES CORP.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001314052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-0608404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">51 West 52nd Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">7th Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">US<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">689-3939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock Par Value $0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AVXL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,487,852<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140141841184696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 47,357,599<span></span>
</td>
<td class="nump">$ 29,249,018<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Incentive and tax receivables</a></td>
<td class="nump">6,577,807<span></span>
</td>
<td class="nump">4,849,340<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses and deposits</a></td>
<td class="nump">398,840<span></span>
</td>
<td class="nump">443,839<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">54,334,246<span></span>
</td>
<td class="nump">34,542,197<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">4,216,948<span></span>
</td>
<td class="nump">3,989,054<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">3,816,521<span></span>
</td>
<td class="nump">3,316,574<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Liabilities</a></td>
<td class="nump">8,033,469<span></span>
</td>
<td class="nump">7,305,628<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Capital stock Authorized: 10,000,000 preferred stock, par value $0.001 per share</a></td>
<td class="nump">(0)<span></span>
</td>
<td class="nump">(0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Capital stock Authorized: 100,000,000 common shares, par value $0.001 per share Issued and outstanding: 60,082,291 common shares (September 30, 2019 - 52,650,251)</a></td>
<td class="nump">66,964<span></span>
</td>
<td class="nump">62,047<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">213,766,108<span></span>
</td>
<td class="nump">186,851,752<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(167,532,295)<span></span>
</td>
<td class="num">(159,677,230)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders' Equity</a></td>
<td class="nump">46,300,777<span></span>
</td>
<td class="nump">27,236,569<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders' Equity</a></td>
<td class="nump">$ 54,334,246<span></span>
</td>
<td class="nump">$ 34,542,197<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.5(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140141844213272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">66,962,957<span></span>
</td>
<td class="nump">62,045,198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">66,962,957<span></span>
</td>
<td class="nump">62,045,198<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140141841142040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">$ 1,470,656<span></span>
</td>
<td class="nump">$ 1,352,035<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">7,925,519<span></span>
</td>
<td class="nump">6,348,668<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="num">(9,396,175)<span></span>
</td>
<td class="num">(7,700,703)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expenses)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_NonOperatingIncomeFromGrant', window );">Grant income</a></td>
<td class="nump">(0)<span></span>
</td>
<td class="nump">74,944<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ResearchAndDevelopmentIncentiveIncome', window );">Research and development incentive income</a></td>
<td class="nump">1,269,316<span></span>
</td>
<td class="nump">943,215<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest (expense) income, net</a></td>
<td class="num">(1,559)<span></span>
</td>
<td class="nump">46,720<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange gain, net</a></td>
<td class="nump">332,634<span></span>
</td>
<td class="nump">53,113<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">1,600,391<span></span>
</td>
<td class="nump">1,117,992<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before provision for income taxes</a></td>
<td class="num">(7,795,784)<span></span>
</td>
<td class="num">(6,582,711)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Income tax expense, current</a></td>
<td class="num">(59,281)<span></span>
</td>
<td class="num">(9,214)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">$ (7,855,065)<span></span>
</td>
<td class="num">$ (6,591,925)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net Loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted</a></td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="num">$ (0.12)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average number of shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted</a></td>
<td class="nump">64,295,143<span></span>
</td>
<td class="nump">54,773,685<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_NonOperatingIncomeFromGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_NonOperatingIncomeFromGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ResearchAndDevelopmentIncentiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ResearchAndDevelopmentIncentiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121605123&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140141844016920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows used in Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (7,855,065)<span></span>
</td>
<td class="num">$ (6,591,925)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">939,314<span></span>
</td>
<td class="nump">1,264,424<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in non-cash working capital balances related to operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable', window );">Incentive and tax receivables</a></td>
<td class="num">(1,728,467)<span></span>
</td>
<td class="num">(1,087,927)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses and deposits</a></td>
<td class="nump">44,999<span></span>
</td>
<td class="nump">266,026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">227,894<span></span>
</td>
<td class="nump">395,834<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="nump">499,947<span></span>
</td>
<td class="nump">820,077<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(7,871,378)<span></span>
</td>
<td class="num">(5,725,159)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows provided by Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Issuance of common shares</a></td>
<td class="nump">26,243,419<span></span>
</td>
<td class="nump">10,997,952<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Share issue costs</a></td>
<td class="num">(263,460)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">25,979,959<span></span>
</td>
<td class="nump">10,997,952<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Increase in cash and cash equivalents during the period</a></td>
<td class="nump">18,108,581<span></span>
</td>
<td class="nump">5,272,793<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">29,249,018<span></span>
</td>
<td class="nump">22,185,630<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">$ 47,357,599<span></span>
</td>
<td class="nump">$ 27,458,423<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInIncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140141835146536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Sep. 30, 2019</a></td>
<td class="nump">$ 52,652<span></span>
</td>
<td class="nump">$ 153,633,807<span></span>
</td>
<td class="num">$ (133,396,760)<span></span>
</td>
<td class="nump">$ 20,289,699<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance beginning, shares at Sep. 30, 2019</a></td>
<td class="nump">52,650,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">&#160;&#160;Purchase shares</a></td>
<td class="nump">$ 4,394<span></span>
</td>
<td class="nump">10,993,558<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">10,997,952<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Purchase shares, shares</a></td>
<td class="nump">4,394,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2', window );">&#160;&#160;Commitment shares</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="num">(36)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2', window );">Commitment shares, shares</a></td>
<td class="nump">35,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,264,424<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,264,424<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(6,591,925)<span></span>
</td>
<td class="num">(6,591,925)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Dec. 31, 2019</a></td>
<td class="nump">$ 57,082<span></span>
</td>
<td class="nump">165,891,753<span></span>
</td>
<td class="num">(139,988,685)<span></span>
</td>
<td class="nump">25,960,150<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance ending, shares at Dec. 31, 2019</a></td>
<td class="nump">57,080,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Sep. 30, 2020</a></td>
<td class="nump">$ 62,047<span></span>
</td>
<td class="nump">186,851,752<span></span>
</td>
<td class="num">(159,677,230)<span></span>
</td>
<td class="nump">27,236,569<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance beginning, shares at Sep. 30, 2020</a></td>
<td class="nump">62,045,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">&#160;&#160;Purchase shares</a></td>
<td class="nump">$ 3,346<span></span>
</td>
<td class="nump">17,458,056<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">17,461,402<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Purchase shares, shares</a></td>
<td class="nump">3,346,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2', window );">&#160;&#160;Commitment shares</a></td>
<td class="nump">$ 56<span></span>
</td>
<td class="num">(56)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2', window );">Commitment shares, shares</a></td>
<td class="nump">56,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Shares issued under Sales Agreement, net of shares issue costs</a></td>
<td class="nump">$ 1,515<span></span>
</td>
<td class="nump">8,517,042<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">8,518,557<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Shares issued under Sales Agreement, net of shares issue costs, shares</a></td>
<td class="nump">1,514,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">939,314<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">939,314<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(7,855,065)<span></span>
</td>
<td class="num">(7,855,065)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Dec. 31, 2020</a></td>
<td class="nump">$ 66,964<span></span>
</td>
<td class="nump">$ 213,766,108<span></span>
</td>
<td class="num">$ (167,532,295)<span></span>
</td>
<td class="nump">$ 46,300,777<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance ending, shares at Dec. 31, 2020</a></td>
<td class="nump">66,962,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitment shares issued shares underterms of purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitment shares Issued value Underterms of purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140141839671096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Description and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Business Description and Basis of Presentation</a></td>
<td class="text"><p id="xdx_806_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_z1q3wTYSqXTh" style="font: 10pt/115% Arial, Helvetica, Sans-Serif; margin: 0 0 0pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Note
1 	&#160;&#160;&#160;&#160;&#160;<span style="text-decoration: underline"><span id="xdx_82F_zDtKOiXoQljc">Business Description and Basis of Presentation</span></span></span></p>

<p style="font: 10pt/115% Arial, Helvetica, Sans-Serif; margin: 0; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Business</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Anavex
Life Sciences Corp. (&#8220;Anavex&#8221; or the &#8220;Company&#8221;) is a clinical stage biopharmaceutical company engaged
in the development of differentiated therapeutics by applying precision medicine to central nervous system (&#8220;CNS&#8221;)
diseases with high unmet need. Anavex analyzes genomic data from clinical studies to identify biomarkers, which are used to select
patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. The
Company&#8217;s lead compound ANAVEX<sup>&#174;</sup>2-73 is being developed to treat Alzheimer&#8217;s disease, Parkinson&#8217;s
disease and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological
monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2 (&#8220;MECP2&#8221;).</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Basis
of Presentation</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">These
unaudited interim condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the
Securities and Exchange Commission (&#8220;SEC&#8221;) and accounting principles generally accepted in the United States of America
(&#8220;U.S. GAAP&#8221;) for interim reporting. Accordingly, certain information and note disclosures normally included in the
annual financial statements in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations.
In the opinion of management, the disclosures are adequate to make the information presented not misleading.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">These
accompanying unaudited interim condensed consolidated financial statements reflect all adjustments, consisting of normal recurring
adjustments, which in the opinion of management are necessary for fair presentation of the information contained herein. The consolidated
balance sheet as of September 30, 2020 was derived from the audited annual financial statements but does not include all disclosures
required by U.S. GAAP. The accompanying unaudited interim condensed consolidated financial statements should be read in conjunction
with the audited consolidated financial statements and notes thereto included in the Company&#8217;s annual report on Form 10-K
for the year ended September 30, 2020 filed with the SEC on December 28, 2020. The Company follows the same accounting policies
in the preparation of interim reports.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Operating
results for the three months ended December 31, 2020 are not necessarily indicative of the results that may be expected for the
year ending September 30, 2021.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Liquidity</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">All
of the Company&#8217;s potential drug compounds are in the clinical development stage and the Company cannot be certain that its
research and development efforts will be successful or, if successful, that its potential drug compounds will ever be approved
for sales to pharmaceutical companies or generate commercial revenues. To date, we have not generated any revenues from our operations.
The Company expects the business to continue to experience negative cash flows for the foreseeable future and cannot predict when,
if ever, our business might become profitable.</span></p>









<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company believes that its existing cash and cash equivalents, along with existing financial commitments from third parties, will
be sufficient to meet its cash commitments for at least two years after the date that these interim condensed consolidated financial
statements are issued. The process of drug development can be costly, and the timing and outcomes of clinical trials is uncertain.&#160;The
assumptions upon which the Company has based its estimates are routinely evaluated and may be subject to change.&#160;The actual
amount of the Company&#8217;s expenditures will vary depending upon a number of factors including but not limited to the design,
timing and duration of future clinical trials, the progress of the Company&#8217;s research and development programs and the level
of financial resources available. The Company has the ability to adjust its operating plan spending levels based on the timing
of future clinical trials.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0pt 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Other
than our rights related to the 2019 Purchase Agreement and the Sales Agreement (each as defined below in Note 4), there can be
no assurance that additional financing will be available to us when needed or, if available, that it can be obtained on commercially
reasonable terms. If the Company is not able to obtain the additional financing on a timely basis, if and when it is needed, it
will be forced to delay or scale down some or all of its research and development activities.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
December 2019, a novel strain of coronavirus, COVID-19, was reported to have surfaced in Wuhan, China. In March 2020, the World
Health Organization (&#8220;WHO&#8221;) declared COVID-19 to be a global pandemic as a result of the rapid spread of the virus
beyond its point of origin.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
global outbreak of COVID-19 continues to rapidly evolve as of the date these interim condensed consolidated financial statements
are issued. As such, it is uncertain as to the full magnitude that the outbreak will have on the Company&#8217;s financial condition
and future results of operations. Management is actively monitoring the global situation on its business, including on its clinical
trials and operations and financial condition. The effects of COVID-19 did not have a material impact on the Company&#8217;s result
of operations or financial condition for the period ended December 31, 2020. However, given the daily evolution of the COVID-19
situation, and the global responses to curb its spread, the Company is not able to estimate the effects COVID-19 may have on its
future results of operations or financial condition.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify; color: gray"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Use
of Estimates</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify; color: gray"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and
expenses in the reporting period. The Company regularly evaluates estimates and assumptions related to accounting for research
and development costs, valuation and recoverability of deferred tax assets, asset impairment, stock-based compensation, and loss
contingencies. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors
that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the
carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources.
The actual results experienced by the Company may differ materially and adversely from the Company&#8217;s estimates. To the extent
there are material differences between the estimates and the actual results, future results of operations will be affected.</span></p>








<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Principles
of Consolidation</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">These
consolidated financial statements include the accounts of Anavex Life Sciences Corp. and its wholly-owned subsidiaries, Anavex
Australia Pty Limited. (&#8220;Anavex Australia&#8221;), a company incorporated under the laws of Australia, Anavex Germany GmbH,
a company incorporated under the laws of Germany, and Anavex Canada Ltd., a company incorporated under the laws of the Province
of Ontario, Canada. All inter-company transactions and balances have been eliminated.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Fair
Value Measurements</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
fair value hierarchy under GAAP is based on three levels of inputs, of which the first two are considered observable and the last
unobservable, that may be used to measure fair value which are the following:</span></p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Level
1 - &#160;&#160;quoted prices (unadjusted) in active markets for identical assets or liabilities;</span></p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Level
2 - observable inputs other than Level 1, quoted prices for similar assets or liabilities in active markets, quoted prices for
identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable
or whose significant value drivers are observable; and</span></p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Level
3 - &#160;&#160;assets and liabilities whose significant value drivers are unobservable by little or no market activity and that
are significant to the fair value of the assets or liabilities.</span></p>

<p style="font: 9pt Times New Roman, Times, Serif; margin: 0 0 0 103.5pt; text-align: justify; text-indent: -40.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
book value of cash and cash equivalents and accounts payable and accrued liabilities approximate their fair values due to the
short-term maturity of those instruments.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">At
December 31, 2020 and September 30, 2020, the Company did not have any Level 3 assets or liabilities.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Basic
and Diluted Loss per Share</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Basic
income/(loss) per common share is computed by dividing net income/(loss) available to common stockholders by the weighted average
number of common shares outstanding during the period. Diluted income/(loss) per common share is computed by dividing net income/(loss)
available to common stockholders by the sum of (1) the weighted-average number of common shares outstanding during the period,
(2) the dilutive effect of the assumed exercise of options and warrants using the treasury stock method and (3) the dilutive effect
of other potentially dilutive securities. For purposes of the diluted net loss per share calculation, options and warrants are
potentially dilutive securities and are excluded from the calculation of diluted net loss per share because their effect would
be anti-dilutive.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
of December 31, 2020, loss per share excludes <span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pii_c20201001__20201231_z2hbCbPRj5I5" title="Loss per share for potentially dilutive common shares">11,801,266</span> (September 30, 2020 &#8211; <span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pii_c20191001__20200930_z5wMgNEZYDLk" title="Loss per share for potentially dilutive common shares">10,576,266</span>) potentially dilutive common shares
related to outstanding options and warrants, as their effect was anti-dilutive.</span></p>







<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140141841002952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recent Accounting Pronouncements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract', window );"><strong>Accounting Changes and Error Corrections [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_zawa9YYWxJRc" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">Note
2	&#160;&#160;&#160;&#160;&#160;<span style="text-decoration: underline"><span id="xdx_826_zF0lfF6c7mYi">Recent Accounting Pronouncements</span></span></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zB6lChZMEpAj" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Recent
Accounting Pronouncements Not Yet Adopted</i></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company does not expect the adoption of recently issued accounting pronouncements to have a significant impact on its results
of operations, financial position or cash flow.</span></p>



<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingChangesAndErrorCorrectionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=113356391&amp;loc=SL49131195-203048<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=113356391&amp;loc=SL49131195-203048<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=112272810&amp;loc=SL108384541-122693<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (i)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=113356391&amp;loc=SL49131195-203048<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=113356391&amp;loc=SL49131195-203048<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=112272810&amp;loc=d3e31137-122693<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(1)<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(2)<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140141839716056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Income<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_DisclosureOtherIncomeAbstract', window );"><strong>Other Income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_OtherIncomeDisclosureTextBlock', window );">Other Income</a></td>
<td class="text"><p id="xdx_80E_ecustom--OtherIncomeDisclosureTextBlock_zEeMucGadMU" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">Note
3	&#160;&#160;&#160;&#160;&#160;<span style="text-decoration: underline"><span id="xdx_826_zGYW3F5d6vO2">Other Income</span> </span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Grant
Income</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">During
the year ended September 30, 2017, the Company was awarded grant funding in the amount of $<span id="xdx_904_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20161001__20170930_zAYd3rsxJrU5" title="Grant income">597,886</span>. The grant was received in
equal quarterly installments over a period of two years ending during the year ended September 30, 2020, in exchange for a commitment
to complete clinical testing for a therapeutic drug candidate for the treatment of Rett syndrome.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
grant income was deferred when received and amortized to other income as the related research and development expenditures were
incurred. The Company recognized $<span id="xdx_90E_ecustom--NonOperatingIncomeFromGrant_pp0p0_c20191001__20191231_zoQoFvKawjja" title="Grant income">74,944</span> of this grant on its statement of operations within grant income during the three-month
period ended December 31, 2019.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Research
and development incentive income</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Research
and development incentive income represents the receipt by the Company&#8217;s Australian subsidiary, of the Australian research
and development incentive credit, (the &#8220;ATO R&amp;D Credit&#8221;).</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 45pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">During
the three months ended December 31, 2020, the Company recorded research and development incentive income of $<span id="xdx_90D_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20201001__20201231_zxnVKxfSO0Kf" title="Research and development incentive income">1,269,316</span> (AUD <span id="xdx_909_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_pp0p0_c20201001__20201231__srt--CurrencyAxis__currency--AUD_z2lnXGvYJpM8" title="Research and development incentive income">1,735,962</span>)
(2019: $<span id="xdx_90A_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20191001__20191231_pp0p0" title="Research and development incentive income">943,215</span> (AUD <span id="xdx_902_eus-gaap--ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_c20191001__20191231__srt--CurrencyAxis__currency--AUD_pp0p0" title="Research and development incentive income">1,345,000</span>)) in respect of the ATO R&amp;D Credit for eligible research and development expenses incurred
during the period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_DisclosureOtherIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_DisclosureOtherIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_OtherIncomeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_OtherIncomeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140141864044600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Offering Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_DisclosureEquityOfferingAgreementsAbstract', window );"><strong>Equity Offering Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_EquityOfferingAgreementsTextBlock', window );">Equity Offering Agreements</a></td>
<td class="text"><p id="xdx_80A_ecustom--EquityOfferingAgreementsTextBlock_zB5zLH6eluZ1" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Note
4	&#160;&#160;&#160;&#160;&#160;<span style="text-decoration: underline"><span id="xdx_828_zMuukJ5RA2ac">Equity Offering Agreements</span></span> </span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">2019
Purchase Agreement</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
June 7, 2019, the Company entered into a $<span id="xdx_90D_ecustom--ValueOfSharesObligatedToPurchase_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pp0p0">50,000,000
</span></span><span style="font: 10pt Times New Roman, Times, Serif">purchase agreement (the &#8220;2019 Purchase
Agreement&#8221;) with Lincoln Park, as amended on July 1, 2020 , pursuant to which the Company had the right to sell and issue
to Lincoln Park, and Lincoln Park was obligated to purchase, up to $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pp0p0_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z9m79178NJbl">50,000,000
</span></span><span style="font: 10pt Times New Roman, Times, Serif">in value of its shares of common stock
from time to time from June 12, 2019, the date a prospectus supplement under which shares of common stock issuable under the 2019
Purchase Agreement was filed with the SEC, until such date as the Company directed Lincoln Park to purchase the $50,000,000 aggregate
commitment, or July 1, 2022.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
consideration for entering into the 2019 Purchase Agreement, the Company issued to Lincoln Park <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pii" title="Number of share issued">324,383</span> shares of common stock
as a commitment fee and agreed to issue up to <span id="xdx_90D_ecustom--NumberOfSharesObligatedToPurchaseProrataBasic_c20190606__20190607__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pii" title="Pro rata basic number of shares obligated to purchase">162,191</span> shares pro rata, when and if, Lincoln Park purchased at the Company&#8217;s
discretion the $50,000,000 aggregate commitment.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the three months ended December 31, 2020, the Company issued to Lincoln Park an aggregate of <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pii_c20201001__20201231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zrJr9MScFf6i" title="Number of share issued">3,402,930</span> (2019 &#8211; <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pii_c20191001__20191231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z7dEUyxfYHRf" title="Number of share issued">4,429,835</span>)
shares of common stock under the 2019 Purchase Agreement, including <span id="xdx_904_ecustom--StockIssuedDuringPeriodSharesNewIssues4_pii_c20201001__20201231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zTxlBsFnslhi" title="Number of shares issued for aggregate purchase price">3,346,288</span> (2019: <span id="xdx_901_ecustom--StockIssuedDuringPeriodSharesNewIssues4_pii_c20191001__20191231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zbrComGf8ARd" title="Number of shares issued for aggregate purchase price">4,394,160</span>) shares of common stock for an
aggregate purchase price of $<span id="xdx_903_ecustom--StockIssuedDuringPeriodValueNewIssues3_c20201001__20201231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pp0p0" title="Number of shares issued for aggregate purchase price, value">17,461,402</span> (2019: $<span id="xdx_907_ecustom--StockIssuedDuringPeriodValueNewIssues3_pp0p0_c20191001__20191231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z8cCkKGRDvb8" title="Number of shares issued for aggregate purchase price, value">10,997,952</span>) and <span id="xdx_90C_ecustom--StockIssuedDuringPeriodSharesNewIssues3_c20201001__20201231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pii" title="Number of shares issued for commitment">56,642</span> (2019: <span id="xdx_903_ecustom--StockIssuedDuringPeriodSharesNewIssues3_pii_c20191001__20191231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zSrUgxwg1tqe" title="Number of shares issued for commitment">35,675</span>) commitment shares. At December 31, 2020,
an amount of $<span id="xdx_902_ecustom--StockIssuedDuringPeriodValueNewIssues4_c20201001__20201231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_pp0p0" title="Amount of shares remain available">6,649,794</span> (September 30, 2020: $<span id="xdx_905_ecustom--StockIssuedDuringPeriodValueNewIssues4_pp0p0_c20191001__20191231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zqBUCxvbdDaf" title="Amount of shares remain available">24,111,197</span>) remained available under the 2019 Purchase Agreement.</span></p>









<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Sales
Agreement</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company entered into a Controlled Equity Offering Sales Agreement on July 6, 2018, which was amended and restated on May 1, 2020
(the &#8220;Sales Agreement&#8221;) with Cantor Fitzgerald&#160;&amp; Co. and SVB Leerink LLC (together the &#8220;Sales Agents&#8221;),
pursuant to which the Company may offer and sell shares of common stock registered under an effective registration statement from
time to time through the Sales Agents (the &#8220;Offering&#8221;).&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Upon
delivery of a placement notice based on the Company&#8217;s instructions and subject to the terms and conditions of the Sales
Agreement, the Sales Agents may sell the Shares by methods deemed to be an &#8220;at the market offering&#8221; offering, in negotiated
transactions at market prices prevailing at the time of sale or at prices related to such prevailing market prices, or by any
other method permitted by law, including negotiated transactions, subject to the prior written consent of the Company. The Company
is not obligated to make any sales of Shares under the Sales Agreement. The Company or Sales Agents may suspend or terminate the
offering of Shares upon notice to the other party, subject to certain conditions.&#160; The Sales Agents will act as agent on
a commercially reasonable efforts basis consistent with their normal trading and sales practices and applicable state and federal
law, rules&#160;and regulations and the rules&#160;of Nasdaq.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company has agreed to pay the Sales Agents commissions for their services of up to <span id="xdx_90B_ecustom--PercentageOfGrossProceedsFromSales_c20201001__20201231__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_pii" title="Percentage of gross proceeds from sales">3.0%</span> of the gross proceeds from the sale of
the Shares pursuant to the Sales Agreement.&#160; The Company also agreed to provide the Sales Agents with customary indemnification
and contribution rights. During the three months ended December 31, 2020, <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pii_c20201001__20201231__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_z4yBKQ40fH16" title="Share issued for offering, shares">1,514,829</span> shares were sold pursuant to the Offering
for gross proceeds of $<span id="xdx_909_ecustom--GrossProceedsFromSaleOfCommonStock_c20201001__20201231__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zLFv1c37d7a7" title="Gross proceeds from sale of common stock">8,782,017</span> (net proceeds of $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pii_c20201001__20201231__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_z75SIQjjvBAb" title="Proceed from offering"><span id="xdx_901_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20201001__20201231__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zQbabuPih1Q1">8,518,557</span></span> after deducting offering expenses). At December 31, 2020, an amount
of $<span id="xdx_907_ecustom--StockIssuedDuringPeriodValueNewIssues4_pp0p0_c20201001__20201231__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zeYGDf5g3cR9" title="Amount of shares remain available">33,718,084</span> (September 30, 2020: $<span id="xdx_909_ecustom--StockIssuedDuringPeriodValueNewIssues4_pp0p0_c20191001__20200930__us-gaap--TypeOfArrangementAxis__custom--EquityOfferingSalesAgreementMember__dei--LegalEntityAxis__custom--CantorFitzgeraldAndCoMember_zfkOGPWM23Wc" title="Amount of shares remain available">42,500,100</span>) remained registered under the Company&#8217;s effective shelf registration
statement and available to be offered and sold in the Offering.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_DisclosureEquityOfferingAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_DisclosureEquityOfferingAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_EquityOfferingAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_EquityOfferingAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140141839454888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">Commitments</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--CommitmentsDisclosureTextBlock_zbvqLma7Cab1" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">Note
5 	&#160;&#160;&#160;&#160;&#160;<span style="text-decoration: underline"><span id="xdx_822_zEzYUFIn54D4">Commitments</span> </span></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.75pt"/><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">a)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">Leases
                                         </span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; color: gray"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">During
the three months ended December 31, 2020, the Company incurred office lease expense of $<span id="xdx_901_eus-gaap--LeaseAndRentalExpense_c20201001__20201231_pp0p0" title="Lease expense">68,387</span> (2019: $<span id="xdx_900_eus-gaap--LeaseAndRentalExpense_c20191001__20191231_pp0p0" title="Lease expense">50,054</span>).</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.75pt"/><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">b)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">Litigation</span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; color: gray"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">The
Company is subject to claims and legal proceedings that arise in the ordinary course of business. Such matters are inherently
uncertain, and there can be no guarantee that the outcome of any such matter will be decided favorably to the Company or that
the resolution of any such matter will not have a material adverse effect upon the Company's consolidated financial statements.
The Company does not believe that any of such pending claims and legal proceedings will have a material adverse effect on its
consolidated financial statements.</span></p>









<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; color: gray"><span style="font: normal 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.75pt"/><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">c)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">Share
                                         Purchase Warrants</span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 58.5pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">A
summary of the status of the Company&#8217;s outstanding share purchase warrants is presented below:</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"/>

<table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_zkUdaD0EO4L5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments (Details)">
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: left"><span id="xdx_8B4_zAas41cfHNY6" style="display: none">Schedule of exercisable share purchase warrants outstanding</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Number
    of Shares</b></span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted</b></span></p>
                                                           <p style="margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Average</b></span></p>
                                                           <p style="margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exercise
                                         Price</b></span></p>
                                                           <p style="margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>($)</b></span></p></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 26%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Balance,
                                         September 30, 2019</span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pii_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zgpKvn2g3U29" style="width: 26%; text-align: right" title="Share Purchase Warrants Balance, at beginning"><span style="font: 10pt Times New Roman, Times, Serif">350,000</span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_z12EXHH5wlql" style="width: 26%; text-align: right" title="Weighted Average Exercise Price Balance, at beginning"><span style="font: 10pt Times New Roman, Times, Serif">4.19</span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Granted</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_pii_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zD4KMttUzjs2" style="border-bottom: Black 1pt solid; text-align: right" title="Share Purchase Warrants Granted"><span style="font: 10pt Times New Roman, Times, Serif">150,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_pii_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zOIcTJGf6Eg3" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Granted"><span style="font: 10pt Times New Roman, Times, Serif">3.17</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Balance, September
                                                                                                                                 30, 2020 and December 31, 2020</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pii_c20201001__20201231__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zEoc0LS7ftif" style="border-bottom: Black 2.5pt double; text-align: right" title="Share Purchase Warrants Balance, at beginning"><span style="font: 10pt Times New Roman, Times, Serif">500,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20201001__20201231__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zCNxEAjaibJi" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">3.88</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="display: none; padding-bottom: 1pt; text-align: left">&#160;</td><td style="display: none; padding-bottom: 1pt; text-align: left"><p style="display: none; margin-top: 0; margin-bottom: 0">Granted&#160;</p></td><td style="display: none; padding-bottom: 1pt; text-align: left">&#160;</td><td style="display: none; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; display: none; text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_pii_d0_c20201001__20201231__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zPapjFg1Zze4" style="border-bottom: Black 1pt solid; display: none; text-align: right" title="Share Purchase Warrants Granted">-</td><td style="display: none; padding-bottom: 1pt; text-align: left">&#160;</td><td style="display: none; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; display: none; text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_pii_c20201001__20201231__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zLx7EkHnlDtc" style="border-bottom: Black 1pt solid; display: none; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0408">-</span></td><td style="display: none; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="display: none; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="display: none; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif; display: none">Balance, September
                                                                                                                                 30, 2020 And December 31, 2020</span></td><td style="display: none; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="display: none; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pii_c20201001__20201231__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zEh7QVXxtRz6" style="border-bottom: Black 2.5pt double; display: none; text-align: right" title="Share Purchase Warrants Balance, at ending"><span style="font: 10pt Times New Roman, Times, Serif; display: none">500,000</span></td><td style="display: none; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="display: none; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20201001__20201231__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zfXdqFEMA4Cj" style="border-bottom: Black 2.5pt double; display: none; text-align: right" title="Weighted Average Exercise Price Balance, at ending"><span style="font: 10pt Times New Roman, Times, Serif; display: none">3.88</span></td><td style="display: none; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif; display: none">&#160;</span></td></tr>
</table>


<p id="xdx_8A1_zAUdHTujm65e" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>



<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0pt 58.5pt; text-align: justify; text-indent: -0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">At
December 31, 2020, the Company had share purchase warrants outstanding as follows:</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify; text-indent: -0.8pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"/>

<table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_z3rcRMOw98h7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments (Details 1)">
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: left"><span id="xdx_8B8_zNseOy8SObC" style="display: none">Schedule of share purchase warrants outstanding</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Number</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Exercise
    Price</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Expiry
    Date</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20201231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pii" style="width: 10%; text-align: right" title="Number"><span style="font: 10pt Times New Roman, Times, Serif">350,000</span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20201231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pii" style="width: 10%; text-align: right" title="Exercise Price"><span style="font: 10pt Times New Roman, Times, Serif">4.19</span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 45%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20201231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zES9VgNb277" title="Expiry date">June 30, 2021</span></span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20201231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pii" style="border-bottom: Black 1pt solid; text-align: right" title="Number"><span style="font: 10pt Times New Roman, Times, Serif">150,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20201231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pii" style="border-bottom: Black 1pt solid; text-align: right" title="Exercise Price"><span style="font: 10pt Times New Roman, Times, Serif">3.17</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20201231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_zuKfmMumvdFi">May 6, 2024</span></span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20201231_pii" style="border-bottom: Black 2.5pt double; text-align: right" title="Number"><span style="font: 10pt Times New Roman, Times, Serif">500,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>


<p id="xdx_8A1_zQfAD7HHKkCj" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.75pt"/><td style="width: 18pt"><span style="font: 10pt Times New Roman, Times, Serif">d)</span></td><td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Stock&#8211;based
                                         Compensation Plan</span></td></tr></table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">2015
Stock Option Plan</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>



<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
September 18, 2015, the Company&#8217;s board of directors approved a 2015 Omnibus Incentive Plan (the &#8220;2015 Plan&#8221;),
which provided for the grant of stock options and restricted stock awards to directors, officers, employees and consultants of
the Company.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
maximum number of our common shares reserved for issue under the plan was <span id="xdx_900_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_c20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" title="Maximum number of common shares reserved for future issuance">6,050,553</span> shares, subject to adjustment in the event
of a change of the Company&#8217;s capitalization. At December 31, 2020, <span id="xdx_90E_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pii_c20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--OptionsMember_z5QYNkLiWrwa" title="Maximum number of common shares reserved for future issuance">146,371</span> (September 30, 2020: <span id="xdx_909_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pii_c20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member__us-gaap--AwardTypeAxis__custom--OptionsMember_zvfECJ0lQCmj" title="Maximum number of common shares reserved for future issuance">146,371</span>) options remain
available for issue under the 2015 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>













<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">2019
Stock Option Plan</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
January 15, 2019, the Board approved the 2019 Omnibus Incentive Plan (the &#8220;2019 Plan&#8221;), which provides for the grant
of stock options and restricted stock awards to directors, officers, employees, consultants and advisors of the Company. Under
the terms of the 2019 Plan, <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c20201001__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_pii" title="Additional shares of common stock available for issuance">6,000,000</span> additional shares of Common Stock are available for issuance under the 2019 Plan, in addition
to the shares available under the 2015 Plan. Any awards outstanding under the 2015 Plan or the Company&#8217;s 2007 Stock Option
Plan (the &#8220;2007 Plan&#8221;) will remain subject to and be paid under the 2015 Plan or the 2007 Plan, respectively, and
any shares subject to outstanding awards under the 2015 Plan or the 2007 Plan that subsequently cease to be subject to such awards
(other than by reason of settlement of the awards in shares) will automatically become available for issuance under the 2019 Plan.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
2019 Plan provides that it may be administered by the Board, or the Board may delegate such responsibility to a committee. <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20201001__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member" title="Description of grant option">The
exercise price will be determined by the board of directors at the time of grant shall be at least equal to the fair market
value on such date. If the grantee is a 10% stockholder on the grant date, then the exercise price shall not be less than
110% of fair market value of the Company&#8217;s shares of common stock on the grant date.</span> Stock options may be
granted under the 2019 Plan for an exercise period of up to ten <span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dtY_c20201001__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_z8HO18wFsTid" style="display: none" title="Expiration period">10</span> years from the date of grant of the option or such lesser
periods as may be determined by the board, subject to earlier termination in accordance with the terms of the 2019 Plan. At
December 31, 2020, <span id="xdx_902_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pii_c20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_ziByfxBYEcZ7" title="Maximum number of common shares reserved for future issuance">1,936,665</span> (September 30, 2020: <span id="xdx_90E_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_pii_c20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2019Member_zyoJmtleP3n4" title="Maximum number of common shares reserved for future issuance">3,161,665</span>) options remain available for issue under the 2019
Plan.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 56.7pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">A
summary of the status of Company&#8217;s outstanding stock purchase options is presented below:</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"/>

<table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_zQ83AOo3Wsk4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments (Details 2)">
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8B3_z30bCJkFbRQ2" style="display: none">Schedule of outstanding stock purchase options</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Number
    of Shares</b></span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted
    Average Exercise Price ($)</b></span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted
    </b><br/><b>Average </b><br/><b>Grant Date </b><br/><b>Fair Value ($)</b></span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Aggregate
    </b><br/><b>intrinsic </b><br/><b>value ($)</b></span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 49%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Outstanding,
    September 30, 2019</span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zRluj2hFaNn4" style="width: 10%; text-align: right" title="Options Outstanding at beginning"><span style="font: 10pt Times New Roman, Times, Serif">8,462,933</span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zG1zRQRfJ9nk" style="width: 10%; text-align: right" title="Weighted Average Exercise Price Outstanding at beginning"><span style="font: 10pt Times New Roman, Times, Serif">3.58</span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 10%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zwrFMVqhACi4" style="text-align: right; width: 10%" title="Aggregate intrinsic value Outstanding at beginning"><span style="font: 10pt Times New Roman, Times, Serif">4,115,032</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Granted</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zYDhSO5E6rgj" style="text-align: right" title="Options Granted"><span style="font: 10pt Times New Roman, Times, Serif">1,695,000</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" style="text-align: right" title="Weighted Average Exercise Price Granted"><span style="font: 10pt Times New Roman, Times, Serif">2.96</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zTXoYceDOcA8" style="text-align: right" title="Weighted Average Grant Date Fair Value Granted"><span style="font: 10pt Times New Roman, Times, Serif">2.27</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td/><td/></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Forfeited</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pii_di_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zdhsTfjeaaK6" style="text-align: right" title="Options Forfeited"><span style="font: 10pt Times New Roman, Times, Serif">(68,332</span></td><td style="text-align: left">)</td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" style="text-align: right" title="Weighted Average Exercise Price Forfeited"><span style="font: 10pt Times New Roman, Times, Serif">3.01</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td/><td/></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Exercised</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pii_di_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zuBTOBMvg9v2" style="border-bottom: Black 1pt solid; text-align: right" title="Option Exercised"><span style="font: 10pt Times New Roman, Times, Serif">(13,335</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Exercised"><span style="font: 10pt Times New Roman, Times, Serif">3.15</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td/><td style="border-bottom: Black 1pt solid"/></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Outstanding,
    September 30, 2020</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20201001__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z9VnCIB1mldj" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding at beginning"><span style="font: 10pt Times New Roman, Times, Serif">10,076,266</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20201001__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zXiuyUGbwmEc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding at beginning"><span style="font: 10pt Times New Roman, Times, Serif">3.48</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20201001__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zbEd1Q1eVc0k" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value Outstanding at beginning"><span style="font: 10pt Times New Roman, Times, Serif">14,982,581</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Granted</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_c20201001__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z0ppO71T5UY2" style="border-bottom: Black 1pt solid; text-align: right" title="Options Granted"><span style="font: 10pt Times New Roman, Times, Serif">1,225,000</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20201001__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Granted"><span style="font: 10pt Times New Roman, Times, Serif">5.49</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_c20201001__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zGWAAq1VABzk" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value Granted"><span style="font: 10pt Times New Roman, Times, Serif">4.16</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td/><td/></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Outstanding,
    December 31, 2020</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pii_c20201001__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zHiaRYRbvUOg" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding at ending"><span style="font: 10pt Times New Roman, Times, Serif">11,301,266</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20201001__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zcwxqrZBq3L9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding at ending"><span style="font: 10pt Times New Roman, Times, Serif">3.69</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20201001__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zvwDGiJXDNUl" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value Outstanding at ending"><span style="font: 10pt Times New Roman, Times, Serif">21,622,986</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Exercisable,
    December 31, 2020</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zEKTySVmpVuk" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable"><span style="font: 10pt Times New Roman, Times, Serif">7,540,018</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zF0445Jcte8g" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Exercisable"><span style="font: 10pt Times New Roman, Times, Serif">3.64</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zK6C3LbNdaJl" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value Exercisable"><span style="font: 10pt Times New Roman, Times, Serif">15,482,966</span></td></tr>
</table>


<p id="xdx_8AD_z2TNSdglgbgl" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted market
price of the Company&#8217;s stock for the options that were in-the-money at December 31, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>













<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 63.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the three months ended December 31, 2020, the Company recognized stock-based compensation expense of $<span id="xdx_900_eus-gaap--ShareBasedCompensation_c20201001__20201231_pp0p0" title="Stock-based compensation expense">939,314</span> (2019: $<span id="xdx_901_eus-gaap--ShareBasedCompensation_c20191001__20191231_pp0p0" title="Stock-based compensation expense">1,264,424</span>)
in connection with the issuance and vesting 	of stock options and warrants in exchange for services. These amounts have been
included in general and 	administrative expenses and research and development expenses on the Company&#8217;s statement of
	operations as follows:</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"/>

<table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zjfVdEfcVdmf" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments (Details 3)">
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span id="xdx_8B7_zmRwDlcCoC2a" style="display: none">Schedule of general and administrative expenses and research and development expenses</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2020</b></span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2019</b></span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 45%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">General
    and administrative</span></td><td style="width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 10%; text-align: right" title="Total share based compensation"><span style="font: 10pt Times New Roman, Times, Serif">422,823</span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_c20191001__20191231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 10%; text-align: right" title="Total share based compensation"><span style="font: 10pt Times New Roman, Times, Serif">481,101</span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Research
    and development</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"><span style="font: 10pt Times New Roman, Times, Serif">516,491</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_c20191001__20191231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"><span style="font: 10pt Times New Roman, Times, Serif">783,323</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Total
    share based compensation</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20201231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total share based compensation"><span style="font: 10pt Times New Roman, Times, Serif">939,314</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_c20191001__20191231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total share based compensation"><span style="font: 10pt Times New Roman, Times, Serif">1,264,424</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>


<p id="xdx_8AB_zXmajV4ska21" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0 63.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">An
amount of approximately $<span id="xdx_904_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pp0p0_c20201231_zALuO9cPrmV9" title="Remaining stock based compensation">8,185,000</span> in stock-based compensation is expected to be recorded over the remaining term 	of such
options through fiscal 2023.</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0 63.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0 63.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
fair value of each option award granted during the three months ended December 31, 2020 and 2019 is estimated on the date of grant
using the Black Scholes option pricing model based on the following weighted average assumptions:</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>

<table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zDvhjoWkbkja" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments (Details 4)">
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8B4_z2vwROq8pDac" style="display: none">Schedule of weighted average assumptions for fair value of each option award</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2020</b></span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2019</b></span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 45%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Risk-free
    interest rate</span></td><td style="width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 10%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_c20201001__20201231_zyp1NGTe3ZM3" title="Risk-free interest rate">0.62</span></span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">%</span></td><td style="width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 10%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_c20191001__20191231_zgNCsM05hm9h" title="Risk-free interest rate">1.88</span></span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">%</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Expected life of options
    (years)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20201001__20201231_zEP40vMBknfa" title="Expected life of options (years)">5.59</span></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20191001__20191231_zfuRzahAtwHj" title="Expected life of options (years)">5.21</span></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Annualized volatility</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_c20201001__20201231_zFoqecu8LOl7" title="Annualized volatility">96.16</span></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">%</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_c20191001__20191231_zZdeGvsA4Mz6" title="Annualized volatility">101.60</span></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">%</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Dividend rate</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_dp_c20201001__20201231_zgZNCxhfwSMb" title="Dividend rate">0.00</span></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">%</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_dp_c20191001__20191231_z3Ix7rYAIo07" title="Dividend rate">0.00</span></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">%</span></td></tr>
</table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0 63.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140141841115304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p id="xdx_805_eus-gaap--SubsequentEventsTextBlock_znyQNgALn8Lg" style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt"><span style="font: 10pt Times New Roman, Times, Serif">Note
6	&#160;&#160;&#160;&#160;&#160;<span id="xdx_829_z7Yfmp9MvN7d"><span style="text-decoration: underline">Subsequent Events</span></span></span></p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"/></p>

<p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">Subsequent to December 31,
2020;</p>

<p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 0 42.55pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 11pt/106% Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.55pt"/><td style="width: 18pt"><span style="font-size: 10pt">a)</span></td><td style="text-align: justify"><span style="font-size: 10pt">the Company received $<span id="xdx_904_ecustom--GrantReceived_c20210101__20210211__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MichaelJFoxFoundationMember_z5NUEPoSiFO4" title="Grant received">497,931</span> of a $<span id="xdx_903_ecustom--TotalGrant_c20210101__20210211__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MichaelJFoxFoundationMember_zcV8a2sHcyTa" title="Total grant">995,862</span> research grant awarded
by the Michael J. Fox Foundation for Parkinson's Research. The grant will be used to fund a clinical trial in the Company's lead
compound, ANAVEX<sup>&#174;</sup>2-73 for the treatment of Parkinson's disease.</span></td></tr></table>

<p style="font: 10pt/106% Times New Roman, Times, Serif; margin: 0 0 0 60.55pt; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 11pt/106% Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.55pt"/><td style="width: 18pt"><span style="font-size: 10pt">b)</span></td><td style="text-align: justify"><span style="font-size: 10pt">the Company issued  <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pii_c20210101__20210211__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zt5c7WpwRRk3" title="Share issued for offering, shares">683,279</span> shares
of common stock under the 2019 Purchase Agreement, including <span id="xdx_90A_ecustom--StockIssuedDuringPeriodSharesNewIssues4_pii_c20210101__20210211__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_zUhmnfm0ZkW1" title="Number of shares issued for aggregate purchase price">661,708</span> shares of common stock for an aggregate purchase price of
$<span id="xdx_901_ecustom--StockIssuedDuringPeriodValueNewIssues3_pii_c20210101__20210211__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z53G7fcR0Ogf" title="Number of shares issued for aggregate purchase price">6,649,782</span> and <span id="xdx_90F_ecustom--StockIssuedDuringPeriodSharesNewIssues3_pii_c20210101__20210211__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreement1Member__dei--LegalEntityAxis__custom--LincolnParkCapitalFundLLCMember_z6XLmh18eVl6" title="Number of shares issued for commitment">21,571</span> commitment shares.</span></td></tr></table>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 0 36pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 11pt/106% Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 42.55pt"/><td style="width: 18pt"><span style="font-size: 10pt">c)</span></td><td style="text-align: justify"><span style="font-size: 10pt">an aggregate of <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pii_c20210101__20210211__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zZo2FTuhEqV" title="Share issued for offering, shares">1,841,616</span> shares were sold under the Sales Agreement
for gross proceeds of $<span id="xdx_905_eus-gaap--ProceedsFromIssuanceOfCommonStock_pp0p0_c20210101__20210211__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_ztYP7YQD4mVe" title="Gross sale proceeds">25,893,861</span>.</span></td></tr></table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140141840759048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recent Accounting Pronouncements (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract', window );"><strong>Accounting Changes and Error Corrections [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zB6lChZMEpAj" style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Recent
Accounting Pronouncements Not Yet Adopted</i></span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0 0 0 42.55pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company does not expect the adoption of recently issued accounting pronouncements to have a significant impact on its results
of operations, financial position or cash flow.</span></p>



<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingChangesAndErrorCorrectionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140141841099800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock', window );">Schedule of exercisable share purchase warrants outstanding</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_zkUdaD0EO4L5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments (Details)">
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: left"><span id="xdx_8B4_zAas41cfHNY6" style="display: none">Schedule of exercisable share purchase warrants outstanding</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="font: 11pt Calibri, Helvetica, Sans-Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Number
    of Shares</b></span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted</b></span></p>
                                                           <p style="margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Average</b></span></p>
                                                           <p style="margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exercise
                                         Price</b></span></p>
                                                           <p style="margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>($)</b></span></p></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 26%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Balance,
                                         September 30, 2019</span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pii_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zgpKvn2g3U29" style="width: 26%; text-align: right" title="Share Purchase Warrants Balance, at beginning"><span style="font: 10pt Times New Roman, Times, Serif">350,000</span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_z12EXHH5wlql" style="width: 26%; text-align: right" title="Weighted Average Exercise Price Balance, at beginning"><span style="font: 10pt Times New Roman, Times, Serif">4.19</span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Granted</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_pii_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zD4KMttUzjs2" style="border-bottom: Black 1pt solid; text-align: right" title="Share Purchase Warrants Granted"><span style="font: 10pt Times New Roman, Times, Serif">150,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_pii_c20191001__20200930__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zOIcTJGf6Eg3" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Granted"><span style="font: 10pt Times New Roman, Times, Serif">3.17</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Balance, September
                                                                                                                                 30, 2020 and December 31, 2020</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pii_c20201001__20201231__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zEoc0LS7ftif" style="border-bottom: Black 2.5pt double; text-align: right" title="Share Purchase Warrants Balance, at beginning"><span style="font: 10pt Times New Roman, Times, Serif">500,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20201001__20201231__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zCNxEAjaibJi" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">3.88</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="display: none; padding-bottom: 1pt; text-align: left">&#160;</td><td style="display: none; padding-bottom: 1pt; text-align: left"><p style="display: none; margin-top: 0; margin-bottom: 0">Granted&#160;</p></td><td style="display: none; padding-bottom: 1pt; text-align: left">&#160;</td><td style="display: none; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; display: none; text-align: left">&#160;</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod_pii_d0_c20201001__20201231__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zPapjFg1Zze4" style="border-bottom: Black 1pt solid; display: none; text-align: right" title="Share Purchase Warrants Granted">-</td><td style="display: none; padding-bottom: 1pt; text-align: left">&#160;</td><td style="display: none; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; display: none; text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice_pii_c20201001__20201231__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zLx7EkHnlDtc" style="border-bottom: Black 1pt solid; display: none; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0408">-</span></td><td style="display: none; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="display: none; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="display: none; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif; display: none">Balance, September
                                                                                                                                 30, 2020 And December 31, 2020</span></td><td style="display: none; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="display: none; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pii_c20201001__20201231__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zEh7QVXxtRz6" style="border-bottom: Black 2.5pt double; display: none; text-align: right" title="Share Purchase Warrants Balance, at ending"><span style="font: 10pt Times New Roman, Times, Serif; display: none">500,000</span></td><td style="display: none; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="display: none; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; display: none; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20201001__20201231__us-gaap--AwardTypeAxis__custom--PurchaseWarrantsMember_zfXdqFEMA4Cj" style="border-bottom: Black 2.5pt double; display: none; text-align: right" title="Weighted Average Exercise Price Balance, at ending"><span style="font: 10pt Times New Roman, Times, Serif; display: none">3.88</span></td><td style="display: none; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif; display: none">&#160;</span></td></tr>
</table>


<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock', window );">Schedule of share purchase warrants outstanding</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock_z3rcRMOw98h7" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments (Details 1)">
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: left"><span id="xdx_8B8_zNseOy8SObC" style="display: none">Schedule of share purchase warrants outstanding</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Number</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Exercise
    Price</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Expiry
    Date</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20201231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pii" style="width: 10%; text-align: right" title="Number"><span style="font: 10pt Times New Roman, Times, Serif">350,000</span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20201231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_pii" style="width: 10%; text-align: right" title="Exercise Price"><span style="font: 10pt Times New Roman, Times, Serif">4.19</span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 45%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20201231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants1Member_zES9VgNb277" title="Expiry date">June 30, 2021</span></span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20201231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pii" style="border-bottom: Black 1pt solid; text-align: right" title="Number"><span style="font: 10pt Times New Roman, Times, Serif">150,000</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>$</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c20201231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_pii" style="border-bottom: Black 1pt solid; text-align: right" title="Exercise Price"><span style="font: 10pt Times New Roman, Times, Serif">3.17</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: right; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20201231__us-gaap--AwardTypeAxis__custom--PurchaseWarrants2Member_zuKfmMumvdFi">May 6, 2024</span></span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c20201231_pii" style="border-bottom: Black 2.5pt double; text-align: right" title="Number"><span style="font: 10pt Times New Roman, Times, Serif">500,000</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>


<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock', window );">Schedule of outstanding stock purchase options</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfStockOptionsRollForwardTableTextBlock_zQ83AOo3Wsk4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments (Details 2)">
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8B3_z30bCJkFbRQ2" style="display: none">Schedule of outstanding stock purchase options</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td colspan="2" style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Number
    of Shares</b></span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted
    Average Exercise Price ($)</b></span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted
    </b><br/><b>Average </b><br/><b>Grant Date </b><br/><b>Fair Value ($)</b></span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Aggregate
    </b><br/><b>intrinsic </b><br/><b>value ($)</b></span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 49%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Outstanding,
    September 30, 2019</span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zRluj2hFaNn4" style="width: 10%; text-align: right" title="Options Outstanding at beginning"><span style="font: 10pt Times New Roman, Times, Serif">8,462,933</span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zG1zRQRfJ9nk" style="width: 10%; text-align: right" title="Weighted Average Exercise Price Outstanding at beginning"><span style="font: 10pt Times New Roman, Times, Serif">3.58</span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 10%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zwrFMVqhACi4" style="text-align: right; width: 10%" title="Aggregate intrinsic value Outstanding at beginning"><span style="font: 10pt Times New Roman, Times, Serif">4,115,032</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Granted</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zYDhSO5E6rgj" style="text-align: right" title="Options Granted"><span style="font: 10pt Times New Roman, Times, Serif">1,695,000</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" style="text-align: right" title="Weighted Average Exercise Price Granted"><span style="font: 10pt Times New Roman, Times, Serif">2.96</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zTXoYceDOcA8" style="text-align: right" title="Weighted Average Grant Date Fair Value Granted"><span style="font: 10pt Times New Roman, Times, Serif">2.27</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td/><td/></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Forfeited</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_pii_di_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zdhsTfjeaaK6" style="text-align: right" title="Options Forfeited"><span style="font: 10pt Times New Roman, Times, Serif">(68,332</span></td><td style="text-align: left">)</td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" style="text-align: right" title="Weighted Average Exercise Price Forfeited"><span style="font: 10pt Times New Roman, Times, Serif">3.01</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td/><td/></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Exercised</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pii_di_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zuBTOBMvg9v2" style="border-bottom: Black 1pt solid; text-align: right" title="Option Exercised"><span style="font: 10pt Times New Roman, Times, Serif">(13,335</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">)&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20191001__20200930__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Exercised"><span style="font: 10pt Times New Roman, Times, Serif">3.15</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td/><td style="border-bottom: Black 1pt solid"/></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Outstanding,
    September 30, 2020</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pii_c20201001__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z9VnCIB1mldj" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding at beginning"><span style="font: 10pt Times New Roman, Times, Serif">10,076,266</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pii_c20201001__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zXiuyUGbwmEc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding at beginning"><span style="font: 10pt Times New Roman, Times, Serif">3.48</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20201001__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zbEd1Q1eVc0k" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value Outstanding at beginning"><span style="font: 10pt Times New Roman, Times, Serif">14,982,581</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Granted</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pii_c20201001__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_z0ppO71T5UY2" style="border-bottom: Black 1pt solid; text-align: right" title="Options Granted"><span style="font: 10pt Times New Roman, Times, Serif">1,225,000</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20201001__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_pii" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Granted"><span style="font: 10pt Times New Roman, Times, Serif">5.49</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pii_c20201001__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zGWAAq1VABzk" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant Date Fair Value Granted"><span style="font: 10pt Times New Roman, Times, Serif">4.16</span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td/><td/></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Outstanding,
    December 31, 2020</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pii_c20201001__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zHiaRYRbvUOg" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding at ending"><span style="font: 10pt Times New Roman, Times, Serif">11,301,266</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pii_c20201001__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zcwxqrZBq3L9" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Outstanding at ending"><span style="font: 10pt Times New Roman, Times, Serif">3.69</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20201001__20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zvwDGiJXDNUl" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value Outstanding at ending"><span style="font: 10pt Times New Roman, Times, Serif">21,622,986</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Exercisable,
    December 31, 2020</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pii_c20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zEKTySVmpVuk" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Exercisable"><span style="font: 10pt Times New Roman, Times, Serif">7,540,018</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pii_c20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zF0445Jcte8g" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price, Exercisable"><span style="font: 10pt Times New Roman, Times, Serif">3.64</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pp0p0_c20201231__us-gaap--PlanNameAxis__custom--StockOptionPlan2015Member_zK6C3LbNdaJl" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate intrinsic value Exercisable"><span style="font: 10pt Times New Roman, Times, Serif">15,482,966</span></td></tr>
</table>


<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of general and administrative expenses and research and development expenses</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zjfVdEfcVdmf" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments (Details 3)">
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span id="xdx_8B7_zmRwDlcCoC2a" style="display: none">Schedule of general and administrative expenses and research and development expenses</span></td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2020</b></span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2019</b></span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 45%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">General
    and administrative</span></td><td style="width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 10%; text-align: right" title="Total share based compensation"><span style="font: 10pt Times New Roman, Times, Serif">422,823</span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_c20191001__20191231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_pp0p0" style="width: 10%; text-align: right" title="Total share based compensation"><span style="font: 10pt Times New Roman, Times, Serif">481,101</span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">Research
    and development</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20201231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"><span style="font: 10pt Times New Roman, Times, Serif">516,491</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 1pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_c20191001__20191231__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total share based compensation"><span style="font: 10pt Times New Roman, Times, Serif">783,323</span></td><td style="padding-bottom: 1pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Total
    share based compensation</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_c20201001__20201231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total share based compensation"><span style="font: 10pt Times New Roman, Times, Serif">939,314</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_c20191001__20191231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Total share based compensation"><span style="font: 10pt Times New Roman, Times, Serif">1,264,424</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>


<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of weighted average assumptions for fair value of each option award</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zDvhjoWkbkja" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Commitments (Details 4)">
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8B4_z2vwROq8pDac" style="display: none">Schedule of weighted average assumptions for fair value of each option award</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2020</b></span></td><td style="padding-bottom: 1pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>2019</b></span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 45%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Risk-free
    interest rate</span></td><td style="width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 10%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_c20201001__20201231_zyp1NGTe3ZM3" title="Risk-free interest rate">0.62</span></span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">%</span></td><td style="width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="width: 10%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pii_dp_c20191001__20191231_zgNCsM05hm9h" title="Risk-free interest rate">1.88</span></span></td><td style="width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">%</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Expected life of options
    (years)</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20201001__20201231_zEP40vMBknfa" title="Expected life of options (years)">5.59</span></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20191001__20191231_zfuRzahAtwHj" title="Expected life of options (years)">5.21</span></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Annualized volatility</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_c20201001__20201231_zFoqecu8LOl7" title="Annualized volatility">96.16</span></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">%</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pii_dp_c20191001__20191231_zZdeGvsA4Mz6" title="Annualized volatility">101.60</span></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">%</span></td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Dividend rate</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_dp_c20201001__20201231_zgZNCxhfwSMb" title="Dividend rate">0.00</span></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">%</span></td><td><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pii_dp_c20191001__20191231_z3Ix7rYAIo07" title="Dividend rate">0.00</span></span></td><td style="text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">%</span></td></tr>
</table>

<p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0pt 0 0 63.8pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for outstanding award under share-based payment arrangement excluding share and unit options and nonvested award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140141847470552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Description and Basis of Presentation (Details Narrative) - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Loss per share for potentially dilutive common shares</a></td>
<td class="nump">11,801,266<span></span>
</td>
<td class="nump">10,576,266<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140141852871288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Income (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_NonOperatingIncomeFromGrant', window );">Grant income</a></td>
<td class="nump">$ (0)<span></span>
</td>
<td class="nump">$ 74,944<span></span>
</td>
<td class="nump">$ 597,886<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Research and development incentive income</a></td>
<td class="nump">1,269,316<span></span>
</td>
<td class="nump">943,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_AUD', window );">Australia, Dollars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Research and development incentive income</a></td>
<td class="nump">$ 1,735,962<span></span>
</td>
<td class="nump">$ 1,345,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_NonOperatingIncomeFromGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_NonOperatingIncomeFromGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_AUD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_AUD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140141842363816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Offering Agreements (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 07, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,243,419<span></span>
</td>
<td class="nump">$ 10,997,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreement1Member', window );">2019 Purchase Agreement [Member] | Lincoln Park Capital Fund, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ValueOfSharesObligatedToPurchase', window );">Total number of shares obligated to purchase</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Share issued for offering, shares</a></td>
<td class="nump">324,383<span></span>
</td>
<td class="nump">3,402,930<span></span>
</td>
<td class="nump">4,429,835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_NumberOfSharesObligatedToPurchaseProrataBasic', window );">Pro rata basic number of shares obligated to purchase</a></td>
<td class="nump">162,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodSharesNewIssues4', window );">Number of shares issued for aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,346,288<span></span>
</td>
<td class="nump">4,394,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodValueNewIssues3', window );">Number of shares issued for aggregate purchase price, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,461,402<span></span>
</td>
<td class="nump">$ 10,997,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodSharesNewIssues3', window );">Number of shares issued for commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,642<span></span>
</td>
<td class="nump">35,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodValueNewIssues4', window );">Amount of shares remain available</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,649,794<span></span>
</td>
<td class="nump">$ 24,111,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=avxl_EquityOfferingSalesAgreementMember', window );">Equity Offering Sales Agreement [Member] | Cantor Fitzgerald &amp;amp; Co [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Share issued for offering, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,514,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodValueNewIssues4', window );">Amount of shares remain available</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,718,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,500,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_PercentageOfGrossProceedsFromSales', window );">Percentage of gross proceeds from sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_GrossProceedsFromSaleOfCommonStock', window );">Gross proceeds from sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,782,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceed from offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,518,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,518,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_GrossProceedsFromSaleOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_GrossProceedsFromSaleOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_NumberOfSharesObligatedToPurchaseProrataBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information related to number of shares obligated to purchase prorata basic.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_NumberOfSharesObligatedToPurchaseProrataBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_PercentageOfGrossProceedsFromSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents information related to percentage of gross proceeds from sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_PercentageOfGrossProceedsFromSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_StockIssuedDuringPeriodSharesNewIssues3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_StockIssuedDuringPeriodSharesNewIssues3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_StockIssuedDuringPeriodSharesNewIssues4">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_StockIssuedDuringPeriodSharesNewIssues4</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_StockIssuedDuringPeriodValueNewIssues3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_StockIssuedDuringPeriodValueNewIssues3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_StockIssuedDuringPeriodValueNewIssues4">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_StockIssuedDuringPeriodValueNewIssues4</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ValueOfSharesObligatedToPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information related to value of shares obligated to purchase initially.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ValueOfSharesObligatedToPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreement1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreement1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=avxl_LincolnParkCapitalFundLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=avxl_LincolnParkCapitalFundLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=avxl_EquityOfferingSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=avxl_EquityOfferingSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=avxl_CantorFitzgeraldAndCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=avxl_CantorFitzgeraldAndCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140141852767496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments (Details) - Purchase Warrants [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share Purchase Warrants Balance, at beginning</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Balance, at beginning</a></td>
<td class="nump">$ 3.88<span></span>
</td>
<td class="nump">$ 4.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod', window );">Share Purchase Warrants Granted</a></td>
<td class="nump">(0)<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice', window );">Weighted Average Exercise Price Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3.17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share Purchase Warrants Balance, at ending</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Balance, at ending</a></td>
<td class="nump">$ 3.88<span></span>
</td>
<td class="nump">$ 3.88<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information related to share based compensation arrangement by share based payment award equity instruments other than options outstanding weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_PurchaseWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140141843198424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments (Details 1)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number</a></td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrants1Member', window );">Purchase Warrants 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number</a></td>
<td class="nump">350,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 4.19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiry date</a></td>
<td class="text">Jun. 30,  2021<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrants2Member', window );">Purchase Warrants 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number</a></td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 3.17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiry date</a></td>
<td class="text">May  06,  2024<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrants1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_PurchaseWarrants1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_PurchaseWarrants2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_PurchaseWarrants2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140141842340312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments (Details 2) - 2015 Omnibus Incentive Plan [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding at beginning</a></td>
<td class="nump">10,076,266<span></span>
</td>
<td class="nump">8,462,933<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding at beginning</a></td>
<td class="nump">$ 3.48<span></span>
</td>
<td class="nump">$ 3.58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value Outstanding at beginning</a></td>
<td class="nump">$ 14,982,581<span></span>
</td>
<td class="nump">$ 4,115,032<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options Granted</a></td>
<td class="nump">1,225,000<span></span>
</td>
<td class="nump">1,695,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Granted</a></td>
<td class="nump">$ 5.49<span></span>
</td>
<td class="nump">$ 2.96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value Granted</a></td>
<td class="nump">$ 4.16<span></span>
</td>
<td class="nump">$ 2.27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(68,332)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Option Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,335)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options Outstanding at ending</a></td>
<td class="nump">11,301,266<span></span>
</td>
<td class="nump">10,076,266<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Outstanding at ending</a></td>
<td class="nump">$ 3.69<span></span>
</td>
<td class="nump">$ 3.48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value Outstanding at ending</a></td>
<td class="nump">$ 21,622,986<span></span>
</td>
<td class="nump">$ 14,982,581<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable</a></td>
<td class="nump">7,540,018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable</a></td>
<td class="nump">$ 3.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value Exercisable</a></td>
<td class="nump">$ 15,482,966<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140141844046424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments (Details 3) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share based compensation</a></td>
<td class="nump">$ 939,314<span></span>
</td>
<td class="nump">$ 1,264,424<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share based compensation</a></td>
<td class="nump">422,823<span></span>
</td>
<td class="nump">481,101<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share based compensation</a></td>
<td class="nump">$ 516,491<span></span>
</td>
<td class="nump">$ 783,323<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140141844037592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments (Details 4)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.62%<span></span>
</td>
<td class="nump">1.88%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of options (years)</a></td>
<td class="text">5 years 7 months 2 days<span></span>
</td>
<td class="text">5 years 2 months 15 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Annualized volatility</a></td>
<td class="nump">96.16%<span></span>
</td>
<td class="nump">101.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140141842173448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Lease expense</a></td>
<td class="nump">$ 68,387<span></span>
</td>
<td class="nump">$ 50,054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">939,314<span></span>
</td>
<td class="nump">$ 1,264,424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Remaining stock based compensation</a></td>
<td class="nump">$ 8,185,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member', window );">2015 Omnibus Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Maximum number of common shares reserved for future issuance</a></td>
<td class="nump">6,050,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member', window );">2015 Omnibus Incentive Plan [Member] | Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Maximum number of common shares reserved for future issuance</a></td>
<td class="nump">146,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146,371<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2019Member', window );">2019 Omnibus Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Maximum number of common shares reserved for future issuance</a></td>
<td class="nump">1,936,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,161,665<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares of common stock available for issuance</a></td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Description of grant option</a></td>
<td class="text">The
exercise price will be determined by the board of directors at the time of grant shall be at least equal to the fair market
value on such date. If the grantee is a 10% stockholder on the grant date, then the exercise price shall not be less than
110% of fair market value of the Company&#8217;s shares of common stock on the grant date.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avxl_StockOptionPlan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avxl_OptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avxl_OptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avxl_StockOptionPlan2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avxl_StockOptionPlan2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140141842109064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 07, 2019</div></th>
<th class="th"><div>Feb. 11, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross sale proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,243,419<span></span>
</td>
<td class="nump">$ 10,997,952<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreement1Member', window );">2019 Purchase Agreement [Member] | Lincoln Park Capital Fund, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Share issued for offering, shares</a></td>
<td class="nump">324,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,402,930<span></span>
</td>
<td class="nump">4,429,835<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodSharesNewIssues4', window );">Number of shares issued for aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,346,288<span></span>
</td>
<td class="nump">4,394,160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodValueNewIssues3', window );">Number of shares issued for aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,461,402<span></span>
</td>
<td class="nump">$ 10,997,952<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodSharesNewIssues3', window );">Number of shares issued for commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,642<span></span>
</td>
<td class="nump">35,675<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | 2019 Purchase Agreement [Member] | Lincoln Park Capital Fund, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Share issued for offering, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">683,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodSharesNewIssues4', window );">Number of shares issued for aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">661,708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodValueNewIssues3', window );">Number of shares issued for aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,649,782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_StockIssuedDuringPeriodSharesNewIssues3', window );">Number of shares issued for commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Share issued for offering, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,841,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross sale proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,893,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Michael J Fox Foundation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_GrantReceived', window );">Grant received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">497,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_avxl_TotalGrant', window );">Total grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 995,862<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_GrantReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_GrantReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_StockIssuedDuringPeriodSharesNewIssues3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_StockIssuedDuringPeriodSharesNewIssues3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_StockIssuedDuringPeriodSharesNewIssues4">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_StockIssuedDuringPeriodSharesNewIssues4</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_StockIssuedDuringPeriodValueNewIssues3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_StockIssuedDuringPeriodValueNewIssues3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avxl_TotalGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avxl_TotalGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avxl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreement1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=avxl_PurchaseAgreement1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=avxl_LincolnParkCapitalFundLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=avxl_LincolnParkCapitalFundLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=avxl_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=avxl_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avxl_MichaelJFoxFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=avxl_MichaelJFoxFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>38
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M**9S,#B;KY8?O'R2N4*I6($KO@P@#67S(=!L=+&I9^EEH6$RKY=K^'@2I3&
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M)HT!_+\20A\&Y@7U.7/R'U!+ P04    "  \A%!2JP'VP+($   A#P  &
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MZ=*3(1;+,$99#SZA'3^AXP!4CRTZ02E;*/+<'F$[A$+_/4,A':((L;L;,C)
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MR8@T?XANR3\5F[H87<=_+L#'C:<%>#YSL'OZ0!>4WPX^_S=02P,$%     @
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MZ3*"OWV<], <#=HJC@ ',;W.)\/I,&46G;F>PKL1]5'82O'?H+%D:#9Z>YZ
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MF#%9!T=-_4O"&RJ2M) H8QOPM,^GD):H#^?UC>*[ZO2YY@K.LM7EEM&8"6T
M[S><J\<;?:!M?R*9_PU02P,$%     @ /(104L*K)L[V @  1@D  !D   !X
M;"]W;W)K<VAE971S+W-H965T,3@N>&ULK59=;]HP%/TK5K2'36I)2/BL(!+0
M;JNT2JC5UH>J#R:Y$*N)G=F&M/]^UPYD4$):K>.!^..>XW.N[=R,"B&?5 *@
MR7.6<C5V$JWS"]=540(952V1 \>9I9 9U=B5*U?E$FAL05GJ^I[7<S/*N!..
M[-A<AB.QUBGC,)=$K;.,RI<II*(8.VUG-W#+5HDV VXXRND*[D#_S.<2>V[%
M$K,,N&*"$PG+L3-I7\R&)MX&_&)0J+TV,4X60CR9SG4\=CPC"%*(M&&@^-C
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M.B!- ,XOA="[CEF@^G0*_P!02P,$%     @ /(104E3W9A^V @  TP@  !D
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M=E'0+L!^+Y7"X\0E:/OR["]02P,$%     @ /(104J $=(=W!   0P\  !D
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MM;^():+X1(?2UC)0E O)TA*L(DCC[/A-'THA&@#L] !("2#G NP28)\+<$J
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MVN$W^3D4I&5Z,003O+5_0$Y;?C5DW=M&]%E;^[M=7C1W!;?/N?0/4$L#!!0
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MI?GX:?G<7+R]$\Z:_0^??@%02P,$%     @ /(104O[?4.AO 0  %A   !,
M  !;0V]N=&5N=%]4>7!E<UTN>&ULS9C+3L,P$$5_)<JV:EP;* ^UW0!;Z((?
M,,FDL>J7;+>T?\\D?4B@$E$5B=G$2CQS[XU'.E(R>=MZB-G&:!NG>9.2?V L
ME@T8&0OGP>).[8*1"6_#@GE9+N4"F!B-QJQT-H%-P]1JY+/)$]1RI5/VO,''
M43D[S0/HF&>/N\+6:YI+[[4J9<)]MK;5-Y?AWJ' SJXF-LK' 1;D[*1#N_.S
MP;[O=0TAJ JRN0SI11JL8AO-8MIJB$6_Q(F,KJY5"94K5P9;BN@#R"HV ,GH
M8B<ZZ'=.>,*PN_*+_3N9/D.LG ?G(TXLP/EVAY&TW4./0A"2ZG_%HR-*7_Q^
MT$Z[@NJ7WGB\'RXLNWE$UBV7G_'7&1_US\PAB.2X(I+CFDB.&R(YQD1RW!+)
M<4<DQSV1''Q$)0@5HG(J2.54F,JI0)53H2JG@E5.A:N<"E@Y%;(**F055,@J
MJ)!54"&K^$^ROCNW_.LOU78MC%3VX,^ZWP&S3U!+ 0(4 Q0    ( #R$4%('
M04UB@0   +$    0              "  0    !D;V-0<F]P<R]A<' N>&UL
M4$L! A0#%     @ /(104L/'C2SN    *P(  !$              ( !KP
M &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ /(104IE<G",0!@  G"<
M !,              ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M    "  \A%!2)I,=QEL%  ")%@  &               @($-"   >&PO=V]R
M:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ /(104DV2X/U5!   F@T
M !@              ("!G@T  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+
M 0(4 Q0    ( #R$4%+FU?8#N0(  !$(   8              " @2D2  !X
M;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    "  \A%!2[9*6)&P$
M  !S#@  &               @($8%0  >&PO=V]R:W-H965T<R]S:&5E=#0N
M>&UL4$L! A0#%     @ /(104JL!]L"R!   (0\  !@              ("!
MNAD  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( #R$4%+2
MJ9#*@@4  "$9   8              " @:(>  !X;"]W;W)K<VAE971S+W-H
M965T-BYX;6Q02P$"% ,4    "  \A%!2P00O,A0/  !'*   &
M    @(%:)   >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @
M/(104E9Z<%=] @  E 4  !@              ("!I#,  'AL+W=O<FMS:&5E
M=',O<VAE970X+GAM;%!+ 0(4 Q0    ( #R$4%)'7BFM*0,   T'   8
M          " @5<V  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4
M    "  \A%!2FJ,\(RP&  ""#@  &0              @(&V.0  >&PO=V]R
M:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( #R$4%)ZRI(ID0@  $D5
M   9              " @1E   !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL
M4$L! A0#%     @ /(104A]I-@-9 @  " 4  !D              ("!X4@
M 'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    "  \A%!27XX[
MIH,"  "'!0  &0              @(%Q2P  >&PO=V]R:W-H965T<R]S:&5E
M=#$S+GAM;%!+ 0(4 Q0    ( #R$4%(QXP"EP00  $4-   9
M  " @2M.  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @
M/(104NSZU@QQ @  H04  !D              ("!(U,  'AL+W=O<FMS:&5E
M=',O<VAE970Q-2YX;6Q02P$"% ,4    "  \A%!2!XQ[PI4"   V!P  &0
M            @('+50  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4
M Q0    ( #R$4%("C";XEP0  "X1   9              " @9=8  !X;"]W
M;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ /(104L*K)L[V @
M1@D  !D              ("!95T  'AL+W=O<FMS:&5E=',O<VAE970Q."YX
M;6Q02P$"% ,4    "  \A%!25/=F'[8"  #3"   &0              @(&2
M8   >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( #R$4%(X
M_/OT" 0  #</   9              " @7]C  !X;"]W;W)K<VAE971S+W-H
M965T,C N>&UL4$L! A0#%     @ /(104L4U7NS  @  !0@  !D
M     ("!OF<  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4
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M  #;"0  #0              @ &,=@  >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0
M   ( #R$4%*7BKL<P    !,"   +              "  >IX  !?<F5L<R\N
M<F5L<U!+ 0(4 Q0    ( #R$4%(,SX:#J@(  *00   /              "
M =-Y  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  \A%!2K^R3I3@!   ?
M#P  &@              @ &J?   >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E
M;'-02P$"% ,4    "  \A%!2_M]0Z&\!   6$   $P              @ $:
L?@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     (  @ )<(  "Z?P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>58</ContextCount>
  <ElementCount>203</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>19</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="e2415_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="e2415_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets</Role>
      <ShortName>INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="e2415_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="e2415_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="e2415_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="e2415_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity</Role>
      <ShortName>INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="e2415_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - Business Description and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation</Role>
      <ShortName>Business Description and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="e2415_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - Recent Accounting Pronouncements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/RecentAccountingPronouncements</Role>
      <ShortName>Recent Accounting Pronouncements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="e2415_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - Other Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/OtherIncome</Role>
      <ShortName>Other Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="e2415_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - Equity Offering Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/EquityOfferingAgreements</Role>
      <ShortName>Equity Offering Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="e2415_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/Commitments</Role>
      <ShortName>Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="e2415_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="e2415_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - Recent Accounting Pronouncements (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/RecentAccountingPronouncementsPolicies</Role>
      <ShortName>Recent Accounting Pronouncements (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://anavex.com/role/RecentAccountingPronouncements</ParentRole>
      <Position>13</Position>
    </Report>
    <Report instance="e2415_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - Commitments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsTables</Role>
      <ShortName>Commitments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://anavex.com/role/Commitments</ParentRole>
      <Position>14</Position>
    </Report>
    <Report instance="e2415_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - Business Description and Basis of Presentation (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationDetailsNarrative</Role>
      <ShortName>Business Description and Basis of Presentation (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="e2415_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - Other Income (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/OtherIncomeDetailsNarrative</Role>
      <ShortName>Other Income (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/OtherIncome</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="e2415_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - Equity Offering Agreements (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative</Role>
      <ShortName>Equity Offering Agreements (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/EquityOfferingAgreements</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="e2415_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - Commitments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsDetails</Role>
      <ShortName>Commitments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsTables</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="e2415_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - Commitments (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsDetails1</Role>
      <ShortName>Commitments (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsTables</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="e2415_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - Commitments (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsDetails2</Role>
      <ShortName>Commitments (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsTables</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="e2415_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - Commitments (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsDetails3</Role>
      <ShortName>Commitments (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsTables</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="e2415_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - Commitments (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsDetails4</Role>
      <ShortName>Commitments (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsTables</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="e2415_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - Commitments (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/CommitmentsDetailsNarrative</Role>
      <ShortName>Commitments (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/CommitmentsTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="e2415_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - Subsequent Events (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://anavex.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>Subsequent Events (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://anavex.com/role/SubsequentEvents</ParentRole>
      <Position>24</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="e2415_10q.htm">e2415_10q.htm</File>
    <File>avxl-20201231.xsd</File>
    <File>avxl-20201231_cal.xml</File>
    <File>avxl-20201231_def.xml</File>
    <File>avxl-20201231_lab.xml</File>
    <File>avxl-20201231_pre.xml</File>
    <File>e2415_ex31-1.htm</File>
    <File>e2415_ex31-2.htm</File>
    <File>e2415_ex32-1.htm</File>
    <File>e2415_ex5-1.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
    <File>image_002.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/currency/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>43
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "e2415_10q.htm": {
   "axisCustom": 0,
   "axisStandard": 9,
   "contextCount": 58,
   "dts": {
    "calculationLink": {
     "local": [
      "avxl-20201231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "avxl-20201231_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "e2415_10q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "avxl-20201231_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "avxl-20201231_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "avxl-20201231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 236,
   "entityCount": 1,
   "hidden": {
    "http://anavex.com/20201231": 5,
    "http://fasb.org/us-gaap/2020-01-31": 11,
    "http://xbrl.sec.gov/dei/2020-01-31": 5,
    "total": 21
   },
   "keyCustom": 20,
   "keyStandard": 183,
   "memberCustom": 12,
   "memberStandard": 7,
   "nsprefix": "avxl",
   "nsuri": "http://anavex.com/20201231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "e2415_10q.htm",
      "contextRef": "From2020-10-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://anavex.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "e2415_10q.htm",
      "contextRef": "From2020-10-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e2415_10q.htm",
      "contextRef": "From2020-10-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "avxl:EquityOfferingAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000010 - Disclosure - Equity Offering Agreements",
     "role": "http://anavex.com/role/EquityOfferingAgreements",
     "shortName": "Equity Offering Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e2415_10q.htm",
      "contextRef": "From2020-10-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "avxl:EquityOfferingAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e2415_10q.htm",
      "contextRef": "From2020-10-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000011 - Disclosure - Commitments",
     "role": "http://anavex.com/role/Commitments",
     "shortName": "Commitments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e2415_10q.htm",
      "contextRef": "From2020-10-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e2415_10q.htm",
      "contextRef": "From2020-10-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000012 - Disclosure - Subsequent Events",
     "role": "http://anavex.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e2415_10q.htm",
      "contextRef": "From2020-10-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e2415_10q.htm",
      "contextRef": "From2020-10-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000013 - Disclosure - Recent Accounting Pronouncements (Policies)",
     "role": "http://anavex.com/role/RecentAccountingPronouncementsPolicies",
     "shortName": "Recent Accounting Pronouncements (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e2415_10q.htm",
      "contextRef": "From2020-10-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e2415_10q.htm",
      "contextRef": "From2020-10-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000014 - Disclosure - Commitments (Tables)",
     "role": "http://anavex.com/role/CommitmentsTables",
     "shortName": "Commitments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e2415_10q.htm",
      "contextRef": "From2020-10-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e2415_10q.htm",
      "contextRef": "From2020-10-01to2020-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000015 - Disclosure - Business Description and Basis of Presentation (Details Narrative)",
     "role": "http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationDetailsNarrative",
     "shortName": "Business Description and Basis of Presentation (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e2415_10q.htm",
      "contextRef": "From2020-10-01to2020-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e2415_10q.htm",
      "contextRef": "From2020-10-01to2020-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "avxl:NonOperatingIncomeFromGrant",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000016 - Disclosure - Other Income (Details Narrative)",
     "role": "http://anavex.com/role/OtherIncomeDetailsNarrative",
     "shortName": "Other Income (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "avxl:OtherIncomeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e2415_10q.htm",
      "contextRef": "From2016-10-012017-09-30",
      "decimals": "0",
      "lang": null,
      "name": "avxl:NonOperatingIncomeFromGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e2415_10q.htm",
      "contextRef": "From2020-10-01to2020-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000017 - Disclosure - Equity Offering Agreements (Details Narrative)",
     "role": "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative",
     "shortName": "Equity Offering Agreements (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "avxl:EquityOfferingAgreementsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e2415_10q.htm",
      "contextRef": "From2019-06-062019-06-07_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember",
      "decimals": "0",
      "lang": null,
      "name": "avxl:ValueOfSharesObligatedToPurchase",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e2415_10q.htm",
      "contextRef": "AsOf2020-09-30_custom_PurchaseWarrantsMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000018 - Disclosure - Commitments (Details)",
     "role": "http://anavex.com/role/CommitmentsDetails",
     "shortName": "Commitments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e2415_10q.htm",
      "contextRef": "AsOf2019-09-30_custom_PurchaseWarrantsMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e2415_10q.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000019 - Disclosure - Commitments (Details 1)",
     "role": "http://anavex.com/role/CommitmentsDetails1",
     "shortName": "Commitments (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "avxl:ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e2415_10q.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e2415_10q.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000002 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)",
     "role": "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets",
     "shortName": "INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e2415_10q.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e2415_10q.htm",
      "contextRef": "AsOf2020-09-30_custom_StockOptionPlan2015Member",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000020 - Disclosure - Commitments (Details 2)",
     "role": "http://anavex.com/role/CommitmentsDetails2",
     "shortName": "Commitments (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockOptionsRollForwardTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e2415_10q.htm",
      "contextRef": "AsOf2019-09-30_custom_StockOptionPlan2015Member",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e2415_10q.htm",
      "contextRef": "From2020-10-01to2020-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000021 - Disclosure - Commitments (Details 3)",
     "role": "http://anavex.com/role/CommitmentsDetails3",
     "shortName": "Commitments (Details 3)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e2415_10q.htm",
      "contextRef": "From2020-10-01to2020-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e2415_10q.htm",
      "contextRef": "From2020-10-01to2020-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000022 - Disclosure - Commitments (Details 4)",
     "role": "http://anavex.com/role/CommitmentsDetails4",
     "shortName": "Commitments (Details 4)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e2415_10q.htm",
      "contextRef": "From2020-10-01to2020-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e2415_10q.htm",
      "contextRef": "From2020-10-01to2020-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LeaseAndRentalExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000023 - Disclosure - Commitments (Details Narrative)",
     "role": "http://anavex.com/role/CommitmentsDetailsNarrative",
     "shortName": "Commitments (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e2415_10q.htm",
      "contextRef": "From2020-10-01to2020-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LeaseAndRentalExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e2415_10q.htm",
      "contextRef": "From2020-10-01to2020-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000024 - Disclosure - Subsequent Events (Details Narrative)",
     "role": "http://anavex.com/role/SubsequentEventsDetailsNarrative",
     "shortName": "Subsequent Events (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "e2415_10q.htm",
      "contextRef": "From2021-01-012021-02-11_us-gaap_SubsequentEventMember_custom_PurchaseAgreement1Member_custom_LincolnParkCapitalFundLLCMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e2415_10q.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000003 - Statement - INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)",
     "role": "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e2415_10q.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e2415_10q.htm",
      "contextRef": "From2020-10-01to2020-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000004 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)",
     "role": "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations",
     "shortName": "INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e2415_10q.htm",
      "contextRef": "From2020-10-01to2020-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e2415_10q.htm",
      "contextRef": "From2020-10-01to2020-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000005 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)",
     "role": "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows",
     "shortName": "INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e2415_10q.htm",
      "contextRef": "From2020-10-01to2020-12-31",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:IncreaseDecreaseInIncomeTaxesReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e2415_10q.htm",
      "contextRef": "AsOf2019-09-30_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000006 - Statement - INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited)",
     "role": "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity",
     "shortName": "INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "e2415_10q.htm",
      "contextRef": "AsOf2019-09-30_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e2415_10q.htm",
      "contextRef": "From2020-10-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000007 - Disclosure - Business Description and Basis of Presentation",
     "role": "http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation",
     "shortName": "Business Description and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e2415_10q.htm",
      "contextRef": "From2020-10-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e2415_10q.htm",
      "contextRef": "From2020-10-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000008 - Disclosure - Recent Accounting Pronouncements",
     "role": "http://anavex.com/role/RecentAccountingPronouncements",
     "shortName": "Recent Accounting Pronouncements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e2415_10q.htm",
      "contextRef": "From2020-10-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e2415_10q.htm",
      "contextRef": "From2020-10-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "avxl:OtherIncomeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000009 - Disclosure - Other Income",
     "role": "http://anavex.com/role/OtherIncome",
     "shortName": "Other Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "e2415_10q.htm",
      "contextRef": "From2020-10-01to2020-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "avxl:OtherIncomeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 19,
   "tag": {
    "avxl_CantorFitzgeraldAndCoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to cantor fitzgerald and co.",
        "label": "Cantor Fitzgerald &amp;amp; Co [Member]"
       }
      }
     },
     "localname": "CantorFitzgeraldAndCoMember",
     "nsuri": "http://anavex.com/20201231",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitment shares issued shares underterms of purchase agreement.",
        "label": "Commitment shares"
       }
      }
     },
     "localname": "CommitmentSharesIssuedSharesUndertermsOfPurchaseAgreement2",
     "nsuri": "http://anavex.com/20201231",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitment shares Issued value Underterms of purchase agreement.",
        "label": "Commitment shares, shares"
       }
      }
     },
     "localname": "CommitmentSharesIssuedValueUndertermsOfPurchaseAgreement2",
     "nsuri": "http://anavex.com/20201231",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_DisclosureEquityOfferingAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Offering Agreements"
       }
      }
     },
     "localname": "DisclosureEquityOfferingAgreementsAbstract",
     "nsuri": "http://anavex.com/20201231",
     "xbrltype": "stringItemType"
    },
    "avxl_DisclosureOtherIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income"
       }
      }
     },
     "localname": "DisclosureOtherIncomeAbstract",
     "nsuri": "http://anavex.com/20201231",
     "xbrltype": "stringItemType"
    },
    "avxl_EquityOfferingAgreementsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "EquityOfferingAgreementsTextBlock",
        "verboseLabel": "Equity Offering Agreements"
       }
      }
     },
     "localname": "EquityOfferingAgreementsTextBlock",
     "nsuri": "http://anavex.com/20201231",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "avxl_EquityOfferingSalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to equity offering sales agreement.",
        "label": "Equity Offering Sales Agreement [Member]"
       }
      }
     },
     "localname": "EquityOfferingSalesAgreementMember",
     "nsuri": "http://anavex.com/20201231",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_GrantReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Grant received"
       }
      }
     },
     "localname": "GrantReceived",
     "nsuri": "http://anavex.com/20201231",
     "presentation": [
      "http://anavex.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_GrossProceedsFromSaleOfCommonStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross proceeds from sale of common stock"
       }
      }
     },
     "localname": "GrossProceedsFromSaleOfCommonStock",
     "nsuri": "http://anavex.com/20201231",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_LincolnParkCapitalFundLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to type of legal entity.",
        "label": "Lincoln Park Capital Fund, LLC [Member]"
       }
      }
     },
     "localname": "LincolnParkCapitalFundLLCMember",
     "nsuri": "http://anavex.com/20201231",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative",
      "http://anavex.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_MichaelJFoxFoundationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Michael J Fox Foundation [Member]"
       }
      }
     },
     "localname": "MichaelJFoxFoundationMember",
     "nsuri": "http://anavex.com/20201231",
     "presentation": [
      "http://anavex.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_NonOperatingIncomeFromGrant": {
     "auth_ref": [],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Grant income"
       }
      }
     },
     "localname": "NonOperatingIncomeFromGrant",
     "nsuri": "http://anavex.com/20201231",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations",
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_NumberOfSharesObligatedToPurchaseProrataBasic": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to number of shares obligated to purchase prorata basic.",
        "label": "Pro rata basic number of shares obligated to purchase"
       }
      }
     },
     "localname": "NumberOfSharesObligatedToPurchaseProrataBasic",
     "nsuri": "http://anavex.com/20201231",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_OptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options [Member]"
       }
      }
     },
     "localname": "OptionsMember",
     "nsuri": "http://anavex.com/20201231",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_OtherIncomeDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OtherIncomeDisclosureTextBlock",
        "verboseLabel": "Other Income"
       }
      }
     },
     "localname": "OtherIncomeDisclosureTextBlock",
     "nsuri": "http://anavex.com/20201231",
     "presentation": [
      "http://anavex.com/role/OtherIncome"
     ],
     "xbrltype": "textBlockItemType"
    },
    "avxl_PercentageOfGrossProceedsFromSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to percentage of gross proceeds from sales.",
        "label": "Percentage of gross proceeds from sales"
       }
      }
     },
     "localname": "PercentageOfGrossProceedsFromSales",
     "nsuri": "http://anavex.com/20201231",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "avxl_PurchaseAgreement1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to purchase agreement.",
        "label": "2019 Purchase Agreement [Member]"
       }
      }
     },
     "localname": "PurchaseAgreement1Member",
     "nsuri": "http://anavex.com/20201231",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative",
      "http://anavex.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_PurchaseWarrants1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Warrants 1 [Member]"
       }
      }
     },
     "localname": "PurchaseWarrants1Member",
     "nsuri": "http://anavex.com/20201231",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_PurchaseWarrants2Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Warrants 2 [Member]"
       }
      }
     },
     "localname": "PurchaseWarrants2Member",
     "nsuri": "http://anavex.com/20201231",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_PurchaseWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Purchase Warrants [Member]"
       }
      }
     },
     "localname": "PurchaseWarrantsMember",
     "nsuri": "http://anavex.com/20201231",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_ResearchAndDevelopmentIncentiveIncome": {
     "auth_ref": [],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development incentive income"
       }
      }
     },
     "localname": "ResearchAndDevelopmentIncentiveIncome",
     "nsuri": "http://anavex.com/20201231",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_SalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales Agreement [Member]"
       }
      }
     },
     "localname": "SalesAgreementMember",
     "nsuri": "http://anavex.com/20201231",
     "presentation": [
      "http://anavex.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of share purchase warrants outstanding"
       }
      }
     },
     "localname": "ScheduleOfSharePurchaseWarrantsOutstandingTableTextBlock",
     "nsuri": "http://anavex.com/20201231",
     "presentation": [
      "http://anavex.com/role/CommitmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Purchase Warrants Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantInPeriod",
     "nsuri": "http://anavex.com/20201231",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to share based compensation arrangement by share based payment award equity instruments other than options outstanding weighted average exercise price.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice",
        "periodEndLabel": "Weighted Average Exercise Price Balance, at ending",
        "periodStartLabel": "Weighted Average Exercise Price Balance, at beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://anavex.com/20201231",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "avxl_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodWeightedAverageExpiredPrice",
     "nsuri": "http://anavex.com/20201231",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "avxl_StockIssuedDuringPeriodSharesNewIssues3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Number of shares issued for commitment"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues3",
     "nsuri": "http://anavex.com/20201231",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative",
      "http://anavex.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_StockIssuedDuringPeriodSharesNewIssues4": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Number of shares issued for aggregate purchase price"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues4",
     "nsuri": "http://anavex.com/20201231",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative",
      "http://anavex.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "avxl_StockIssuedDuringPeriodValueNewIssues3": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Number of shares issued for aggregate purchase price, value",
        "verboseLabel": "Number of shares issued for aggregate purchase price"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues3",
     "nsuri": "http://anavex.com/20201231",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative",
      "http://anavex.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_StockIssuedDuringPeriodValueNewIssues4": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Amount of shares remain available"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues4",
     "nsuri": "http://anavex.com/20201231",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_StockOptionPlan2015Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to type of plan.",
        "label": "2015 Omnibus Incentive Plan [Member]"
       }
      }
     },
     "localname": "StockOptionPlan2015Member",
     "nsuri": "http://anavex.com/20201231",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails2",
      "http://anavex.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_StockOptionPlan2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to stock option.",
        "label": "2019 Omnibus Incentive Plan [Member]"
       }
      }
     },
     "localname": "StockOptionPlan2019Member",
     "nsuri": "http://anavex.com/20201231",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "avxl_TotalGrant": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Total grant"
       }
      }
     },
     "localname": "TotalGrant",
     "nsuri": "http://anavex.com/20201231",
     "presentation": [
      "http://anavex.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "avxl_ValueOfSharesObligatedToPurchase": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to value of shares obligated to purchase initially.",
        "label": "Total number of shares obligated to purchase"
       }
      }
     },
     "localname": "ValueOfSharesObligatedToPurchase",
     "nsuri": "http://anavex.com/20201231",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "currency_AUD": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Australia, Dollars"
       }
      }
     },
     "localname": "AUD",
     "nsuri": "http://xbrl.sec.gov/currency/2020-01-31",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_AllCurrenciesDomain": {
     "auth_ref": [],
     "localname": "AllCurrenciesDomain",
     "nsuri": "http://xbrl.sec.gov/currency/2020-01-31",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r210",
      "r212",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative",
      "http://anavex.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative",
      "http://anavex.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "srt_CurrencyAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency [Axis]"
       }
      }
     },
     "localname": "CurrencyAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Changes and Error Corrections [Abstract]"
       }
      }
     },
     "localname": "AccountingChangesAndErrorCorrectionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r7"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r36",
      "r37",
      "r38",
      "r115",
      "r116",
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operations:"
       }
      }
     },
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r92",
      "r112",
      "r121"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Total share based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Loss per share for potentially dilutive common shares"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/BusinessDescriptionAndBasisOfPresentationDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative",
      "http://anavex.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r34",
      "r59",
      "r61",
      "r64",
      "r67",
      "r134",
      "r136",
      "r140",
      "r175",
      "r183"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets [Default Label]",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r93",
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails",
      "http://anavex.com/role/CommitmentsDetails1",
      "http://anavex.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r12",
      "r198",
      "r199"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "periodStartLabel": "Cash and cash equivalents, beginning of period"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r12",
      "r33"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease": {
     "auth_ref": [],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.",
        "label": "Cash and Cash Equivalents, Period Increase (Decrease)",
        "totalLabel": "Increase in cash and cash equivalents during the period"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r16",
      "r75",
      "r178",
      "r186"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies - Note 5"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsDisclosureTextBlock": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.",
        "label": "Commitments"
       }
      }
     },
     "localname": "CommitmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/Commitments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Maximum number of common shares reserved for future issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r36",
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r6",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r6"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Capital stock Authorized: 100,000,000 common shares, par value $0.001 per share Issued and outstanding: 60,082,291 common shares (September 30, 2019 - 52,650,251)"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r35",
      "r125",
      "r131",
      "r132"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax expense, current"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss per share"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r113"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Remaining stock based compensation"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r36",
      "r37",
      "r38",
      "r42",
      "r49",
      "r51",
      "r58",
      "r68",
      "r84",
      "r85",
      "r115",
      "r116",
      "r117",
      "r126",
      "r127",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r190",
      "r191",
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r141",
      "r142",
      "r143",
      "r144"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign exchange gain, net"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r22",
      "r59",
      "r60",
      "r62",
      "r63",
      "r65",
      "r174",
      "r179",
      "r182",
      "r189"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Net loss before provision for income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement."
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxesReceivable": {
     "auth_ref": [
      "r19",
      "r177",
      "r187"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.",
        "label": "Incentive and tax receivables"
       }
      }
     },
     "localname": "IncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "verboseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInIncomeTaxesReceivable": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.",
        "label": "Increase (Decrease) in Income Taxes Receivable",
        "negatedLabel": "Incentive and tax receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInIncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in non-cash working capital balances related to operations:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedLabel": "Prepaid expenses and deposits"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "auth_ref": [
      "r181"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of operating interest income (expense).",
        "label": "Interest (expense) income, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseAndRentalExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "Lease expense"
       }
      }
     },
     "localname": "LeaseAndRentalExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r11",
      "r34",
      "r67",
      "r140",
      "r176",
      "r185"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r15",
      "r34",
      "r67",
      "r135",
      "r136",
      "r137",
      "r140"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total Liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r75",
      "r76",
      "r77",
      "r78",
      "r79",
      "r80",
      "r81",
      "r82",
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows provided by Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r29",
      "r30",
      "r32"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows used in Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r20",
      "r21",
      "r23",
      "r32",
      "r34",
      "r41",
      "r45",
      "r46",
      "r47",
      "r48",
      "r50",
      "r51",
      "r55",
      "r59",
      "r60",
      "r62",
      "r63",
      "r65",
      "r67",
      "r140",
      "r180",
      "r188"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net loss",
        "totalLabel": "Net loss and comprehensive loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity",
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows",
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r39",
      "r40",
      "r43",
      "r44",
      "r52",
      "r53",
      "r54",
      "r69",
      "r70",
      "r86",
      "r87",
      "r88",
      "r89",
      "r118",
      "r128",
      "r129",
      "r130",
      "r159",
      "r160",
      "r161",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.",
        "label": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/RecentAccountingPronouncements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "Recent Accounting Pronouncements Not Yet Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/RecentAccountingPronouncementsPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income (expenses)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "negatedTotalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r1",
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Business Description and Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/BusinessDescriptionAndBasisOfPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for loan and debt issuance costs.",
        "label": "Payments of Financing Costs",
        "negatedLabel": "Share issue costs"
       }
      }
     },
     "localname": "PaymentsOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r93",
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails2",
      "http://anavex.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails2",
      "http://anavex.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r5"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Capital stock Authorized: 10,000,000 preferred stock, par value $0.001 per share"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r3",
      "r4",
      "r71",
      "r72"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses and deposits"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r27"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceed from offering"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Issuance of common shares",
        "terseLabel": "Gross sale proceeds",
        "verboseLabel": "Proceeds from Issuance of Common Stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative",
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows",
      "http://anavex.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r27"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds from Issuance or Sale of Equity"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r90",
      "r152",
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r90",
      "r152",
      "r154",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned": {
     "auth_ref": [
      "r123",
      "r124"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Compensation Earned",
        "verboseLabel": "Research and development incentive income"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r122",
      "r200"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r8",
      "r85",
      "r119",
      "r184",
      "r193",
      "r197"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r36",
      "r37",
      "r38",
      "r42",
      "r49",
      "r51",
      "r68",
      "r115",
      "r116",
      "r117",
      "r126",
      "r127",
      "r190",
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r92",
      "r111",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule of general and administrative expenses and research and development expenses"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of activity for outstanding award under share-based payment arrangement excluding share and unit options and nonvested award.",
        "label": "Schedule of exercisable share purchase warrants outstanding"
       }
      }
     },
     "localname": "ScheduleOfOtherShareBasedCompensationActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r93",
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails",
      "http://anavex.com/role/CommitmentsDetails1",
      "http://anavex.com/role/CommitmentsDetails2",
      "http://anavex.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of weighted average assumptions for fair value of each option award"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockOptionsRollForwardTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in stock options.",
        "label": "Schedule of outstanding stock purchase options"
       }
      }
     },
     "localname": "ScheduleOfStockOptionsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Stock-based compensation",
        "terseLabel": "Stock-based compensation expense",
        "verboseLabel": "Share based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetailsNarrative",
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity",
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": {
     "auth_ref": [
      "r91",
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.",
        "label": "Description of grant option"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Share Purchase Warrants Balance, at ending",
        "periodStartLabel": "Share Purchase Warrants Balance, at beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Dividend rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails4"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Annualized volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails4"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails4"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails",
      "http://anavex.com/role/CommitmentsDetails1",
      "http://anavex.com/role/CommitmentsDetails2",
      "http://anavex.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Additional shares of common stock available for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Options Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Weighted Average Exercise Price, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Options Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Options Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Weighted Average Grant Date Fair Value Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r114"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Aggregate intrinsic value Outstanding at ending",
        "periodStartLabel": "Aggregate intrinsic value Outstanding at beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r98",
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options Outstanding at ending",
        "periodStartLabel": "Options Outstanding at beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price Outstanding at ending",
        "periodStartLabel": "Weighted Average Exercise Price Outstanding at beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Number"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r91",
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails",
      "http://anavex.com/role/CommitmentsDetails1",
      "http://anavex.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Weighted Average Exercise Price Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Weighted Average Exercise Price Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Weighted Average Exercise Price Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails2"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r107",
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Expected life of options (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails4"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r114"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Aggregate intrinsic value Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance ending, shares",
        "periodStartLabel": "Balance beginning, shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r18",
      "r36",
      "r37",
      "r38",
      "r42",
      "r49",
      "r51",
      "r58",
      "r68",
      "r84",
      "r85",
      "r115",
      "r116",
      "r117",
      "r126",
      "r127",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r190",
      "r191",
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity",
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r36",
      "r37",
      "r38",
      "r58",
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity",
      "http://anavex.com/role/OtherIncomeDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r5",
      "r6",
      "r84",
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Purchase shares, shares",
        "verboseLabel": "Share issued for offering, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative",
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity",
      "http://anavex.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued attributable to transactions classified as other.",
        "label": "Shares issued under Sales Agreement, net of shares issue costs, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r5",
      "r6",
      "r84",
      "r85",
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Option Exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails2"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r5",
      "r6",
      "r84",
      "r85"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Purchase shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares of stock issued attributable to transactions classified as other.",
        "label": "Shares issued under Sales Agreement, net of shares issue costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r6",
      "r9",
      "r10",
      "r34",
      "r66",
      "r67",
      "r140"
     ],
     "calculation": {
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance, value",
        "periodStartLabel": "Beginning balance, value",
        "totalLabel": "Total Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedBalanceSheets",
      "http://anavex.com/role/InterimCondensedConsolidatedStatementOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r151",
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r151",
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r151",
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r151",
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r155",
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/EquityOfferingAgreementsDetailsNarrative",
      "http://anavex.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in CCYY-MM-DD format.",
        "label": "Expiry date"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/CommitmentsDetails1"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "verboseLabel": "Basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average number of shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://anavex.com/role/InterimCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "740"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "740"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=121605123&loc=d3e30226-110892"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(1)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(2)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(3)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.5(c))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r201": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r202": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r203": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r204": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r205": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r206": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r207": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r208": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r209": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r210": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r211": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r212": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r213": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r214": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r215": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r216": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r217": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r218": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r219": {
   "Name": "Securities Act",
   "Number": "Section",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=112272810&loc=d3e31137-122693"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=112272810&loc=SL108384541-122693"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "http://asc.fasb.org/topic&trid=2122394"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12021-110248"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12053-110248"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>44
<FILENAME>0001731122-21-000261-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001731122-21-000261-xbrl.zip
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MNY+N3)"23-)S34I"4@<OT0ELGXS8K 0=0%\Y+9Z6BV?ED-P3Q1%"TXAEB,3
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M"A_"ZY $V3H$ENUFH$>"5MOT.]213?TJ3!/59<G&E0Z%IW[+@G#H[]Y#6%L
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MJ$E0=(Y,',M5RZ33);;)'?:&Y4HFDM /$!,.G*2TKT#F/(ZN;$=4CC<(+9L
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MI8>8^R'F?HBY[V?,7>YNC(3T&XNZ-W]]1A+!:2&63M6^>58535&U9;*R=.S
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M.A-H'L_Q8]N"=M 1T@_)_H]^-1W!.7#ZR+.%BV$JE1+2>IK! US'=GEA6P>
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M3[-K3+]4*Z+S=19?7IZ8NX=!%6^]A"/XIK,8D ].D!$@%<9(+<35FK4M5SQ
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M&R+(&0]T"DV/\Z2(<"H1G;/?=#>V6&1]T\0(MT\511 474SHC)21"C5SA H
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MGN:&Y+E,'1JOSY:K-'\BY(;0AR0BAO$K%5A$J!9_=VR1)7^06)Z7$)<_NK>
MR?,+TU9V5&SZ5C5Q9@#;WVXLM+74!<D(Q:GP+.-XF60)=\B(YW ZKY'PR$%6
M//?5TR0/),U7XGAD+06M06_*KKJI=<9[LG8'Q\_AR0(MBO52_C9V')LDDT##
MW(0%9!@%)\@!8".=T"Q;R_Q:/<..L'R''>%-8FB>4S3'"94'AL02";/&F5=!
MOQP0C 8YR\I$O/S.>I0;$JVIN#WV[#%*US&)^>7<O&M;UP'09YCR&X'X79^B
MF&=+[A(QA9I.D[;7D. IBZ,3*SQ%PF :VY36]-L8?QZ6WSI9K;YX2UKE)6O&
M"4[3)U1G"_'R]T_5(#S+XM/-$#SCJ\:%<!7RO6&^G7*;LZ)@EBW9!%[X8XKV
M!((7%XD-13]Q'CX;UTZ*I]W()LT 2EC-+HU3/=V&6632/,*83!)../5L\H0M
MAO%=+F?&K3+A81W\/6K#YUOVMP)'FPG X.1BNHS"S"JG+BC]S'*J7, ,>#LS
M38WB:.FC5@*B2;;_+:-[RWN<H:X2J,MY)RBNRX%K?:?-PF\ T_2%TPUWFBY]
M,$UQ!T;MHA%>NMU[_(SM+GE/T;RZ3.$N3<2;.&STKURYNLV281UOVU>N\)MM
MJB&%X P=@[)/N5O^Y@;*ULL[QJ?-A3QYG0!_G;WVT</HV;4/>%%^P1!;\'5N
MB.DU8!?%X ^M:0T9?&FMHQ6<CZ.AJN]>2T7$"PQM7EZ3]TAQFDKUD'<2[?*6
M6GAW2(W#;7GD+!:.E;PZ;K'CJVL_BF[-TBDRHK%Q$_.+$")=ISHR 6]CV%:&
M-0/:*.W@O<G6D#6]"N(R_'*S)/(TYIE"AIP:U)^U<2>NJOX"@L89LXG_<=.#
MP<!Q8)7W\_ID:W6&>+&@XEW)33#$BB:19^IU;\1_.Z((%,W0Q#.8,L2[GAIH
MVNFQ3L&ZB=YJ>5:_-X9]JFIH^IF,&=GOP2:@ >P8!D;-P;&0/=V8,5;1#$TU
M@RGC>CK8 ZP>JW(UE-C9;?&,DB5.,H0?<))RM_2.*,8P\@TJO&!+VA]I7A3M
M-:^X]%AGJHN6-VJYF]#0:E@%!J6<<2I+A491Q,)1$1K0<4H47'M'I-)"[;Q1
MKS/61<L;J=Q-:$@UK *#5,XX^Z3ZT4 C3K$ZJ(2KPW6S7F0)CX:Y7K.5<E1?
MF3'"^6?0#^UTM9HUY'O5*@=GZK:(#9Y82=;::Q?([:IU)YNZ%&<E>,Y6=\BN
M?O,YDMKH!D[_HHN;[42SMW98/SSI8VO=0F>>G7[H..QG%<M0"/96B8/IWZ:V
MR!9X+;0/Y<L8[3S:&_,%NGOJ"%89(9$3K!"9P1(S%=CET'O7$R3L_:G=20IB
M^'V8,:G":653F:+=&!QH4@,MZG*Z>)? S4KN:5]D14G7HB\103ZW]SBKCH]\
MS+,'4I0DEEZUJ2MK?/Y[T4BW+=9)VO+8S,&^W^W1>'WT0//H;7W 'GVH'T?"
MY>;-\%VYDG=6!JU[ GZI3G;-Y,&N,WFY!;GFVS):CVEX4/X<X.%M[?O60R."
MU%> *I%^!U*KH$H'U4I(:+V0CN1'WBM>9'+7Q&_U]+)^ 9V"MC ]-/U.OL'G
M_P&,=1W\A>[SKSS;MI4:G0EN1I.X-EOISE8)92EN/>3[ 0:GA?NL"/?V[P/5
MGO0.'HMB[+COT(?\<T'[W#4=U&=@O1J_S9*6#-[SMG_3JOU=:P&B,; 2><YJ
M:YCC>^"WK2_W$0V?OVKXN"*1.)S ?VH5YV[<MJ.SWPNO[9:%.LD8-S+OX!.Q
M0 ;K8WW_41KS"&<M%% OJ^&[3B!@(/H'ZB2V\-!VIP@PNI!Z4LY,_<0-:D^,
M?L(EOWOLZ127IL;NKNZS68XUJMV 7'7!4'TD8)64JX0^H9A)P&#D<YNNKZGH
MGL\YO4PNP\XB=[WS/V"D\F!L=7MI2W[2O3APS2_ Y/%%SA(#3@<ASOO\-^L=
M[,;_PW0"%UE)DZQ((G'$<?=UU<]O3QNZOMAVU+2[F;WPQJPU5CEIV]P;D-3B
MU67C+[OABLW"HMZ,%&?Y=E0CVISVJ;%:BFK*9JK)!LS2<W>VF>;.$P7$>&IL
MQJ@ K?V[F"Y/B0!4XYR^:$<UVNFRAW8NT[_I.PAH =0'/*>TQ$?NNSO'"=WE
M_'DT"E!]P6Z*>'>#^""$%SK N]H]V"$(3<15$==%0OEE]0OG.9V3I%RS&C5$
MN^\TIWUJWY:BFK(-:[+QTT[?R7::B?7H;D+^!DTTS<<KC;UI=4.3%TT)A)B6
MCX8!JKWNJ) GG:"/Q+ _(_)N#!\[1X?6+]BN=VR_75B;81QLMTC(:]O<VE#G
M"]RUJ8 ;";>U0#_0-?2&PN?G]@*U/4%'N9$@]FJ,VZJ )QWA1B%X.>/;-F:/
M'=V<>@/ *Z9 L3^ 3I?LWDC'Z)\@YY_^@0)37C;G=G)TZ84R-&1$Q<MFH<'8
MK6,J7M)YN:IM\0L1=QJ-K,D'U'QYVV*:LGTJF>S/K'=+RTR3D);\BVMF :*.
MG7/?TR;I>W+GF/5+;+[3KU8/@+;VN^'RNALNK^[<X\A603O*T'N;WFG!*<UX
M)[G!:KF[--%]$@RNE5[F17&29R6;BY,L2DAANXC>).RS==@!MYFMEP3#2BN\
M/J.X,.I(P[J 73'F<N!B=9M"4#HIP*V4N@1WP?D@1!=J74*[B7R6BL1)K)^%
M\0/\66'JMER5??)NG$%M#KII@N'C*+A];M[F)4[E.WA(C,[\=:E&%P8UMUX7
M-!&1LZ)8+^54XU-2?#FGA,\S"*N)\I/Y5@8/^>[%2G9L,4ZRAG7-%$PS]&5I
MOP5ST<,YD^5382','RX',OG=>F&@*Y3F$AE"EY,O41TRW(LEJG/!3;)$'<P-
M5O/<I8F:&V&$#$J3N7@2*J^\QM\\$4R+;P$UT*EZK=KDG_.4)9,FY9.OT=64
M\]Z.K_:BW-D(J\\65B/V8JOB<,JR-4Z3/UA[?FCD7W 3/DT>DIADL>\&W,UW
M[YNOKAAWWGC;F;[LIJNQM-]P:Q% D^)+PFSD]\PQ$W%J]ZP89+TZ\&QP.[X[
MG2 8 MK0*1X[+HN(E(%!FI/-D[XG>)4P$V04_B=2$/I XO.<GJ_Y>93Z)5]#
M,6R1CD^R;6UFFXBC$P%#TFV1]PG\$WY,ENLERD082_O1>)$<HE5Z:)Y3-!<I
MHJ1*$@;?MQXO9.3.U7P6QPE7J8MPMB[O<\IG<%./4"XY[L5,QKWH)IG##&<'
MIEWNWD9EP=$HU&VVU8AY_X#P TY2OD,I&O$+:;VGI(AH(F9Y4U=%)^F]:(^:
MPIBDX;72W?\6IAJC+ $V$KP1+<2U%](;!ZBU;..;%+=."^'ANRVF27\O?."F
M8IG$Y=U/'%8+FM B[17G0@S)HQ&@#K.X=Y"_O?5:926AVUP5UJ!4G@/C@_^A
MNE</:[EZMERE^1,A-VR9D41$;V/S IJ@82%B$=K?3_*B_)B7?R?E)Q+EBXQ/
ME]JGS@T%ZBEOGUVAU^)L-R$O&8/I0GU:J^SCDR5.^!6XU?0>;#3.^JX@OZ_9
MX''VP/YCBV;5BWJ=0EC =D8*C1P85EK *8-#(XJ$+*P8UIXAEP,1K&;Q@!12
M0%MH= DN=G4 X#"=+J>+6S4\IRWN'V0])TD>%%>=3L#;\]):8,VKHYVOP>O;
M"*E?P_(.2%H)[:A*Q1 I<M+!;'_U5IDJI*8F-Y]@5*."1Q_#*]P:05X UE\2
M)?9L/Y*OXDOQ5BEF-S7/9_XM-SMO UK_ZB5W0E4^W40D)1RXN#G2M*J?>EX-
M/7"WPV'OFN81(7%QSGZM-YNNYJW]*=WX-Z@$;>WM#ECM./FIC@*GO)ID(B$:
M'X>:E-R5(_<5)#?EWS]G,:&L");%U;Q^/GS&2":<0<=*@]P^J=_B//)6IRPO
M\19UQ^O3;J//MJ-?U9L$>\VV^M>Z292W[*;UXCK=[^ 00W14D_#"(:5]H(6[
M&<.LD"E6YU _0R2%L/9J+@O@ZBY-Q V0MWEMM%+W0PJPJM@1;;\F+S(V_BZE
M$Y62E.N@,J_J<3-6YW6"_&-3H4F6E E.TZ<@%:JP]>@GTK_WQ2H(JP('4*HN
MLQ4/9,G* I7WO"HV];ABC:]RI[5K*VSS8XOG*$^S:TSKZ)YS-G9<7IX8*FU
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MH%>?":Y[#?(44"N)4,M=4I[@XOZ:YOS2X_C#T^>"Q!=9LQR?167R8*Q*=VU
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M2=(F)$A:SG RX6W/GW:GC, PJLK7A&Q\Y31S0Y X)4F;D& 4/03DCX@7VUM
MQ)"E;[]-W_&APG;)CFT[7TK#+(ZM!Z]:1&F&O8YKUR2T7"^XM9B8&Q>5_7/G
M@AL>3W3E!V1M<[S1%5>WG(9;\JH:C::<R]&./&?Z IVU*]&YOD3G[4ITH2_1
M1;L2O=>7Z'V[$H&[(2!K&_.PKIC0_"I9YZDQ?,"_R&0ASR'AZW9G79"0&K;K
M#]U0)%V98<XZ)\)F$PE$^<<DY4J,M2 >M3-U>\*V07-F!%%UP.N.+1@!L=].
MZ>+4(>ZIP$5\B $Z>7>VLE_\A7_U-:ZN^Q"$S++#=7F>]4"\N):O/$TNR>G>
M9%NC,N;EEHN639&7+$U?E]D=ROC&B>.^+LMB=H:THOEGE>)T'EL 3NQ'U]OP
M/6%T)L-HA0>5")J&BU>Q3TR[7 I'2-+WK&DYJ+DD0%3/,& MU087U]1BL +>
M3$H@RN>H*)?HA@+VNC?=DZDKI!8";>PEZI%"D@4(_P7FV*'4%I6'KN]'EG=/
MYI15P)]-"43]/2;J9;JA@OV/R&(A8=X2@G<A,1#R[S$AEVB(BOJ867[@"I0@
ML!=3 W'_ 75Q(M$1%?C1(_$\<:!J^: 67Y8>"/Y?,<&7ZVD,_/%&ZII//' &
M4EF )/S-%!(*VJ+R<$>82\6A$ ,P4$@,Q/X#)O82#0U O><[4,PW2<&[)GS(
M<^JA MYW ]OR$KGZ_+M #7I)<BCP*/O52C4- /^?Q&)@Z%.)H<"C;&$K5$2!
M_2IB+".2<IR1IX8"C[)YK5(2!?F>'[KA4OCJW4:SAZUA-HMX,144:90-JTPI
M1(37%@L_%*Z(*I3S*:%(H^Q35<HAHGW%M6*6=^,[Y/E7LE3!74@*Q1ME?ZI4
M#Q'P.^;.++8<N7;U,%),"X4<95>J5A 1\['U?.-PW=R)F[CW5D,OS0)E &5+
M"E(7D0CA-\+F-&6.OA+^16QY11WE4%^1$4H*REY50W5$:KJ.PT$+5O\,7)^<
MJ0@I30X^C\*C0:&F4>"?ZX%_#@<?90];J:91X%_H@7\!!Q]E'UNI)C[X5\))
MCXWID^3\6YH8"CS*/K9"17S8XWEHR.X87;C)3:@J[ LYH 0@;F_5RN*SL%H(
M0%K^.B44=<2M;KER^&C?T2"TO/]SYU5KSO+T4.01-[TJ17&,EDD;$,8/F8-3
M+@D4991];JDZ., *MAFQY$TYFP(**\KFM4P9%%0'5)RS/%)?:>DMIH*BB[(+
ME2F%,R +-^A .ABD?@;[V*$,MWDU4,#\G;DAET.XV$?^RN(C.8>3)(6"C+)U
M5*J' O@HOOTF;L5]ML1=W.W][BS:9>F@4*-L%.6*H>!\QXA@G:QN'8[%S0D6
M7^4JQUN5'HH[RCZQ6E$3\+\)@H@P719*<D&Y0-DR0I7&&7F('?'A<'EV_C 6
M]X$DXTXA%11QE.VB3"D4A&_IF%DBSL]H.7N@GOS"2VE"*,XHFT.%:BA09Z0I
M!SF7! HORJZP5!W44:+W;,=!0.1^%.4IH3"C[!)5RB&/R5/0F#S5')-1=HLR
MI5 13CS<>1\;/GCN-!,,IASLT@S@^T.8N"M4Q;FI&%]H$A'BV"R6IL\_E(,O
M20J%'>=*J$H]', CQPV)DPC6=WW+M_EV;!N^2H)]92XH#3AW1H%*(QXB_$X\
M[U>?/ODC8@74)TZR05"=(TBS0+E /+NL4!>1B-^H%W&L6.R\RB3]09(4"CSB
MF:5$/4Q/T<0I>S,S)2%"5;C+<D#A1SR\5"N+ZD$7$B&YNR#75FBMY%2Q(,L!
M90'Q(%.M+/(M ';%IZ4I59_;YQ)",4=TWRU5#1'JT<SRO'70-!74N810J!']
M=$M50X2Z-R-LR@>[3XP^A8^K&ZTJR"49H- C>N,J5<6DX'E[GSZYZ:?$OR0U
M.%8#(OA2)7$#DFR"78[BN.Y,@KTJ/11]U(ND<D51\(\C2J976K%(-WS/IW*_
MJ,X%Y0)EJPM5&G/F3<4U4$Z\F710U!$WM66*8=X(BQX\U^Y[U%*NXS/)H"@C
M[F!+U$($^=+RO[%H'MK+.T9M0L113;#I?X!M%+  *#&(>ULM*# -#G0VHTGX
M^M$C5ST81F'\X@J74FEV4.:#$H1Y:16@..I**=A>9B/.Y?*>3 @3#A-C\AQ>
M\NJ^J1=.@.Q0EE"C+X%A*"'KI]."7@/^14N19/4?8,E$FSWOG'0V5GC^^>9V
MW+N_^=RY&MY>]VY'O6OQ:30<W%QWQ_P_E]U!]_:JUQG]TNN-1YWOOOA68MC_
MK]HA:M<M=6(%#S&C47 RM:QYTER)%P;K;_+M=O7UU]33&)N3A3N:;$(4H6Q7
MV6&Y:_?$W=7K!@&GKUJ1?#JL\+=:N&9[H$23YL;%IMA83:504@K)T8+HJA$N
MHT&BJAELB(=^NKXC_A'/ 2PL3PS>W?#*8FS)Y]3XD3,Y.\#L:,%X0430.BJ9
M1&+RY,38>B:!>)N$R_Q0ZFNS2B])CA:RMP9)2HW-(.6.D;GE.KWGN5A6R'=1
MJ_22Y&@1?6N0HM38#%(2=:IF&\2HOOK32PG 7%J^W&;$&20*2F6*!0II:'EQ
M2E1J!J[UX'I\=4,"/OP67V:K7BK 2T +'KS[TDX7)C/Z74IJ\,I/E0<M '%=
M%J0D&KTZ7)V&!'?64DRPE9.8+#U:J&(XWA2DB&'DL(B/\07=E/S(LJ!%--Z!
M(K7Z9K"D0\\.O+00][@N,2!&#G*)DGJI2^P0:7Q.3/ST:X\E6V15)KS@RLU,
M9 !$S.B&=^OV%JM88=4H38P7CKD9JA0(F$%1ZFBGRNI42(D7LGGW%;U,;S-8
MZ3I.K 17A^_M;_PK:^[RP3@EM&*Y <B+%P*Z 3,[&!LSN+P73S;ZQ.E9S!<'
MVWP)%<TB3YQT79.)"&\@YQ*2%R_(].Y<PK$Q@TOYT_5E)W3%M'@!JG?G2J[[
MH:\PJ^;X^L8OS/C8[5N]6N'?4#^$NQCK1Q*Z=BH(3<8IX:(IIX3.=YG:CDX*
M>]J@)+Y-W2A\I,S]DY1Y6Y<NZXOY#M>) 8:(&;-Q5E;>9X8LUMR)5_1WA,7B
M0UF4Y\=V>VB,SBJ(S*"UX&T(Z9'*3-B>$,WL4\WNC"E!]7LB*#.VJT0S+!YH
M'XROV>OTOW4&;%^*)OM>%@1#F5([I<M4J^62?@B<P5S5S=EU;(.+#"?#.6&Y
M\**9'<=[O1W':,S_^=R[Y;N-8;\SO.O==\<W/($A#M&)>]E&G^KMA30#8G=<
M4>9/5PY9  ]H11;D?40%([FN5ZFZ&0/F)^)S.;VN[W2=F>O'K]^)@ XKJ>4\
M56;$WB=4$T#U%#*)MGN.)9=!> E?DP7QZ%PTR4K2*K)A[PQT*0.A8 9A!=4T
M1D#\Q?Z.0U]]T^B'9(G@DZE8#8S-L)#?4I^N54R062E:/;L!LF)O$?2X!F.Q
M:S>T%L]>3,C9^8H.\8W@8IBMO\\5^B2><"UA0611YL!>Z\/AI$"-6D6_? #F
M,O"_^=29""/A 9@7VT^Z%B-:N)@Q0<6[,!*$&1UOB7+#(<N![1JMS5FE1B8Q
MU:>,N%,_<6RTEW&P'A&%C?J?+-<?T""X)!.>9FP]R\G3*@3;=[HNGS60,H-B
MJ<(U5A;X?M4-K2A>BH-%HI1H?6*:3AQ6(Q%+>F/?2EIEZH)A[YDCQFER?8LM
M112B@*-D\YQ<+R_&*1FXJJQ#+56*[B"NU\+V0,"AM]&5U_P&@547O"0^F:A<
M]*KRH3N;Z[44& R[;FOQZ>9KG&VG4,PQV63H[NB:$TN9DH?>4=>^HNN#TTLK
M<&VQ[7"]2,1JK[1(@ M ]V_78UL3&#/6?15"UV;1 !]W73ZTV#2+Q=_YIN-1
MZ+3@ZXGIZD'/X:1P EO=.?5+0O=_U^NE=:$RG^B4\.!>7+<\=$?ZVC3"6T,U
MGK6G<E[; PV(L:[7:2<($1.H[]$GB0_$][OX0%QU1[]T^H/A[Z;X0*0\7S9Z
M:_E9E^3"764+@>X87;B."$GXA1-]L[7==\53"LFEY9(]*>!PJ:'RS?'7EK)>
M7-HWB*P9DTN[>[+63+7-,J&W@T.]H_JO*$ANH0O+$(<@MA*-Z3VQ^?]=CV2$
M'U,@2H#HA*W7C.T6TFJ;VA=Q9C33]>9)+#!FPI8E>Z9Q/19+TF,[I.R--0J"
MPR2*N=:,<!&O2?)O2L_5Y7"0+RFX#&Q_E59'!WTP36T$^@$Z805@>\S48*B*
M8FADSP,U]A<5SD;-U&D4^9S8WCHMM(9R<%YB,\A%G--I!X6LV"Y +30$"3P-
MFYU,:0FYP'::C:&0&]N%J)WV( 'I\)L$?%'5A#D*WT6I59O32SEKEFB\NI38
MFOU2NWQT=Z3F6E--;,W8A*S>KXJ]K,1E81$_AB,""=L&R(KN2M0P9?E0%4#L
M#*':6JX.J#;J7]% %>9>G@/=K:A=8BN0.OR-!1R^)J8" QR36AWN7\KBH?Q-
MF^1]X?S:6N%?JE4*NM-3C991!Z>7T#;4G!O@V%23RYTYFL?4\]I9> A,?3TW
MP!^I)E="]D;8ZOGY>=A ;R*.S:/E3TEPXRNB66;<BWZHZ5X4>Q?]TKW]U!OQ
M//S[X=6OOPP'U[W[T7]:<QK\V.G]X\O-^)_F^1W5>00(F!TU<N]*PK':T)M/
M5]6Q"YVG[=ZM'8(^KU':%F "(;S?D_@H&T!**JUAQ&2:E8R!E/@;#Q)#6$B:
MDCCCI[Y8?G6?70@AY=D.D9MR35+.8YB7)+*R7=.9Y2I<6"3)#6-%U>+R=R'*
M%4KY69@1@.\S$>[;BM5B,2FV]V(=.J0:FV&9DSP0445.139LE\ Z1(&0,(.T
M_$L056S)TF.[Z=6A2:V[&?SLZ^6+UGDI+#?;?^;"*'N&1I#8^I%AVQ\%*VD$
M!'\]9!9%*TW"$5]'C*N7F$OCB-*WY"G^1;E^!V4W9C %=5HH' 8-J$61DW9;
MG\)"?FQGY5TYE #24GBW[=.*Z8C?R><O/D<J)&P6#"=W$;,?K8!TIXS$VIV7
M,"5*W*5 ;$?C:NIVU1"!RWA,:)!*4'G83L*[,*D!F-$C:ZS','Q4[2H 6;'=
M?!N9$S,P&,W::AU7B[9,7FQWW&;F01.)V^\%N_8=8D%;"\B5N,/UA&[S&C8Z
M?P;?J=[-RJ+CB&"BH:5%9X0#,[3H,&F@K>7%>)5<1@'7/0BN26 S=QY#[SLB
M&H]8!Z>J*7<>^6OGI'/M!K9'@X@1_I]U>9U4@1V.62<NLD,GG4RAB(\WL*GE
MNW_&8FQ=:1+UTR*F'FC:QNP!/'G33/&8KUOLHL&V38QY<[STE!<#FJ\).=I-
MHVTK_Q!'2[2@/QDFKF7[X>I"IM@4,.KSCW8B>?GP\[?\\),4TMF6TLD5@WAH
MNY%IY:+'">LQ1MD5Y7.&#;Q/I5<*ZAK[2<:E<(5>>RFFT[B\M<X]$@"&C&9*
M1QXFZK2(PDJ_.9311X!XZY][1R/3W3_DNWN<H[/*TJ!A=5M)2B9%YQ29*O(T
M:?=-50";:$6NJDQ8G0& 7=&0"T/@H*-')CO&X82++2X/K4W1Y3/AV;M\UTBR
M=];Y.ZD"6NDH,G'!O::Z@":[D*RVJEX$R&=&1X+RD>Y58% .NF-M#X$D?>DL
MWY?2.7#=,%=2B+D]OJ8Z)7PV)ZEU??4*4K,89+_3E:1:^\FJ?,C+OEH\ECBH
M5D.#OJ(;10\!^2,2SH(+>7\[S_>W;;;.*A^BD3.G N"JD#0'IJTV)Q2@&RFR
M8$<3KN D;[VMTAV]GZAM'W?4<^WTM?%,[[G0M8%TOEL7B'D?[V@.R="[3/[>
MS?0A*>E%FSF4Z*%W[-0\'=_1DO3A]XH59^>[)"=F9WUU2\^1_4B<R"/#26QI
M*'>(6 7T6,;\0";470I] 8O6!D!MR9%R*UDLU-K_[W>+B0>7TP>_E5R+\NH7
MAWV)9">:=U/=*"^5K1;"AV,8'V,']]3S^I0]6<S1[_+ @K"OGS3;S[70,XWZ
MWFSNT24A(\(6KDTDPY47RQ(?N(HX]5/?_9,XB4-C' -,JY$T7B7V_99FFU-+
MC)C6\+9ZK0++=46G2?<EX>*<*!L$T2SYKL:0U$@]V-=O&AZQ&L0>??<!=NZZ
M%O=SO>!6S-)\^55^_'KV_6[.7IWO5M5T-O5@[FF.#F!5%AK>DQSQ'!\G:D3L
MB,6Q"WO/MA?Q!I@\LSV;1VLU\L]Y=F=BOZXPW313_ MV]6J4 /3!*'UD#QIN
M?E!Y>S0VF!CN ?*J8X-INX9(U#@&!'NY <$"%J88X/_+H\^_^GH5,:Z9O93$
M_.))LBD. >F"T$U$\@K6^ ;$?CNEBU-[546"\?I_>8S7WW_EFZ^54&+Y+8OB
MM4Y>FAH9^P*L6=25HF_7&G@$?+E6 2Y^1=NP*;&3P+Q5IR73[RW=/N^13"YB
M8?5)6"LET[PR!_;)..@:/$!G,VPB]QP\+H,(GGU-%L2C\WA++FS)TUA-L=T7
M"X$QY:O>"66S/F7Q.B%(FX3$RECU1GO#U6 ;\<'7VEJ!]Z!] V4>D+ =2^$V
MG-P)=W_[%U,=<YNVFEY1CZM $RQ3;5A8!<5[LI*?Q_Q38-E;,Q[$<MI<74;M
ML'1]AEO$Q9 M6P,* 39[S=9BR.:EM8Y9<(5M$CQ#HE:/>07#24I<=;1J2?)7
MUA(D*)@1X;JHKE6N86447]V"S&@%RA:=-WSKJKCCQENRABJ$ 3N3<B/2RY-C
M;PAJMKWTEK$*BY9VY]D5R<CR2+"10$D&)"/VR74#M,#Q:6)#7S!..<1-1D#^
M(3_P\:^^#LC4\GI^*-[P*)_ >*I"(C,&K/:GK3+=4_Y=^Z,I$4!JKN5)LBF0
M"2K#K8!L5N)V)@B^;N3D^W<6^[8*/-^/?&<PN%(.396YT*:+ FS% 0>H<EL!
M3RV?)^V[X9]3PBS/B1U^E& K<Z!-  "@ :JV!'(2/W.RBGGUX+GQ&Z1CNEX"
M2)"NSH;NPM[\7C[-&!0W,TSKI8\1,[&"&$ZJ O-!\F*O>=MD6P,&DR@W+"![
MBS[LK5-?.Y3[WB.FRHX](S&3*$8KWK@Y0I;PY+0E([YF&?B^Z.V._[4@;>M"
M$ZA]OI<0"\Z-O8-NFU)-&/=+9O;MCPL]+@N9L9]B0*)2 B)JM]2DLI@;^S$&
M,[HE$IG9%J4YQ!8R8S_&8$2W;'N Y76*D!G6E"_</S$:!.F5?6Q4E9G\ 1FQ
MGV5HFT$X>"VQ5UJIL-INWO"4L ?)B/UF0]OLP<$S8P];MN>^\=W0M;R[B"^Y
M[?59B)[U0E($^I,/2%8,):+F-H2J3J^RV]3J]NT],H%EOJKH^8?GT9F.E)=X
M7&[4ROAN%D*)9T+PK+(>8_"@N'9*+OJG>L7ELOSB-MBC<^<JS#BT;NLR?$U0
M#/'BK-1#ID9A"(4^]J57MAEMI_'^!GI53 \I0]PS$UUY+6JWS%RRUT%S3FDS
MO"_KJ[I5QW?N/,N_M69$ZBD#;>FU:C.C^90V?=V>7DO_=IT\UQ'*0"Z>^<38
MA]UM-N\R+]!RL,S8&-:>9I(C^QN?+XZB&+/XIMOXT?)7D7_XOFM!@I XR4E?
M"VL"?1&P[YLVMK)J:K%0E\7:F]SD';]1:+&PA7/Z]G!(A6+\G;C31XY(EV_8
MK2GI/1-FN^*\VK5EWEX&R&7\H*O=]@T!]I5VB/C^^XV?'$#MO=GG:L?VH3JT
MQEU*7EL'O[576S UB+-6I-!/YR[OA3N-R_N1#=O7"ZGY[I/XXVI[WTM%C3>K
M6_-X._P%MREOH!\7W'IR:;3^UIP$#VU5H@%M2UT"^[#UK/RTM?"2:]EI:^?L
M>-YZ/&\]GK<>SUN/YZW'\];C>>OQO/5XWOKBSEMA,74*J8TW_K=TXKJ?L#OY
M6L^U2#K7) G/B-T22><OZEQ\_>Y-;,,1;W<^SXD=7VP57Z6VN*T9ZK0E.)Z*
M-\/A:VFYFO:XO;'QV@[ #0'6I,:_GE.X-O="YK1-\;,5BD>!EM=6J&BF\!*,
MGZ_K-BA=$-$?2RH:4K<FXK0A]?P=R)!Z?C2D'@VI1T/JT9!Z-*2^;D/J>B^K
MMJ-F4[T.DK,ZFV%%A=H_S;1<EK4U">CMFAQ3K_>*"OG/WROM68KTV%NN:EM4
MI;)F;&MVW>+MT>QTM"_MS@JV,[EQC1;'XG0T+>V9PF.[SX%VXX?,]0/7CB-\
M[:6EYZM\L5:NUFDZMN:-JWZP]M2/ VBUUXY+*WMYMRO:1.N@EKW2O6NIABVM
M(IH4XO5>F&B>2LPXXB:.O3G,XA_%,4[?<EG+ZPMM05[>U0DL) ]J/*]0OD_9
MA+AAQ!N#XN9Q0TB75H8=*]K8=JF@1G\<_I",PSZ)GP0X@'&X:O(J00=I,:(M
M"79(;7-7)#5)-60H5@6%3UG%@[4.JI&V1EG8<;[;:U:U@3V.DQM,L$=)33FP
MPYZ;.T;6(M20$?* S]PT;I^W%XW=V+5J*5R-V&QW#+)@7,,U^MQ-IY$?C][V
M'TSAL)L^^M&;3O,^GKYE8#LVZ-SZ2WCRM;T(*:D*VGQ?W]&;E)>7L?9-J8>S
MA  + &VB+_#$K5D.#6JX#]5*/U0KG9U6SBK::DMU0IOG@1Z$M<J4@=?2MH]L
M9JZEG8&NI5T<KZ7M4>$!#8*,?!5WS&3IS;A=T,2%,9F&AMS^*HA7&($ I U,
MNZVE;H95# V,NU)UX_/AD8PXC/$@/Q U"4"5-ZR4F0Z0)Z4^9ERFDHA8=;>J
M(IL97 ':((RPABYB-</8)^+SU;G'A_>N,W-]5XSEXKU+$=7!#XCT#M<J/S [
M]E4'4+O,L:>%C!G[F'N.*I?AD<M\31;$HW.A+9!*4&9LK^@Z1&J@8@:-72\N
MG#CEVZB5Y'(FH?F1;]A5+[WR41BU<#%P(_>^?"-W#MK(O3]NY [!EKEQHNT&
M031+K [W;O"MSX@P.1#>O,)[92RA/52-W/,;"42R+X+,F!-J&[[*U-V$[")L
MUH:)$E G]HJPL2;8*B<&M;VFNMI:S]^HQXOQW'"YQ]%05CGV=57C!D0U2R^X
M65Z["]?A:SR$1IFM&GNG96R3+&/(P+7^K0B'*.P%Y6O^"]":?U/(<>V_SX'E
M&%OP&%OP&%OPQ82=:P(I0P["CK$%C[$%C[$%6X\MV-JJVH#8@F"0/VB"_$$3
MY-:NN]<!^8.1!T'')[DTG^0Z-WR]=WR2ZY4^R;7R/U4.J;DTQD=U:NAEIU)H
MS!B !X2K)AZT$+A[E0?ODN0O-9*M$ATS"!1F">K'T_V5-7>YF$E(!>$3PA;$
MZ5/6CT0P#A%[P?)5ETMJ%(5]R-4:\[5A-:-5U,8EN74UG'0=QQ59UGIWH_"1
M,O=/9;R3-BO%/L R[SX2G*H#;Y/7)+"9&\^A+32^3.G8NV?S6ED)^ 8UISJ^
M"7P:=UF<&!0JKYDJC%_J[OV^FHP&@UI7 2_=X>?5!>PL(5$OQD!(F D19GNS
MN4>7A(SX8L^U2;FRM]1?)&]$"L"",>6KQ/3O5S0(;VGX3Q+>$YM.?3$EIR.=
MR5O3GJK'-F.VUCCW2A^Z:\8H>@C('Q$OK+> ^V>\S_MG;(OI).48YJ615[/:
M(4.> W-FR0I5Y491FMH,"V85(?D9HU054_P8LL(5!IA*9@;&^1PHVIF:F8%Q
M3@%Y72H/C*09#IV;PGD0L@- B7B5ASKR+&:R4W%&(U?'B/NO.?FJ+DE*DJ,;
M>JO:F9H5$X]>[HDGKOK=62Q<COF2-^!3IUA77B[3OZC'.9TRS.Q<BJ%/1SDS
M3L?3<E4-@V5IS:!(OV$JB&OWT/FS:S]:Q/N?/GWNT\AW8J241]#*'-BCG+S]
MI(^3 4J;,<*)47HX2>WGU8.9)+D9G4)CW)+HD3H[P/2X2GDW='WGEOK6]IMT
M;Z]:*&@79 :/RC:9]\#25;&=0>XN8KS#!Z0[922N^DPYPLF38Y^AUFQ[Z;&O
M"HNV?$<MCP2;.M5NHZ5)L0\6&X!>A4$3\TVP'MP"8K^=TL6I0]QD7.,?\L,9
M_^KK@$PMK^>'KG25S%,5$IDQ#$&FDS+I4^>$^P,Z$4"ZH.5)LBF0(2[#K8!L
M5N)V!NZ!Z]O4\_ER;NU$U.?+M<'@2CF 5.9"&\8+L!4'":#*+0W3\4-_]\0F
M[J+444DDRJ7!=EVLL#NGL2W5KB4DX].PN$()C.D$V-LF'1"+BIFQ5U*^CW5+
MGN*?5!9O8'[L-2"4*TVU"E3N_6E;U:VC2@7>2WH9.#?V^E*G"VI"TN9UL*(4
M<5"&C1 7>KP4,J.[?>U.BP20@^UJFI06<Z.[=#7>U<I(Q;Q4S*A-B!/TN>9K
M]_KA).61+Y\% 5G1G9[T)D P&(VZW,D=F%:_B+^$2R?_YO\!4$L#!!0    (
M #R$4%+7H)>#5?,  ,GT"  -    93(T,35?,3!Q+FAT;>Q]:W/:RK+H=U?Y
M/\SVV>N<I$HX$F^<K-S"&#LD-CC&CN-\H00:0(F0B"1LPZ^_W3.2$"">YB%L
M[;77L@W23$]W3[^GY]/_>^YHY)&:EFKH_QY)Q^(1H7K#4%2]]>]1SV[&LD?_
M[_/AP:>V#<_!L[KU[U';MKLG'SX\/3T=/R6.#;/U0<KE<A^>\9DC_M#)<^!S
M<5&4/OR\NJPVVK0CQU3=LF6]0;V7-%7_,WU\_-9[M&YJZLBC^(D[2>+#Q-#P
MK3)\P?]P^@/_<N11._#1%'_4=A]5+2,9ES*SX.!/>"\\3WM60IAAA?3GZ<WE
M\'$[^/GAHQ]L4]:MIF%V9!MHB".E8F(\%D_[!HE9M#$R$/Q]W#(>YXZ3C24D
M=YP)XHRN%+^NRY:'<86.H=N=$[Z -^)B3)1\HYNT.77P] ?XUGVP9\5:LMSU
M'F[*5IT]Z'P1,#9\8QH:M0+?8=\$O*0;NM[K!,.DV.8'N]^E'^"A&#Q%3;7A
MO3?_I=$7&D9/M\U^,+*<+P/@:_1,$[;JM/><;P->M$Q[$A'P8<"C\N.SYCTK
MZ_(C?3YN&!WVI!2'YYAHH+("/PG^[Y.MVAK]_.D#_PG?=J@M$QPA1O_VU,=_
MCPJ&;E/=CMT"*HY(@__U[Y%-G^T/7()\P/<^.,-^^D\L1LY5JBDGI$KMCZ0L
M=^@)>5:>/Y+2&?NE)L9/:W?5?^)G%_G\-?Q \&HN!D@LMN@PB40-5UP;KK3F
MKG2)49))_A;(NE5>3^5K%+8(+ /^7]0!D?T"8,B4M9*NT.=OM%\38>B$E!13
M\67&S?G&S7>HKL"_]KDFMVI-6;/H,D.=^88J,#S;YZK5D+4'*IM%73F3;5H3
M<Q\2XC*C2KY1SXQ&KS,R[#E\8B%"ET+F^=0QKV$/&@H?]?LR8Z:1V<YJ4LV1
M[7QP^&B9,>*U:ELV*2RHQE09'\1BGRTSSAG"<NV,E9@ Z66#YVK7/9/6DOY1
MNO"),T;=4/K$LOL:_?>H"?OXA$ABUR:W:@>F*=,G<F-T9%W@'P@PCZDVF<10
MU$?W/46UNIK</R$@22G[4GT^P:U/3293V)^JHE#=$3'X 3Q;YC*4RX]G^P:U
MQ[EI=)@,DU",V0;_/<[DF0[K@]FH>A*XI8X^#_?4IP\C4[QL7JY0_ST")7Q2
M-T#5R#K;;7Z(1C;CT6?V_<: 4&!K=N"]MB+W_4!,V\: &=S':X5G..N4;7[T
M&??Y5N;TB8&CS]]GSWENR@TTCIS!'(/CI&H;C3\ER^I1Y:QG@N7,Q_PA:ST*
MVX!]8QW-@'0(9\T9LW8#:A,L,Z4HFSJ,:%W13IV:1T15_CV"S1E7<4N*\43J
MB/1TE0\*^QT4-U@@*BAMV^P![=SEN)#/7 _JOI."T>FH-N*'"Q6^+O[['>P6
MTZ9FQZHT03(TVF#NY5LFI?AX?#,K3,;W8X6CW#:^B,0:%[$(VU7L-N)R(P3)
M;6(MB/U30+8"U.E2W6).R)(+0,(:.D/+%-A3R;#"OB#R4^D-+*!,[1+X_!UZ
M:5C+RJD%<+X)?GD)R'E%47%(D/VRJI3T@MQ5;5F; GY:W/+6G:DQI)R[+/QM
M%0[*KG,]&Y"G:UAA9M]6.+F$[$[EU P:S-_ON74J[+7"OB#_Y#:A).8*K)?A
M?)TLOPZ0EY.QN76R.]NQP?R2-TU9;[&=:9WVA\]<RWW\+/\DFTKQ;P_<PY)N
MP=3L069*W;9EO=+%,:P+&,.FL"8NL^^IVFK#W_E':LHM6GSNJB:,"+X#75 O
M@>=A&YV:*SSN9832GL*=27$,5X[OORC*/HSZTXA"DS8I1LJHY3Z$H=P3B\7H
M81K" N\G;1:A1>S&W*C6\;.E'#E?8V3SWR-+[70URD-XWGQC$_ Y+0/6.YR2
M11A.''RQ-<\PK]UHH_L:92Z]]ZGWN:K@-TV5FH2MA@;&P NE;Z/N__C+P^D^
M!,[GS-9E_# )A67+IHVN].?A<MR1AM]-O$:Y__UYN.[A],K(*^[G(P"X'SHH
MG8[G/"@N]+8Q:2#%]PRW/,UC?QXNP)O"^6:M2-I/!O0A:8R3-H0D,1=+B/N,
M)+: S2!IJ@VX7^CR"S5W,4L)-7?=FQ1J,,=^LZ*[@$WNUSUEP!$D;4VHS;#)
M=X6^X9:D+318?5\X7RD S'-74QNJS6$EB@I/\I*/84@"$P/P/C> T6PV=+1_
M\\^J=?39?6QBW9\^!$[A!^]#,'SAEM-3Z#[;L7D;/# 3!V^,'Z;$%-X&(P0O
M_K5RP JQ\+?!!CO7"2'WL%^8D7@;3!0JI;+O#!5II9UKI9"ST&A *U)ANU9A
M6X_111HHU!IHQ_P0*9"=*Y#M<H ;:8PT07@TP9:BOU& :T\TP4[X(=($(=($
MF^6 %0J1W@8;[%PGA#S;^L)RL+?!1*%2*OO.4)%6VKE6"CD+C18W1"ILURIL
MN_4:D08*NP;:,3]$"F3G"F1;'#!N3.QI@>J+]>UX=<1&3+:T9[)E]A_+Z56L
MFLSFL1QXB(1W.ZGE[\[V58I9INVT(6CTN<!R5W4"JXH2N(NY2!$GO#%/Q^,$
M,0W_]W[+C!\L\TZE2AQ?[O>7JMXP-/U:-O\X%N%Y3U<N+PNOPR;"/E.5IN_H
M'V<H=DQP&FKF<]@B$&"SD4O:DK4BPYAOWCDHWS&#,SY:EL$9RVU=Z44,'C'X
MD@R^7[H\8O"(P9=D\-":*-,E. ]75)I-BLU0JK)&+8^@HZQ>D'7;,,]5>]"B
MIJPI>5TI&*^?S><C:-,,/P/QD31?*-X4,7O$[*\N[#=6-32[E\F>\RSK#X.,
M&V!_C*[TK50(C8NVB.Z1<)A^9C9BDMT7DN_B?&Q$]YT+AQ":R6,G3R(FV;UP
MV-XYHRG4EMX.N1>.4[UF>L??#KWC;Y'>K-Z0]\V\UF0=[Q1Z'13'U>"5&3Z"
M3UUK1/*1H);31C7B@]6"5K-DS@AJ7SW;C3B5$=M%;+=3[W82_[DWQ&NYR,5]
M@8:,..7-::>(Y*]&,P2GP"+7YPWGP2+B1\FP%_HM$:?LOV98WF>(B/_6?8:Y
MO3TOJ(XU27E=R2L=55<MVY1M]1%O'@(RT-?!0/SB*>\XZZ71X!<XC1QC70@3
M$7LMUUDC8J^]8:]]*O0>GKNWJ&PVVH#5,_I(-:/+CJN_.>9:  ^1Y%JV)U#$
M6GO 6N&56A) Q:46OTMNR%K57MVB?WN(QD<Z7J5_I3;:,M6^GAO/YT9/5QA)
M7@>_C:U[F/>9\L F,DXW5 -**]? )?U;4]8M?J&E==KW?^/S-&;08Z<BU6&O
MY42JPXEAY/LW?BHQ#'LC.AGYMK=@T-FH:%]M=E^M=A[MU3,UWDG-.!KO[QY?
M1X?*5L^DGU7+2,:ES D\XP[F?C4Z!8XV97SGONMI4SA(8 ^M/(?O7NWQ>13U
M$7A_$K?X;KG7H:9L&P%LMP0.QF$,&M4WZ1G5C8ZJSYMV/E[&YPT:V/U^! L+
M(!24$9U#LB[\NCC!/DQ<(LZO-J>RPO;=IP\ (OS$?SYUB67W-9!O3>#<$R*)
M79O<PJZW2)D^D1NC(^L"_T @5>#XYD?2D<V6JI\0\2-!7H_)FMJ"/QNP3U'$
M?K*ZLCXV:GK>J/!:_?-=N71;/#L\J-[F;XO53Q_JGS]]P,'@1_=SZ*"M%@MW
M-Z7;4K%Z>) OGY'BS\*7?/FB2 J5JZM2M5JJE'>WA+FCLB7<RU9;U5NVH0N'
M!V?'A6,2%U/)W&;!UFC37AGH__T?*2U^G ?<7 *NA-/X0C@]K]Q< 4CL?=S>
MS\IS+2=*-0IF82QV9C1Z'4=UUQH8%Y+ ?JC5V&_QA%0;W#P\_'QN6?*O/W]@
M/-BWNJ$S,:<VB*-=;FAS/)QH&[XKV(DNH\6"=JA_OJ//\.AW)@N&8PX)O><T
M7P$X54=+[80DI.-4=W7XWEV!/7]X4-'I^_!N]C%^S(_QX_<>6$;4U/HWM&N8
M=C!K/N:__VKE\U7[,KDR:S8-LR/;_QZIS_9)W3 T*NNVV:-!/#L&$S)"+I-,
M?YS"P8#N^N?O=_F;V^+-Y0.Y*5Y7;F[)]=U-]2Y?OB6W%0(2^Q:D,I$2I')#
MI-0[Y3VIG)/;+T4R%.:>'.=LER_<\E_@02F72+[%?;(>%CPWS,,#NTW)7Y>N
MA)O0!"QLJIP0(-_(T&QNA38,DX6I3@CXRO":JM-)?AZ7K]=LY"(WW8.YN3_X
M??KK>ZGUI_M[+=RL8.09WFLK<K]/P9;4@YAZ!+"CSV>TP3VMA"00''FJ>'ZS
M4GHS E <5\@8/F4MP&=)P+/'7_</N4%"NI#7*0&;LF8%BL!QJ!P9F)PI V]O
M\N5JB4FZ2 B&C T](6A[E'6E8!-XAM3P?[;!?T8H7@4\O,Y!M3!H=7APKFJ4
MP!X!"0OZ957EXAI+/)Z+8_(A@V5$,B.FM?277"^=78,!/SXG!ARE6"*3QC:D
MLU7%'C-/=B/,DUS(@5N939(C;')#6ZPL1K>QVF^*.I&E'^>_TO)3:G439)Q5
M1N<]^IPOYW\4?Y++TCD(^$*I6"Z >"]4;JZ/=VEJO'"/ORL^RPW[\  73XPF
M,;U%$]DB5I<V,/ZN$!7H8UNDT686YP;=LPWL"5NN@_!J4$V#SQNJWOKW2#QB
M?W=E17'_7GH!3ZIBM_%1\9^/I&Z8P,ZQAJ%I<M>B0!?G-PQ(?K)-=_A':MIJ
M0];<Y=I&UPU9?K*5D<VRMN#4RONP.+(/L2[$[#KOL?*0@M$#G[-?,)0IV_*N
M6[C2[W_\:1=3Z[#R8A9M8.K!IEW3>$26'74-%H#SZ'.9/LJ*O,26M95) CFT
M3R'I0T*LS BQ;N7GDI,]X^4[LQ1MZ?OO.XW6FSEY=3*-4V$* $>?<]F8F!:S
M23&Y' W@/^:.]]([QDW$,(D!EJ=)?O=,U5)45BK"YS6:,]EFG;"4;L"YZ'0U
MHX^IP5#A2?7O0(*&.L.-V9)U=< ^?+\M-(WR("D;Q^^#D/6!Z8C/8==DH3$;
M7B*H3D<$55Y13&I9SH]+>$,*%E)-):6TOW^3VS]6CYF."ZF R8\^IR1R3RV;
MI.*Z0JJV2:D]15()9+;&G!P^'KRV]O7#X.>/5C9SGM[@VN)'GS-VFYQKAF$N
MO*)4T(H*V#K7O#6>]"EZ7[1^%_]F*M=?5H_N3%G/<&I4Y4_DP3#_++R8LZ#%
M,*%>,:_!I #!-<62^=9LE#IWXJ^&L78*C<T/RWJ8LJ")]<0#B<.MG>!UU+7T
MP]?K*_-G4UD[9?B\1Y_OJE/@ST\L(!^T@&L#;#SME]J=;EB:WWXWOUTU"IJ8
M6?<R1F;'3)\HY?;9P7.6=7@ WEW7! Y3N[)&Z#-M]/"@"9@LH!VI]9Z\@S43
M7/1^>7>AP?0R.E&*30NCHWS+FU2>SOM=M6!V?E=^/*?5-?"^?[ZCS]GD-*M\
M N"" S">#]"NVX8^,Y9W^WAW7\_GG^\?ZVL >GS.H\_I;"Z6R"7V>J<. T[_
M^S_9N)3Y")O6IAKMXD*)SE8J$-C!6@^C%D0&L@'RWM*&A4?%'6[;\H>\GY/J
M)OD :WIW;IC ;8P_!1:O@#]D+G:)#$:D\U%3M8!M":8T@8Q-#*;I+0I>#ZI]
MHLE@<YHL.;5!>O[N6> .]4-$TO7"5P6U9JJV2F'O\/U$34#Q=<^T>AC4M UX
MDCGL?"52_%W]/08^,964;]@GX5U:>(.;DQZ\\T;=L&VC<T+JFMSX0UAQ$+$,
M354^DO&@!']TO1B[56V-NH$94I0;;5* ;6;-##X$1$L^$@>7WH+84C9*WB#0
M0H)54T9<<.BJ_4[=T"*$O@103"^-<FGQF>L&8NCDOJW")T-9MG2L#_8O+*ME
MXC$UW,.&>4+^IU H%L_/ \* SL9/Q/]9[R+'S<=SQWQT!'9?BM?9=@TV'\O-
MPETUG52* VD-YN/XG#S5#;AF_4/(M6R2'[+6H^2_XK&(AQYFVY0S$@32FK&X
M $]OBX!N&,\1!UP0!%,OG;F_5!+FK8G1C1=3;V3"H\_Y'S\O]Y-"R0U3*#VV
MQ5RI,CV-+F7/^YW'\V:IN7J4:SQ?1V'6R51=$$P@"?/5L_RTPFI'X; MBH7"
MU":7EX5M1?-?N^%<TA5,DH BJO?!,Z& 9)CI#WEJ4Y;K0OO85QSP3GI/VK(%
M/HT&YK6L:8[K8L'/OST5;6XPM>O4>0#&=,QN+)<S3*=<SK&[AT:[I_D.#\ 8
MQ^^Q2HXH/;RDC3W;-6F#,O=7BA-6)6J1=S @L!VQ>J IK;:!)0IN,9C=ENUQ
MX)_D43 11OZRLXCWPN$!.F[OXGR5=>!>>*#^&]: +[!GX2T$PQD(BPPM!@6#
M$IVYG$@4N6\=;X[HIMIJO\0]9U7@DV<L$B-167Y'NLWK)E'PVK+=LX(%"+5_
MI@N9A\N?W]IKB\L&SW_T^0'/F 7'R9W:3E(VPKOA7IE P&T".Z2CVC9L*JK!
M3C$-'4U1K4\HF*5]4L(X#396>*3D3+9EPHH*Q^3%<(RNX[,?'L W-SUX-"FF
M4"2 +=S3>#ZW&KLE[Q"3F8_Q1/S8><!NJZQ4J8NE2B\5'KS*=(;TX!![,H%:
M[_=OQ^?'*GT\0B&=G T8O.-_=V[/[YY[\2MS'='H6?/O?,>_*!;ZJ>[M^$W&
MH+>\ZV&?R40#4"B1&PW8]28V2V';P!0( !#T*0'ZQ0*_L#H@+F 6TY7UAP<-
MHP,+Z0MH-,!XH&=QW2T"_NR3W2;.U\< /V7 *;2IZJP<W$)1@)'TN/AQ&HCL
M:^FC^]C4!PX/G"<F('0A\(9"N\%Y> JP[I.JSL4:N*&QN&L+>:X_V#\;E".O
M-QBY7-63,W0\M69?[!(9CL\VP52+.(=K!\@[[K*#N?,^#)R'"0/KJ)5;M]<>
MGS@C818 <RUC6DG'\Y?G>.;/W\OJ]_5IX)%IP2\?$]@.$9</NJR=GNG9'+W6
MU-*D<L+9'*&^-3!FUS0Q($][EJI3:XJ/ULT]7;:?;\6LN'H)T *'CP/@F7?P
M.&Q;<X%8WAY/5QRU3L+!S:-5["Z(%PS" H=M2K>'3B[SY4E-9E/:1@^4S@!L
MWIG2*%2Y)A^EB=&Y::X 5LAP'X:,NC!J,RAFP2(5H-)T@T7V>A9W(P!<=I@^
MZ'@I%K3C9%H?9W]286Z8E^@ KX'JX5&UF*FGRWI#E34T +$T$A_&QO^*;"H6
MP1,LJN(+<_A*$XB4>">_#_((0AU82(:89T+/TROXW58;'"N7[<D[8&;F_/+3
M>K,]RY"'J)+@<#_ 4XZY,%$V/'I M(IXF*D<'G_8O^Y*:271W(9R\,.#MO,\
M==!=?PNQM[-=D+-Y:23R.6\]1XR>S20MBESXE&)-A;,+5,OJ4=,ML"0-K >B
M+%34X#4 %B88!3S]ZKR!_7\M&P0V1B0;+,*!'4K&CL%/UEC<MU4[X/A+;C2Y
MPB9E24W>"[ R!+VFEA@[2_#_>&UP=]%-VUE5U1_B1\3&NH5_C_@@Q%^^ #CB
M2/"-Y#']N<D;&T\F66; <32R1YPKAGAOQ_CHO@!"*(:MT(8*9O\1<7ZQ_CTJ
ME<^/"+;68T.X70_3.2&9S0A9[/@Y"M\PY^M2=)0^(Q3FI#JG=;,GFWT0>JP!
MC'0<O,]>Q,5KWE#_B<7 EZ::<D*NY1;]"$]CS]$&,)<HDEC,M;T5]7%*R=(I
M*UF*#PN6.*@Q<(Y.2!I+JIP/W!?2K#_7,%#G#\R-!^Y&IYR,N(U%YA ;,4L=
M4(X2G&9V75) <'VR2B+QSQ![:#C/KZ/P"H)]Z'41^Y%@ [<3DC?ENMKX2+#N
M@"._;"#"_>]\<%]B7TR9//%/H/;S0XRFOFOHNRTCQ\G:!0AB=9/*?V)U"EL*
M@)*U)[EO+4I1CZM]M=)#,+JC$_L7B6OGK!:BO1$B58-]@/*GE\7#@\HY*53*
MM\7R;94LD,7)A4M[CP7H%]CWOLT]%EM?G"CC6WQ.127SME"CG)!>%_RMAFS1
M.4$>/JI;3\IV"3:8G"PQ%?T?XEOPD:IOL;ST=+*\=%)L+;J4E>'&_3X[T+95
MZ@95IYJM^KNXF!3BB:P03Z7>3\_;Y,8;,.R*&S[)I&VB;?,_U_F;VQ*@&7Z0
M$@$Y6RKGRX52_I* $52YN<K?LGZV\F+5B>/K8^IEXSR2"#F#.*9U*.7"D!,
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MF]01L54;P? &X!:)0"PV!I&]028!R"X/ +]THIQK2=HOQ7RZ;2\'P+P3WC-
M6$-^J50^]\7J^00; 6J91$(P4)(HB"+[-R"),"VKP'[P3=%UP>;L[)"D*YOD
M$8UK\M]Q7CB;R@O7LEDQV35#"C/,KZG)H!QCRL'-><9J5*AX_F<Z3W@ 3#)C
M8G4 .%/F.C?5N\&/TL]X>C$ EJ#[-!#6SI1WU;/K51AS20!79U _@.*Q* 85
M$"W"G]3D N)M&D<>VV<S\[Q@MSI$P<K&:G% 2VG_MNO_EM-?;[JIYY^_/:X?
M\4V)SQ(E0[%"NE.W!ODO(RSQ:.3YWXIJ=36Y?T* O'3A^H,EV'C)MI$#:AJ*
M;+6G)F8M .3?H]AXAC8VR:.K4/<C&4'('+-G.>2]@.F6 \L9%?/R!9B[;JH"
M^4*U1XIF$XPHZU9LQ(#9U Y<"(@M[LRY\:FI.Y/KHYOO7UO%COX]>]'8_,Y<
M H%C?+C!'1N@9?9JQX:$*_<DXC%NT$EC"65#7\2W2;5_W/\>G.JMO[GAKF%O
M+^'8Q)><FF_8WL.@VLL5.MVKQ!)3SVY9.WWR'?DSRT.T#F?FA=Y,@P&]J"MS
M&DS]!?V8=O;K9?7'I?S]>W,*%\QP8K(K3LT9\.'NX8_QMVFGI-0"4R]*YA#Z
M+JM#%SDN450WBNI&4=WP1'5+EM4#4QV+S8R>;=GPBZJWHJ1/)!XB\1!^\;":
M@]1UO^O(9DO58[;1/2'B1^+\Z=;QBW,6N; K59CESW !-&;%YMI?DW=9Q1:_
MSW&C5/;VY)13C&@^964HZ,;F/>W<J=_J5]>Y^IQY?;)R:9>%KS@L#I0/&1L#
M*9T6<NFXD$L%=8U<V(%R<.\]T'68?>;_UL7LTW?T.^]J;+P5FR#*2,S9YF-<
MF5QB(W"?JG%[W[RJ)@O?6W2UC7"V[$;@\S95M?)8??Y6T*4=;827^^UKWP@O
M!PDV@9A,"5(NZ'#5S(WPWL?V;\PJ&\:TIRB2L8!V4)[INE6ZZO[2U,1O::%H
M]C"</2)[9@6SR113FJ1AH&Q<B.>DT<'(A.20<B1&4G$AG1)!G4OOC[9BD2Z\
M3]9X*]JTPX=,4RQ\1#XREU?81,45-A%7"I=GZE<YWRGW[I1]W$0AVS%K.J[+
M5,K"W;AW626?5Q0589.U:UE52KK#.CYT!;#?X&OJV3XMB.;WLTUVD%B]4-9;
M%,'[/6*J[EX#RA87Q5%VU)=H+J]M5H_%I820 64FB5%/NSV(_6R(F=8DXJ5L
M6LBF)"&3BH=5SOL]VQMJRZI.E:)LZJ"[K7RCT>OT-,R1G=&FVE#M(#E_KG7N
M2JU[-7.SK]WNW$6ZE\6QI49M@_:J;="[V9)@/FNO6ZU,*2B2TADAE4![.!7:
MED+O%P<DZB84?A9>69E-8^%43DAG,B"R%[X><;.=AMXOY<U,7AQ24WV]\!RU
MYN^%IW^Y_*NVJJV[Q_H^]L(;N6ADR3M&(NT6"NTV6S),<O2&NWZGA80H"IG,
MR^X2VQDI0\;2X>#?T#'KFGRP."JJM)!Z80O';?MERUQ\-:*_AFKKNG5U_;73
MO[LRTOOHF 5W<YV\.BO2:-/!V\.+6N<Q>W2%ZUM4;6&_PG5%KGUSE[M^L/&&
M$?@-_QF6^"Q^CHI7_[RD[&<,N"X#YM-_8C%RKE)-.2'7<HM^A*?_]JC>H#"5
M2&(QE_<5]7$F[\6'O.>O6THC?L<JE])L;S*$D ;5-(<FC+[X-P#8</\>G1)4
MM"9W+8#-_>TC>5(5N\V2M_\X\L=2!Y2C!*>96J0(\ 62?L@LSM")Q#]#[(VR
MD_M$\I_1H1H4F-Z$P7SH=1'[D=SVNP!@WH2MT_A(RK"A./++!B(\X7_I@_L6
M?C-M]L0_@1O>#S*RH<N$GSX ,0/HV@408G63RG]B=0I;$Z"2M2>Y;RU*TK'*
M->"@K@^,[NC$_D7BXCFOA6MSO 90O/K!2?Y<8TVA W3]<[Z<_U'\>7AP63HO
MDFJA5"P7BE52J-Q<?_I0_WR\9\LJE6^+-Z6KPX-"I7Q6+%>+9["4<K5R63K+
MW\(?U5OX<54LWU9)Y9Q4KHLW^=L2/+!GRSPWS,,#NTV)W38I)1UXL6T1JBM4
M(6>TX12K2$ZM*'HB6+6R9XM\=Z?+/46UJ?(^Q/M\,;7H^LL),5Z3I$1M4#6K
M9XK][3J>3X'2['4 O#Y[!/0.'O;##LTD1AQ^)DNR,_'A;OP(_ *X6DQ['ZWK
MR%%4<S!20)?,Y6JLKE04I5IM6&%Z9_1^#?Z4OT@/?S90<;:SPRFOAV12SB49
M_,9/F2@_NI?RU\IW;.CP>DBVX'FB.9$XS^9>T<^M>Z#5%RE2V=1TPS6">,./
M_SW*C/M!"[G]+P?P%JT!#L]4DV "6WM#S+FA@"U2.+$C"J,VB% T!T5HZ4YE
M\F'FPE^F7NE24\:+,(K/7:I;U,K7+1M#4S7UM#9(WE9__(A_*?:T[>0G5EZ^
MMPQ"G76\&E7[>K1G1(4P4"%((O@;SEY0'?:2EM>5O-)1=17%@:T^4D= 8/?]
M6D<N#&COKC90L[<IX^'A^=%6UEAXX_A:R=0_:PQY.^OBDV%D0!Y9WA1*N&[?
M/YM,TGB3;"$?X_FQP:'8C>1>YK#4:.KEW#0Z/&$HQD3)-E9)'HZ5PPG)C"BD
M4PMG##=!CYG[/>*RW7"9E.-<QG][&8\E4G%!3"Q<,[PE'IMWH=L-M:AL-MJ
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M'KXGLG]4S_>9H,S6O1_Y\5D[61EC._6&4FDAG0R%3-GG+;1[/EM$N&[/.;)
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MO:'UT)XD)F)X^(750Z1;!%QD,%7[N@(T PAD_IP%8,,/AB+-:"$=#P\ZAFX
M#I'*JL5,4-*0&<V ]3H]+M@MXG#NSQ@PP!_X$M$N !_:[;X6*W0O8G651?>!
M26$]\'3<X\"K8N$Z[O+@\9L39<>I"2?LQ6H!E>_AP33MNV[,O@E5"[+! NG0
MTV7862B&571OU Z:Q"#@^$DEU\*$/YJN08G2W[$H21OD)\@(JJ.L[L*>4[ #
MKM63062AJ( =9/8T  ,WODE;/<W97D!*&X53E39ZIFJKSB/%YT9;UD&WL,.L
M%I/][K:J%@N>.L)GY48#))C-]R!("+6K<1$.XA%E"WQ/NWQA#) [G2V3V<,,
M@#QS >3# W>&N^/J,;G(YZ^]>5 0NWB!!1HF3@=Z Z8V<?=K?0&DEXGQ.7B.
MASU<BU$'N8 RQK&Y+?@ OD;(N#CS(#L\D'6]!X@-1#$\([/I6/Z3Z3$/3A_^
MAU0#D$&)V?88+9BH#"3&\>%!B:/(Z(*V _ !.< QH,(1!(&K<-]"4+;*"CBQ
M "0.W9'_<%WF1T&7[U3*$$& F*AW$'N10%S;YD7&8,H=-\'+=K))FVBN$&!0
MH"W"QSX7V*NJQ;89&B&,A]& Z9G89@=@\#_,K2!U!C<QYM'!_K$LV>RS#=:4
M5=-E%\X[7#J,L!,ZZBP*3L!B 'W+C)N1=1T>U)TB :M-P<23V2:OH@S >#E)
MB%CP$1?)$WP#:A\L*(4;>3B7B[M96['>P] KV\FVNXD9PGR;X_# A(VAFMR>
M\'8J!W>-]++:1D^#.4# HCVG,@S][NDL7GIXP.2$?UWS1W1EEL5,4HJ&[JB<
M(N.6I(,K+A@)$.D<R 7\&_MV>.":L'TJFUBU@9)WDA1-58,O/&!!Q.,P;J$.
MB6?Y<QQ[SO3 ,YIF/#$PB25WZ(@F@#6"MV-YK@?72QY;C0IS:W/"Z$W8$)4N
M<T50# #K]S3@(L]U:9N4$C"V[;;ET-\C*R^] O(S66#8GCQ0F7($5X_[-XX8
M<(=F_E-'[B/3T^<N2"MD93[?X8'+:,@%$YPFK9/0&T+F'JF?2Q5$',B5?J3+
MUQ"JT33FV@1)6,]7)HK9:WE>.S?!' GGA2C\418>H4&1[AL6'%T=MUN=>D8K
MVU.JS=06.-4FNM/PDG\HVFRBJ.21"W@5#$G<K<V>!J8F^.9-WR>"-^!TT-DX
MZ)GC8'(7_.='5-ZXD2U9XR&6P+@2.@GPD!, 0>7? 0N>J3$3QM-[+.1A8/0&
M7/4GRJUC7+#["JKWOO<P5_Y&#^QE+L>X+>Q7-5S,<%53=T/#&(,R4-WTF/6+
MSY@LP 9RK,4E5T.VVJ3)M)0K$#'Y8E'*,F3-GMTS.7D<DH": K%G@P%%=0&4
M5Y-A2&#0>1-W, <$6,-B9HP[-%66_)F0;>KS"7UFJMN?28@G4K6!5+8JQ9]V
MXN9'(B#<OX.<#$OUNM!.0+],)G.XSK/:X%:B@_:I=BMEI#E%HIO)<8X@7<D\
M?#F_N_O[]3K[)K.?F?G9SR&^LK6!GKF]_3VX*Y4,Y6@2\I?E18<3B;7!7;-\
MD\L_?OWY,-P-:\B8#N?(U ;B'[!N^V?W9W^H-\>JN=39F\4_<;PVD,^EQ\=,
MYNK;'WD?MGIWE ?2:*G_R%W?9N)!T._$J-A /G*E?"-+TDC21_*NX.@AY?U,
M/$=FV4HA%B]W CI74T$A6T/SACX[01&FZKDFAU_0]W\$*X9%0V3-@ >8=^L]
M/G2]&UZ_/LL-0ZBF0L!;Q7"HP.RDPP-F<#6;Z-3R.%X'8QL( 9MO9!"P-  Z
MC<H6//ED,-\;3,4F"&X>PV/Q.ER!C?&CA>,.AP?^, %:GJRU(/?*P0Y!XX_E
M]=#0\YN.8-PP8].P;(R4NN:HK780%?BGT;/1FF&O>X:LC;3'*]9@ISB&ZC'G
M'$84&6;O='D<N=>%_<*C3GY#MRU;3K<M1BM ?8=%?1%X$^:$/0>N)@5*]1RS
M4'$]2ZM7_XV!,+3R6"QZ.#61&W8/T2%W,-Y IACM:!""'VJS6"FS=A\QU*70
MKN.>,J!EHO>8BPJC-&%@P[1\>2X,-:%=J &J;"?OQA*I6,P)!J(/A4IO&-YP
M#,LQ3 I.),1HF0ZE@L">Z@"P%^6.Y=%/PR^9SS+D9G@;;%5,,LN/LJHQNW0D
M:H,D80&INJJ!YX@KXJ%#1B+#C220KH:[U445F\JEI:'[V(?/'[C>-Q1BAB=9
MU<UF9& %(X' ;+ /F"?"C"WD%$WV,26[^-"[W,9K*^JQ2Y5Y=<//WU&99VT5
MVF0179"NQA.ZLZA@2?*]P".0CO@X/-"!56#/FRRXR^27[-7SNRS(!"UW4#T&
M1 ![%O.I6,*?)4>8Q^H]XCFLKJPRZDZ8F<6<70=3ZZ.#+%LP(QL7.ZD>D]+(
M1D)YA5O6G9F/Q'D^"%PF X"741+54=MSR !I#&  "0=D8,,W-L9T^?I SC<X
M]A4@1!]]8M9+E2C&$Q 9G4/4!/ P!CSM&3L;JVL?6?;M#6V9S9D,)?WP8!B[
MAEV!E0BZ ?B&L4QD!M1RA@F,\*B:/7BQ4/E1.HOA@YB4X$%I3EH6NP">!]7
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ML7A C-YCE'&=+2.V)$W[CQ20:/H.LO6VX9]7 ?[*N*QD:*E]?Z^L7M!D4(5
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M2I;\A?K"/MTY\_43;>R<?;X[.K\X?O.N>Q;'=GXP4_IV/K=P-:N1>R=X27$
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M9:M(MK"B'GP7\G)01HJ%R7/;PJ?&>[8",*\EXCN5B)R=P58%.JC%HN'Z':S
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M+(] \5(G$BT5%_EO+"S;Q",&"R952P ?SY;*TMLF5"_^$R06%V/22H6XR<F
M<T!C3V:DEDS*6E87;EN?\'KSX7F;&W@BX2]#> VI(5J1&WX,^HINV$[Z\&P0
M%ZR ['C<$E+BZR8,0M$"V^T>*C4'US)HMZFLUY%KMKFA%HWE>.*Z20T_R\NW
M\> *N(SL2(4S':M%AJ<'F@\ES;-O,RJ(T(+IX<<_J^#G7[Z+;Z5"]:@B92WI
MXQFW@A9<BU)C!; Q#A% A00\]'3-\+AA+KEAQ3(MAC7)2NE(5O;7)"ME.1WE
ML:>;H,6(>7U&V@6B4:=B/VE*W8XP""11_C=P;U;,DGWYZZ8/AOPW7=_?%S !
M_IWU%EL&7R*< >^-8_# M]$>]-05+5FXK+8G;!RKU-*2<N+6-;G<2[?F3X]U
MY1R]X6/I.[V0%M 37^#'/'0DY)L;!5)NN9'9_  N>]!@+3<8]&PPNMLBH;N&
M#&LT_83?A0]HD\:LB +K@^TA1 Y39 */ACV@1T1@SH#Q!D;&$&T*]/%<\D[Z
M:/?!]E*6%[X9DD<7W@0)^(3#"!TCY;H>O[]4KJMJH!"Q)]2#>P).:U_$Y V2
MP6@CR=*=P-J^H ^"#9:.#;XLVF?YX&\&\ QSIV =VLQL8-]2KPB"P DT)S&E
M[)+-R(XP&HXJ:DCJ*ITV&)2^Z+BQZ@@!%KS9$L(721@X0I8?*J=%_E:O+ Q4
M3?>I*YE''!^I%&SB8<W4PZ."!Z,E4%CE5C"%"^V?U?3N>@(>'VJ*+[E#E;3-
M1_Y/',P8!#&=#W06./0R1NK5EIO!X1 ]]?0/7.R.74YB,%J'O@/"#2.P^7,1
M#!L=>Y0F+^AR6JP?^ &(&YX'-R)CE)U"<C?ZB8I0R>/]=Q5.RC7\$2447$@1
M]X9>]7CPL@HNIL,'&>8#GV[H4_KN]/A#0YW3M;PN%'B4T4,0%0I!QK>(A G)
MM>R&MB) N$7%)!S]VVWK'"./V0_"#R"W-W;HDHRAFF>J_'$4'(8"JI#G_[C*
MJD3[O #MF4"F7,\+;LF%YSK1I ]/!E<OLJX%H=F(D)5X "DN+'-&M(]+97):
M[9(>P7,*VVH^MV2CZ@N1[XTX!PNCV^]:4=C^[T]N'T3Y<ZU6W_XRZ/X$CE[\
MWY^TORT=R_V#VN#;<PM4-OB3X&?6X,>?K%]_?SJK60+CL4<,".BB@0B[@>RS
M03=IA(J%##L$AKO=OEVMDTDTB,'NV;JL7SRSU(V1DK,PS=SEZY?OFA=UNF+
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MT-A?GK@P\ID4(?![&#&E6#1V\K'94X<#:K? ?8PQID./JA]5Z[N[SS3*B(!
MZDC08/*0)LJX$!X*9*Y3]1!7GW7UXUNW34UCO !!3Y&45BIH4,']IV8(E6A\
M5[<!>RG8JH6 ]W1XJ3:6J3TDXCY_O$ESV0C!%$YZ -2)2*\E_.I>HXIG0%XW
M*@C$DAGS^[DW4&Q3I>1$MX>=$J;X@ L$_9+$5_V';$I1T.BQ5:A4_>16X3Q
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M+9LC=AO=SPYL)]>*3D\*J) #MA'AF,,D ;@L"(.JI7=ADG  N\KDL67* :2
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M'+B".ZZT"ZV6'<>8J<ET+]G<4*R3:^3#&ODP!_)A=XU\*,OI*(\5,LG"VSF
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M_2IB.\PX,)1DSKQ(>NRWV#"GI?@0X4.L ^4PUIM_[_%]$A2O@%64W+[,&*!
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MD[=)3.X;]7%B'4*MG6)7FIWVF&Q"JBG*9&BM2PE*5TJPMRXE*,OI*$_*[YA
MK.4=WSK<_[U8'^_H.8BZ?@>V@@\?R=H?X+O(( :"\6TKNG85PA^;(ZHO]^67
M"6).0/Z@W2:0HOP3$4V!QDY\7>;9"N#2UQWUQ%!L6WHT,N*MGBI#,>QG'>S]
M0NZ<(G4834L:@^0<7AHVDHVVB0B975',B][8JC\-X[A5A-GYDB!M8?I]+/>$
MSW,X'PL0 B8Y'))1ACZ(<K;HMSF/\?6[2Q7EHFR'CHB-+F0&PY'+,&(9 N47
M=\%ES.87&^O0SUICK!C"H$JICF6EA:DN+@W;NX_]4W7AE:P*(L^>6F[I6@WV
M6%2R3W-6R"]B&7K7LU.U@?D.)/D/ ^)OO%&&.@$>^+AG*I 0B*VK1>Y$6A*B
MAS:^&J0BFY$B7D)"IUJ!+Q,\WK _Z('# MI$QCR(K]%@/65]E5\"C%F9QUE3
M]*5(KY_K.]M[^FA3S*BQFXV;G]@QMFO%KCE2I[1MLVO!^.._5@!K!; 8ADF7
M3Q:I@ _YZDJ5%U)7G"^8CRKMY,P'0/-5R+Z5EWAHX+79Q,L>)3^ICJ)M<S&8
MBA;DWZMJ<^!2[OK<81D1ED,X8PP-R/:$W*4'&ZW8T<!P109!P$-V0VT"Z3,I
M(88<%E;Q6[E UB68)P)ILBXI_3T(,7[!X0NXMTV #VH, 1.+TX(D:01H;I(Q
M&3&=CAI="+=@76D%.A@#I\P3O/ 4(TK"IMY9V#%+R#4P]=//C>VC/*3I28$I
MN:!#G<RRUV_P:#]0\@]A#U=@80KF#<?M>VV6 'U0)4#EGU;9W6\J2T$NE. 6
M"\5Z[@"M>_&-VMS"B:&("X%3,!'SU_;EMDS0<FUU&(OLK\W:E8B+$%5]\(?C
M*WYV==SGD:G:LV-Y[1=4T5;0O.D%3L8/HCP*.D.RYI&_&2HMHRK;UJ5A"PD)
MUGR"/6A1YR@GL^68\(NQJE[V(9K8PA(+%.'L,D86%#<('\)"L:*:J)ME>T19
MM!^Y*0* MYXNAQSMO>QZ9+4]V^W+?*S^+L:YB1%G6OLE9B*2*03)04A9M"&<
MC*X;$;@^3V>IJ04X5Z?1PK!4 W'G>@;;_]BIR@[4<C5',;8N5P._23!2WZCM
M[(*@MR(N+ABJK\%3^XHD2[8SD_R-&.QWA$=@MD_"(DJ#VZ!@(^'%-AP8FH!<
M2G--VB'X';:'<]C<0+\FFK*B[*$P:[!NB4MT8/)U\B7&@ZU9GENA#M086>5/
MRZ)7M>,$7D0!HY(*X]F3'BGY+%FYX& SK3+&MT"VF(<<P8$S;R,Q+._LWW\7
MKQ!(+I.[DQ8V9S^-6R-[9 >F;8!Y(&=9+FMDM3*#F>, X,H=J)7#=A?S'P".
MV4TX!<CPQ:B+=%Y%LKRY4;#F^H*BBB)#2LFH)6,5:_8EJD-AIXS/93;&"VZK
M2$=F)NZCH;P6I<:1%!3<QOTW:\M]-KF),,87$'K)"@SC!2U03/'8\U$_JM9W
M=Y_CW;WECG\X?VP;+#>LNIH@G*IHFY.]C(8>66]P9K@53#4&08(30PUKR/^@
M2W^4#"ZS0G ^-0HB71"+QS@R]-S4QG[,H&>S<"U'/K%MO4"$AIPIB&<N_I'*
M\GD[#K#X#<1Y;R%UKJ49>45&A%D2".=D,R.*]D0P-WRRH!4G@KKE!G#]X&1M
M/5%B*@K -(%P%C_#EVB4H911Q):1VW>QSF=\TQ"ZCU V9]$SMI_8X3"C:N;?
MFPS#S"W=NV!%Y2PH]G?&7KEY#8M+K3,%LM&506ZD$1!+6(0ST0K5*M3NO0IK
MKL$U0&!V@,#^&B!0EM-1+N=37W*&_AS,ICHS=QVE*!BA2MSCKC^5<I5M4VI]
M-%%?OL?Z47FCW]^T+^\V/!'N\3.LE9CHNDPQ1J98(<XD6:%['F554KVH'F<H
M=H)I[,QP%[4'3-"&]1#J>&S[MH/_W0,;MR)CU!6P1@8X37SUJP">\$> -104
MU"^V+NU.C(D*M"Q++$^E5SN@%S >V;7#22:5;&[$897"L.D8)]/46X@,U;1<
MAA)C[NI)G;RT\5<4OD!Y4\%7W>$L+2T=]=)UP5 $-[,L0%":+QHG;BC$LK\?
M&8HP$,. AM^8LYM;,2+/Y*BO4[30ROS57GR8/6Q<@1L6GLI)!W%S(W<2_P#[
M /Z*DO.OL#%?7[$ND)G-YME?!@E>*1U,BTT\J%E7H[8^K$NR$23 822]D+$/
M!"9HW0#$'QXCXU_P+XS!R(Y"\%,2"9G$D+E2128:^/JTD5SU[2%QZ-U0T9_9
MWT\W_T6Y1O,%/6K$;L,IQ3R%!'<828YM7NVRKWG9QX<R(=6WUF Z%E_,*"B5
MB8U!N! ;MB%9<10);#"AT6VHQ/":C[&I&Q4$!(/8[2/>!E4G\2/BYIJO(-G@
M=Z3%_F20@@0H8@Q+TC@.#1W-L3'%7YOA]TQ%BR44E(H7N+&.A^6)$XTQ\#PS
M(0IB4W0]>"?"B!S91GL,?2/HMR"D3D^T%'(D$Z@:*5S<#OP.4UM2L\Z4:;:%
MJ"4DI2*<5"BXZ9[!0)"AP\5:N\17I5X*4XD4E9(6UW@TKTQKR-0KLD[7'(<K
MV2C]P*\BP:878(\$R^Z&@MA@(DF["@>;F3<5- %O2"[10H*X-EQ5::=0_66X
MM*B#AQ^DO\1F5AVL"(.+,/"26&0VDON/IF]7*H4*351D'I08-NO0%+'DT!#_
MJYY!1=5NM-V!:B<M_[2^9A9CZ2V6<)7+0$+3:TFQ2YE'L'-:>,TX.@5C^W1P
MP)-,_#05ZJBF:9'JDF5YH+TD:EBT>[)SU]<$.=64*$H>$,TGS5\!<\QO8\B6
MC;;$!Q,,'^TP-05=/^8!9#5)\7;LUBY\Y!.6>73QS8V4[]Q)8A @;1$B"X10
M2=\+-[JVSN@D1"H?J_X;)O@!JZQ>5ZS72-54;RH%U?1]7,8+@1/ Q,L9RGB]
M5OT#M9'*IJ*07V*Q+.D<;G)^^HW[W6!;EKXKN^CYUHEH2S?\L$)L>$]=W$&C
M@P%CM1"C,==8X:.UU8!TSJC0WT5I?*4HYF=EB"W5=):O;_ _&"1<JM894/4N
MXN[0B? CD5Y#G)#\"CZ$!#AT0,_;'H'5F./QYZ.TV+K"^B=D"_CG@^T#78:M
M'L@?H BU>BJ<7GXJQA3@0%$F-%"#LO289+T!]>3N=E&G<)/YGVO;1^D(["@[
MB/KVCAZ$O,_&3(I?3W7E>%VW[:A'-?6HK(S<!SX!'6[BHB#\D>1)AP=%<8"-
MF08RZWQNXH1RY$U6?JTW-V98[(/,5/T44(CK4-_>3_\X0K/1P%J/&S&R#;#0
M;H"W PY O4_N0MKR'%MDQ*';2CB[H%MI,:NXH\B^59,0U+V!WPU(YV<:.9<Y
M!ODTSNM[ 48>-5Z=[93"B<C*#7P+SDR]@5O/W.NCQV8_)TNY+Q")OR%(Y#X4
M#B!W098I!['.T)4N0W>PSM"5XG24VJQB*_&"R@@B:MXL39C9&PF4:C[SV.F/
M/EA:^1L!ESXO]9,8=&E66#;HG#GFG/;I,4U'ZLA#!B6E 9'\ _NG$TWGD)J0
MP?9$R(K)[5?0CA,#'<^Z%8J+/(W@6+(!>^8)FQM(VN;A%]K,^0XZU(UZ9(*#
M;4 F,'G0$H&LH@]H0L@!HT]0U?]6W5C,?BZR*,<(5D^U$4NV54]1O$")7O5"
M 4+6AZ_V(@N[T3II?&.GSO&-C%F(K6V1&F;\%^I'V[.KWQ*MQ<S8@[*H-.RE
MDSKNI]*97)%.+KN;M=SQ72$))=@5HR&(^X9%.(P:$L^1C/KG77<C5"*KJKEA
M6RY8,LFW*M4BEGV3594H1WLG!69FV>V#22&H?2,$96Q>)H!#9JP9P5E= *;"
MK=K@_H<G#2O9YVQN"!^I$,WG?.CA"!JM7W<F5%[0LU6BT&:H!<'S8>3\-VIK
MR6R#2!Q6*1X\+02^E6#AU5!T.=,M!P%CT-.1E7?%;6HS?-"5M'&=L4;IWNIF
M@_26S8UZ;LTFU*L03,9)PC2;2I4)/=OKY XK6TJ=H)VH[C+9$9^%L!X!9GVY
MH?H)#=2UK:VSJY-G1G+947\PVW&5]Z2571.<T.8Q%DH?<FSX1[26+--F.<B-
M2%4$G_[Z]IX^X*/QY]U\_+E0K6>CK^5=K;+O)MI%>$HP0HE$A@464:G&6_;U
MI%I '_PSNX]<!G0G2(A+6X(&9HQ!&Y=;P2FI3T@585:ZT/S)W9%^=F@%=Z9I
M=YF@/']\G@9]9Y_)<=1S"9;A2]R5SB";#Q:P^"X%>75[7:9!=D46ECLA)4/)
M= &;B'!$RD5O;G1M%W%FZ74CLS>DAW))JHZ7((A 0X$)ZYE.V,$P<FC9]$BF
MQ_CK4O]6%O&I1V++B#;>S;[U6JT'(P?L;U0MY=[@R N&ME9EB\0YW[I?$^+\
M9S/UV!Z@^X84)W!#M='?*S-8_HGZU9\";%,%%H%<[B*G>JX4SNP;,5NR9PH-
M$R<F"IB85GAXLLD9RD7="DS%_$9!]N>67":=-:E3UF3Y;%"P8/CK__ZTD\^@
M99-V]31I5S#:PH36/<U+&2#C(:JPVGKAI@[V4@QB<^5J!2LG&:*GG04X6##T
M;HBE#'BX@O W*^RVMAJUW4ICY[#2V-M[-IZY;'?OE^7JF&-NRZ#[FXHX&B,/
MZM#_\@#,:?5?"G/"]WOMSU,F5"M.V][S;7N[E9T=V,K=_6GKN,0I3M2 ZXV;
MZ6VP:7N[C4K]Z.!Q-VX!/?*IY\9BMLMVN<H\HT7>NMP;S17C5,E#W2,SWAT/
M<PSG&<5BDGQ8J>WL5';WCV9?_H=:A/7.KW3G#RH[M;W*?N.P+#N_6J-HY7I-
MNU_4_$FY8#^49(^[A!].J'?W0:IKE8.#<1?S6I]]A[O>.("3OU_9*\\MEF\!
MM&!\"R-&RXYQA=:O,+!F/(J=H>K%GNU8/^\>9-- 5%Q .4G\A_B:N#>VQS5/
M(]" 0S,VCM@ [1AKGWA[<^,D#;RJ8/D81 ^-BF.V\.>?&_O;M1'L05KA@%4-
MB/C6M9'(7D=E#FG/)X3];&Y\2,(V)6F;JKY05T\R5[/^/:7(J4J,2S$=@:VG
M6]BU4'C![5,/&9<*7/H?]_=CD+'-C3-8V4)\T#J4.5<H<[7!MX.2!-\D-I Z
MIXR#^]W'Z/R!MK(L<=1YPLT_RHK4CQ[08YH21DZ])S2>?K/VMG<7,&BI.@P'
M0)9%!Y6^[O>:(AK3;/0Z?KF(P;QU4#D\J%=V#L8Y_ZN8XK/UGBVT9WN5@\9>
MI;XWSLE9_9X]=+AY58J%W(4.E^M/TBHKE,>'"3DLT<7>JQP='%6.QDK?:B>T
MW@G]FGJM<G1T #O1>(2=>,08[3*4P6L-6\<W3PIH/$'Y&W<=+5'T#BOUVF%E
M[["^5@*/M@E[E<9!HW)PM/-XQ[^TO437U BEHT8X7%,CE.5TE!>ZRJ%>-,ZG
M./W?5^G^7*-<&2</F3Z3EOV^A#V94HD]HU340-O/6BTAN?NH6[<=Z7(+-\K4
M+V#!1SH=<O,*)Z0JFAB*)"'_FQLN%@(4%5Q,9\.B:JL9OZ1+,U3%1UJ)4-G<
MR-68I.LNU\18I:777*U"QIZP+I(THT256APN^('UT?)STKSRTQ8]K9N=RNJ
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MW#&GSOI5 <8!H!3TJ"+**F8:0&4N9 %PIIBO2D2:4<KHS;)V:XK#!@'V&]N
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MJ#+EQIS=%]GEW>6!YS%5[PN=M%N+2I@ZG]PW4RHK4P+4UM<C4:1-[#WP->F
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M9\?^Q-.=[''GY++[B0V&G_J]/[?\4"4'K-6,$C:4$Z'9A9BRZW#"5<T.U-A
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M,[+0]'A.RV,N5P*_7#0T&VWC(8Q_*GFZB\=E'91K<;"\II3G51SJ2+A)JMD
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M>_?JU=V_V5/576O5?E]ZWP!\D)64D01 00, IG\_@/<3 *:XFXF-)P *  L
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MI[ZX-3325[U.>>.G14C\Y/9"#X2CLMHEE[M*),BC-97+LMCR\J1\D2=K]$S
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M@N"]X;FU>,E6J/Y=?8LMB>I7U;Q5\R6;YF<5\T1LHQ^MU=YZ)'02J]QT8,R
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M3(N?LH.\D/9>.^B>4=455S7V1V2\2=R^W@H1/AB&+.LCG Q.;PFP\+IS20,
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M=7NMY2;S=O2X$S(Y_86?C>RK!I7SQ!)IT@?L$ZG>E-3<D2A>T'3*^F_6IX9
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MP&1GZ-WJ[?V:]\^SW-\M93 [UB)U R;?*51PBC[V#1 $2K6R*APC-!LW)C8
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MMR*G4ZH &PI3;X#J..0/50@<J3,U:D&;9;E9+6-'M] IM5L4BFA$,%&>?N"
MYMA6#9Y,Y=P[E(A6,>U3N"_?B3P$W.Y^^BJ*T>!0-81;D)$^.!9!AJ&S 8*_
MQ>X^I'X!0+$XM0E7X+-6.X>;&^F]K%]$&6C:ROA#UAQ(AJEEMX/#_(A@@NWY
MUW.@GLL2%U.0B%<>^*DU;9\J-IZ6 ]D,G@_N6G/7/KYX)6FB;HD]92-LVNS?
MJOW8K(>O7_I;G(89W'_J@Y*P5,/W@V#2VU^"J.T3O]32WX0O%ETY(@ T:$62
M<_#]W1M@<C@B!)W\%,;->D=IQ1\4J]!2(.O'GS&^[]2\AG801;+OV1K'#TU/
M*MI^ D?:])VL*4[?NCB7.<19Q-/_.6MRV"3W&(*Q_"2JN6\EX4H7;R?9/AN<
M[0/5M<HGVH70 JV$L=WWNY?Z?K^%@F@L#5OOQO_).X%)0KE,/AK<V_0=[1S]
M +T'YMRXNM!-34MC@?=_\>3L_^('M/XD]P88JN=OHGP#(+%"-CZ^ ?IPT-X
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MM=WA7DAT7&#U$E$6?:)JKO]4,%**?V8W/'GG=5L$]GW*9[CV[4SV;C?GJQ2
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M/W2GET/I9^*SN\Z,*!!:Z5/[O!%QZPNF_MB"43>)@.WL]EFC;]Z@PG:2T)U
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MAC\@/Q4X@]G'J%S*B>YX-&J_2I84FUCF_5]>=O[/?R1*WP#U6,_I1V=G%V^
M^_?]C)#5&\#"[,:S4%AV['60?G4M_PUP86MW+>.[3 EJG'U\S??D+&,"#QWQ
MDFT020.)SP((!^3C* JQ)=56R9P^D93!]@,.HF3\XQ6:IQ^J>]!(#HE]F966
M&WE6@:'+"*(:]05 J#,0T;<+8O^[Q#4'6IV]:QEKW4*'J.&.2[U(@Z8[Q(%N
M^=T\U*.,Y<N9[P)SBTQD7'BTCK+6XE199@Y@3?/Z13\<6VGE"4[ 6MW<,!$>
MEML)'J>J;7:\J-H?53_^;(-X0S<$(2=D+A5BK]O56DSF%,) E-J.6QG-$Q"#
M\K!1E \;0\>VJ)K9\(6CM9!:(J[;+3)+@;[Q@X0%ML/*('\>/R_E(4S6.1YW
M9/^2(&.8O9.395.3#"9Q^R<7_#G+L5V='.T,7BN#5:D?EW*BO_"J9;K[%:*F
M/QXB8GNFZ-ITR=C]/JT\I1[5X5K4?*6?QI69(OSCU1C)%K3@$)XJ%+'S-(W(
M0:XLUZ\3L;M;P#R 8F7+8C+$,0;F":T!&CD1H;+R1)Z,6]WY$>5-.JKA'6R5
MTQ939FB%3*9!+3NX!B(1,) $T._QMD?D(I@'_/AUHZ.F3W8.<TM^B#0#^$C[
ML;!A0P>,+T=IE=CFW4:0,!9VFA-,S-YK8LQBD<]@1:4A%[&BAVS^>4---=T@
M3)M)*J:F*M+"H4_&9K$C-*_+%B1RFK[D'U9>E,,Q?7%BO)%3CG5I/5?UEUL5
M;Q## 64'5#[SM>46K2\U*B_9)0:+M0&Z0I0,;^-K,.#C1\!Q^$8!*6ER?>_1
MRG&#C'NF+=^RIN8PP#H\2+,")O.6]4]*[)G@[[F 9C3BZ:NFK4C0,:FW=V$9
MXVY#U8"$N_V2L9=G-NY]'ZU#?H_Y;OB7JNF@[.E??T:5NO]0M0YIHRSX_^;V
M"- T(<=K=&1^3V*N^\C1X;NZ><ZDGV>*6+"@AE2@^F ]4\0,>@394\SD0H?7
M.M8'V%AY:X%$GM.+FF-N)&/#)#K$DS$@*!%)?MSB+2%?Z(T_\T+=21$UM9G,
M85HD?(2E32>IT\;FR_,C<H!R5_6P8.+R&7!I].(@LE7=JE -&RO9\0GIU[[[
M4+S<G#T/+7>ND?^-G+<.BC-H$WV'X 2($'2PH$&##TX([@2"#NXZN#L$=W>W
MX.X#P0=W'UR#NQ,X^7;KWOOMM=HZM7OJ[#GO?]W]=/?OD>Y^NMZJKA&[WY'I
MR0OMQ1 F_7V&6;MQ9VWHT=W32Q=E8@E;UA%NMP8DH<&MX/;\!@I>N+)[SAD5
MV/Q#?Q+FW?@$O(_QC;%9DZRLY&W3](EA17&JSS1LZ#%3S,)R];A+'9A.AZCN
M?X"E4\JO*P^4OM*6! ;9T.+H.(_.>#A_@F>[CJ+6D JB]O.I>!(/7"FMT[#^
M^-+.\L3;IW5VLJ;I>GR5'+<BN-)!]S8-K1"%-++I0HI2&V)L%<WZ:@4&X7.,
M(Y'_W'#\)ZF12 ?HH6^UD.^1[O!9C'/ @\8AU1*8YR-+\=O/%;O,4E/9HN6T
MQ3G*V,02;W.1Z8WNUSY+WQIY]4-$O'I#]SIG6H$DUEI[9J6DR@'!>,A,F']H
M*+ZRK^\M.X/4[.H0_Q/!P$43GBN7 CMDKZWA]TY@-6?;E+BF%@PNJ)'6+TG2
MJD5I+1*"@6 #>[VW23LX:FAN%Q<U1FB]$?2-P[YC?QN&6<!9F/RV>S$T(BSH
M6/5>3I/UFH_JJ2TU?W">T2$Q%>6M[?%.6B<T$&7'[&!FW0@(#0O/=MX>Y+ 5
M/Z!Z%=K;O]79$I79W<QX%:4LE)1VMWON1E@N5U'1XOF6%VVQQ<E#0[1Q0O;"
MA0H3D[]/EFJ3N$FSL@<UJ*D1@GTSQ=.S&Y_O!),&D4R\FJ+QM#9;-2/W4["6
M5]GIL[=NKG#%R^&$2%,7+,W;A;\52Z<,LSN-Y?O\^L.,]]A(B6%8MB:)01@-
M9!WH*P-I;< [A\P'CPXZIKP.1]%J(Y]4[_I8X8'$69;&K /7<XZ[K5<M5%_I
M[_Z#Z%":&6TV8Z?3L:QAO>S"L'2BT.U7F9'M/T]J4+%3IE-?/J-7'NC%2E-^
M8<QKH]'3J%044.U&/OO':V;)'J/9U"A,*A97!1E</$V?@[0)0.&@_7XVCE]4
M'QB5:[UR/*=YTQ"?]S<#_:IINF]-:$_C$#C,RX6(Z?L.NA19*N<_WT(\5ILM
MQ[NTA*<A*D)D1.% >H0D^9$)J7>#X=8(F_PDJ[N!,.@WWC=910H#/YP/:"DY
MHGVO:#Z]8_T2&H;TMQ+U0?\INO-C3ULOJ@"%942 K4KG7$;Z#%SNM),V]1$D
M/[M'[>)U2$I//V_/[5#OK"713KP# <<R6YM:CVW5>_<P)BQ/86J1YEK+X;])
MUN'BQ&Y0;_L:FBA29&(]W(4ZY*D<C)1(FOT%]H@XDUV!8@H6%'Q_^,W)*]%_
M<;SVU[+#\AU%OC;N5AH6&:Z(88M ;PX*]'2B;2]9 X*N?S7I\Y8C?BO@'7^G
M@L4%@6'B=G9O@/2\N:.(&:Z#^&]R:QG!N JN_Z"3]?]68++WRK\:]AH+J"12
M/IA[+5.DIE:9Q54E*IBL76:HMIJGAOW>( PFAD-O^XF@$_ O#X=?_\GE%5(Y
MQ$(O/G;,XGJD=<+3D1!(JI;B2YG7')C8X^)J;BCLQ=H2UDX$F\Y2?EOGV"T=
MELEN;ZP-L[)4A\E1&EIF3[/"<\?(57VS5'Y&=;N8.CRC<:F_  Y4@G^=H7E/
MG#Y'>>;8(+M.K WL6XO#G+VC6L]D/--[HX#0D]'TGI/HZS9OF\<^!_^6$5[.
MW3,FCK%N$\;#:S.\VDCSFX("(++X(K5M9(QHYW@9:E!,+"M6)R_YUP\B6W8C
MM2S++M$(V.][Q':93C;J&NJM.VM_K:*,[<_'+D_G%LHL@Q6@-1O)@76[A2.Z
M%HRBC77:VO*_L6;;T:$-Q@61E2^ ]?Y.RW%-^K[!;)9Y%>.$V$E\$ZKTS.*Q
M(<[0(C!!@RLG[\:A,!%:W@P"#5MD(EMI#-\/Q34<7U3,=HNB<YB:SC#3:M"H
M1N/!PY@;T-+4>\"WMM'I[SY 4 89SKHOQ3ZYM<>-EU^P_24/%^TJL5.^:TB<
MA5+/<XW%L;LY,I.Q@[+E[I;FJJWA;4HJVM!B#F'Z&W&PO.[>I.HDB65PI)=,
M+=58XPT/J'S2^BU3_K0Z$(G?;Q'].PY:7BIJM&1N<IFU\!S+ZJB76_XEZ*V4
M.[.!OY;Q!%X=;$H"/7 TJ!T_;'"SJF05TQ+MUN_;:%$S)TDZT]E#.-#X4ZU3
M?:7QT6?0ER1^7L5[L_%^L2D$$I3+_<5OV_EN48S,E4%.!55O>KXOXF<'Q"C%
MFE+N#1+V6HSD[N!1"BVJB^-QXWSI RB&I.?"_&22T#:W9M0SF2+2)4TK20JK
M^I;9^$A<IF2[YY3F#">_[:*R-((N^P]PEO_N)F<YVPXM?$P2X4T!BH9PQ'60
M[3O$'B.V7Q<)-.;$Q%\6%:5V&/8T M<25\,PS!A&RG#4C^=H,9=GCD<]R6]Y
MVTK+XQ$<9U,8P]#8;&EEM]=SB!';>N@<&Y*!CD_BP(K766V^VZ>0!W9SK]=:
M\$,-QK77*Q_ \ JC*1[HK-8>20^TU[[I$,)%6%#7U&"Y:&>U.;<D1])K<U)
M>G]4R%,RTJ%@[L&ZH\U;ZEFI V?5.[%^>E7"OI!7#BS9K8E<)=CF@U2J%ZI2
MA>-7;2+CH/NDCCEH@K76S'^5UISM*3;VKVH8-UIJQ+%T/J94]%::7'=<1;\7
MJ982SVSXF7>* I:!FX"SD[47!1_D0^M>62U36<E[I*\X%M1=5$*&;M3"JJ16
M<#^9FWSSA&H_>7Q^_XRPDBL]NXVG@_VM6X;?9/=MZ \^F+&<8 4^JD(8];K>
MIY]*V;S[C" "#N?,MMJ>W[+C<PR'IAH=UW-J?\CKDUL3BU;*K4B8U.>X]%P6
MYN-6RF!*QAPH.>,BL4,6CVKZ3,5.O<[5@Q;HF34$O5$9S9(,[:HU[8/DP6^G
M2@_K=YVDP#.73 IUF[NGT3%L4^:S%3;$7WMRR:%YUW<^;PRV0\0[7.D(UO4V
MD2%?L &4B:#/AP3VA- "(F4A;!D&2C#Q<6U[ZDT2O.^TR2^NIK./LM>C#^;6
MEH@ 3C?O>A=9W;]L<AZW<8XG'SL1NA[>?V*48Q7M0$J\GV^I-1\6@QGL7/%Z
MN4W[XN"K?3]QBY8B5(,\2VWW>$.K_3KNYU W)2+7L_S;DCC<[8@XNDP#]/C?
MY*W^MG0CR&\[I&*VZ*!M,S&VMTPH;=#:.'2;OBS)TU#KQ0^G7*-ZH9=:D+13
ME)HH3MP%Z)IE3Q.\ZT>\^N)@'A.M=:^JN*5.TLJQ\Q,K6.LJDSR(XGB1WF5Y
M;L(^\3M'-%M>20(6OC.YVPL Z$Z.EVR.&Z(^J5=3AF1KXF5N.;YC,.%9PGT5
MV 7HRBP8LWMJF(#EU:W2.-S<$V5XS4>@B." *C2?P_*69$(6^5)UO1$*5?BY
ML=\G36G+1#)SEUA+G;>YJRI=3BL7/-51>N2:WV$O?<<=I;1/JV#7C-A9/<6N
M2#7;*:\]/G2!T282%,-B38SR=!)=!^:#'&UQDR5]G0"\U =#-'1Y+G>0SU*%
MIXZ[^%],:JH&.X2(XOAD,W*/P\T<*!/P8%3%1E7(L[@+] 4IAZ.H>#E-H[J6
M0,*C(T2X.>)NG7D$%('FZ3B^((F"89)S.2BP1T]UJ[H"?A1@XAZO=X]BX%,#
M8?4>LO@\.Z^#;A1=GT7J[O)F+\95](C!^9%\,:M@05 X^I]$!*=<W?:7A;*$
M-W#^:13!ON:^1[J?O]2T7:D>I3;VBFV?W5!_R'<WV=1BI1[(!6P3/.)MX1\5
MY?W1=EJ//Z8-SLKLN=\F?<>'L=(QP&5:PO4FQO ('*%;FQ9^[33OK_!?#P-7
M!S69Y-0@-2+ N.143EL:*I;&7,2@-,DJ)Z9LRYY*"*IX;S&8;@_(%,/F!Q22
M$DOX&A\J.+EN"1:/@M?)IWF:J5MCQ*FRIES)C=UT.6I9RXWD@#I2%<@ 6OU&
M$]>6G@@N9L^,EG*CFAY".R.7=S*4G4]HB\",S5M[K@!]3BJL,D]HO?VD\LYJ
MR7I$%WHZ= @M:P7")H";S:R#>FZD3M>GRH*9^%R0_):M"+M&GO;MJS]=!]>S
MIS)G;Z1!A-$K;;,@+)2;^U&$2[[D?%,^\H@C0U0FT)J:O>? YBD^NZ?J>#J\
MM<O_1ZRUU1L'(/(7A_ML]N .'U [9&B>AEUOCNH_*?MQ]<H!EAGO-U?H;&EI
MXI67"=&:?]40S=_,#N_-3^VA'PE"%_\L'?J-KQ U%)#'[P%U13%+UH&PV*'^
M</=1T#Y[)+>"G'ZN1+J*PF^5U \#X=6/$OL5X!_E6TCM+(HT"*BZNA3<!60,
M=959$[J96EKCI,P+BG\;=^@32:7D,>.QJ)9=ACE,J&S!B72.U-@&F:&&AHHY
M"#W;8!!E$T:3Q.AS]7[>HE)&_SH F07M]E)">PZUTB=*Q 1>_C-IO](3ZQS,
M/L790&M[5SG]1;("8<%MKA_6DU7.!I9SVFQ\Q6!:4Z=ZLUF=2JR^&G_>]FE=
MI$23="C:8^72'[M(/7*N5ZUA+BI[O):3K57-MER#A&J5+P'">?8MW+E8RS=W
MYI6?NSZL@] @OH(6;&;SV>[2Z(*IO3_Y#HY5D6G]PZ#*<6W0(RA*;JLV+[$"
M]\I6N>PPI['-A&MRKBF>C2"+^41&FRKR<V3BOIO.7-SJ*/Y*,!?QSK!8:T98
MX^+V1JI3!_ZG[GAMQ\&W$)WT?(Q]M1&1Q#P?PF^?)7$^^:;[&JM$:T0U+3(:
M7JIJ8&:DA&QYC'1/3?2""<H&7.N9/@:L$84ISL<JK=D&ET6!&$BQGX?Z&:&5
M6%;RT!;L$LBC!:]<^F9ZX@X5MI."RQB(:P1(L@5_ZE$MR0R39FY0*D\S+Z/I
M-=J*9XU$ J!Z$9&X"Z_Q"A'PI5IV')K.90,1*ZOJU&+!K$?Z'A5' 994!JK6
M7/4G*<*HV;'?E_YJ>OTTTEC?K]FQ*8[?D'>R68!Z!=E)3JPZT6*H/J(O81W5
MY;G>C=!5T#PZJZ":H?@V1DWGU"C5\4T4;?N'%4/GV^\X(,5B[-N^M\2M)NXC
MUZW3DV M4S:WUS*6W;RHPY9F_=)HYMB&F6:(:2X+H/1O:H"2&GZR@_V,]F22
M,-CBN ^B3*'A9V9B0X0Q\[65!+^& BO:M/K28N@>:GKS>BQ'X(E=K &5<G "
M>VFB]OOJQ._AGS(L<Y70VI6G"Y9WD6!;CM*4J\-.MYHG#:[]R[\^ID(#&Y-1
MT%V.CX*VCX%C/UX U$_Y8E(V>JKU*L[+[]9QUYO.956@10>4C,)-:E0=Y"*R
MOHX=%P58IT:?Q6RRCG]MW;G/]E@/L'OI69HD1CG7KQ;GL9X;?TG,33 D!5/3
M&'N(U8J!OPHB$L-_'DK'95)C4&@MD_Y\J(O,-#A;A#8Z@(W.]_!=;%X#L;($
MY<XYE/B3;>"-@87^"3_)*SP/$7YL-*'9$[0Q"B;5MEK_@4YQ#SNY+:=D]?NN
M+ 9_LMO94Y:&"2'2E5'=)-P<+OV$U:;,VM4<-W0O 6U@\M1UAM16;&*FIE5J
M%)NQU19$D?9*.COO]?!MCS3L-DOF9/.;@@,\O]M%<;N&9GB.K5&])C8YLZ13
M D_8$TT6M4\N-%QG2$SJ"4R9+<LAZ.&V=A3JF-&+_LG2Z8:");R.*AR 305*
MRWP&X!ISZ75Y#B8/%?J#?70G8XS*9IN*O@;++MJ3= ,+:^X!M&M58>;F8)6I
M@1C$0L;F@^,^H*Q EKLW]1Y6D#0J[TK-UGD<?RMM*X_FNA[D=^1HV>"=7 ZG
M^FY/] .8KHQ-\ROLBZ%V3(\6RVK+O-J(E?-I9"WKL0#/*ELP#HZ;%L&?O 15
MN,.E6+/YH,7BBOZOO4J.]N+RCURR5- &@Y#X<:1T^W,JS4\)GF@4<:.2\)Q6
MD\T\9@S'T15F3_@AN*^2SQ91R["^ T=C=75)QY!?KT.&#V Y)84K?O1A25T.
ME69L:$T>Z3<SOAU8=G6/[<%B:>X ,UFT7\+!6=V058*)?E]J@>H#7*F\^!<J
M^_-,YD.+T@6-)7ZEC<;'Z@.Z0;(;/-VT\F7W5EN]M"9DDC</H_,_%+RQ3?^4
M\%W;%V[+NN\YQ?[)S88N>EMD57H27A%[.SAMX*P%I+X +.3_:)6XX9"VK!CY
MF)F><NFF%9=EHWBADF6LN(K>KN_Z+,7_4J/7$855NFB0+1$^CB;OEASL=64+
MP_9 .N\$[GBR;PI.9X>28UD/,^<D;H*\+XWO2]U;SDPG[.[_]Z+PH+P_V+4+
MN%'XOJ!/'R]AQJW))MX&9B#\H*2(649K8OIA<1'<0HXN2_<IS1>QMP@!0-R\
M\7#L%%X]!%]=WI5;@2HUC/FK,[GSI+UQ H[82E"*!(WN\N-=!(K%'LQV/0[3
M,5G7H*RZU <-X_;NG,</G)'><IQ<Q @C0WXEC^GM+W=-*U7/SS"@SR&+M9>6
MMO;R1R"%#@B<8:,X$!Q)&G+9(DPJ^G6ZT]*%Z=;R8VU%Q6U51IL434?]KMK*
M9SXF7C=N3+%OF+F=;)Z!D0.K;/2[1LEX7;-[B&]?7^.<M3B?+L7)XM2[O*]+
MF8_AQ["I2RRN1:-Y-C%77_F/3!C^KT(#STVQ;P1-,N TS> (X8&"]?H90.;K
MNC=B<_Q9'Y(ZI>8;=*7!T-I\R=&'+'_*$#1:_P+ 6,DJLGK3,>-Y>BZCN/H;
M49EJ.7'G,1QCIU&;1"Z[FN:;OY_+A\U@LRBQ!7E-R<C%JT!GNGA59M$X9()X
MYIV6H5>=P/0"Q)5UA+3$M$WO\+9-9DMJ8M7*GC_XK@MKT\L-3;6"K_46TGC%
MTQV@M_/Y6!0_ '7.(%&+WQQ<U!6M4'QEXXK5N<:EF;M\RLP3-I41FG5%?Z19
MDBR53S9UUQDD_IIS-W)/M6":KPVD)T3U^<(.VO.R%J.&.^9S^@F2F*U?]V\5
M:3Y&;<#"ADHBIX2($["ISMJ02ZH:\)0NP.E,&G:66+VJIY']Q$;.SOTR#/D?
MD3L56+ 3T\<=DZAX<WO3 1-:PB.;*.E-==8EG;6;\DGK GD'^Y>I%"T_1-'>
MLT9^3(=76)HP 3](GCCUU/90[([KNN@439F4K$CM'4W8'^UL1AM^R\S+ZB:D
MJ*^F=7$\SAMV"NAMIXPU2,!XQ?I[_,U.H__0%JN>;<JR8Z,VL)*9T'$X1&XX
MMRV(8'FA$"(JR,LZZE"*%IM0"'G/KBEPN5:'ZX:G]$A#R^F_9+;M;X-G(\R^
M>DDEOE@>PYY/,JH)'C(GK:[2;58IVE2'EY:3(F9J4*3(2],1IW=_.>@SH'EG
MD&>M=IA9FTR:HWSB/;B,\'9@-W]PO<$YVRFSPX;$XFZO6WINY#GR*JH79C\Q
M#?3SM&=!?85&Y5MU1^QM*K-W?$&(*?Y5_4F7"==ZZXTMVTK#61K.J:P37-K7
M EDMWDNR2[UH*C/ 2=AV2<J$&K5A?[^I$=]P\U.1?T,6Z\.!>&]L7=$N>?CW
M:0#WK>OY,"JPUG5DU2GYP6(+[3>O9/]U0]],/$]?;%^[PX<31U:>P$K7MVQ<
M1Y7[1<,O /1R!^X1RIIYU<5OGX*4#%KJ@[B)1.,DU8>#$!B#Q/F<X]Z+G_,/
M3S=9LZA:-!C04XS,27\-V2$@W/D2*.J,>)V;2I7599(++LC?K!;S%75,)FWK
M4H3\]%%5IF_N*N$XR9E:.&(&TEHS/6,],[D>3"[RN./%QC(CMCH SLGW7.2-
M],=.,E10,5G_6B"O9="8T3ALGITL4M,7'8_5<=R\ACR-!9^, "%S[')Y59Q3
MYT12W\Q85Q]^Y'"=$O[**?78K.LUTWZ%<%M8?[\UQF;_1IWQ5E;F92_Q]S1_
MRX0^E"?95\I7S\SK+P!3KOJI!P49BY0&% 42@\.(R/@MJUM642U"S,ZDX):V
MSN^JB87.Y>_F*1'3ARTP@36J+BZL,'-[8L,@B:!X1B/$YGG%-(<IZ-!E^P0T
M;W(CFBW21<W:-6U6&\[;&%IO12_7[S\'_XR*JE*S8MG @['YK:;)8UGKM9(,
M]!#GBSMD.98#S_E<K"/-H+FN^RCJ*Q#]6A5E]#2QN B_<3L(J\HRZ@703JD'
MP-'1,<YW&V6J.F]>O.".P%8]_6SS.H(EW+R)^-8*.ZZ"9%BR<K2^@FO2K32C
MUG[M#;!2?!8RQ_?1_8<6O?+,,&0]+#EGY8@S84=SBK92L1$M-6 !4:U_K+(?
M 7GV&Y=DSO(3K@K2F 9*[B%)CU5#?0I80-C/A)10BRGC,]./F"93R3EO-E_I
M,UU:)BVI/<5(DDXF9;^.AW&F2G<Y$0]#F95#MR:(J4/$Y%5[GSN?6G,/,E<(
MUSOM<!R>XF)+>JS*.I49A9Q1*7$*&&]_BTJJ/ONW?-X&;=.C]YS2L89$]=;H
M8'FQBW%@OQ\O9L31MHR_]JODS>R;P+TSHKIP H9,D(>YF\4((J7'1A*H)@J$
MTYH^:H=JZ+?047(M5CVTZ4@CS=]>.-O>4\>)%0?B'"M_6YT4C)(YL4M$9*]H
M/\.HLY%&N,+7F@-O6@/M,#6^X\EW;+@F:Z?K^>"BYVGR5/![Y4SW7-JVCV2!
MC/ 7'2_($_])*8-5PAFUWV9(/G(-^07PH1CSVXK?>?I%?+Y+ET_?_Z">;ZX\
M,D^X?V=_Q#0O^''+X>!URRGGC'$17XT\)>X'3#E)+%RO_];FDEF-<?F](NU/
MMB:J_@!\ZU8S+J[^@-^,!S+<]0+0MZL>TN.5D;C&2!@H4Q%6W"S=(P\KB\'P
M3>AC"WQ0F*'TTSR1$\,GJ&2&V!%)<PT"*?4_+GYU?KO+C<<[6E1<4'19:/8[
M)-=V*JL^0W8JZ8ZLSE)]<\ "H&D<V\G71\PP<&8YK:P'F.#(/$Y ==:X0?=\
M^,^YBC,J[,9KFLDE3*5,NZZ^2DN026W"[7HMJFUV@0$5%R!DNRI(;SZK;9+[
MX/%C8P+GUF,C#3['$ 0EV=2.8H.%MRA'-#3$N<"G3AAT8L>MK..*Q-M\;#G;
M4+JT&TI'GHCG^*4FD^==EGEKSH=3@6^3[_F*ES&9&1>F0"ZAG%5,7/:,(MAJ
M/"CK)"3;.:A_S8JAXK/K#=C:7 NX=E S.FB:Z?Y"*%CJ$*ZCV\1DJ7TIW7;A
M612PL% 7WSPZ)[66.#UB5^&\M4<RS_>3%" X45R==9@1\ 0<V+@3VA"OV%[K
MRM(I79&.9OXI5%'A-BB$6"MU,W3M N0=@LX^N/W(TKWU?/3ZU<_L->^&=K/K
MO1[B>Y.O>F)W^@+87"59/AHK$Y#)7[7D5.ZU ?#\DM&8G-DN8<7W^&Y+F19>
ML^6BH022S]*WT5O04KZ;N05O$TN$G%(C>4"1G!.UO$GWGIF>'5EXRZ^9K$7=
M"ZK?B;0EU2,%#-$;,,/'OPH$SMC5E?\L?@',IRH"%?YB?**[S X<.AD\(K]H
M&?AR>QO;UOX,_%I.[ $5:=E<)9QL5W%/K-.;58+,Y7BQ6HMG#?O@#P\/JXS#
M732L5];*CI<KS#?Q/VP7CSEC')XT#0@UL3]'/WU2:?N%^M<*RUT'93.9HUB\
MV2W$"<-@;.VB8@?(["S4_)"\<RZ2!^\0&?A\^K>MGBQBNW*&5-4-F?3Y#,?G
MM-'KNZO/'Q!O6VFV4C( N\0)]070IDFV(:J6LQ6L$71L N""MC6"F*J:I)#5
M2 ^)_9[XVJ)[GI4/_GHRWT>"QU1%OM#N<5199/%!:2#VF#30V8:$=ZQ_<U?O
MIV1NQ8^3GT<D>YGA?CN6,<QGIP#L/5+$NH-?J X;D6,"RJV)W#98\@<>A#)"
MK[(A7J8\9^+%-<;VJ,NOO@A>;$,K+E [D=H& $BNMUR)BKQ?!4[VPGU=S\9%
M9B5*+#V2#TQM .++A85?<CX\10TIY2]2.[H 'X8:_JQFZ+ORWQWZ6RY6/D\?
MI56N'F;X/SJ\ /Z4?+_PMG<ON6;:>1@5?I ?[ZQ\0^P^9)_)1W8 CTYJ#698
M]@LYP]JE$/+E2E27> & 7.KRW<N<Z%S:9[&$7@!TQNO)-HW/M4$_S!><PZ)O
M/>$21MZLSG_# @@/?:ZW>):#E58I52WY/4R-=S$+PA^&O,?Z'EI]T+(./0,\
M[(3F(G4'FZ]5#E0>%84T->ZH'FT.Z1[Y\ _VGR@\*BZPCGM? )J</C1;LVHE
M:L=?_IB;KL<?_RHO/CK2+2L^"_WK<5 3SA^SV:?T:!6=0MT&Q.O";'^%OSS9
M=37>E=G=M*UKY*O+"M?Y:A<0@;^AY#WS9B[)&_V_)$?Y?(OJ-H_;;T=-ZX0C
MYIDX,]4)9F=K-R,:+:?>#X:JPF7B8QDTYU]>89C_%/F)\MOWG!BZ?U*Z(MN1
MT8"7.G"!3^., A>BMM@=V_1(R1A8@$'Y)_ :.MOB,\$.Q/:''TF97>2"\12O
MC'B=U:7GQ=&6UO=XN@JP[=&(R\PQ"=C"C::X./.=WQT!*4;#\<R*5LK$(^/I
MF>!<PA2)'(IB% C22KX @"WF [NIJ7ET0U1_/_=&;6"DD5U-;KDAT:>YAAS
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M8V/753 I=>Q]\9.$<S(I3^3]W)/)S?2X0.;^&K-/FQ69I-VF!EF:S]^^_ [
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MK'UJ[[.GSN1;:/="H^<"W#Y%.Z38OCQ6QZH)-0?0G W:'JNBYIJ:0_31WEO
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MX]1\'P:/UI(_]JJ]+/.62=+LB\%)=]T66,I7D/:K0ZGXZFG.;=J6&&V[<QX
M#):T:6J/!1XSR_TU]0VA3E(,9BQQ 4Z!QFKAATW#YKTA<]R[OP4JO@Q;6_>$
MQB_^3+YR,;#&/?IB;:/8/'O!JFB%'">W;I?G9\0O&'^MP\8>USN/&+#WMG6W
M>3\<31:R($R/0QDPD8 _436&Q/M*I6EF2RW!H^Y5:%-KW(@%V,1IR(CS6\B$
M_:>!18N(CG;[YLI3&"S375*P_$)_:)K@D33:$-88.4T*.:QC$NB8&0V@-3$O
M@%6>C[&7K[.Y"J1JG(C)+E]8*S3')$4R$NH5"WXDSQ%#U3[Y0U22,'(]]S4U
M?+LGUM!)^YW-,E]KR*@)N:4H,;ZX"7<^63,*3VEY;<WDA!EU#2R]R@18F/$6
M(WPU7 Q!0@NJL$2T"#5--F5Z*"S.ALY--\3,>+2VV>0V9I2#!""]RS.\35)M
M92ZP#&C^Z'X#YM>K4BMNN_+W5*0_A1.2+8A4V)=4WA4S#4?*GKU<\!JP7/Z<
M[JQD"YN]Y3OCJ%V8P^?1UG9C)=7:IWL)JYI  RCV4JQ\+=,Z-@SH6/0FO=UH
MK&SL1\B#,3#8.X1S@4.&2_5("R:Q*7X-71Z!)7,GQQ.E)R+W11IF6W0J2\W]
M-A$_RO5D/C<;-V^+E--7)_R*B67*8S>BPLV/2.Y &48C'TQ"0YX@;[4ZYDVN
MN6O97./9&:.@_5 POL!HKVR@D">0G@)2?I0LJIP;'6OM&(V9O'C7UVW <"VM
MO6<).4+)>KR,JVCHV\[!N[4Z6"\G/AB]0_"&C+1]LW[2R))[:JA25IT:KU*T
MP?I&F7&>)^QC;.S-DU7S5?:\R(^JG,'9"&M<H/$09\$UU>J#* 7^.G*C<XR
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M^*IU>VA(:&M2.L*5VCC<K432YH-8:MEG:N2XCG9QO\B>,_P?),N:Y:?@^N%
MJAXV.NQO+AU8F$LV4K_WKO#E?C'+3381-3FL1KAATF>7?21A@9@NZTCH;" @
M"3$&N]?T>5MDTPBYJ6AS[+, ?MTKE)&^&2_Z*?*?=\T'%3)&S6LWW#R7OR8I
M(T=N:[R8?-^JQK=]TUORUNST9A\5-G#1S/NXXN!%ZM%OA2UM_K#02B@:SCBX
M6LEJ)U*Z+I*T.;.K[B&.N?NJH[ L\-<?B/U(ZKKJ36=:^3W2SN9!*_Y^Y/^G
M78 ?C$0T'OW!CI>&K_[T"?*6MI:"?TB)8ZH^57J1KOU5%>"[O]#&8Q^@<[.K
M>OPZRSL[U>97HWG"U/T3GHG!A8DD;/CVLD*,NR:I;^HC!OK&)74^/8% ^?27
M01:F>+HIB>^.O YN2C!-K-,;]^ Q,\[$FSI=^;"$=S29WO?3D&-2K?'/=-A>
MC$-UT2:/CMU"OGB<.IYD/ZH&JS<0[ 3=0W:DG2/^R^.>P>_4[J=T5#-*+X]3
M NL(_XG_J3&1-O.Y]^1+=F[IJ<,BAU4V0],N6#1YHUC,YE]+,..A?4.*_1S1
M7.HI) _?0Z%7ZATHW_@^?/N"!D!2WDQRIB>XA$1VDDNA#:YX?G:DRS\).!?T
MD.(.R!_ARL)\B>844SG;NLX:-7M;N\.-LCW,2[,<C<IA+K4\*SSVRJ4])693
MU> 3$;YW[S/ +'%7V>7N<II*RLG)H]V1O<]S;TB).[8VFQ*:]O%/P&ZZ]+DF
ME6/=@MGMM+Y/B\NKB;3-XV= 2$8X[$);T.K@L M;QL#]7R=W;]I7#UT4-3YZ
M'&#G\MW[;ECD H5F%1<]&G]W31)GN% -*-4CCJH?#EC;#!I_[(V*K-XD_QLI
M ]K\'T"J)SSW+&T"815ST*P[SJBZIP\>'%,CIL>%I148PM3NN\H/<?<1K4-L
MHSF'EX=%(N'_/Y/_=S&)][X%W9,\C6!ZUI=H-D+[8E8@.N  %APU9KO1N6N!
M@VJ0QRL+?GI-J#B[ZT<98@K"2063]&Q-)!*U4<"+!$SE/JSWV[^KC>URS2)^
M=KF,AA)+R AE"2_%;W$AYG-:K2)?./2AIT=Q@_;9[->Y3<R2J[EP^^4_$18"
ML49'-.[ 2.5^_RM^NT=,COS[U8$1OI\/X/$+J[7J/]?W<@[8[53%/XL57]P@
M7WZ,9VP7!?@4X.7SO5K#GNY4*P0\O+A+DHM;H_(357VCDO:/!Z;_U#2@1]7O
ME1LRP>N&?R,9AAK6/665/P..:29AD+ :TZ?#(K@P?_B/+<52*=8RA,@^VL)F
M=8XJ'Z=&:2MR6MX+OKB7R$U=O#:EQTM:H\3;%3N8#J;G,DRS,1A?C/*5.$OK
MJH9AAF4NN>?-7[M-3%:L8EYOT@EWYLC2$68M:%Q W&?K:9[&K)HD)RF1$N&6
MM6AE6^:+OW67 CQ&E,TCNE3F3:Q8B\:HRS"B?>(".N^-0T("(<D)YL?N>%%?
M<F+R6>5B0XE^;1;TZ\\GR),=MYMX(+>R2EW(\^^CZ]+%SJWTK@P0=E?];G5G
M,X9]OZNUYX1/X3. [.NXG)6^G=1M.9HJ\[EB1T^3H0X9*F[C*6[G9=C67K^V
M+$X8]XP9CD=2R;9^5XR>BQ^I<:"-/N5V6<*]  ^CGH@R?53[<FG:@T=.P(_&
M[:[X;M'8!9_K8?;^K"T;:3L\O$>[QR3/-P[H@NW,7WNN_G7SQM<QIGT@/7 +
M/A$B7[Y,V^WW^5;,4+]=YEWOBJHT<FVHE7"_2V"Q;4#>0BV* $V7O>6=4\A;
MMQ#)U46KRKOXJXFD9I)H0$F'1O!VT><J]7'_K2VTQF""KR!P:B\6G;:!CKR[
M%6A7$G4OIJI/HV6. A 6"XI[L"*?F(31,2776[E;N%.*/.U)NSK,R;[>IY(%
M(C!BW?H1M[3UM*\2?9H[I(_THI<.JRYE\T'P5P[$E'H$.Z1,MM780BA5BY(S
MV]OPGP/3,AF,]5V5]=+0QM"H'^C2C%!E/+*&?6+<JJEDFN^8AT5.]C!/7EHK
M,,F (X74?#_6E7S@WF(SZPW8VY0FYF#3:<7S]0GI\2U%XRWIR#P=IB#=BML5
MLF=NE>=Q<T)=X9&-8DLLPB5P.4']PPE9ZP!CQ>FOZ)23#X0/Y.*N'\NI>GXL
M)W6N<QI9S[Z85CI2D?Z*):Q"@Q:5GHCSOK6K*R&(TM6>LE<G5&R3,VU?/,3R
M) <#)%$O:F_<'.+==686T]";>KP/RO%*I)C.DI@-+N(=6'8'YP'LCA:&6\:7
M@N9/JA)LL&KFN4IGS&J371K@1RG*^+_8KCS=AHHF++BW3#%*C5O\%[Y> .=>
M?%L;S-N32?ZJ_5F??8R_/M8^,F9EC-/RQ@G/(/B]923'_.*.?>TG]ZX42>&6
MK*\5GCYD^J9DP%F>W;R^ZJ%"(XYZ >DW9/@;2+"5%7K7FD;-[]@Q?\P+N+?Y
M>.(_YU]8%Y<83I86A+AMJS/-/>H\ ZSF"[9):O%'"EIDD]C#+9>)2C".2JOL
MICUD(SUDNP402K'P2J]Z2XQCCA,I9A855 YV9;F!9;[ZE(\ _<%FGRQ)\C.3
MDW/,,&;F;S[K7C^=57KIO-I_P,.++.U;'5<*:6I=? S7[!#G;'(S$ F3H@$:
M.9:-1_;/M;.!N'RD92W0]EF[$-8%,G'98//?8;SJE<[MAW\\T-Y(!QN\G^'5
MN).\"SSO[OAEH^.!1.-6FD'ZPI,)\_/*2XBD.G1.#K%\4+M_:-,W9&SPFU4\
MST9>I_-X;2Y]'?;UQS5!!^M7BB]=*+W1U0S70$]ZZ92ZF9,0247-U/[^V8II
M6V_3_/D<$)!$5I5^;?4(%9M8O9]IW"2>::#(@1=I M/=GF!2VV!1EDB*; (C
M^H]CRL<>EA%/&8HYF5G4O@6?WS3^&H^?ZKUP]1$&'#:,Y1AEGF;>Z*ETRC)=
M==]")N&3X$#;;56S6_)P^QJ( 4S3@4?PD5L^'GZ46SNIJS"\)%X?EN\1Z99$
MZFZ"+NA@PG+7&]9_*_4)F-;W:S!$MCO+!D0N'>.E1L*C)=GDR$SVUOFJK)0*
M8W*F/;1JA!VU ;I%%U$0VJI(SM[ G&;#5N@:*G7!%1&Z/AQQ-D*@:->EK7O3
MN79SA?/*3">/7S<^829US%Z3A3V&.X+-3.P-S+G<0P<.FL<]UJN16S7^7BZ'
M0R4!S^)."3/0KVE;0"1(?J3<QTZ\LMY+C>Y;KZ &N0LVN6?\?MO''F7CFF6B
M+\>G9]<_/[;._ST5#58G*>+E\F0\NGYN4L[ZTC']&CY9E>4\!J1OV)/?!'=<
ME_LL9^N+GW_\X1VE-F-7NT5M.QDG6QX" HUI@OA1U>^61*I5K7Y&2"F\[N1$
ML-#EX'-^.!1_^^F<CAT-]1W2#Q,+7#NJX,91;X+UR+J$MSK7LJ .EO.EVB6.
MR.*0>&ZV7\K-T'EHQ/JP!= J@%]@5:]:EOSM4(@  VV=2T?<U\DUP!3)7G!I
M#U*W?ICBC_RE]X<?I[!8AFEZBM^PO_^2DB/J4'(T[M2H:)V@@F='=QRG)0.H
M!Y1\14$_^T(BW&N@9PHD POA(&1\ 2+H_JO4+UH/?IA57=TL_2@[/OG0$$[E
MH\O=<!-37__8\_HWY!DPB_O4JW2O5W'2A'M="XDGEE@-8//RM16B:+O\Z5L5
M^S1',6<L<C4ZZ:QPHW+==S75@7@&:$G?DX@>.RY#:$]!Q_3_%RVFKS6/2E?B
MVF9Y$DJJ^R?MIQ>XS X3^%3CB</U\\_49-6Z<W[<[/:_B7:><4I_!1QUGF:(
MZR2Q'S)V7'A0NP%-XRQI#7>.HY.B,]\HT-K:U,TS'?X<VOJSHH,QB[5AR9;E
MYB*^)+Y_P_IR,F[>D]KG5F3H&0!']1_K>?G.0HHC>=B% XC"]@>)]0TLTS)1
M8VFN\1VKH_:E[<$.]FO[[A.:.5&U"IE 23,?SS/5@ 4LRFW>[-5,Q9%:DF+]
MQ6= :IR_5+_H30 V4.R.N].'Q80O*FPYU@E3%I WKA%?>-M?8KTWUCA5>8$/
M/^H>8OM??HC!?UYA=&9T=8- %[N7A^GO':&JQ:5K%[&^"D/I*,X+T5IT?=,E
M'3]>4,G-.6XR\ST=V?_EDD0!8$VP8^:NW?1&U_?;:QLH*]2D>*LPK%>Z'I)I
M8CQ^4K7P(FPC/O!S>P)B 2'#^+O1'775.$R+=FQTR7Y1Z$">WGB>]S@"V<3&
M9L$V&Z(JE]!6-#RJ:]UXU:17T]40'LYENZ+/R"EBI_;%+)GF/;72I(@IL4,-
MKL/A6_I :BN4TOFG*/<HKUC46NF&#H2GGXF]$=1AD0AH0<#Q6][5VX;S 6*5
MRP+V<P1]C3$.R0I%Y9YV)R@&Z\B'H-58[F99)"\P@?;POMX5?HM\<JF">\J7
MY$,5A^W9\!3J4B/-M7+Z>@=L1GZ@I37+%4J:X;\CK'S[<__MDN[OG2MD2KF-
MJ^7;4@N=X/?.9F,@2.J(Z=^'Q297,"KKI$'IG?ZI6Y0-<Z8)1=P/?+YZY^A7
MR@'7@E!/OVVR*%OC10^!7\SJAU7@^=%=Y^^MNMRNX65QED'J^IX< >D?SJ.Y
M9".X[K6&E8_0PTF&C+Y;&;EQCG>^EW3+A>X7D:AIL&DJ6'6%#:%;'1W;;]J6
M+SURM<,R>T.ZR[U,/2=U;^HBLD)5?\7T.Q*QQ/U>&ONVJZ\K91PR<_TK:9G$
MSW?^VL[!@K-V+EF:QGU!/\#";"(/ODB$9M<U?C>G2DUTU^Y,,7WLS 34-9 #
MO7VU)Y763W2H^5T_=^?=UWVZ4C!:H'*)L="2P\*4-U4<L;(W$%5.-ZC.X8\D
MU#/?U.X;317\'HJY4G )&?_5 JSWLTWW_0;,X]NO.D/ $3-QRF41I]CO)A6#
MB>Q??.4OA6MH[HK%Z81#<J35EG><&R]U9\0&R-P0,@L0:QQ-DE"72!K4H$KY
M+\81=G H2,W<WEB+_]LM<ED-M!Y0&DR\N!IT*QZ=JM+C8F2?R5DK%9S-XI?
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M]<V40_"AA#I -?QD]@VJO>,=\+4V:]O$'UB7!NRT+ ^#"RLK3:7&D/J@H)3
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M#5A$A+_X3S'[MY)I[/[WXW36SP;IU$R#^F F=IK*HB6GF]3K5YU/'%<T],!
MK2J:ALC>";5"UH=Y*\@BZRD6((1O.Y!@\@W5*A4]L]/+^N<W+:V5998!TM\T
M!T8;5I=*R'ZUQ)!U?A8$VHX;*-+Y!*0W7XE! -)^46#^A[UWP"D1+4H\^SO
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MM*X(404NUEP$N:23SJ36HR]"[X.N2QY[M;L<55^" ^3;.3/D)]%VGV.;=OA
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MIA!!B\_)2$E_&_MZ& #$KXT"Z^P."X&+ KC$!VUX3U<PX$.=O0-VKT,N-@B
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MO)C_>R*LW,>W'<VQB<FYTA-XT[59%?4#>!"F.!W=N5[YK5NHG+040KX\1EH
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MO <>6\%S++-78U9B^Z*GH=ZWZ/![5>ZM\UNCC%<\S@NI1\><%WRV_?L8['>
MU^2*VELMJ][,[NOLC/_ZK"OLC;5@CP9<\JUQ_)].K=9/*=X!).SO@.LDF'=
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M?AOT=SGH^O[4TP1:G.M/2XXPB ^6ECLW.H(AN(]W:$8""70;5=8L<FHAS.D
MZ OPZD00# 3N6\VM(C0+$%.O:7I-3;UH5/M5I;PUTD]"VO)D>2U9:JX^Q)D>
MUK%O1Z[&++<H[Q*3*?J2&5!>@X@Y:-,8,%?4!\(OQR@TE\4.#)UL#9$/]$3V
M^,YG5W]5R/,CLW3V46)NC,@F/@F"GM-2TM@B.*;/4E*GN^\BUO9;V+)//&G'
MB%#'K16+5 ))#3@PJ1E<M@;(D?05G12=U6 TF:<_AZ'1\>G@#R@+J5 W X%
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MN+C(KI79:>$J9:E3HJC:AU+Q-'>0](BS_^2XUWN7=\T;I"JEG:,G2YX7EGL
M)Y&-]/:S\QOH:*7?<;=JCQ,!YS65;R-VM[Z"-S9L/RFC26QY*<R05_'S[.T(
MP;">Q;,7__<[^K)'3CK<(L)1ZLW?KK=UA1-AX(:LNJVX<1-N_EZ=)H(62\V<
M[0C=90FK2OT[%3RK4\NX84N)FF4&S/I?^91&>%_VZ-[@);ANC=444$QWG:=,
M5Z<_QH$6[E#5D2P%_0NWWRY-?>9$66#AN\J_,1X"NUR,*AG> :K<ZU-U/M!5
M231$/7UR/AZH/O<KIP,^QZ3LKP)ZJ[K?"-_*J@7S#-[@AV6&RL@*49G"45KF
MEMPB1(NW*S#@'$4FJEP#0U268D[(PMSO':YIN42+8ZP/(4-_FR??^&;K']S#
M^D::9"(<\@G4S8WW[N/L+Z1Y$ HY6)2Y633D$SI6W^.[>%N)':CM,S&B[L",
M6T,'M1DUE=5,V._ACZETON)/N@WILR._*I5>(._\^&Q3QX7<!\M5R^>T@MM]
ME+)?0CA!5N!]-=/D<!]6P7#($F$ F>W>T0+]@A6'*;^JHK]/E%83)X)!%_7!
M9 J/9HF,RN4RUC%M,/_KE!A. $Z+ B?=+$T^$W:N\8\/$ ?WCK_=)7MBC!U-
M%[/ #0.%=I_2F?CX!C4EXPR0H0EMPIHOTR(FFB^Q5Z58R-.V&+$:U^F8;W*V
M+YUS#* 9KO"WG+S0L@MH#;UP<_2PF/I]1*KJF"0(T+A)&9"(AT$'I[^I1Y._
M&:%T$T-"Q=^U,VXDG#;]6!::K\M;7W2P]XRXFCB-=51F](QD=!B=5NUS<*'5
MO3]#WIG+3[HQ%/K%PY.$8@YKHNJ?2N@6F!O5XTE<*X8/?]:G*8;@#)&30)JC
M88?B8O' '<U%%/*B0.5[+^08;?_LZ\758-]D?48,.&X)M,05?JGBLB\R2U&I
M"WWQ\43TN^_ TY04((7!%:H\?-$=_15V!8^F0F&5]F9?9M[@8) 5XP>^H**+
M3\X6&D)=5"1!RFYB+6;ST_7#H(I"ND<9?4;"N-"C)KLTHM]J]FK!Z^5MR33W
M." O)ES*Z=S&QG-P$&:0.[-R<#AW.Z5?HGV>QRE^NM.J=JHD;^G>AX3)=WIL
M0U\(8CF$GY+;,6^8*Y:@@)958#7!#*16WHCM%P2<W2!"K:&@W@Q=Q/FG6)70
MU:A&-#<'>+.Q[!E-G8(B7\SHA0D7=!B:IP8]@:3-75W?F&4D#%P:FMR$=;+"
M3AAY^':O[3=  QT92[MIK+&BGVC(O^TF*J0,<!I',(G Z6:4]'WWS9+.YG_[
M-)Y.MO%G:NBR[MEJZV"W-7O1TC;'/Q^TQEQ(?#'=-AFC7QL;@8VP"[&RL7D8
M8K6P\L$>DXHYI4G]MG"=6>X)9UQ $1^6H-&*&FL\SY3;*ZQF^0DKM-9I"R Y
MM5(N3*.?G"S'?]X7GX3/LJ%3*2*C/=%H<R-+?L+I!,N1UIZ77T4:M&;KHH:,
M^7#.'\[B(.]\#*<-18:ENAM9^0[8='9>;+;D+Y"/^&/*+7$<9+(Q)[%1A&7X
MOW]0N=P'V;^V&;BWL<&OH>QI3'\$J/"80#"C(T4'(Y8.V\?Y<U7&[]AL!=9\
MUG4[VX-UYK7'=4Z &#*2W%5^>&.^K*(!/7'<:>RD?NE>.*5?V=A:O?X">D$]
M_W[3N'><'AQ[IH\[+EW%-0[X:3 S'QT49YH<RD5S&BT4'K2#HMP./0! 90(X
MH(Y:<!EU']#E#:\,(;JBU8JSB+IP'/?;?N0MRE]6=$72"71<8[R<NF=1'^+O
MZ0RH%F"UL)ZO^<GVT9[YA-A-?$%'8>\ZW8S>>*TQ+<%^%-6I(=4YLCU0 1A,
M36&B(B(IT@WWJ3P&"#*D(F<6XHH"G.U;<&GTJ*_;055L8R?9?]+_L2HSPRI<
MY"A37[(HE>ERY-XR^"1/:V?L4I"_A1<*4]%!DC"5@CN$%.[17V]-#VVSU%G3
MONR4Q&(Z$)*<&,^Z)QYKB,A^@I?CB9_6-Y3QK%L(7/5DZ9!1P$3HSS!WYKII
M2YFX1W G_['^B<O0/R]:G.+V=S>+XF3TY^UI:]=]EU,&NH>&H6_AZB\N_3-P
MZL91KDMSM6+S-[8QOD.*4(U*\57Q49SM6_T,B^7E.^E619$A WEF2V\PI6>$
MI:DTA5,8B?XDOYV=T_/U9:"*>D3N>;.YYV8"_P_VWC*VDJ99$SRVNXUM9F9F
M9FHS,S/#,3-CFZ'-S$S'S-AF9F9F9KOMMJ??[][1O1III!W-W=7N:NI'J:I2
M]40\&1F9&16IR@V4'D37+*:Q(4Z/E,T)[[B].3>I$4ZII\ +AA9=@_V0.*/V
MMM:?ONM=B]FMA2T0OP2C#GE[N]=.MK,('/"[+/"6^OY,_/@9"H=!?Z((Q^NF
M^;AD_3(9)_]-5;-JDU.)732/*#W<D"D,;%KK1:V7UE+/F4V)8S%IRS]ZNGUN
M5SWX93)DDK>_GDH#V=$[EG5BW9+AP'<\D+A@;:VX,+G_UB?@0F#L8COSRF%+
MEE[?BI_LS+-'D[8OOV8G*5FT# VA;>$G'5([,3)10)IH  #\KP_CG0K"M1("
MHWZ;[V%PXBIROAOO-*;B</R0$E%9T2O<.\8[ZL8:8<AY#_P2"N>M*/=5;YQ@
M<K9QT6/A6"23#3G!:6_IL,/#0K(V5<^+WA>M8)L;/7(U*6(QF(K%96=R 1Q9
M/R)F,3/ '2K$<&<;>B)^/8HBLZV 9:#7E36;[GMR?%)*2$&'VX6JDF-_U-VZ
MC.=#5";0GE&,-1MH]T4Y8XYSB4%#Q0@7]G?K,65FJ"75X6;^O/DIC_F@6FJ!
MQIP49ST]V+LW.QH;H5!L+@L33:0Q/SDJ$K.02$>.TLW/8)61%=O+=++IF#MF
M4%M6:CU/!-[VD!-3$/X*L=?X4"R[,$QK:U=\'(<X\Q7'TD+,G9]<];L![1/&
MVU>O7>ZK(^DF2U-0B6W6.58;08E7);EN2)C2&C6>LL>OJW3Q9G^<ER#P+YSN
M>650DB6,*#$,$@'OW!-&Q;D*]9)V9 $"V-BT6YL%>7'/O!X$_B9Q%1<:FK%D
MN\Y*PF5%L7MSW.,4,;<2N"?PT) <C1 K F>;!*7K:)>3\D;.)8)0LKIARJ^1
MFRA2WT>1BC&9E4$!?>97,ZCN4.UBT$1.,.&&R'.7<B5.:PHT[^+&+..AEU;K
M[4\$$K7WC6]Y%VS$]@Q)BQZV9F'F0!BJA,UUO+68DRW^!WN(^,F:1C'H%;7Q
MD=\)_P4KRPT)J0P.<[/\[ZO6_V N]7X"%%B',0X19]LYF/7WD:Z[36CU/9B&
MX4VJ#EUYJWZM7B#$^3[FI@<N]?^/H)&_G)7>\3DIGR/8/^JQ!7=U,K9(C72O
MO1]^&/1IGD<%3NVF.(+6]F.3O$$%+W>Y_\HK)6+_DU?RJ#KJ"7\M95KLD91Y
MJXQ%JIN]&88<OG 8%A5\4?]^)*B%_<]74+"G./\XKMS[>-U/P*0ZWG27CF#5
MR"<@?_(3H ;LT?H$G+5] N8-/P%5C5VR9G#$P "@B4^TJ\]<3$JF6]NO'V0Z
M(G MY4@>B)=A<K,L5&&(T14AB&&<K"H;AS8/CX-#")Q2<2Z\(*"G>QL8P>R:
M;TAA&IR-V9'79'H8],5.Z[8GK\BZ]A6!M,VJ7O?<&+5OH'1G@KP?RU01?-^@
M;,/Y0NXZ&O#;$1\,7U^_+CK> ,TM!=/4.2QW3?Q,.+B8& OUKQ+D"5J3T(5V
MG\'@$4V!9[GAN-C7BR;G4I"1,\&P/7NR>[0_-7TQ1TJ I[I9S_1.0]UH2EV7
M64D^U[,6ATQS.-67@::]6 ^(P5,[&%)#Q++GBBTVN\E%J^SO(L8+NC)+]C=N
MJ2R(%_)+4?<>1LB&NUELA:&E\FJ3ON)=J,VV<Z?@ ="N 9"[Y)RH)HQFDSI&
MC";]&WN'S1%!R)UF+)C-4IKPQ@C5?<('(%6U#UI_(P22>THK!NUU:OR%>FS=
M)1=;H.;)7D)@0P:$T' 04*@;0V;#II-C62UZ;-2SOSWO(F[VK,,IJOB\]SA^
M@T>N%MH%B4A0HHK*8<<,(MQQK)*?S:;FY@]]HNRMU:L6;3^.9*M#-+CU'-PO
MJV)@?9%RU-B;LO:&UA&NK3.:W.]I0)3O7.C#-]?^K;,(#ECN)#1Z$ TTFP'\
MV16*]=&1,?.@ZLQ<0[VUAZ_UTL?4GWT-8%[>F-1 C]<NE5D@&#*-)#+:A",*
MM(_B[O"W3GO"T(REPQ;XCHCDC01(T64;4A=)++PS@E%W,\];6&_=[KQ(&:FJ
MF,R#F([;J>?VI/+D"7<'3BMI)B;;=37GYO<FV$7Y)%9<>OMA9EH.?7 4'E.\
MUSEH A;VH9%DSQU0$IQ-B%$077*8+BJ+!015(!?:AI$N1_/"FK\R\U5]#JY.
M91ANA Q^^Q+^,0>.+2[(D^%4),8-8@QM7W=KY][+ YD/H:LQ0.(+;U^- P"[
MI8/!%O(0GEO8 -^DEKI,[$RZJ\ Q$Y+]R$V'%8;]FPF\^M:/A]>1WEM)?#;-
M]9VL9%+'/4"Y#A7_+[RJ)1P@VWLLD#$R2&-=3P:]SK!F/S\^QC&^>X*%#<>V
MC $7'3)A@>N$N37+3GN/V-<"+_6;1_Y)D4GXR;3%WS-(C H>M@AE5MO4E]1$
MZ5!56Q7[_(=%+F?S*+V-';,\'CG)H+8D/P:^J+L^++[I>M FBDM _X#'XA_T
MC-;FZ16)K^?7]A:M]";TFB\G']%U?3L-?L55R%?7@?4=W.A?/RS 3#C ?Y\!
M.?8N]R)9]IV.QO!ZB8B7=G<S0^XP'T**%E(N-_5HE%W'8(P+S*J2(P[!>QMM
M@!@(KJZ%X!P*NMPU_:RN;!/AV)FGPSOD<F3#?2A48;+01H"IURC9[CS?Q<GL
MXL5,/@-">ZG"+V$L]\7);S]M=7$0[@?=W9QFW88,C!WDFQK']'3TA^<--M0Q
M/^C8G_IXW6!(G.6DT \K]=3GS30JEDU">]1SQ98N%W\WE)NWCVE5J1[<ITU_
M_5&U;)J'KTIV,35PWA,'FD0,3>Q;.,=OT8S$C!CY"NNCCDL>.,ERK+1GSVA#
M?#N$.8QJ:EJ=841J;@H>$Q-KX03A!DY=YSYR3,>:5HY;>H>A[LZ""X,+5^2-
MCQ4))4+&D+X^[8G 3^Q=X1E^K);.WZ$;+5I#7(2K"8*ON1F1&*_A^""@GQ_R
MZD;)I?7)-(0/7-A ;6/3X!0SR8-]$!U["-A3RFN>28]Z_88)[X,UZJBBBY$"
M);D4U2*#7L50=NO)Z:XM(Q+E"2'=.@VZ:>UP&[4^TC7+&^^%]G E=<FAWKON
M2N$A2"\H"D4!R^/M]4+K/B^==U&?6;*8T+;6BU$P^W9F.4EJHC\3R3RKTDVE
M%'E&M\?/G18T006'%@KPR/_-YZ7+JV/U1P6^65RV*=S%T\9LX!J=I9VW.8R'
M,OL),!R>/<,&NQ  ','L?-VD9K_B;GTKA=JK=Q#!)HP"7L+CTIFRKVN_^A/(
MN7EOFPF=<59DJ9(K83\Q/7&.V'-C[X-H.;DV![XQ)U11)*V"LY\[52\<69:"
MZ93(0S^WFOY4LNJ\:-&(,]IZLT3(1 <:1T>05=4P+SL@75TEV^*W)&LZ9*3*
M]Z)7M5EJ\14J>N^3!3L)[&8N,#B0Q( 0ILQT/2VJ)WK'-4SH9^I8&Y(K:;%.
MW>LA<'J)+C.\QH[ #BK$4 8]QP'M,A2N7\*KO@<B&$*$X<HX+*MCZO/[QK:V
M#@U[ UR0&XJ<(X8&9HFLBD6=[-DW@WQ#S@FTUZ[F!ZKN,&[,""U(,_G""H$X
MC,44-)$9W?R;?^<4M*XRB5%5:]<$SBMQ]42^%F;AI"^9J -\#G_ZH?M8PR/J
M>,PK/I#22A?B#B4/F,B(TAX\$.0;FC&Q=1$$Z/02JXQ^*V]<34)(QA1?;WOO
M(>#VY[JDQ#21H<//K\+QZ5M_R&:OV]M!LAS4#E);L4 VUK*_E23S/?!'*NE9
MZ-#$6%;S@>1',YB?)FK&!-))28GNVL!8"7JCU9O%QUF):F5I&0WL543/&;XH
M#O,5A HBD(#%VC:65,V_IAS<.L!E\M&/&\=<>6?2W71BVWEQM<CHX)7LN^9Q
MKQ> -2Z;B[0O\<APAZ7BIL;7ZA]=RM;7Q0>-D)O\4'^;*MMR,8;B2\#MF5<Q
MO]HZN]".C#D SC54+8-T+A="EQ A5*M38^SQJ\ZC5[37$PN,F!9!=*TTY#L4
MQ!@RK^\GD]QET8[;QKL9N.^N(<OBDD2"I>UIW806?IBPA)8S#),+'J24X0>'
MD<!O*=_!B-"NY!J9PX^>GM>D[+=I\3A,GIR\,9[)"6X[@Z&6SB&:E>&C*:P?
M*^[L$((;O]F=%.PR0Z#Y(>%-XC!L/2U+FUS*BN.67>P#TZ[49SO#:KU)TXWQ
M#>BSMPIZ.E@>9KK/ON-]Y8RQE%R_H*L^8&!T;%LG)JU>AG0Y"A6F3SI3XH2J
MYHE 1BW&,U5AYB,9<T!F19;]5< G>DQ0)*MB+%_+F<&=8=6<O@1U1@+3<C)R
MJGWU?>\,1VRT<X[*,_810^_LU PT57T+8I'U<D#>[R*BP&1-XTCZ4+JQ&N'V
MS@#='D75Y%/_[V>7M<]54JK-SW!QK75<(3<*EXPY]$"#\?-:7.Z(A# ('</?
M9IPTD.HM*1H8L6CD$R0 B@7@@@#(7YSA[SP3I^_JC)I[]G9V=6[9$-^4FV*(
MYHJ>Y1S79H2.CBN6N5XL!C;YRYU6?3&3A]=7#^U^NS=;ZCZ#PY4!\@'/$A[W
M]TIJ;TS'Y_=!RP15Y \*?-T--XA/[I3'$GTTN96;QK[\8?>..Z@-"'X]7/2.
M9WT&HK>/N0'^#6V"/ +( C6N$0]/A)/# ?(3W+_?=YJ&*V%\48>7_, ^I@[>
M3UY$?W<M4<ZO^',2@/'^)QF$6B]0;[R)]X6[J&?/FKD*1N\;'E\N^G-KIN!T
MO6I39_E\+78(+ZX4IG[^4/C_EPJ*]-J4V6_%3N:EIEOM>]\A?8-FZZN"NLT+
M#C,# &I$#DO543^\#/%X1)F@S?P8]6X48!);)HQKN:GJ.1HX)#?WP?H]2QKI
MG4>([O"3+VS5)Y9^[ \5#NCN.+U.R-RF.F(=@(,OVW4D-393Q.V.<<S70Z\T
MR,@K99_SZXGG]?AM*5VJ=PX1KS]%4$5IR"M218YQRAFL"A/4[GT]=6 *<$0"
M(P +:3*WS4A4WK8HC!X8[T@=P]:^NL:9J^2V?$=]&$JMG9^3FI>RL!Z).I7;
MZY6>7]6@)1V3_"<;K72,J;#Q;%=II%A0BE8T[AW-MQ;(2,0,$HZB8+E<1JF&
MWXA(.2= +=#_Z<+U[)V>Q"565>>%JM'"GV(3VV3;&5WX5?Z^Q:J^T+ROCA*G
M41YH<))J]0Z7;R>T,4C$DH#=WN?>'"#G=J$]_-;%'?NN''5N])Z8R8NIA0\^
M%&#4 ^)XAB^] NFD5B(B;=SI"'!%7O!>$SZJ7-T?\=Y*,X+"[N2=O$8M*9V&
MX[X0]IK@OJ/0Q)P-#E!<H.Q#"\+<"6YL695N'.CZ;OD,WQ*N)1EH3W^$7<M[
M\E9I($3E$H61D<<I#:=T98<,]GBZ/UKL*9D8N[PTH'H"RMPW/0R=NT^%WOC:
M?B* [30:[6[MVPBZ/WP"O)P7'A-FO.\DETRU7PGP]8;<V7 [0.4'?(]ZI']%
M4ZTLP3";PM]9'V>T70 YP^GSB3@*5\F=GSWO"5^*,9<&^1*S?VH)$'9LB_A>
M/'];O[S4=WHTW.-;FFS*V,?17,((@K%:DW!5[&UT=G;[OO_O1'<_SM'NU)W/
M*?NOY(/>G.M:UPB[V_S5+OW^S)D.73,'YCTD.#O?.>6X3F\>3[CO)1GH(![D
M]F8K:!$09@3"O\0F;6[80M5SW%5W5W8*H]&EXBPO%5V/JES@9T7][)A.NQZD
M*OSMUO]*2=UE].)\W0[WD1G7X=A$6NM=X7M68Z_N1]%2?,)0=YNNB6-YC -V
M(Y(F1-%9_@^E[1MIQMZ-^]IWWMP_B3?';H^1N^O$+LB]?DM<K6]#=VT=I7][
M)X+INCH'K[I;Y(F-T[J>HZ?K48/!#N^=#WS+:Y.$B']@;AH+?GXT$XYR;W:9
M>'@-/T1'D9&QE7\",KV"K[[P:W'%BMJR&D\XIE-Q7)[2UF:/98\]\P)7*X[_
M5H_@/^W XD[>^9PX3ZK\)XF<'P2W "(CR8V%VA1177Y,)K[0#/_;4_R+_G.R
MXU]9^/]8H?^Y!^HM,7A)1)@+8Y1 [%>.&VMBW?B(1J57K2,L9]/M9 PP@SN7
MDK&/?YKF^-]M<&<;Z4E)4(\#4<3RH 6_M[GML24_S$AR\E&Y(>H-\>WE<N;R
MVN]#?[I+X=]JM/L?/K-=)HVHVB):">B\DD#A9^$+FZ=4AK.N <PX P:F&9NO
MTZ37+0TMZ[3_6.$3$%*,&?:\4NI_E,5:98!0Z"^YXD0^G.H!!;&RHBM$=/F%
MX:,J2[KDM&WH"D$(QI:75P1LC0-)0] ]EWD[4JG+1N4/X5;6XV/\[J/UB?W(
M$6[,ZBII^R$OY-8OX<6H\ !%N9CR0][K<OR?WK7P12I926^=K_]R.>,<J>&J
MG!]DF U$9X0!4PK!M7<,U7^5!-<V2<29G-=+D+KNQIAQFZ^M;/K9D.LNF!L%
MM/96"JRFN<CA2H[-4-86+D3Q<>V$%!P\09X?E-8/,G2."V$.D.4#B-![VM5[
MR?/";(8V=R:2/2']NEFJ[UPD6F!SGK<WTJWCUW"-JE>_&M=;:< CJ^H(N?([
M9>?-"X 1F!H#C0*[W%46DZG:]1CHN5HEB]K)J!QX2ZMCP799E.6]R'E7,2.A
MI-3D-I%W  !%:A'Y^[:-G*(QF=1Q2=/.Y$7*- 3S1F<V)["KA03U,ZM-WHBY
ME;*;%\M,]"R3--BVC6M/@M>I8T$'10#:-CWLR_]V C4_Y<S(MAMBKG'CW ]B
M^>9>_%<58<CC'XT/_$62FA^/_!H7/AXN7N+O7&)AR[;)A4V/&?+Y9EN9HS C
M9LK?Q3ITT$/.Y):UVADBP]N^DXU0Y2OI!AE2AQ4.!SP[XUMPY><W+LG+JNN_
M#,>%Y$\;FM9L?E'5</Q!=7E4TZNE-_JS-0FN3!OO!F=?R!.&B*K4?J/-VV/;
MGT_+)S[%OP4!VTOLSY[_E[*/69>>J=B_?5A"=H_3X>6^[_NMV9VXP :7Q2GF
M<\0[BF_!J7\V_NDG@)S7[W!\?>CM=6_\(-JWU6%ZCO$:]87L36SN$\##._\A
M[?9G/+4EYOE^,'44Z\UA-[?(8(OR1NHIJOC#Q;WT/>GR+971'O?Z.(HQ@?EI
MMU]0LJ=382?Q$E/F_>1:X95Z_9E!?XMS>QK#@,SDLC_4+][?([>7<HTA]75V
M*_=.I>5*MZO3OB>'KEMR>#WLVQ^2CUO!((5&/<;[PB[!@_],[N=?;K__Q2W7
MLMW@6,++?U1^N\WIZ;;[PZ/^E930#H_U(>IMX -&X+^4.=(G(.P?\DF"#Y(6
M"/MAWX)E8L4>P$MO6>\0WXI7'!%E>?*DN6'>$U^[]T9^RPG4U=$B:\"6;&[<
M(;'"5%1BBG>,LBEN(>R:1Y546BB=_K5YJ] A$K-(.YY(.#3T02>'#G[VT&#*
MH#3%\-3F$9^&Y5NCP(DR'.ZY;G8#X\5FCSW1BJ? [8%R]9#*4WY;E[_K'5];
MQ<"%F: U;N;RLP%I'Z4)]9OBQE9/^RL!LF;V/J?*S"2M755+CJ%9T,296"7+
M=_U(Y\*] 5RZ70GP&QPT6'LX(C18$A(^[U_8,$OOPKTW'TMP[_MF3!//S/DQ
M".P 5$7=K1'U;T_Y]?.S$OPGGL!1R\U2CBTG7EH"_C-VC<,M2U^/F%=]$^<E
M"5'XH&4*"5.=QI_N14J"C=D"6P=1&3^!AY1=XA7O79.(-<@]M%/\IHT2"69\
MF]W( G.-GP#CXPU"ZG\!7?T;T/\I_U\O=Z-D^YTGGT;0.PD&;0:MAGC<Z/F[
M<> 7E$J>AB]I!"P)/])59AA@6K)]^,23S,9\G>R7).Y48'Y!Y\%#)C@!^>GN
M&(.G!-.K#"?-@O3A$CC+M.:&CI,^BEX=/K//LF$[,X*(^[>,$ Q?-CPB!Q2J
M]%\(Z;^D#<' ODUQO6>G:$_QA?)?I$RI!RUS6I*^?W&.571#%VC*V'J"W-0>
M,8 8%(;ZT/$FEN3%45@+/7Q\71ZI;_%?(=@K.^GQN7;]CZ=U/1>(CCR,V[R;
M\D.)?]NVKY_K'9W]&\2&?-3SU+,&?@SEI8BSU\?Y@><O5Q@V7/_#.B\PH:_R
M Q=6_[WM3P4HJB2[4924KXSY+7!RUEQU2V15H]8E_2FSLS?8]/D)G1U=^N\8
M'J+_$Y?AQ?ZKS]'CG^61FXC_@/DA_Q_N1N+&DML$/WG^5A._^W_ _XO!HZZ6
M%2D6QRWXBR^?";[M8N*+5*X79S(N5*AYI5)%"7W-K)P]R>KT8Q85@:[^^-<:
M;M0RDH+#MN8C,VK-E5>V.?%VE\0XT]53%*Z"F0*7L4-R0"C*\Q>1,*1)WUFW
MYI9WXT7S)ZHCYN95T#903TBG$39X7*ANBP*:8AE;A15G?V:((\#-9K7)_&=Z
MTB= C-: 6>P]E=5_IM6>K/E:]I7&=8_#@!5SP-Z*;Z+T-[7V:R3C0>MO3/B#
ME,W37'(^\?$CXY>82\K_]"[A]]W.A/4NUH/2\%6?"0/DKJ)[EMR38N 154_"
M_HDN9X*.>XE/TBTN8WK4'F=CCKG*'S20SR#FG:XO7.B=C-W#=$(.J=D]LX_X
M4^+$F']!<DU:P8?,SWR'+2G;K?0[E0&;;G/&\*TYSW2%!^6F>S2#4<<'!MQ1
M^HYY 6F/F-2)P5O<-056ZH](]6[CJ%<&@9!^3_(6+XM1!>3ZU[1N4F^I(S/!
M6>GE"25_\N'_3I+Z?YMC,>0:.DX!SKQ1=8QQ9^3(+*BBH$*QKDB)7"4@CL>:
MPJD9 NF 6^B?0R16BYV#$&F3,\[9UC8X)/I-5/:U].-1YVY)W790MZUV (_^
M@+35GLJHE*5%-^TG@:[KS4\?*3[2WWZ.8P<:012=K$.?@/!/P#X>R O]*E%&
MN^NHFEZPCY;JGH[:Z>_4K*GX*>83T*:=^@F@T?D$K"EJ5>E9<!C>FCI%M0D&
M+4:^E$C6-I&F%KM??0THL5 'J=(DL#0UK!PPR)5NI:^6%)'"(<TQ2'FX31K/
M&RL):Y&T"NDR6'S5[-(*%R+V> C3-S7/&MB[M&,TO!VO2FL'%W$D]:+&'8'0
MWIS1](2<X4^.G5!_2DN[,@]0<&<;"')3:EKAL*$Y290=9I%0I:9$I(!R-J_L
MOV!H&IN<22 ?13LBE<+)1YPS1+X4ND!G]D#\ 8!^]KYSLY2AVA]*SS@;]K9C
MD'+^!&#CQ;4;][?$]=R*)_'RTKR[+)9Q/7$W>N/K_'P3VE</OH3/Q%2V]HK7
M^O)"2?2[\<QX61"Z0GY!ZGU2 "&E*83F6K98C8U<6[9)+;,I4H1*ONP(X=5Y
MS18JO+GX7-=\^&7P('Y.(C8#VK;=C24O X)RSQKLKY@T0Y"1#3?X+'F;ZW@+
M=Q86#%"A::1@D6.!]AM[R4B7>@TLTYA:.ME<OT-S2S6^E09K-TJE!IVPIZ%+
M!9TRL8KB&04%<32X/A]+;[AYXMCJIIF/,E6FC+CH\*9"ZW+7?02\-F?%3F_#
M"EZF&@</G=J"T\:&,)XC^R2:<Y109<#SNN2%<FA%*;-$&7'Y^FJ\:2]V?+G&
ML70ES"EG8C YIW5B%->8$!=)-(Y:$'>I,*48,QH40 @9687&J=U"8?4D,2/5
M?2C3;GAI"QA!5M[F3*-#!+^Q6:A[I53[=4Z'3FO^LKL%*3/8HD=]3-\]NMKN
MZ=3R"*V&HU=LOW2!]AI+3<47F9#BZGM\/<-8AKB:!T?UQ@"W-@LX_T.!/8X'
MGC.K:%E%+EZ6?.LM)P+V\8_Y%W=AZXTH+"\9N+<@TPS)#1&\67A)RBW;DM[Q
MYLIMN.BZ]EL5AR&DDXUC#?/;XJ\*G.2J:[BZY]3JJ';II7B/%<[UW]H/+E&L
M)9ND.0V(31*,Q$DLT;O:UF%Z52,\OIOLPH]N$YS>_<%(F5W&2&T8>#.!XRWU
MITTL,C%N.1TW1+O*)<V<C1.^@BE9U+ /&Y3Y4@-O57D(S_[<4<>]@#<4NT:[
MHFAJK8:<"JQ)"E,TTP/N:<>XWE;NM4KK#;+966%S=0M0XYQ1.U@[17PU(J!Q
MS>/_5>^+7H*?X)9I5GL[&^,[7WJ;[JY#UES=&E%HQH,5.HS:*#D#<Z1:BFN"
M/E/K(CS%<3O:L[(5C=J0D%S3+@UB"5J^*J4ZBBP=U"SG\!RI^"57:EE/S)04
M/+"?[+7D1U?9PB877ZZF> ".AET5$: "X;"?[&CU#E$R-&WV$S,-KJ5^LSYJ
M/9#VD!FJM2O&%F+-&AJ7@U'8(MILL_O@6\+LI0.E+0QD:(>G!,G5N(&HS*S%
MU8F2JMTA%(L*$[,MV9%:L'J;I--F=F#B,P,!@>S4A=!I7SE>&!AE5,SB@U ?
M]CFPF)F;CWS*;1W;%;W#[+30,L>]<7W=C\:M6T-I]KIKRKEL3CC*@H<5U8*!
MQR=S#XBW3!#+W^@LL;W^\?6"W%F_/3/14MO7C[Q*ORRT,^AN*<I:J4)&KJFJ
MRK1(K^!PO$B3C:V]6!2%"&OXY&% A%<L:L[YH,2T65$$OIFXA=$^>@L)[R,@
M,GM+_3I>W^N.4;+JEB'^[>D"8#Q0A&))H,MQ=U$R:] )>NJL%EYM_C+& @^\
M/(_&EN4YSY*1QDA%.W[B8&(@,YTX;-POPT2YBI?,4X/=5:'1YP- _?"7-K)Q
MQBDYC8GD-%D9QEHEW2)!*'7N% G<K&%8M.K7TMXZ.MHVD0NPHK??B1UN&!<C
M7'ULK.08CED59X3!>"\D1T1Z52&0B_9H<Q@(>$5'US(/.APG5Q,*XPF]42FQ
M2W]Y"!VOK%UZT;V^$Z9E:A"7A?=TET0D_6V>6&NO47!1'V9/4S!I\JY\4T]Q
M)4;N+F'HNVVE1Z#''9D[V_!'NAN943350;A60VB/TL[919)5,< 9W'*,2&@O
MG_>'B]!)9F! *8P_'%=IW(P&^-B#@!S/<2(IK?*,IP'A=5CO@</J!'3'J9P"
M0U9V\]26;_#F)DMG<JD;[8@$UP&I\1:Y]CR8:T!TP^+!NLQ?UR,M8<S(+<J(
MR'PMP"O\==(JND.FQ!HH_^_SV6T?<_EA5B,,!5Q2L_KTP$F'8ZAGZ .B2R@C
M'2@K=WM?N_5*C;!?MXH2[VW>-,+)9_G_9?\BK#61](?+L?#_W>3\Q[;$4 _B
MC\/9]8?&"[D04^YMM\H?//\=K>GT4X7Y_W'I-OA:ST&/J;^'!N*MEP2==N$'
M]L@G0+CU@_IL,^T3,&?74RCU#D7+/!IVX[#<\ZY[_3)(&R</[:_NL7UK^L$\
M)IC7LRNC<*MP$SDF.PYK_!><WLJWT/]*O?@3,);R"7A*P@ B:DW_0<3\PZ"P
MTV1<3>-_^K1]JO<6")Q"F*TU)/J&-#[&64UQZ9KH86EJ,#PLX*!,='%!EC/<
M+D\^GP F65M4\-WOF(!T>UD&;ZAJR"2'SL=:EY?,.9#C,KX.T_LJO!5'(RM2
M(]O$TMXI9<FLC^E$VSLC<MZ,0R/N3>9@:M;7A).<9O:BC9(R>LM)RLALJ<U'
MW0Z&;TI54:TBA-1M/$_CB^J/+V/IHD)>^!.%4:R5EU?9O#Q23HQ@5R9G8E]U
M\=O=[,&4X3EL"TX8G4INNFNV',K_;'>VAM=?0(XN%Q(=4/9RL")6N;K1X=(=
M?%?;_9I5N#*0:%<0*WW)%IUQFE@2^,&$U35O 6HV4*OGE?GFF#@DTPYT6$OX
MY98RM(8#,?6+RG--@UG_4*MU))L<:T\;L)7OWKUI3\QPC!>6K3'IO@Z=H+8[
M\LIA%6S.4DXK&W%+BXA9T=$\4DG0"!@8K H..Z,BG9$31O?(#(=&4/,U6>S#
MMML[?1=77I)<I=<^*?2&(0KE@6SQ]LC "8*+P*L,=]):BH!8%910JENZ,''#
M3W; A>:5J"]#.&0,'T:^7RC)%!4(O->,S1+%AFY11-BBIHE6AL6/M$V2DC V
MBT?Y&%&!0L$"0(2P7CV:*@J<1.RWI* B/,1Q<,'INK<  + )G!G48S!ZN8XI
MMFVH'"FQYCNVO!FHBH"#8FO?)A6;O:=.."JNM<VPZA_T&3!6D$QW#,E80&X=
M>G)MGX ZS?! S%,ZB%LU1&BD';!?3@74KKIIK1=&39VW0U!U\Z*3=R>YWXW7
MKS7EY[AACO3C95)O*716ASCW&;;8UG!V1R]HV'C'%YQNZQ2MY,G.:%2F6D^>
MXF48+F%06FB94V@=S"N#D2X3J.'GP40'P<# ]HA3WJR:N--,;B=[S)4Q76Z7
M-IM\0':[5FQK\\BN$L00UL7-?OI(6DA\3:6&\2+"%S%A]9A=F^-&3#^ T+^%
MWZB&;Z-:3.&8S%?/;H1>75*C;6G@8>@T5;>;E9B!R^"BS*+9X&'.#!H9F1HZ
MOXB[DF=-3*,?E$>Q8C5$+W]&%OSH[\;C!':,48MM'9-G ;\0WPY33/O,=FIS
M@&EKN"@':%B0W'2M<%)>%1!P93 Q?B61LFQ@-\$9")=.+ <DJ4'*9K9XDSD(
M!9@MTT1B%>^0]O_$I=\J7N#,!C.-^TZ46@1,6VH,F\LF(D*X:#%_IN=0\Y1)
M'1EY:DUQY\O,8\^[CX.<[/R3J*9 WCR4N5(./E:%2(Q%P$"O2(*/485^L]56
MKGS&DTC1.LHX?YK4Y]?8Q^?QS&>0TN,S*TL9Y42U,:;HO9R@O^9DU]DVV!\_
MD !4.W#RI+P:@]D,5\[JOW)BU*%=K.9^+<:1@='/@<^V4L-CB?$(FJ%#L0SF
M&DSG,]]- *T7#2(Q2K'B1AKR>1SJ\F2R?SV_WDN!86$1)6%NRVNZA;5KFB2)
MM81'@S+,NV T2F_GU&<7;C7^1A(4TOA<Y$8[T7E1C8%U:@53PJAD\UN-?"81
M?$@L/?AI2C8CBLT5R4T\7*FL(EX>YA$?)2V/"$ \S*-CP?)R7LZR--V"R=K8
M+-FBC=WN*7[)Z<D?LFL;W]78Z7M !+B5!E#Y1CHQ--.Z1FXT6'!(B9EM-DI.
MKK<[)1JWTAHAG;"CQXNQ(RS6(L$&B2.3?'DI D]MR_&T.3)0E-M/ERI,T :X
MP>]!$=4P.H_P0ABN=#&R:'##0%R%D.'E],7ZEVZ,2S)N&X&#$+\LISGGVM!P
M1C9VY.1<UUW21]U!YBSB?ANK"V5F)TK^I0DN60''7D44X$&8J7>%\@.9,A0K
MM_81#TR>YM&'P[DRV-6RO=U'O)UYRE5F5##FZ.03X'M37I_585G? P^I>RTI
MQDS>6,KQZ(81.VVQ<GBD8S#9H>7Y__B@LY0AL&1GXLX.58\O/,Y7O6S1,A+3
MDWX.S@,TT.'0?<B&2WV:)*-M[]N%5PS-](87.X*PD![6(!1TR+ =ZZ4</(<U
M[*,#.[+(S5XTT,@6,&5_.FPO'XL=G\-K5V'O<V14ILW1<1O:FHG3H92WQ8*Z
M6,\>(.,8;US!6[0A<N6A+]6(4-F#^F&$OK?N,W_5E3[5O52L]-1\M=S.:OKU
M$W#Q-U1L]3(;(U10YDX*RJ=V+;U^T6O]P7UZ98_P&BBNH$M/H#&LYE0O1DH^
M(,H4^;7VM7\;;]KZ8^-$0RY>/*!JDYO@D&"UQO)-=DT86\ ,M&Z'8I#%LQYU
M5T8C[=-$5D-2/CH* [_C2XV2&E#&)>;@]K&^CA-F<==49L1Y-%<!W/RCM1RO
MN]V1OE'O_>2>I+WN.U*([UMGY'Z#SG%SW9;:*L.U>"[%H$RRTB6;("H[*T-%
MIB&3(B_9/?-'9_*8USO8S3F3*#1J(QXCM+U+W7TTL_),IUP&E],UB@P?PN0[
M]S+/'VD]+?3,I  )^AFG5I(,8!-5UH ZG);=>??JK&[N7+,]UYN"@1#M:"Z7
M=X*WRZ_+LK'B>V,[>,HZJV2OFAR- 62%87T3Y:K88_W^)!0+(B(Q DZU"GQU
M9-DRWE2/-<YC(@R=G*EUI<=J(/L[/ZT[7_ 19/=3:^QRAY/YU0E/<\O8HVN6
M:ZZDK) ."9[FI /S0ERD3SBG@SUDG!!NO(7!ZIM^CG<==\7*+6^BEXTO[+H1
MRZRVLJ"#;13#@CW9FS2!/JG3)18V+<DUAASHIY545PT1%1T5U58%7)*@C6,?
M?<XN&ISU)R#A3_R?75W!P5.\.NN?+Q:D?R#W7THKW4P^ 5+M'S&4-WA5PQ2$
MO?WZGX!;YYY]M&IA+N(_6OO^@XDOPU0?09^ $'K!P;^!/S4K'77D_RSP%WS@
MTSR^_5?@WUK^"2C5\?\G\ ]/YE5EM=:#K*[<#VY;M&]Z->&J0TYV@D09I!CM
M6)5Z410]\GJDFE%3IU 2'5&35@%@";&B&#5]_8'%9TYCT2APM'<' ^: &T,1
M. VU%?Q"O@"5+NKXG%*GN;[:ZJZ0=&V[0BN=^ G@1]MP0U=;V+<-T<HF];0>
M]#9>S&#-M>S#-R,> CL?(V7#1A%^-=5LMJ.5P/((7$ (_-(IRK51O(B56=G:
M)$YSP'&,^_6"/N;!*J%YCF4!X-:*<%ITYRY2CSZX_(3)&49O+YX258)T!BZF
M)0TQ!@U"Y#I0';YK8NWEB"S0VC<RHVQ:[U_NI-"-EU[&]*U=SLXI;$O54E6)
M\/.89:$J*XB([W?YQ6,(ZX#C>5V;L(JKQ\RGF-GI\S-2B@RY?<O$[5@!J'W-
MGH#HM3NVAERG,F+H#5'':$*92MB^N0=Y'GTPLQPW;[?9^(2)/JZCJ3TOO?&G
M. M4("YA5"?MR!LYIQA?;7H2%W\K7M<$X8'W[G4$P4)344;5HMO% O,K?8B4
MT=8DTBST^QUQDC.#4'PJ8QQ;IL>O2KV-[#,,V.PPRS5,']=U4-U-KS^I@6\7
M5?4-Z1:.O6TQ=XCGJ=BA3]&7K.J>A/2$2/G2KV *"1F:J8UFV3WLY@6;8GGQ
MA=\B8&?OZJ.%RV!4B&.-".("\"3XKS>C1DSKIL?D8/H&X3N.XZ3[GNNYMHY%
M9I?R1H1,FE7M;?48<(%L;JDLW$6BG#]=$&8XX!<'#C>S*M2C7-1F7_B;K$\I
MG$Y:W32IV6N0[IN>C-^-TJ6Y21!*C%!%3ZDRPEBZM+NV(XE3UB<NL+FVR_(Z
MR[N&,,9QPTU")MP=P?^,+;C$03H[2:C-$WO;<\88_+)\M2484P\MR-I,G'Q.
MYM\HIP!^C:A>)RV@K]1@-Y[2YZGC#.*+5E6EZT-%%N%K*#DE^\VC-X>@8>,J
M69#%H_O-V&&*HB?A33[:#>>#5W>_H)'\\!+P:VATGM4CPWZAI0WD&S([SW.T
MN/3DQ)P.I:-CUS8 5A>[A4Z1#)G\95'GK4X7)5&:KBC(Z1ZRWD8M2 E3W$L+
M*]\7-D"2[/%[O(3-IAS1C8JJ2%#P'-+U+=967O*=<=W, 3DGZK"W]VQ'2AR6
MT49-K>DII]2*G"5(2S]K'Y3NY%Z=Z7"Y/ZXD_JP_+@5"I*1I$@Q[N(,<:Z9@
M?\/#$G34%)&3[[_^>56*],X][7S!L.!N^/>2.+)E19J@5Y[X182[[ DEK%8#
M3^0FU&E&U]V$B)MJMEDN^LF-+OVP/Q5F\Y!WUQYL0;PKW$5Y:CJI2WMZB2CI
M*#B()02EDJC< WSLAADG;D,B8B $KZYO"F,+N%YBL&4O4KR;>AL0A/?< A2A
M';_($1+84>ZB+:YQ_;(';&_ &K8M*WGD#C/ORC'KI%FTALW]BJT-$F\._Q%F
MG<GU! \S(X6F@O#RTV6LJGQ OB 4F2>,*>WOD(JWS>?&,XYN1B!(B&O<$-$(
MU*8"? )@^(Z3DG-!MK87>;9-E2)$AGD0Z1HL3:K_9?LG8'RS0MQUGKC^!&A4
M?P) #1,P>8+5^ 9_8[=/P)<R#/18G'6J/0ZLPD\ ^)3/M+57F6B5^JB9_HGT
M.[4=0EZ&.MY:%,8(G<S2BJ WS5AWU0SQ/FI?4U*\PR%'0:FBV!)/@'[\#]'(
M;_.B5ACLY;]UZ/DKU^8O+<6;&A:1\M420"N9(H'@Q(T;V"1]+$K0U57=W\3F
MN!5/PH3@?C%%MLL9@>8"@*KR@;+RM4,3V8O)'LGARGULK856[+NT.I:UIM_B
MZBF=F<8A]N+P?L1%Y>3J\O.1Y,M9QI":EJU08>#S5QY;-J^+O'659#)_KY12
MJTKEEHJKDUJWR",0 V'2F\7E KP:#N>4YJJ#0<P#GP!<Z/*;K+:[-ZU*A=GS
M#$XE(15Z)3I#FT4N6T?%:-"*X=YRO"LV(COT&#[6JF3KL?+5HEW0:#:9FDOY
MB")+&#)):W-DLOJU3FK)QKF#^ECTNU>=2I,WF0QV^_N$\2 X")\:D2PX[?DB
MF0J 3:["_ 6B'4O,;'0,DP9&#4L)Y3!3J%0RL@G^B"4G)W?YH')X\VO%-P6@
M&;CVBUA3'=5@O27^+@IM<(&0[! *U#>2].&3;%+4^EP[RR[!*E*WATR1NO@U
M.BI7-V^8-W8=LE'U:P;ZO?E:;CES^GFA'7>(>3$6"CY)Y0!D>:":UR(+<HQU
MOD%(I08I;)N)(;#.)M]H!7T\.:<-TK%NA,-\O4^_3<F,YPM"1@76T9X)= 2Z
M.W2>CL9[ZL7/:]C=#T;)PRA5FWENU(]\QW>5Q0[F3T#1IK]XZ@N"NDDBXLYN
MC?]+V_9MI :1#R+1S3B.!,5%[A"WQ ,,E-0:\FC[]2YZ4GJ*ZN#?!JC.Z79"
MD_-DH6]EE9 =0V^U_BRK&NPP"T%E18:;MQ,KO,X9PBV$$R?S"Y9X\_IVA*!S
M]PHS7)UIQ3R;E23H^U/:B%4Y +^(H._G\<-A;&$HEWU4/ZDCJ<N\52EC:]WY
MU>-"=]*V=]<G8+TV1VS"A:?U)(^*H3Y .3?%/E@IU6$<\AAU3A[LS\TEY>9Y
MN2]U]\=ER!V#\]EA(5\-]7;ZSK)! Q[AE*Z/T9I"Q[+R;Q7?J^=/@%W?*R9!
MM3;CV%WV:PZ\P(2#/[?C;9B5P+6>S*G<\[,-8[SCV6'!^[\ YB^&H>Y3";'<
M$J\>_E'%WZW/$Y/KT6G63RWI>N+&ZLDD^'7\9S2OU+.7M8&T?4^'D4]4UN\V
MRVX#W#&-/ZQ\.+YI.Q].^_L(<[Y;[8F=')DG83N8M5F"*@-MBW]T74SV3][M
MJ;X"7\V=GIOZ7XR"O'DXI1P[M-]VUPQ<NZ<O=7= (WO[M<ND;'SH^>@)X8H@
M'=>*F@5.ZOP?9<7+="8/T@!\4NCG 8_?4HOKXM/M=G9.+&T@^*]SC=FSVO#1
MN!S)UYP(3/-7U^..&TQL[B)QOH,W;UVNG,4:VYNUW6)3A94ID;BXSHF6%S 9
M4+<6SQJIJ[&(QW8"3/]6GS3_5I_\N@\6R8>\]SXXONF&'V[_SB9UKO+Z:L6
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M/K^]?GG]]'J\GJ_?7D0R.1>R1Q+,LWOWB=-QM=\KH,'4B;E/RS<-8^(USAC
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MNU:][WKV4_4R_[(*P)*7D9,!("$# .;_/("70P"VE)N9K1< "? * /CWT#$
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MMM6L[DG]TM_2.=/P5B =?*A;<ON@:6I:TGK!>52K079>$.=9ERD_>V#J"F2
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MM7<%:T*6D3+)BXH:1<OIH4V"Z0ZR0$JY._D[/Z>=Y,\)PIVPEB\0T]^R!LM
M0P9,^U0T+5#^ [( '1>F*NOL^PGKN=]'EG+M O&<H6B36E\JY2[8SQ6LH:X?
M0,81E[Z*IS$:&ON"K;V2 V6E9M,Y;7.U;Q;DB*X,4_IU(O0_(1=0+?6__1Y
MG=LAX?P+*;(VW7H<9&07R5;\ZP6PMH%!J\9/7'WP +,Y[$\M,#C\_51243N;
MT6CC'4XOT3%!0ZFKEJ>W"0V3;X^JR,'*^=JW^?T-T^HV (7OL?22=VZC@)3-
ME7Q0EU5^@7GH^=MATFW52-=88"@0MOEWH%W-$N+\]C*,1@94(CHS5Y(L[KC2
M>\SRA>$U U+Y&W:&#]'#>5XW=0)^+0(B_7 =ONN_/85*UN1\M5<G':@-W>7K
MR_ML0E^64VA5&_($J/9_S5@7?*V/ ;VEL)=2U-1!E06DK+=C"01;(<C0ZURX
MU7O$PF9$#<@*UJQH:2CUBQ*^@ET??TU/7WDK[$0[P2*71WM//FA)Z%N/.U$'
M2KCF>/Q%[WJ%Q9$=O 79ENP?6DD!_IDK)#A17[Y_ 820L:SU[;KY%?%6=9R]
M;2TPTP%5\U[F;JNFTL;^N1>R: R6&J9+'0PR2TE.)CPB0^'+?RSB]<#C<TB\
MH?(L:/3B&1C$X#3^=$F>H^F@5 3=9'8;PSLBJ=)_L*C/HM//;Y=.37<N)7=W
MJ\85</9@_/+C:SXSDE"'RT9[PO7]W%_KQ%2W8BZBO\;W#J8.HL9. DWJ40<M
M[/1>X8;%VG5+N*%#7.B#TE\.Z#^ N+!MF"9IY&L[^L2W^7QPD2-#8<)A$\)3
M.Q%]4>=AD=N:=#=;K JNUHC#%7/'>RYEY'+"W)JK3[P?X"!2*<@]TB-J4\+3
ME(72YU T?H;()HHS_Z([A0YE8Y<PIW.4. )B^GM,&Z>O)NO"V0=YC7V#?9+&
M16'=*PZI&U:UI2-"/_4R:$I9U'/X__B8L70E+)AJX;!LH@&6GALL/C75OLZI
M/6>7GMM+%?&> <%L9NJZIGDIKXTJX\-!N9>:(@&AU:>1*A]8T.D6)6+6F;+5
M*5LTWL0!9HU3FS' 1[S>PQ%D-AL6%S9.@999+.V<T,5(=^M1E0:Z[ZP1K"']
M]RB( KL2'P*KZ@%1_(BN:6WW/]BSWX>['2OC/Q*"ZKO+/$8^4.9';1*2\"6B
MSTQ-QNH? '<_N P]T'ZJU0XFPYI4!=;\<\YP;:YH 9(6S7<.X"GGZF"U0:0!
M"J)"1PZ*97&G'!N',=!I#!6PSO*1:>V0-C"ZBAO'_5<5]-J8B0H>T3 13U@Q
MMHE8!-9-Q^\)A.E7.6AP8=!JF3TRA>6"_/4Q.4GJ)A?K2NIJT\\]9GTN<A1M
M+6P%/5SD#X]%^@9T\EG5;&BMH CX4=^$!T(-D]B$BDTCOE0@0<WUC=9OJ?1\
MS=/WNZNB<8L^3FL.1#4RQZVIEO:M:OG6>*E/\^;FEAHI55^D/BZ<\B8G,=+F
M$_6]0>$]1N!!R3*70@L!+D2 ]XW_WT7M?W<928[;LS2V[+EGF*1ER@6\8ED0
MBY;-!K]^QC<H1A7'Q5PG$_4I_=6E&="* *PMS&H"MF^,<ORUYE$ 6<PI]7H:
MI;/->;)&:DQSI!MQRT#6^*%P7YQ1%\^HI$&AVG$9V=JX2@'%/FRF2'S=#BH1
M- #T]/]9"9YH_ZS^AB,L[^IX(4O#W1ZC(^;[F ;[3"'8#:CW69-IX-5/O N^
M,^@?A#.^U(AKSV"A*J?4>\!'5,:\AK.LAC4#-Y6-Y^19$FWHW4X;%Y9^6Z1!
M3M_@UP!4J@&Y.FB_;(S<F3K%FK9QCVHN@.$-'H#C7;^_6<36V@[N':X8JNV*
MC^TD.&5<]VMX)HN0D+8Z%*:F"#,<^]J9F_Z+1&*-.G1S6Y7T;2_&W4_$6#;5
M1W,\'Q\?*3!14@++!M4&<5UD>'BD71C#[>WUU^AJ7A:].BJE1>[O"*K\&+FX
M7,4@Y#@   5P_?_G:/[-I20 /[P ELUR:RPOEKPU'XD7ZRQX*,9;#J3M3!N*
M.7K^ B,M8LKXD^1IK&/R([Y(]UC'*^$*Z&XJ]J*0MDX#WLG=GS9)7OH>&4?J
M1Z[? 'Q;V**>*)MU-F9S;EL[*,O?Y8K)'L_<7A4^LSNB'73M84X^U/J*V(B%
M+2']5^)_)?Y7XG\E_BNQU1BJD"N*XO/Y,?BZ7N50Y<'DIOX!6/CXS]B%^Q3@
M0W8U_H-28.X%T OQZ#IX 13?4M[W(?V#/G;XP>N3VT]4VOUFTPL /8K_[Y3G
M'.^CCB+@5!!J\K27+KXK=G=Z2Y:GI25Y*IF/HDG$_[\E3.(A+5>TCY^")X@)
M!U*U5ITT;AK$J/G/K69@ZV0QV[X_+"DZ=D7G%,/OF"]5@D=NR=QR*LJT^<9B
MH> R^R?])Z,2KCB=T+-;,J_H31<"90! *@!^+BF$@*>,)A4M5=*DD#L)2N/&
MO9(2='T^'G>@]:C<^>9KU!?W3,]DG:ZW(_2_%B1H94%P&YAT>1RLG X6O/;Y
MLY,M[H%6 !SY@I.:*P%'8'YOKXPE]?2U(DKWSG;&<;U^E[Y54$LH2P);=!G8
M$_!VOW:]= ?[+0FP-T8ZK\PHH]$#,'(FN-"U7,4/&5^A%5YB#42%JM_=D5$&
M[^T" %B4)J) ]Z:RPL?:,F7E%O_WTR\ B8Q3G1? ;RC2AVV49T3+Z O &_+P
M7'/$_YKJ/V^D%:/6!%E'(*S<2N7X?3AH9;0_NG/Q%;LXQ7+;>*;DMGG7,FUS
M:/6],FG6PQ)[[<-'8F+K.OK+NA3^ S'Y)")O@.^L9&V!?OR5P[9]]=_\&76[
M**4 38Q,#;11S%.++M@U;<MEG+UR>7_'^=+ WC5UA=DK *0S>#,DL/S0]2"6
M)6*QF<#\GD2A-U\BPN8L:T-(G+$)LW$7:>'IN6/8*3FGU""<_IQ>A>(?(37C
M+/+U/$0<+=/='VQ"[M(OS!;BFI_1JADR'>S:-G?TF@#_5YL%6_GO S&T)O)L
M8-9<@8KX\ZS7L7Y0><!0C)6,0@9WQ=B_MGM)6++UA5;?.\>CQ "_^#)%9:1^
MB1Q$1(>9!3%KM)1I<5P"!O_2!119#F?W,//>82$.G.[3,74E6W "FG-W12/=
MG@%#Q>-V?!8/OA;-^)HWSUVD@S7QMIWI3+*-7[V)LN8>12._OI:OJI-9[2K?
M9FFH7>N_)G\\T,KSG-CE=DF$P<JK@*WMJX.LHY2\BQLDM6OK+J25L6L#:VM)
M(B(9B-W#<;(S*-R8:UV*WW7 UX"_Z"YJ[%];3#8V_T-&R2DQZH=@$:Q*.E@Q
M_[8'FHGKTTCJ8E6<*,@*0XX#::Z"BX4S#LIN.ME4/15*94984"<:T>H,"0@4
M6N"HA^GJG CF::Y4M)*L:"_4H4PO2G#H=0K&X:GB"OP6Y_#WEE?#:$P2*3OZ
MZ39,84\'#_=6?\1VN'&_FW+O$VHM!(8W0!5Z$^O6>I1"C"*N)L,=,Y&!C!VJ
M&@4>!<!N9$@@C W:.*] ^-D: 31W%@OJG0$W4"WM&ETMZD.MMG)B\9EN:Q\4
MQ=."P7A'ELH36DVCTX(VN46*DDA#5,@4NT*2U1S,#4;M(Q/<&=L?-R@*^B+A
M)]+WG:/5&=_XSE:TZF)5UD-->G$N]\D%[[DFE.'!,^/SBF,"[_^7]6W%*Z%6
M(<$'R-]E*8WL/.+.6P!U-$ZLEEQ@2Q#VX;4_EUD@B##OZ\67%LQO[Z<U=L0%
MP6:'?G[,"&I;*QNQ6_/<-LQK"KGE\/;"2Z:!S1L9P"%&J^ ;S/I#?S Q_W2=
M###58JD=75#0T6= NTIP!8,IUVEP^KV(T+NY:U\9 [L#M3];()M8J2XQKN)-
MKR'R]Y2(0_._JG*.VTY]!2"W\.98UU W <&?/T36]LG3E<Y? .>; EU^"F&:
M:-KB MP:3Z_].HV?J1I>\25A/KA?\#WMW9S<PVI6B4+^<RY,*Y!5]4C<D7QH
M3;M>",S <[QE2@_"N+$RCHTE=3F?H>\D9YX9#QC!YK^B")Q *0>.+;=3EQN&
M$#?.:A],4K"FE3C'YO)7Y?X(A'!<-?,RI'<'R^-_COGTJHN.(P 2D0.##_?"
MTZ.+0.\'S&4)7'I!G^-%RA>^:!7M>]Z#6,J-,N1#05J:V<8.N%:+.OX)I-/,
M7O2CVF<ZR&3J'XL!P%:T3%=Z!U5>.V,K=YF9)68O[/HW?9Q&1O)IUD!\RX\.
M[>I-(,2HYZW&S[*^5J6:AGQ# ZN$K1A>D4$XARLZ74HH]I=H4ZSC*P#2?H;$
M8%O.HK!PJ@>KGG:!%$S.\]%&[9Z]A(RL=-Z@T1E62R_;Z_B@9'/$2NLPIY)H
MSXZS61BUPV@8CP_(1*6\\]T4Q%2)30(O'0_M\XM:C-CI?9E:+RPYXMJQO"$4
M1^A6)I#/"RTS\MR"%8BRT;XB)AE#*6E: ^8FIV7A(QJC4\=[-UOAOESA R[%
M?C@;Q:Z,0S56<6L(_CB(&#.MO'O:DC'J*7^Q;;'P-]<DP6NW:^^K09!1:!UL
M3:/&.&3BTX0O2 YJL'M&5:!Q\8GLS[^=(-) UC+%WS];= A"#O"$E#(J X!(
M:I4\D^K3>3,DZGUA33@I,Q\=KSW=EJ!&<.2/AZ\NC1.MVQI[ON0GX:>?GM(F
MZ+8- $@15[S]U":8?P]6<!XRCZ^O+>5W?3,NH";=NHAZEKT4"W[#9A[\_J[P
M_(.C4];7#R<9]LT0P@^#11L;FS0':#1Y-\00M"VE 4MF? 5[?65.+ Y @'ZD
MABO6P42?QF0BW.3:V-1@* CN#:53&G16:Z2\REC2-5*9]; #Z3M.<K,8I3-E
MZ#_A<;F7;WE0I3"&[:[I]BMFBWY"-V7L+P"V;B2UGD0G?PJ&*Q7E2$M24TVG
M-4S*.:HDAEBZ9>C.WUC-!7NS+<;S\U  MS.6]1&#6\%^WQDIHE^=P:X ?J,&
M?*@XJJWI$\=1", *,\/HR2)Y?+%^_*'PH=O@X%6OZ^G9NHX0RJSHTE^I(]#[
M$HZ*F)RTQ.I($K6DP KAMCO"\LS$"MU"]2-J>+Y%G.9A_$=DBZ.#N?E]@<CD
MYXP:Q1&#Q$L6.+$7IT-049&\PFV39BIPB.OVJ%W#"+IT7^K:RJU6*0R/_*DY
M1_+PGC+&I 0U0<+\3S2,,U:U  D%:Q,;!:^78H)/E:PW_:#Z_+K.I[+ZX[WW
MHE*Q>F3_RA$7.R[OK"8UL\^W.<&YHT]2 *XEHS\F=Q0S/1>1)K_!DC&2L1?_
MDD(-@H%)E 7*(Y?]GZ1IE<6/&&Z>92MC#0WV'SV9U-)I*7&GU5UWR;U#FB$4
MD3)*I0LV<G.I!=0Y*MUA3"G3[^X&>;&C=\EA!<=?%_!B/R;UJ6EXR),#O.^=
MKZ_'K6Q(CE=[^FO?&O;9-XH&?\U]U&.8<5.$""%?RTCNUH,PU!UBY+3.;BF!
M0(-G@W,GDG6N20<3;:@%:?863K.4NJJ/.%/><;SR#Q,.]VT-AQ5UD?Q#UA&E
M6N:*B TGU33-G"Z?VV(QF\]^^P73FV[V_2[R\#G-4KVVU3V:6VEV/'O4=O1B
M NV3' N(XIMDC.C?KDU)0KU8&!T46<L'>]=<R\?CQOPDZGT#CR6M@8+2-5,/
MQ@.P<FZL]H<=Z!YQ=&L(L*"WZ?:I?Z0\I0!Y%J:QOU@<W?]9QTNR@>M#Q+>D
M'RZ1WP$ALIEX4FAL=.6)M<UW\)OFZR-H2!]S,=X!2$EK$IKB5!Y0%RFSG,OJ
M8"^Z'%FRJ</FD.<FEI<G#QY%:[;,PJ/(_ @PQ?B!C*R&^?6-V^&H!RB\,3%_
M_[S>FXWW&>/7,*OAA;U7]/U7&&'FY<&AVU/E"^"U6G75&A_ZN91^FC/2P/\@
M98#[;[0Z?K2<1L2-", ;+%8?*VS+V8PJ>X&U>?NW9H+C1K9 G -- N,?S54/
MGR<6J\T?BJI;1PQ*?\YN2C5&'5[%2PELI'FLW1@I+\8C;C;8U.WA5)LJ3LL[
M\9#"I?>4K%&!909+C/P^:K=ROFJ44:'@<):;=2A(*0]EA'BX6#?A!T>GNTEX
MLA,><F=G=-EZJ5I>'="2(2.ZD]JPT$U> RAV\=Z;4BI;BDX?_F4+C?EI)B!V
M9MU_PMEM?(66]>6R5*^1J-U!_RE(MH;?280<J*Y$ )CI8O3\N1O]AGXWZ2&6
ML,+;#=.,KCFG)B,#QK;<:H/M?D#!',SF=@J<4JA^> A,+FDF! DLQL7L#)7.
M]6R][L:H_IG>UX#T51G9X=6V%"!_E_X$"ZU@=(1\&1$WNY;,G,2[QAQ^&EK&
M>+2?A\.5\16ASPLI')NYU0;B;]S+HVK+TY@%^*,T(%.13[(/7&+H/FG86>W>
M428.U3H-0I0D+F4WV&\%XLFX[)?\Z(G:<4<1 (RLO3L]NOA:BQFFKQ%Y0#35
M2#6*1J9V2&\]CY;ZIQV^7%_=S2IG=3=Y_U&Q2^(7 *K?;>B.N*27_PN@WH';
M;SG#]P50)J2,]#OI/Q] T+P@2.?M[;&*]#+)L\9R>U(_7%P!^U0HL/+*1?)&
MM6_KI271%3DZ+L%=;?1_-YO,M'<M$@EN&]TV^SI#"V:Q^>/A=8/"'FL!+7@1
M61(J;X2V4,CRCD:2C_QL3E\ L2M+3><*,MW*'C;QM*@G#AG+>K[G-Y$.U\'V
MP+DKN49E1#U#7PU(3B>R>1D2Y50]8"6O<5"6MYE#?ZQ--PHOHJ9)-+.,".#@
MROT:K)$5JO$[N')WU.LF]G[B6K929+BQ@K<OD9(:Q_GGSK8<(W]-/$[=7'W/
M+-#/$Z+K[3_ES$<(NAPZ'%8Z"];R-OH.W]OH)'[+VJN+4!^4*(GFYOI6_LO]
M(/=M@\VW:VQN0(C_.O"D0J2QDET^8SK'PCNMHSX\3V*^D=G'UZ.S9E%ART@A
MF'#55+2VI9Y.N='%X>2-<E\)2$FY;+9VHQ/6$Q*>*YK!I#03+B6MX:%(]07S
M,0MCXA^.\]]6L4$L]BQH@RR\CDIBG7-\C]TV#H6)O;<Q8JV;^<RAO;.UPC?E
M;!"Y&K.$+TN#32I&6<>=U9*DS>N D!:)3Z%(%POE;0=^VLISUW!M;XJC;CWF
MT3U[PW@&!.X:6O]B:,$WCX-&$J -&.AA%6ZUO0HO.3L5]?+I:RDP:SA +KL!
MMFL=,O6I[O/AD';],Q.N)14SF'Z\![M\>M!H!POMPTW-'427]<_/3=$8O\3[
M,3NYE9&L-X##X^XMKQ++3EK-'HI:6$N\3N\,XPW<MO1S&U7OKGT&2)FR+9$8
M80)#)I0F"M.O1$30ZCDWW(]*!-DTU_AK+VJ'XG@-PGV7I2-YX<5YD)^,@0C,
MX<L'+SOGXT[>G$&*5*>#!Q6!T6D(10!9]%+CK'0>.0;QFW^_DDCS46X"OL8W
MK[TKRNX:5>N/K#!_</6'I9 ,M[J328,P>*QZT,+QW35C!8-.>[]=,@XE*X+V
M'@0?_XR!.JZW!?C*0*/V^K59&T8_\W>D*>+@9<;=(9;@_B4$=3VI)+W^#*@$
M.[RQ<+1-O>#'V;J?C I[!-],84TQ.=+W5Y]F:/29E,E#I26ZPCQ06M?9-#M5
MD; NWUR-OO$S&-=]6)Y];*\#ZS0*AU<&>W.H5GKDN83[)O;%?;[9&[?\OEP,
MD37L6SD;&IMD-_+5&9FI1=.^3_^>:JV!T.#V\*W-ZY2LC#'I.-OQW.JV,+7X
M$W.L*5'U2W%<*!CCYF>ED#QU2LNEWO[PM+*?UYFKY\'B+_=D]T="E60!-B:F
ML R4CV*%&;D4X]=H-F:VD+9&*UR=1$6M!L1^K+)*.+.Q"X\<**-01I?\\Y](
MU*^I.7G3.!^QLK5>M:*C8NR!L\E%M2$%[G ;#U)G>['ME)FEW\:/<2!M=;><
M<)W7<RVSK^,+;.Z:O$?'5N-K8K?TV5QODHOR]AQG+^;4[";#+&AQ&0I7!V@L
M[I/DD:7&OEVQ2XQGB.V;[><TBT0UBE#;[^LE3;33$_*/:6F&GAJBW\#JK>UO
M2IJP%YI&[R11#4/5E-.--%U+OA<\=K@.'BRF;!G^"1.^K\+O9NH4 Y 7>]#R
MN?:*BV<[.&J\N0;KR?E)G>@(/?AX!R=DM-_@'5M[L/ \GWDU7 D^'Z83!J/0
M0Q2\72>>.&[ ]G 8_J$]U7Y8_ []1 8&N=9=8NODQ37E6'N\H=^\]_THHTFE
MEOD:M?E*@Z"-@$G3AP$S,JF %0'T+W%WE^W+3]&LW>'Q#9=["T.=56E+99-%
M.N&>?/*ITH<9SM>S!S#[[_?N]JD+LT=]8OKVDS0FYT4A4MY7EY&51YA'OVP/
MQ%3:[:_DU*'YDD5JE[<Y \Z7_,'&L0^?YAC#$N+8FMV*I21_2?Q?3(MACH69
M"A/J$Q&_POH!RB:7S?1WQ8P1X.D(QZ?N4]94.!;0WN&O1]7\X[_Q_*O)&<WD
MBRJCTWY+7)QS#+V QDET%;V O$7DH2L#A@6E5;..A^OVLY7."\!]BD5&QP&8
M C1D[=4)M*>[F_$DZ&Y$#,,1%7 !H51'Q/G9D<&=^M.='_I-ACD9Q3EET11.
M.8(M'&%HS_E<?&2Y&N8LS>VL$:\F89&&]O,U/@ @3R[E\JY5[@6@4ZZRG.*7
M8H>QTB>8<-+O4E%@?:IN>_ GBUBK^,P0QX?)5E+W.+@H0[.R-=?=5J:M+G*4
MT(T16NBD#H$PNI2C5WORZJ]<F\\P++Q9#9$GX>MG_AS-Q/CY^P+[ZD# 5X $
MNV,F.21M^@5@(G34!+&X&9I92DM-%K@3&%+] ]_?BY6'LL45,'E.Y;<^S"TH
M=2^,P$D(CBN=0"Q%ZB W)67E%LH3%YDVLT8::TAVS7N<?+%248+UMZF%H9;&
M3<I!2+N?$'=>5Z3)>[COOAZQ+H5W;BH?8^"Q-2IS*@UG\1'VPB+1GU^54]=E
MQ"U.C(^$7> 7-M6.PC*XJ3U4R/;2_/.%@QIDV1J$OIFK?'R3GT4*+:92XX_;
MY/@=]5XT8%3BN]]TM^4]Z%AZ&3&TZ?!=[*^V%2$]7O$>78RZDO0,NXW6)_<\
M#P5;HXB315[+4\X"N@V9["F'M!C7K4-16I\AX=9#88W&YK@(Q7)KY]#T;D)&
MPH)?,:%$N'Q?\-Y.2,)2+:<3^D]V[,Z:L^!RS+=\L L\=5^#@L#MVP=U/J<]
M@^GE9 2"\?O=Z,*2N\XHJ.S\IB8CN&+ZRR"RB;,'0"0*&R-G81K\"D+N\I9'
MA)09^5G*&5>]GI["<&33I7Z26&(V%Z@!8A.F[4S_Y?@?>@"<FD^/@P26$A=\
M >P12=(W@RF>+4MLT:<-\]PFL4"SV"Y^<JWES)1,5XU@*H7T*ZOW;ANTJ52:
MI,@A34E&9B$:$KBWWY"I3(X E#+&RF<>I+4480^T'LWDPY&II>:./;7C(TTS
MFA97_$P7UH)$M/LJT\\%E5=+P(7K_95MON4<EWQ.-QO&TWTY%S\*M&FCL$%C
M.9M0%P^>%,<>0<6B6_77WG'^V15T:$KT>]$?A2P(+G^3UG.@P/RN;N$/\$9W
M7MX3^$K\%/N28ZTW00ZCFB!-]@8^38RA@=+%F@9>\TH-Q-R]6ZKS6,PY#61/
M5D3ODJUTIQJC)*B13DDOE>Z9E#868CA7!?IH!><^D65CB,*0:@Y8*S395WX!
M>+1.YQV]O_>8],#(6/I0%ME89QC;/QADJA)D:^P4=C%W<?.>(BM?V5E)C+"C
M,<SI/*1%XWMG)9SJ1P]N ]<KQ;_0&(F))R2NC/EK;D*ARGT4]@HPI3J"O/^'
MOC9SVAI3W;&7DW-....%1KQGS'O@QG%K<CSS'/TV,)%I]K/O,KY]OD5?XWG,
MAOK,+#;L:K^D\1VS!WHOK:G7FLH8/A?C^E^!8KD?0>)X2+LN[F^NK49U?-M?
M !(B@ZU+\.2G\HDS[9XNF]';.YZ#4%<0])^;- 1;MJ.LIDB F-WDU-\TUQ;L
M7U^F5X*6H/ ["WJ&7C<F-]<\+<DML3'NX:;J/@,#\*_22*T\=?-AE/FI8N;X
MT,*T37[<)O6'F&2Q^=%A=XV&5+]9M/QPL=9[8:O(IA.&9RL<QCXL^^*:F-S&
MVZFT2><G&H\7@"/(2%;]:.RQF?A@T5*JU"N^/'F2KH3N.;'[A]9M"L Y\B<5
M<+DU\Q.LX#OF+=>(;9.O\FO70V"D8JS-K\XR.:5!,*.*MS#*'EEN.=S%7I3L
MZX[:T"?XPH3L/&4J/&:V</?]Y']LC1W?.'!07A]M.SS 3E:N"JP[.''_\_V[
M@*$1TBX#."/^F>SOM_G08"TCY1@?3!>3_2RPMRO@CB(B6?<[ ;6':E5:FO7G
MQS=\C%M-Q<642D#)N ;"&QUN$"* LOY,T\X_+9-.U9_N(UH5@([!TN(&>%Q4
M_\1PX%&WU2ZFT1C.Q"9B^.U .44LH(ARGQ9J)2FG[Y8TU3.GI._JQUR^"FFR
M&440EQ^\ZQ:,$.QWE-94&_Q-/I6T^M&4_]K=C>Q6\P0M#WAUP]>8G-(7DKNO
M![1?D(<BK!D50N]MI94IJ*>"H1B(:X6:V0=(8:^*X%&QH$S+]SD2OSA3R\UF
M;8MPNB\#]6@NF$C=EN%CDF0H+4Y(G/(F@(^15O49XBM3.S Q=R&=@. R!U:Z
M:Y$PU=RT]8WNO)E;)YDFH9SRLAM$N*2'"3S.M3G1H$0S.[:X8%Y5TZ;T($A?
M6 TGATP#7YW-#.\77],^$H+BA\F=0 7%^8V5I75=-<<Y._LV5ES<)[JBH;]D
M7M-U0L$ZL.R\R%<[47=@QFMBG-"=[U4E@"B<8R2I_1!Y58H3R20I;_?7WZM;
M6G\AR(\1H.WE2F?'BRRQ:&TQ;E]6/LF%"H_U18Z6>\$<+QZBR2:^VY3%G24R
MBL79*1Z:S6C^?,3@K"!D\F,A@'HZTX03TI^S9361<=EY2-&\R%H97^\&5J\6
M2KI*M69JU)9CP]L<'IQ_&BW9$[J?;8^FR.#:3QS*P =2!F$&_94Z,.<IVU?^
MP/=Q-;MX*$Y<;KI5BT_UYM.\VL'">=7)?<BBMV\\<R.V]>AH.\HN=ZU!$[C:
MH5LMCLPFQI"D>$OGA#.]']Q"CE(AZ.Z/64'.#:@58N,K(KD<CEPVVH4&2Z]Z
M/>1?!U]SZ4S2=APB/--<"O_[KK<1:3?3W>T($S$.2A=CY\*5+^..7#;&!?^5
M,R@WV"_;OQ+YN99*<!Z.0TTX-I3Q"^%"5A2W[A+PA[SSZ'#D?.*T=FS=&SQ=
M9SG63 K.WDHND2\3X$V14X,J^=(U^16*]BZE=M<9D7J,I%9#AMPW],?$V#$[
M,[ZY*SOL*0E@V+Z#!&,QH0-<AXE62YH<199//2'H%)3 5G_J#)'YE4F':17/
MFV.@@WN:H_O)-MVQQ0I(55[=WK5 _Q1X 30J64Z?7-33=OT[MT?L*7AI+\/5
MRL_S>JI 1SWG^C9I@7@;/9':+O3+C-Y086HTMUIJK.I0R7[?OA82<@"X**!Y
M.8JBM;$N4B5CBKT&F%CS]8;Y];5H;6*P]?!8>$,7=B->AOR?G.G%;(@<+-1P
MDO5$)ARA-.YW=^-VQ9><:N'&(!3C&$EP[VW@R\-5QZP TY!N#C[\\W2>*V>%
MSE0TI(+]):"G@UR1'NO$6Y:UP!%BZL$VV^X".FH>&R.SVH1M:_XTT-2T5D_[
M(SV$:$+<"!'0);"8K\<49P,ID3?G:**A7^O"H2@).;C+>O2^NSA2 .^;5QMP
M6.L\<2BP0(@S:.5#6#04M+<QK*%-&LP&A:9H7>D<%@3PSS^<N+C?.,XOI\A(
MUJ:#+GT3]CKS^B+:0]S9P+2CL]AAUJ>"8QOR']G!/>QN7/Y$VX+![*ZXC.)2
MWMO10GQ[_4U@LR:.KB,?KJR,NU_I<&'2C;6I1!1!\,I^JL*)E0/'Y>@-\9:M
MYSXZ3NA=++!O_P6@=_ZT$]9RF9(2\L&+:)]-^W[M_(<6"57P[Q\R ,SW0_@<
MN,F<2/LB+H<*DS(3Q_WV0J0EDFU>8\<R,BQ6-HCMI0WB+\5LT%H@K>RNF(D#
MV=^UI:79'.]E6.0H13W3S-G>M49BP-G0[A,>1;J@&T4&<[FE[B@LEG%,&9Y+
MAF \M(>=\H7@R[.38/_B2$*L7;X -O?B\(Z'/,C[Y:LGG ;$_SOW(MVC3+BT
MD),CL0V@,\4%HW@H.E\'6P'3A3JG?8&:S6",;>WR2$NF"@]\W]/<HUI&WM*A
MHJ>954B%URO'L3:2F;95?1'\H^MZV^H_/@UQ^YPV(:2%E5.?FGMP;\#H5.3)
MDG[:E-HD._EB*O>^70M1C5::LRQ7P-:WEPI#+6F:WV#*[<P[FJ.B]\&MC9 O
M-^?]WRZ%P^H^IWV_FQ/4EY?_T,3'E+]RP@1F@%"Z2!K9X^[IXZNH?ZY@%HS[
MW>B*?UZ,2G'7C'$[@(<D^?:G;-%/*91Z4:D'OA9W:,X2JXJ+PT$"F=5;5X.V
MQT$WL6+GV#.'T(*.>YOGE%2->I&TA<E)CS0.SIIY$YX9)P.YT9G!,ZT2MR=I
M['J#A87O*9H?]M;9ZMY;O+TGX$&O)'0,^)G]7E]8-Y^C< U/-O/J1EPD,)7^
M.<YS]'ZILNPH27D;YL6<KQ8FIU70'41(,C'A<=6 $"E9@AQ-L5Z?>\Y1V](.
M;=2LPW* XRBR2P9S4_2;[P;U\.)?2WE7#:)GTC#^+"83]_[M=G3I[VX%IRPY
MZGY:OIR![JPMI=4RS[ONE>/KWE["MJ]O26#'[ML]S94LNEV[.FQ?..,%RN.=
M7P _[_&#*W36W2X2GG%LY)F7D7#!.?XWZ #R28J<"4C:XX''KZ!FOG*(@^%H
MVF-)\D437"50PUHV,DC@]F$D==[@H1XN!G-;DI.D\+XLR[TOTE["]U*[*+K8
MVVXW?)[<1])\$[],TQL8KUBI>H# 4AR*=%U7;IT*:6T7MT*(778<%=R(3;74
M+*6U\]&S&:E6"TA/:G2Z9$6TQ=^PCJ)XC+MT7;(L-HKEL\67;,X)BAJCK+.;
MSD;J5LE+,23'7LG*1_D['O_&>F^".;\'HQ&Y6(B4&F]V?TLKX";GN*;\6>;Q
M.J&T-IV94K"%K5,AF.FAM;="4Y"4DUL0^Z(XM--1\-XJ5%5.DS+Y_>:_) 4;
M;WTINV/=[(&]X'W/= [_YK,K!!:,2J^*=-UT=9<,:?Y0?V3;O$'@]:&?H&L_
MGE%'%HA?I )"@);#ZEUXWA8O]O6E#X)]-1&$2W[R#LQ H8K)IFHM3?Q7,;IE
M9CNT"9QA$YK./]"QI*2D1#K0@#]$ E.<GYN>LS\;&1NV+RHQ7<2WT/*0VLLU
M& 6CYS9HMVTH0G[/E-_DS!Q!5[?4290I#+,,PFE!3*YW@JW#??GC[MV_F7(M
M.SX=#BJV-0WP>0?2//3)?ZI6OO^E)?G[K7QFG#?X[]C()%I^>D9C<P;"OB#G
MJ-3P]\YB6\M"KY).K/VCUU/^C%@16F'$@M[E1C2\U*#ACC1B$X^:2$YIAJ9$
MODD4WR?>8#4R :2_J.I2G8<7Z?(,RJED#,!]B G1YO!H0C-Y<T4Y/SXU#GL=
M5F3W=] >T5K:NSA=62:JM9\Q_'#UI/DY<@'!A6GK.H1@FVK1632?>T\W7VF(
M.O+[38.<U!!STJM<@>XBP+J(4.8_^B6M;WR?L^**;=^=GD]NHE1HP3EH-EXT
M6<A9(;%]T2#BZ-N.F97>- =K?S%B8)1)2YM5(3%T;3"UN6C$EAD_(<>]XGT8
M&,'64H,G^ZL2YX=KRD\!@T8U+CRA4#HMM!V(Z)C/*X^<ZO3E(R"HJ,;-4*Y?
M9F0D+FT+C5!^!EHK371Z^S"Z<Z__7& @Q@PK.92Q*]6=S0IFYBK%$\S=@$G-
M,%Z3C%X -H*H'0Z$=N%O4B*^?=RF(_J*_%,0E?%W\:HD88NZ_X_ :30H!/L%
M(*VBIS?OV'.)L$4:EQCL"\Z@:]IC=VW,35'RG&&:T2+QFJXU&EQ8OE^:J1F>
M: PHW8=82]1K"?#U]MYJ%URDS3ON]AC:J;$JH_-&)OK,H/@'2V+3_D':/7R_
MZ &IX#SU"+K=H-WRN@B]GA(N4:$05GJP&RE)^1L4EN'&(]0P$5LN6),,F@8@
M[>U16A4H=XY !@+34@R'DNL))<><_=T?S&*89Y=HCZTXXQ4G_D-Y?Q'"6C81
M.X*/K-P4K+0?*,/\O]']N^8>P\!T^A(RY(6XK!M?JO(6,G(ZB+ANDS0LFTA9
M4"KCOR8I=\J"R;PFR8ROB\&@%('X2(MKG@Q(#80T^5\=(NO[!5^)U'N7V9ZP
MA2G?;3^%>[Y]"Y\64N:6MPW9MWFKTJF3G4[]CMAOH7BX2Q0L&$+HD_UGTK(X
M).H)_+2*/)_7N6S*/W<37KP2+I3<US0[=3W W-O;BN'E*7\9_UK\3*<&T2R7
MU:D]G4SSYV?W3PF9L] X^2VIGVB ]7JTNQ]P#>$5#'Y8DQI,[6KQJ7-Y4,-X
M7D&#5G0J$(V#=W-+<0 +6/;Q9XDI2PQD6^KJ9\=^G+(J%GO^WGGYMG86XHI"
MC!LV9Q]6<;0H9'B2/WE97 .KT=4XJ45_2K^/L6V0H-E8G-PL&'['=#>0.2B@
MB1&M_)$QI".+MH&[NHB$.RY5#%159:-P0W#M05F;EZ%D9'VNQIN,1GHN9JX@
MHP"MOEHHPIIBXC..=_4W8)/#H\'5HD7_XE^(*IOEZ596Z@,!#XNJ.>BQB7WG
MN;8]8BT/5YUEX\.8A3^($K22VM7UJ1?1U4YDFNU/DQQN.D]=<,4J85.'T(T:
MY#<-$>$BLYLXVHQ2-Y6D% 3/]@@TX_O,GJ6ZQUK M!;8?WY@9!_:8I0!@W[D
MA#"2"[CD?:U6*X6_Y9.UF]^6T$QG"8S#Y\?#5_E!-MYJ%S:;4>CDX3G/^ZM"
M7X \7#IBCE>KU-7/%]MUFQRLZ%C!5/$G#\ZE)@,E\_PNH @83.OEE!)O3<T8
MJDYN"G:P927XE=IR^"&^NH8',PH[2G,H;6.&NCB1I%0DQJ*E,L$NF8@2*)Q,
MHPFO#:)3V@QEQ)= ^A3QFDGW=GC V]_N!1 DJ&*E,YIG%Q_Z:TE&/UFPMZ^^
MRBB-;2H5U]FNF8L_P,G.>6FP+^Q'5&0DXI6B$Z=W@/BAB!MX.E'A=>/"#.,^
M[77A:>6L-R1;H$?Z5SL5ZZ0KYP6V\D!JP\Y>YNH/5RU&346EB5ZD?2)4PC2H
M[3JF&D JW9_ZO VHR?\$5!D>*_QU1S&[E]&BAIQ:(3E/5OI940=,]:&N\* S
MBFTHRA;>,2_VOO&#TQ2!Z](LH6-HOA:NFWCW/++O#V01R<PW]Y*\M' C,W)[
MS]5]][+-O6,FKGK^*T:=8&I"H8?%5L(&;\6**QYK>;D\1HU@M%XP9<L]"$;*
M'668:$WBF)IH.:@>C\P08DB'<,%[8Z$F]RT.1T\JU.0D[CV5<B8U#&J8NBA;
M<#R]J\/G7I]O I^F)G36;C))I\0_;YA;M-%H$.*K3R]186<: 7V;=0P?"Q8<
M0I EJFMJ[LMT\JP0L4PZ.UWPVB)#XSY-J;EJ&>I@,<K6 %Z])Y=<'&$^'B]G
M6[&TAS_XF5L/P>*;HP-_:AK:=H>+H9!XH#E?VK6\2W MT=YX5[YE@^=JR'^V
M;9E,&H\3C??0$2.E1(4G_FZB""L7PQ^ !(>5CXYG*&^M+,-SO)9FSD' "-3A
MJSW[N3^IJT]ID*"FKN8"F9$=-S?S,6C9=.V#-@;(Z'7;C9 S CG3.42=/RZ?
M'W!U@,!HE7+Y+AI[0[$(]_:AA1K4;I_>06D0_!IAU/9E"BB$M.-4!#L7[45:
M[,$5D^/"+*3,>NIYA&%RN]DY;H]:OZ5?(10EP=#3.,@X,+FY+*"I;KFD]GC?
MP'DK,7K3!_&Y'%4%,^ O1=KGH_K&&P)A9T0;]YV99M&%YT-DU&@L*+E>=W-K
M.U%PG$Q HPW]"IO>=><&Z07 E[D-N-EQL]K:&36R[_IOC'SG-QS>^^THB1!1
M0B*ZZ"5&]%X20K312=2(3A",-GI$].C=1#?Z1#<8O7<&@U&BU]%[R_U\R[UW
MW1>_M>X_<%Z<9Y^SS[//WH\!(\%? '5S-#3WDRU$O5SR(;<(I<[RRN#G[+!K
M^6JX#7:#>\/8TQ+&K>=Z^:R6JVUG]+$-AZ(JR7^DC0-G5 O+7J"'?Y\E1BG3
M<0U1^Q%\>#FY*X$*^OAFI/6'"9763P/+;4%WEA\[U,)$+U%CKF&T,..^1<Q!
MYG"M*SF*-N0THURLL!]86KB\([:4,E1/FXPI8"UIN%4?N_+9]8%S?REG>N7V
M=#27MB)=E6Y'3#/W[7G@7P 1-QD1PZBSL]JH.K)U.JZ2X71!NV^PK=;:[VN3
M\+I!^A7-REVF%\W]F7P3V'30SD#X"?M"PQKKA)9JZ<;F7@"I^=EF@5AIZ>F>
MJMA6'XJ'?4H =X*#FY64JE'SXB$N@9><G[2?>-'^%F1G$3DX[^W#8SO;WSOV
M:D _SU&QTD6]L;<P(A&\:M"95D!_MZ ^U7SV&$$MF.@"U"LJF8YN\?5.TQ[7
MAZF]C_CUTBA(^R 5*:DZF6UZ88KR\*%/BTH?H2]S:!URTPZYDBE</W-OX8NI
M:HZ4=S681PC?TXVD<%C'/1 L2C W5FJ4'EG694!F<X.WT?!*--M<(4-Q\RGM
MY8RGQ#S3I?QR1_/[Y+*EZ^O,\OZI[J/USI0@11-JJ=B2#RPO7EDR-$=ZZ._D
M2RO N!^^QL&73DA$RC@9_06HTLS?Z"PA!1\;5D&'HK8Z@"X[$2#5](":BJ]N
MO/.C'8,I]PQ4.6A&$INVT-13M7G%XW1'H2M,K<K1%MD_O0ZN%1XE))986B+4
MS$(FTF<9G03KE!AR;%:=9OG0KBT-Y#I4OB'-=5:>;33U=#ZJL%.99VZD=5$6
MV4+<J%LT<.@12TM*=J)@M6CA_@;P!9>R5M&9A%_4X*[K3L+.IO:K[OU4^;E!
M3]=Y<V^,F4HQW>HOM[C__AXS4ZI] F"Q=V7A3D\SX^4R/].OA\_.X'+P]3.,
MY-Q\!'LH\'Z8^H)XA^ )O_LN&9?4)U98E."PXF=TI7:5UFZG[DY0NO=.P,KV
MI)0J6D_ R0AJNJ)(LJU#)NN%![<-)%5KEBF3)CI?0E<,M*%J,P<;,K(TJE]@
MMJJI@:EZ/56N>JL<QZC0VLE)=!%PU!E:/W]POWM^ _2ZALN#>*)UX#J'?RYU
M8H@$MSL(4B@R<%NBO@M_L_-"\ZJX%NI0-_H# MT/,@NOEDEMA&9+ ^3]H!CI
M3J?]^BP'%B(# T).#(*/@5]%UZRS-R(GW&=TZB^@6-D[PUESNF+U+?EQ(V^Q
M4@B7Z=--H./-1QL;$<07(IGO7\/ KEK*>DE@3V#CHU2EXL1S23_JROT^"-<L
M-&JBW![#0B.&B&NBENS7F_*"311%&4]:(&JQH.D_\][>XA]_EVHC1-FZIRMJ
MX8L6"M$%O'YVK*7/P\E9$SFA<K@)103F31T/L.3G)]8S1H]U]WN=JDYY-9A%
M]TWK)R81M2#P:E<%_VE&4[#*+7*[G@U8E+_=>[2\+W ?TK#C@T-)_F:6IB\S
M9T68@C!.2XY+H4/GG!"_AWP772WDML-Q[6)/^]@D>0]U>NEMXNJNTL)[R6H4
M[0E:\/%A^)#FEC&QAH$QVH6;FC>A/]JK:PC4?K= 5Y;3E:BK[JM5JEBJ/7CY
MG<BI$$<4M 2RL<EV3)LWH2*@]=B]V,?,?4@&R@\X%DRN3)3X7MY$IFQ7U_OD
M^3I'DD_0S]A-V/6+;+=7F(XHM14NU4?/'<A^WH\3LF0U+HFPY*1\-#]0Q!6*
M ) L'O[41=[/'T\+*QO5+8C]!03+Q)TS!/,BZ[_6#,:[(ITFRE5%X*9(O\"[
MD;S4K-0*<7?5-CC)3P2?JZ-69M3._Q9^<1OR1L4K/IC;T)3PHL-]IW:X89,P
MKC&#%EQ<K5TTGZ=5[9:M4365R$U!V*&=JWV+S(12P^G,KJ$(B#C>?CW-R&$N
M/TL02QMNZJS[<DKX@W@]49\1\^>/OU_G;UNFZ+1]2?^DDRK7<\%L"I46_WBQ
M>NUT#3FS:F69+TTYZ/R(9"B=GI9&*)486R:96.[>C"2=TTCO&Q3^W-E#+J45
M[4657DI(WY8F.#TI3,Q?&ICBVM^P,OIEO"1J:;%6&@=<_B@NM\:2\[4J LH2
M*U^<)-M(IHL/L3HX/;@30DI!;$=^_$$X40GGH^JY9B+SS9YUPH)A(:J,%5CB
M><<WE@?JG[T1D2% Y9'$0[L3?Y0Q!HC;U6&N)!@!K ]#3#Z;8K@*+?G&C.L<
M-^EF$8^,]A1E9%&O_PL8K,Q[S_TUSQB"+#B=A12FQ/W<6^;L(.([I=I5O,Z;
M1"G*]%@[=RVNXW+-RVK?;B7*UT!H"U4\K9UBP@O.%GJC=TE,7"--E NZ2WP8
M?]?3=R0>32 @G;\D5@<[5ZS:13SFISB+;C==+"+(#O \?_ /SJLA#US]D7]V
M-+=G4\WF#U1;TN^4ETU1M5".Y]/J75,#G+ 3MRN(_?TSM=H7ANRA#0(6TA*J
M&J,[?P%VCJ<2-U988:L1#6$>G\9W,%.E]@)CO9,',Q(?$9FX);C%F3](/:3E
M\/..FUQ_8@-RX1HR2>Y9!XS.0J4B%P0)*.J!7B*EC9(4(EF'5;W.KJ&*KFOC
MII)=+Y\4HTFGG>?E)KLJ:]>W]%QZ'9FC"8C-@998KS-S"N"V>V9)SG>%'BTK
M8K='MW&[F-2E!745[YL,/F9W5Z2_)V.E\HF6*?DY4);";<XJ;'EYIK<NT<)I
M(@+V0*%(AQYR1E>MA10URI1 ,&Q2SHZ9D^]=B7/U([@&H\6_QUO;_@5DCU[R
M_ 5T&4C!/M,.$=PU>6?<G]Y<W-G-?256^#>N:<6.1];W;)Z8GLB<_VB+F[X1
M.>E0#R\%6YY:XI[L&V $,;(:P]T]GM([J5'1+.D+3FH=V]=6MEFA"Q1!(UF:
M/,/B&\*_'=41LVYK^T?5JMCHIC;O?1%[U:>:5C8L7%Q<2*&[KLE.L;P.Q:JP
M3\?E3\1R*Q:2A'Z:%D&UGCUZ@\=[&L/?4/G,\8\&WY?;4#_-I&4JBOFMC"52
MW)A*AOGS[D:<BDEK_?3S7EKB"RT$>OZ'_FU"AE%:L1A:C=CSGL<@U_J>Z?EE
M\]$$B4@W^\?%,2B-%%7<'IIPVMZ6-FC5XN)+%B46G.>@:]XCM>+%)C)4PF2S
M_G[\[>_@2H-&,S( \F7?/?Z>I/O^A?GB9/VY=$R;*?DN=S)R88P.%K&Z]W!\
M=4'5</>N_MU:4H#2;W.;F>,G">A.:96S9Y:[C\7YB4]UP KO =H,YG3K*T[K
MX[<1>?9/HD:Z!7W0IKIGD*@O#+ FA_<$ L::T[0C(0V&76T?<'5K)>Y<L!$\
MBX7[^0LES3XU@9'<N3Q!@$ZD?&7#;M\(H<ZE19-GOM(+#YEO:R3="X9N5HM<
M5+O)Q4C4Q3M0 M[OVK/RD8IO=?-VYXVGTXT6'$\O/S/\]@U.>:(O0<#,_IJJ
M$?K;MX5+2$;G:RG(>5>=G=%GB_Z!4=J&?WNA&07:A]'+7KWQ+\!JB6D8OC,F
M*&EF8OMX32A#K ZW#!R\;LD3;=HGI"S*G/&)9T3N!/-6?%64[?(OH*Q>N''*
M43Y<QI3N0ZDCY1^@WN@ _P5=W=3U6<V>>O>NXHFFD"UGJ11834#_I>W=J3&+
M%B7%ZV!P8*O>+X_#'I5Z]V*IF6M[1?EX7_P_[-D><*9:DHNJ74?5V@;S9V85
M"^[Z:S;E\6$-TF58*O(@7G)10WU7<0[RLHXWE3X] DS^FLUCE^CL*Y> =0=D
M"#4R[ZR7KN&@J^3ACRD(9!1V5GAF R#'LVX5=ZR:G@'&%KBD->,Z%<&_#":C
M>*QBOH&MH^9J7;6#3G;[C[6"8R5=1FKG!7WNPWF\H+_U1=E*F%V)5@.BJJ2D
MKMT\O9IH]:N&X;CY<?&I!SCC4O$.] ^>R?47?7HE@N/E+M-9O+OI6H&5L##9
MMUQ+9YHM\^B*G1FB?E,2L?%1:3RXXD#(QEX"G/K-AH"[X?TCG(67ZI.STIW1
MN].3O#6%=\7^-2/Q:V:%M[&3UF1_ 7=TJ_QR/M+#P0G,+X\;CP%*0,7%"==-
M"/U'&6U?[CR"O>4>@G17W6M(R[3U$L4YJ*@50_TNIV-?HD;/D[.06R!]C7\$
M8$'P3SFE%T8?+_*9MI&1[::-SNTO[5P-=!?MIKE4<TL85OZ8-_:W'QRN0:N+
M^?KU2'IF>'["EG-O^)N*9MB390VB65M2]OPG_=8/>\[*SAC)Y0U"&;<VXW[5
M]!N^4&(5Y)XVG_1[1C;$JN,M+"QN_:KR3DU%IFP;0:2=4A2CX]Y.^N%N$'4Z
MLKENAQ!'S,7_E/HBZF*!B=PJMZ.S[:"30(C![OE+_0*F#9SX?4RR?A^+.$8;
MN%A9+FZ=;')\GM)66>\_\]YISBT70\,BC4GRN!]*#'HI."^]SJ3-F^P3I7B4
MT2G72_'*<A"=3=BEE&V-9SJ"*E]=&*TGB704][K+7-H2]DX36[<<.,M093C=
M9-_KJ!@N:2&OVC3Z*;2Y,: -YWC+:4S7P4%&3G(8JK4]BTD=C5N@(Q[VVZX'
MOILXH[0M'<4,%<G&674^L>[A+7'Q!3DM57$$1H8^(3=>GA+2UV(2#UR0E O]
M"\BD3O00PJX78R_7;<4NZ&N)$&^E) PH&_A(FV-7_JR99<*<GN:;,038_3!>
MGAXWB"9U%HA[!#S*("#@#E&#+N/5ZW22XX;>)@2"M[=WTP;OI)I@"+X+6A:+
M?:,4V9>N72DIK DEH"QARM:GE^<L;DMC/C&P E?-6M=C77A+3-KML<BM0*QG
MDY1Y'*6?OLFX2EIP=I#D"I,T$DE08=:JF6YY*.QSOA%OZMLHYFK*2+$]:+[1
MJX69\?98T*U<P=R()<>N,$M+_VR)ZI8*^WK5TNARF=2JXUC;MXI:MWD7246#
M;ENM4-**P-DB3EJJ=F)48:;W7A7_%T<P_&B?7+WGN^CDIJ^/N8KJYQ[O>7:K
M_=+4CY_[?9>*.TI='D"YJ8;TR^9O?'3N<0XXNTJ+I7W\KMK3I*9"JV=5^68J
M /=CDG<O@_:1L=8Y>BVK;$</JU@S^!R;F.XQ%LKR<_O=5XH7T!,"31P<W$<_
M]!:1%;N2;I7I^N%U<./*T*3899<W$Y6Y8.>L.=\[R-%">@N\%;AL:9S>6>U6
MH!1O7WQ7N.#A.GWH3=91\YB:)1RTITU!&&7^VITBW*>#Z<&0TBD\=R^:P&;0
M=&%G\L08>(L*$'3XY@YO_/$"BS'4]JRPCZR8"^!V=8A1.=)(:4!4]G,NBD?R
M4WC]^?9Y<XS]693I49</0&G!NME/XR)B6@816Y-1]Q? M5E+(U14LM4R:K<Q
M(615OF.@QT:K7/NBX _"9<-3PFK7,<GV]RD%J;<PZ;;:'2#[LP?I&^(3B.>!
MAW T:%\&O"HV_ZW,2\9ASJW4MOZ46A(IX('9^ NPD'XR&_%DKOZCUM?/A!'N
M^!(1(;(-6\P O!FMP>K&:O"=DM\?)S]N\DI):I>4VH%HF6?EXI2GKO1H-I+G
MQM?QYXR,,IZ&.P6D7MIM8V2O<D=(+)XQ;3DM;J42,P%DLD!^ %OON@L^V%TK
MX@1M:OH.H>AX6.;8#>9V50<ZNOBS[\C"IG<GCT\-\N83;O.U-YKM1II',ZF8
M<"8E/,X8LJJQ&Y1.J:M<_>W^)T<7U0Y>$\XA[Q\$;#^Y6^SYD+F4P&W"VK4[
M^N(_7HD]_]Z+0Y*U1L 9H]*]6NH*QM%='JHUH5ZA<.OM-ZLT]G*+T98 9FWF
M%UQ@U!KGY/MLI. ZAN3=[%L]^ ,*\V;F:>UI9.2C@\8&I;CCMZYDA5N?'A Q
M9U,2?3HE51O=G\)N5''PQ#GQUTY-EK0,Y%'ZO3N0XJ6P-ZW_T"M:,#ZNI^<S
M6A41?&8WM_X=;&]'T6$93\"9F*_K4PQP/SW#DI%:<*J/U_+7MWXU)WRS4/]Y
M3^Q,YA>A%X=&>.["YR%WQWXWYCOK O>!\M:GW?+J<WJU)8?=SV@C.J3'R,DY
MW47SY7]#P$/PZ?.6152=3F>3TQ![.<P0:.?&TWPG"_H9GR>4F,?HS+S\141U
MM"VK,<4]P(#1?0'PFK91YM<6:?4-M=V-<P"MW*1U07*Q!TB%*[_H<B)$L [>
M2R'-)KS>HGKZO/=-ST=FFV</U)<)4PX*.307)#PC3^2+K+R7,!!]IS87Y#B$
ME^-@I70T3>^"@ 4T":Y][**>7WK/2$%X.U>[A_U9M&*.@BD>:HHW?=<%I;4&
MXW!Z0D@U!VVJ*H4R[JH1A;8E(ECC,MB+%D?NNRSS6-/(>L6L H>CGN-5VB-[
MKAL*<$#^%3!980M8Q4'RX_T.>T!REA<B"#K6$UUNN >LX 9F47@TNH\TB1PS
M7ZJ$^U*K9^+!AP;QBMZ("2'&,G]94$)BY$BR7@F\Q0YPP^/ZV^1AGS;E_FNE
M6=,\(-5P9IZMVQ_-<?N49/V&Z^:;-,&Y/\C8$1;B*EZW;!=@M[KB+<#&V8[J
MFN7 %]89K#T+'J4LL$W?BM4BR=8C3@]DYMC>R[@0M$9^QU1L)I28YELXD9?Z
M9I$(&Z>%^Q=X%D0_MI_OMN,I=X,Q-E]/?]KG,-*<J;:CU-5[%^E:5)30^/">
MN(""LH.)90RR[IE5:'WPY XRY/X8#<Y0OHUKF(B$<W=/1R:)LZBD[*WO1_=R
MF2#05/\<$[H,Y[;>)H&BQ;[<B"!*C4MM0OGJQH<DK;<OR7'H^J)Y0!#_C#4N
MMK ISLL6*1E85P/$UZ)^;JO,VZMJ5K]V/@0R%%6CUF^4TOW2E\P@&\>G'94-
M<,?9C>7%WG[)=$B]B,]\23"15?<SZ1P>;F!_4TJE._%+Y%WB9 XK5%R/5K2P
M[W5F*0^C5"/0@.<U+OU7K@C_[V0D6^>/2#Z1?A5R=+,[F-G8\M/_HG+M2<>^
M1'24ZQ2YQZ^JTXN(+)=,]=.*,:/,6.VZJCUY->Y$/</QRJ6 L_)K1&GB4[6[
MMBVM'=.V_?-'UF_M+\4A+:AJJ,?>VA0\HT1]JO;@(D/K-&N>UN K_RGFX,:*
MC7%R-"M<@%!7$PE="0O=<]_='C:_4"7:!U9"U&$DC:ZFK^88GDSQ"!WEPG:9
MD#$9R7H5R2L(;5A],=3F_EX%?F=F-\?;8FWS?[L4)OJ^_\E^A7/]D(PAFQGW
MY9C2FH\9#^"V31824W^WQ(%ID\6'7 <TP:P!IY\8D<N[:+CMM1+@EIR<(6^.
M)=#_C/&+OXTUSM6_UL"^QVO0VL;\!23*<_N)\!]+M'J%BA['.X)8^14(_JD!
MHU)>-1P&3 YUF=O*])X\+E9675CYLCH8OXEG@JD,'XIM[93Z8JDKYAE&OXP+
M?GI&>O4Q"YDZA=5XJ 6E/WB9OR#>\I 94C!V7*N>YN\57HL"/KY-8_0Q'%%.
MF'OFV/E);:MBJ)"S$/<!SC['C!9)\ QUOK,!U:_I_1[]N-*/&LR>^\:1#I':
M.2?1B$K7RK.A#(/K/#]CNQ:N1M%WG4G22W8F)=E)3+BA"-%:S S]K[@=EM32
M1N'=Z9K'$_54J'61O'.OI[Y2'L?F#R]5[.'G]=UWL-\T^1^F8A8!LE]!.'M!
MH7!G)_M0S47(<,7:7X"YM4O!UNU :\]])_"H;B3MKJO);SXFO:PNI24R/ KC
MGM?]ZC60FNG(BN3;6WCI11?^>R8FO(5S!7F9(FG&'4.@C6WYXKQV;W3_*JAD
MG:??Y7#CPT(IL9C%FJK(2JEK@=W%+^C42R:_EY^4%C>YRFSCF.\.*4A=A$#9
M9^=RN=)0Q#\X*G0,@Z1Y&UI;P;C$?7_;9SY5"K:<J:??#8FOT%,2D.:;R8S9
MS!A\WO%C%7'&]U6=M;CQ$9@AUUTBIGX6)5 Z>0ZU]G9MG3IQ/_3G0-5;P56,
MJ A[U.'<W"T[+\J* *1Y-03GH:^=@5T[$^Y6:V!0J)EQLK>!P[Z81,R>[_S)
M6MS/LI1_IQ!)Y<W)^+_+_D._O@(^V:"O?9G9I<?^-?(-";J6JP^NQ52+P%A2
M)6=3:*L@GWX[^K:\V]RT)"K 8$]*W$-O$$3H(H-ICN-5LSI[&<L<0L4I<-@6
M?+*X5D"^C9K=HD=X^CF50>51T]"R61"(6GCG7&3"+$3KY&07H] :W.)LM7A-
M/\(($>W)M3T5#.0B^DU&1/3()_M"NF6T$BWT%U#D@'"P-ZV.CJ\LGZM9R9L"
M.137FCE8MYA#=EO*>\I!#F?<%$FI*RW\79I:\H&$36VXTO(3N'B8=. 98[,P
MIX,H_R94O-\$3LCMXKPP-,K0_67>48-^/IDEJ?LY1@L>Q"@E+^H^3_F."0_@
M<7OQ*=2Y<L]J[+2RG&O7XY>3;L%@L/_Q]X.-S,/K,HN5TS<2[EJPOB@MR[M>
MMP6OSWAC !\),-W,/G;)R$&YORT&2I6TJ=2;\.?S=%;^IEF]![:A)=*F/R4K
MK+MK;M6(/4[GXR6Y4Z[,UDKQ4_Z;'!3\[47CYEB]K2>=,*.*I#,?N]E^A:BA
M_Q.Q$U&\._%7ZQM_S)HX.@:W+W5"2%-2'GM.,AQDX\O#[WV[HCUUZE-2L7,!
MLU.'-^IMF.\6#(0<;]G,KM]<92&2.S553[Z<T7_D$_]O/A@5_.DB-Y5011IO
MAOSTC*Y$Z!:\3/C.MT7FF"Z\X?Y/\0)#.V#O*LWG'*@O),C;WI(!M>,+Q>OW
M0*=-F9H\O&XNB2>D?66AJ!;.5#GY4HUES%?0)_!IC.G8A3Q:Y%VE6YD=QH*#
M6SO?(H9]_=Z9Y6-+U?HK$YI]A8T_\>O[*WYLCC2)Y:85B5$QT30$"KG:J1*)
M/NVS<W@HF%H5,G3_80SB8E$?^G/5'=/*W>H\=.F7&:V'A>H0:$_ZUB1N% SE
M7RX;\'9T</@6)]F"CD:D\27;S-P7^,RNWM*[UIR5SZ,Q)G&TU^[UFRHDB7\!
M#]5NDHJ15!2Y'?Y?T$%I:'7'%Z^=GOVPYA!T+7++_W1/VX"_Q2AYTL8P8H^I
M8H"YB8(.NE%G1O4ON<RVW?V?K?=5TY"L]MV>ZG_)_/Q)D"/F\S[3%&L0XY.^
MV+7M,;GNUX'N3V_H53,*IFK*:?6QF?!-91,G+AC[)7N2E$%0 -S"8LVV!;S^
M4=BP-<A9?-DL.F52VXF=T8OY?;LND47*9O?O&%#PG+2/K,6K7O,\8J2H/LK9
MZ/CHBW*II]?A9KO7LQA8V6W9DY.HRL_KTV@]*:^\%5%SX7<%R>Y->F\4=!*\
M=!/Y1C)S*Z])S>:&M X6,QP>ZS>]LIG<NF)\8Z3!O ^*B>09+&BR0RV]Q63
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M-:J<X]'"N;%9T;'IGY9.0:_0>I.=\G JULALV[3,;*;*1O #G+> \.\0@C=
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MBW%YAJI8%$1;%\*[!X\MNWKS581SI,##P+721V5?MB#4Q[B++I\T9'IH3T"
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MH-A/_M8*Q"=SNKE:FB",7NEWA;'ZBZ!U6)F.T7/.UP+"KU2_P/Y#,?(V"E'
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MIF0+- BF=1QEI=9T5B<'S)Q'6AKMF%T)('!GQ=V+!=:Z\BRF$30JOIJ&TM\
M]ZR-7<XLMG7#/.27\DSWZ8@E)Y'"8VOR@FY?VDINI4]I\S EH&BP.?]A$",J
M5R*O )2@Q^O?9/X7?PS\Q32H_>;V%:![XP^'>_9_7Z" NT+*N[X/S)6U\:!8
M[J8MHJ?=D6B6Z_)_!<Q"2L9RJT4\;N>(::F9P/9'S&7HD.\!\ P?PFM@@F5,
MR'_$K7*Z13<J$]H<M(;JMOT ,J[VH'[W3= DE.K5PD<6_88G+@EX]CF?_9:R
MUNFVL36@D.W-GLT.3,4@4)4:T/)<$(IF+1\5D>KGC'@40$K][[B>&6^ED/[
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MX&\D^<2\0+#_ILI[W>9,SKC?[UH_B([L]-L?=>-3X/:J=!J=(:EVLY/#3![
MMCKLE,?0L203B/=S*)\KU%DI*AKE4<T"5K-=T$W&[TT7".9]?^FI-X$&\OC+
M77-4POUP ODP4CDX&INOW^]$MV1L72CV-INK-J9HGTB$K-A)ZWZAS0ZFS<NF
MH44(^'AQ7Z;61.9VA%WGF%]JTV8VUG5]2Q9&WZB0HN(%V5?7.[%:3*FIE-F@
M R0K/A7NNHR &/G2DG0GR_+EOC)^R9FA&,+)=<\-< #!_"X/DK87*1![%$-?
M%DUX!9S-KQ9>R +*_A+B-[&KA.H5_G7C 1/<O\X(5_[QS">UYU%8ZK:G;^BW
M7!'^W4YI *]'B6#%OQ<T89#+7@%0$LI7P)6N6,KR TOU&/F^":[/7]I!5EB_
M0)-]EN@J?044HL$Z__4K;V\@]@!2#>?TUI_XFNH,9?0?&0Z;^STBS8F?\9_<
M;8P0D/%/;,8PE4'<"6"!R"DN9<U5-2%ZY4=S^L?&\U*#IF62PQ:,Y:SG/IK?
M<P'@=V8&FP=N7M,E*6':+:@7AAET3KF?V[160&GXU3\NHR.O'&M3(C+Q];)D
M-MMD;(=B9^1#%TB&!\IQ+(U<#3-7>,HBB#/+[,VF0<8%<_*?TEI:D&G-USH=
M,L,1<6%JWO\-"1G74Q+3K>#I_/!O<M3<*^WZ5X#W1M?Q[B*"Q%_+?/L***KJ
MW.A\>!$&9/V5BT>^N*QO9MXB 2) KP#*7P&CEM>M/O#C?U\BEMTK0/YM0%_B
MPPW'/YZ "?Z@_0KX3BUVB/X*& J#X?^+.<Z?74]NO7GZ%6 D^1NW^1^:T-O[
MHXF5FZ[MZ&"E?^: FSK-*,F=P6D+CR:4KPT&GN@?0[=TU6_"UG=R*9MO\YG1
M:<HN?L@C:JAF>%NJ9>O>(.2(U%7EI]>ZXFS\"3G*VGP],HI6Q3F,4XSZ)T'7
M)9.SK4L!#"0UC/J_S+F6E*X)7FJ<F[,+;2V6BT_7=D(:':*5<AT__AHJIAZF
MFQQM=O,98NPK'-RPR"S*[U[N_!NBN+07^>3'K-LC2Q=,!)4'%MU70-O9^HV[
M VS>7YW8T/Z(0'O=93T@B"Q8^2_[Z'T%"#B?*SU^"Y;2"?INVKG+_;#Z'M;Z
M'Q895!33N3D4X$?XCP< W50L08/8%->(KX#M7X#,OUBC!!W0.J_8!E7_,=N5
M_]%L+Z2[Z6O^B1C"-G,<Y'MIL 75T^[259O3XSWI3JTQ+/"!ZF_/%=2ZAB\D
M<5PCF(82#RDNVBRP0&2>$K$N;FBI5CE(OR1)E3H>!39$$+J/,+>I9RXTK;81
M5AQ@.= W@A\(Y1VM5ES*7-?-',A%R^R>B@/L\8UP@%H_[ E)[+25F;Z.I]=J
MFW%3946-_=2!S>]>.@%T\S#L0AJ\D_E&8BL/1!+LRG)USN&\W:AGY]^Y"DVY
MSN&*&S"I@5>GB#>BK8NVE>(BQIE-,8]W=6;M)Y+\TW,ZQ4_T8;HO[=@.:BLS
M7P&:4)XFT=Z,%D=CSM75@3<8<2GU<N^*Z[?8-.0<2!S?+ONJ>4J$"@72$P -
MFZMX9(;DW^KN)+AM:(]/R^4YQUE7=^!TB(C>=!Y</&L9I2%P:&O_.C-KVJ@/
MQ_'[B;Z**]<.A^RW LF+@+<-A@\ %<Y NAG:]1FF5;O\<UX!O+\Q"8:NDCG6
M&;K&?.#ZZ@+HWMP.G5X: <X=<N4_/%_X/2T$O_]OL['VM(,VWCA?"L03KNFL
MYMRUGZ @7&)TR*Z-W_J@P<S4YP7'%R[!FO^O&?W/7PMS9^E@HH%<&XH%(,\_
M35I;FY"],*X/EA9G,D$6B$?)$B@]=5?^G2.]3_KQ-VXK/:,,$:HIIAP@P@1G
MC2WI@-&X4R4HXPPIVN)!@? T:7VW'69S230Q]''[]KX:X-.H4I0?>"_R8M]-
M_E^3D3WQ:_PIK>>RQ"(XIT4 M$;>@,XV8FIJ9S^AV]8K  #3PB\@YE]?T#]F
M!SPM!4LNS-7X#>!N<(?C^'XS8<R1_DTDCLOHB1-B\D7*U_-@UM?/!W[@G\'^
MWQ8*^];2^@5+]MH:@_EQBF45TY_\UJ^S"7\=F[^C0WQ5O ,N+_B:0E:\F][_
M7U<]031^"1CQQA;UZPU8]TYDD1E8)YCM^X952G;V>PKK1WP$3-Q> ;*>H)_)
M/62R><@$ZU)0><?:#Y'U4E/60"P@MYE-RLE+%<&N:\8@2M2+2)%^>GU"+9H$
M4[NKU/,&1B@6M)MC1%*$VXIPB%?>Z.Y68<K3@)YVGPQ>N=ZK'\[S:&GUX,(%
M4_M_?[^PRQVCWT$IH;Y;&F(2+JFQ9"K@6[D.JP9ZP[:Q,@MSV[D;Z5+A)\:Q
M%Y<YZ/M[3NA),A[J)I<#Z\YK'3H\=2R=-/"7 08J;,AI-WK6MDH\#4=O^6]%
M%4[TE4J^E'02INKNCP C&1>!7H555 'A57H1]6\74TJ*4HSHJ9"F9YQR>&R2
M^)%1NA=+ -UL/WY-M_HY5>F[@SVU6Y>4F:;I?Y17^Q<OL &UB\8MT KWZ1@*
M<W.8ADOMOF<-HL!O)L#[1KZ9Q)1TE"A?.O9^C"RIR^.%J"<P=<L?[UZC/O#?
M(TM%K-)N&D%FXED?TRX*IG!\9%UH3ZC3?;WEQ $L\O';Z2HM$X&-.H SS5=
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M_+XI'LR'DK.'5$,S<A"A]Y^9V\#\M*^ I1-#=8IK8OMG 2F?HV6AARL'PE>
M;EK7BWROG0[G'_=?;L24>P7,+#"AAJN8B'VMYN>'[@%)G)U8/5+&_(0NC0?,
MD>*?<W@PZN8;!-VGS@E[;HR/!BU$ IL";Q-I59?,:*\1GU$/TY'+KLZ& ;!L
M*SP8(0=+T$=!WH'N^4KSGMG+IZ-:S>233^&:N> RA16=Q7BZT6>"[97"4J#J
M60S'2L$K0&4T*)(;2Y\U5[#&)(4\6T@PWQ.&PD$:7%ZS39HE,L7Q1.Y%*Q#X
M0ELZ\+22%C#@]SG3^Q40].W[G\1OZ./58L(=%\2@\,2Q05KR%; Y58J+?6^6
M?2PYDYCZ;26P=4!]ZJG+O'NP>@V,&H@$$M3G*-WKF6U]7O*RO=O([<185GD%
MC/)"\C M3(\KI=9K^2D1GMMSS?17M+<4(<W>EB]TP!]=2I#2N)VQ6H;GE,H[
MC@"(QC.!8^[7$@A3&[%]RA 4+30]/WSW<?$,3J!+9(#X16\>KR-;QVG@M+A\
MYERH1]CQ%="0XQ&(!>:8<6/8JX8F8DH )PDQ[WM;)_)H7@%YOMP=8@&)PDL=
M?2'EULK3#!3V$UT4O^[]N^2A8>RCB967GHQ=?S)@RQ>Q+..\2&USR\3N[A$U
MH (IM:4X3/'YS^ ^0E?##1A/-0<3G @D:^6USIS16]/=T[>&,9YH:,BZ!YY>
MEPR"##V1,I\:#UOFYM2C(3VD9S>%T1?UET)/>+74*2(G@MSRC\ 'E(3:8YS@
M6W"=-=8-5JM4%M(.ZG&FE\7JSB$*_[WV^BL AZ+A/%!%KAIM0"4@/:ARHAML
M./('&K!8]D^>K]V@J871.>ES$8M$QP_N\)K5#XM-<:U&7NO=>DFY2]@JWK]X
M!1QZF9_7)[P"^%;"?Y'8!OII0I!> 869^:0BN2KZMD@E"I9M_.\M9YZ7YHAO
M*F/Y<N/<@KX<Q(46_'E-Y09';.7$,]?CV?0@F?!RW2'%YJ#JV,P-N^ !N 5\
M7[$">4@6Y:^A>!DWQY28)F2SAGD%S.T&'<2OA\VLC=>T![\"KJ[R,9?>^.R!
MA+]I^U\Y7+\$,AP.475@*I[-U3"]R!B_I V\*%T@WE?PTLXUUH/V"NF&;_B8
M&L9B4O9J)COOV9F(E;;D,N&_I;2+GKI2"J(&5^8+[QZ<*)D_R]P6>MWD-BS'
M74QZ.,3OSF>W>>WY#;58C8+&),?;2/A+^8GHEROVW?=CLBE(XI=S(-#5@PXN
M#[:/VOT_6 ]7VXS\V8UL*_1#0$M->#MZ37-S4OOM6KD7VRO:F5 "WU!^\B6Y
M *LUE!2GSX5!.N>?Y$+"7P%?!V&0NG4O8:S7F4-ATX;*3[I]8<)6'SA/7^Y.
ME5,J;2%KO4X[MH2.C-;+]=O+@SK)D(;?G=)>"PJ.DK=T!'>7E1T*-ZGV7K\^
M_7J!&EYL)9<N1#*5CR]\^*;#W"*SIR$O=!Z/]-LA_IU//]7? @->?&S_%NV6
M7V;5%^%>;H0J8G4GB3+GS 1TS(^BY$Y0[9-< DZ](=V?)4KU9"N'EDR>M%M6
M19N5RME%D1O*]:*1O\F; WT^Y=MJ":#K5M(WCKT,AO/Q*8S=AIU7V>^J-6"P
M.Y<'>#O!.7"K6>AV^#_8:65@84O%,-&8!I<F^&8X*FZ8, LX<RK5^UCF%_+&
MXZ8TK7L[8R?MHDY>D%3@E*L5:A D5]=;JZ4U*:BGI"0T*?'7\[)0.J*QA2Y$
MZ2 YK5)Y4&IFD.3.DTWQ%LRG;*64&DQ]UJI@>Y2,P\5M:FU(&1X[H^\R;.BL
M<E"PL"._L8]D00_\=92 RL#+F5C&JTG^!C\D(H*\@V47Q:#5,3NZC.]21!BX
M6T:<+K) 95YR\2&AR983;Y;MEWQ-K\,(B5R4K]#NP:=,PS+VI9^DG&Y)W]ZV
M]2$@1*DRQ7,J 3\G;;(V/FYVT6\"/84\0KT,H4D:C47&FHMVJ=;JP.*JVLXV
M[0$D!'TYG<"0%J(&=?G)M+(2:!ZVJB;:U2H)56/F#,3<623*76A"R_[CVJ W
MXEB/(]EH8Z'6CL-1'Z]'G3WMTFB4FEDD'A>:.M%O:EB8&<!"5?3HUQ&%LOT]
M?9*/1U#IVA;6-=_5<B9A[R2>859XH_(J+;L?@IE6*XLJ=M%]&M#8[)4TV1]M
M&,N#K:"5X)3N@J24[[!%)?=A@R>MNYGV X:,ZQ:.L:4(K<<S>$MC]4; *49.
M [_%*EZ"_B3O1I.\:K7&79PV9HGV ,O>]WXEE[$_KK?(@!:S6+ Q:SFV<ZLT
M-NVSQ?MX5O-D))4V$(;OGL)=-."PSO8% X,CEI64A0Q?,'W6%_Z 0T30X@0>
M/)E47SMW%837I[ZXCU8<R+%F<BL'Q*3JJCOA5H*2N?8=DG<M9PJ]-(Y6JQN,
MJ3GK_42O\UH>SV= HF*RZ!2?C0&FF--JA5G5:BAQBR&]2<&!>8,Y+I(VDO ^
M]SMXSJ9_PRMC"S%UVR&P/ZZE100:^V%'?:4):1ZO7 QFVBA@M1B5FRTI]GT&
M^2U^N18S,'VR* U_A4.0X\P=+!=[WC_PX,E66]:HO3SSIF'IK&GOG=5<"E\3
MD+YQL7(+Z-*WT(9G>_)\)LU7,=Y'&KM:A!FJ_5LKN*-=?9WD8T*&&::G/H\:
M3[O1KW(MYU80D+>.ILJKW!?<"IK^15!\(""TB:WY^5O96>@[[1.K]SQX3.-N
MK*C\E$3%_2]&;B4SO4NKJTU@]D1+BWB(GV@V&1W58$0&?9<R6&L5PA>\:W=N
MD[: /EE64\Q7R1U/";9GO?"4A N6KBDSP\/ RK&\)'RPBM17.7]FRVUH"CQ9
MRPI4J$9J.:2?!^N7?(ML4H2P.?'C,NK*/9(#_<C4A*!T-(7X@75.DY2<UU^$
MX.&F3"]Q%QT:WXL8M0P(H%38MI@J;8263+%TZ.D<3T+B?,&$%K5B80L'1Y_3
MW^ CUN$@2C"4> Q=?<$E[!XB.@$%(S=3\(Y]MEE.&<X.A#-6F#PEV?2+;6@I
MT7^)N74169S";236)T&(CI\ZGW!,J=(1"ZJJ)HXISQ%(<EJ2LC"0H1U24PTV
M=N9PW!ET$C^0_SA!Q=C@&],C+.P^9V(\[=3?0,-/(OU'#B':U9L]V9\4T!5&
MF.NU:0WP/6Q-% W3JF+RB@#68?^5'J(KN.F/:-B>DA6"G?'8;9:NJF2='(Q$
MH2,$+?8%O,K]5F']6[Z:26KT2[KL .Z=>#U)8YEFK]X^/$V\454LIK%@!PKI
M:;[YKD*_GZW\OD]?6AXOJ1\W'F/=U>>&_2;WJ[Z$4/R,THU%7XWA5D 6/-IB
MVWSLRD:#4R"=6R0-K'!S_D$ /<LEW?+JS)_US7 /GU/6'X6RA1HO>YF+BV;5
M#MEUL+Y *$#)'ZRT."LH>9'#YV=9(UBOA^84H6_+$'<%#D!ELU'$/WR]@,XE
MEOSN^ZM+=39L[9H?,>N=> Z!PMP8YK]ZXF.3[>1DH#DIA5YE("@"*9D8F:6R
MBXAP81(Q9EP?B,(;ZNM5_\;L-+$ZM$#Q;?8#EU').^ZOZ<AU,4=G5-0K%K2I
M\(5;/WL^;%A\^> )0S@4"\??7"3P"L!MM'4C263+J#::)!ZA+YI"76,*N6RT
MB4 J%TXSA6&>EQB!UU([LL)0=ZN0DOC 2&GT]G^=B8Y3/,K-!L3[K",9OZS_
M[3H;[DP*%=8<&48<7DK*%P#PBHB(-P$@"KKZAXLB-SDU2IF'SINJQ"=T#%'G
MY=7:]TF9ZK("1#[2V?@ ?1![TH*_S"AY9J66/B/'6VGP\\O@'RCT1Z(<OF6Z
MZJ*/F[64?_9>99-FDNBQX\[:H ?"YC<UN3E*&\WMH9%Z5;0OWR=J&9A:,KB>
MV8**B89<U86^<EBH^)7;PULR)0PT\A4M)FD $H)]$_Q8'\7-,K*%D;IC&)-]
M;S7)?PZZ]JWJ1:N/#M9_B3>^\:+9775-9MQBN56/2K8X+'::".?SUA7VA@42
M]XU"CI)/Q=B7[0SF,AV'RMG1E4\7]1W!_0'N#673<Q"%1IT)Q03C=PUM-7+R
M$P-RG-11_!Z#TQ\%XITD 9'X$K2XTE*C="?A)J%(*Z!^A_$#J/ZCN?O[EI4.
M9,8=X;KL(_<FH^C:F-RDV=9<]8OI#$<QQ(J U-6 F9KK1[V;+_=^@<;J7EIE
M,K,;?%E5P]%5I=(RVSN$?:*VDT\DLUJ.[H6'\VFFOIO>=O.'"RSO%BJ^/R]@
M%"!O%&G )U$IA%@85S.C!-\F"R9SQ9@> HPQS81A&H3A\BSV(58WRD9&CONK
M0T.#^SKLP]@'7P^^JH509AY$5;^5;^J/;O)H*Z_VUM=O A[Q0<V7:NU'P&8+
M.JF._+J\<WW#SH?^ HP5+L#1]L[0NK_7(M"-#V@XFNN,C?I^_Z-@][>*&[SL
MLT33/6<W_5_??W[3?Y E6WH%;$^O=B[<;\N>[/%N*/,\(:W?GCUVZ0IF_=W2
MWG.[NM:KG6R6T"PI]'5)07-EY1JEMQAB)R[W6^Q^1U&WRMPHF$58QXNI_)QS
M =DN9V?J$@?L"ZPTN7%EM_1=QN33;M$^QV*?U[FY7%"EAKMYU54-*;P+R;(D
M:!$8XIDQFAWUV80WL' F]53;*M25)5>HF5>0&UTN6#PMTA$*-;R<H4Y'V]DL
M5LRSQ)S=1  <3<+1/?HY0*'%)0.R$"*?.R$#?;O5-!ELX!Z31_$<0T]=BL5^
MQ1UYMHK.'+B]-+MR>WUDS);![6I'L*&%>:A)^IA;AR&D_6]"07O;>4YC 8T-
MQ]FSOO :<9B<@PZIK)X)267\,NJ1;ZJS;Y,*./FBF[!<&YN8E9@_!YI"IZ!?
M(2IDWH[5<-J5UI3^4(;8=,_;S?2I(Z&$F.7CRJ.WBKK=^[0D2].YULM88;W9
MG(5M0AK\U?B\JM;UA$J+0\XY 2N,OG;_7DD7G\?F0EO>&2<4;%4^C@%#I(:U
M7"UGD/1P7=3ZV%T+79ZSYD.E!YP>4).N.@;$1N]7$]42;6UE388UU39?6Y%#
M%#?:S,.5F8+=_1[^XJ680N\\]9/P8JI+^)91S)(OO9 Z+4V^ T$$6W99IAV*
M_+7%<HG[ JN:FM*S9T;E,)W28O 53O(?$]A"2MW4@S.5.F817:&?U&X;^/%D
M7:VY= "U!QXXE*$Y8A%8)3KGEQ_'5(YU+->@T#\/'T5+/]Q^MYL4[A4@E$Q]
M^E1_8:["463S&(#^1BE3*.A-)!(02,CPCI$KZUN=%!V1_&>B?JW+^M2PTPHW
MZIIFZG[&+U* 183_@[JWCHJK7=)'&R<$">[N[AX(+HU+X^[N+@$"!'<('EP;
MA\;=/;A+\" -!)= [C=GOC/W.[/._&;.K+ONNO>_ZNZW5]6NMW;MJG=7/;4,
ML1.$QHWH=\>NZB,HH!X.+7K'6=JOOKOU.9D(?R71+F5VJL)<E/HZ)CW29C*M
M@YH=1*@9ZQ':*8)*&:Q;W3(05FOC^NJ7U("WO*X2#XK2DQ:",DI7G>D0/AE^
M18&\=:DRM/&"X[%DZ'?5\]"_2;/Z&3K,GE%JD7X9VP ,P;3=Q1M)]B]KYA5.
M9K?)"5MLRCYL3%U#]41 NP6^U'KQ[*-E.35REX\W>9#H4CJ !%H2IW6[E 9X
M]<K142_C#3#%**U])%TES2>@AHZC$2#]+X/E]GYWYRGMMHZF31^:[.GJ0E$F
MZ;Y%.5+,P<0AWE,:O[.YJ9HUPK1(=*"-IYS%+D=(K+ML](<JRUW7CV<WWY9Z
MJ%":WL3WU$E)@7@/8CN 2?@EQ!H7<SA18S2IN8OWO BGH]I<%"EA(L8#:HB6
MAO &J:@)$!>K"I,>(QH= S()V^J^X14V#B<E,N"-_X]U0ZQ,M'H3F^E3?&DR
M2K-"!7'ILY'1*@OQ53),Q(%97&RN"-CL*A>CZ>-?))^O]G,G_ 26B;)-3]#8
MBM/P,H%Z*:2-]DJVS=E3!7ISYB\%9\L@N7T"+'%5DSX:30_&.JJ:!57 9*YX
MS>H)J1+XEL<CI2WCQ;CF6 @:.W"3)'X#%@+9<34MR>^BM?-+K^]3HU2&J6S@
M'+UCMU:$@SE\WW:0.Z<_4]@&_]+U,6(L<TO))F."K+3$H* <V_L--,^\>=Z9
MP^T;=L+Z8K@EWV1R/4H'BT<8U50F6_21RTIE!LJV@@LZMNKDB3]Q;KU=^[=3
MUN/1N(>=7W%6N482LS;[GF8?VZRB]:C Q+AH<'#&Q%B5(U1C\(-A\CRIV#><
MDXB=%#X#H^/X;'Q.FX5V^O.&.ZX'^U/33)NF?T37D)^=G0&-!B9F9?OIFUS'
M"?0[UC0>C?1V?C'\84&DHG4RW/87@D!$.(NUE,]?2$D#?T*FCR6$9;%-#;V8
M1209RWAONI))E_J^YK:NVKFL1ZG*C*XE^Z<EK2]%5DX-9O/@($;UW+K1J8=X
MMBZ/K,8+R1J?H-V9GS:WYJXL;X;4G,Q!;"(KE)P,<S^V.$P$>OHKVB>Y>R3P
M-NP?+>!Z;+:?K=)E(>*&%9:'I/SE^)X7/";R9E3>\8"]+>K;5/W(1]JAXPK?
MM[? ?$=*1$-7SY*J:<F=4V&\X;EL )G:D>WK YDC_C?]+-X]' ,*]\+V,2I$
M<YO<(.[J'V@FA_<?Q_:)+O+:\ZSKO0I^H.@:#"L4+VIQEC-65Q"]-A4S\T1M
M.YB8,&?@<N2"X#IFT&BN(ZR BX*A31G.X(@,TB!=F05(ZC<RC,'UFHCE5#[,
MDZ6-LOHOJ2*[RP:=BMN()\G#[R-#5N@&I];RS9@^O5SR'\AY+;ZPY3_&9'K'
M?EW\3MKH+7K0L7JD9##$H]N1V1*':PAN\YP3(!RO(#DNK\L8X@@._D[D<XVU
M=T11;?")M*62ZKXK/#?F\_T+FH1S(4MJI%B5\Q'^80L13_RQM4=RC#-GT5E%
ME51IHH#<($N.20E=7Y_R @H\8MG>"%4A/UOI$EZU$LN4H?.WZI$IA5IJLX6J
MID4^(='1A6PZQA*G0HLCF>_V^AW*T\!F'TMS=:54'LYEKL+MQ1 Q?G\.4C-:
MR?7X /*750/8+V )NA*S5M?D;(:OB"3]".D^"# $A_TB<#VKP<K/_>GK@ML]
M&*() /]_@8QX3V6,3$Q_$;9\Q3U__W+GO7T6T)NORA]4CK_I%9$O6]9$ #_2
MR1C8F/M\>?WC$@5=SS6+ZVWOXO"8<T.+H(8W6;_O@,^H1HYP[Q^936$1@\LY
MDC$\C'49^L*,J,9J=O1F9X7MFE)9-ECV)$Q/"PJ::SGO^;)F8*PRY24O&N,6
M\.90-"K07%9MP9+$4<BV%6C;9EC&:_?V,(_W.J#.B%LV243SI%>#M;[J&@^6
MR8P!5V=,D&#-GH/B/C(Z#M@JMQ)6^KC7HWG,()+_*3 8*^$\[D5OOX%?"[21
M 0PT3FL17!^,O@S+S_HB823J/2:*MA:'931ZSG ,GEB_,TT0S?*=4_LJ>=<Z
M5:E7&]J<NMOJFQ#GA.TW3Q=)LUI4H1672*DNWJB+N]XB3H7D$57XB4IJ7K'@
M!P  &)_5@R!+;&8,;Y:S?^$ 8AH?#M'>\:JX*FUT>)V5"#>DUGS+*7XJ?ET%
M+6]_V_+V'_Q#X=^ZSU\3J)JWA;2_I_\H_(7,&1U=6+NV_L)2>%%]EGA[L+'
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M9QAL0A4OT=..3?195-@)5[=:W\_S34\U?=4*Z@=,,ZY)<C$*>V^I&0MA[5C
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M-Y#^P[+?"F6KH+'M%N^TS$!\0V!-<HD^%?@HI'[#H@PZ>X^L/UPB03,C)UV
MON.I9C%SAFZ!RY&/$+6LY^^AX*(,[16,9UNS\]>"B^T,7HC8FH^_S;O[8-^I
MGU^EFI2.DE:1UB#QDZGF,N6+LI$J*,*F P'?H$$$EQ)&E>%E36F[D?KQ32O;
M>[L5(05#C8#\-E"9,=#A>#/ 5I"T@B=7IH]>SQ)!$:)/BM=!3JQI,%6R*(B9
M?%[.6*R.R5V%9&G4.,::HC/O+RSCBJM$Z;1GG=Z\LX1+@):_IT6ON.;_P09T
M^^9VJ:J24J%I=$3WEC;PO,>5J6B5W7>%86>"!YA%I_:C!79UQ6=QG'01=(V<
ME+.4_3H=_[RS3.9)RXLNR[WGJ+X9V*K!1W>2UKF45&3KJ;,(3LLH]R_2G&$9
MG\9S23YB4D9?J4@'C(O:_!2V/U,*Z=RT0S/&I ?E[N*35+I";K:7*Q>G4G@+
M'_4I(?LW,9\8.JPFQRP6Q]K#[8H6Y+&BN6&C*W%A=/*1:C.$4;ST8_%>C89^
M#K\47VSPKZ0Z29VN!%8Z.JNU.\[;/[3@GD(1N.:A+; C_#VG;PTVN7B,.RC:
M EZPJ3(*->-=N-+E;-)NCU L/*?'RGM6EI7BI%=;XJXUHCR&^=S-SS9W\9AK
MUJHY4P,94<;PDQN76EQ1\5T>*VWXE-H4&V@44<5X7R<,W:I?H_SQ#$'M3GJ-
M8E<?PI_))33X48WRPPY H3K'$XM>SHX:%AH5NDDE^LG%$C(TP(XQ618ZN@!^
M.0$U5\3IG!!#-[;Z4:N&C0OOFM:>ACO?QX%!()J^#CTQ=_6I(R/_#Q'SY@H^
M(:T#7],VB(C@@AL^P9'2!I>,8>-\IM=8WI"<\'?5=4D99Y1B<@[&:%=@4!+3
MU42XGK_&:;IK+20)[&DOVCGWY03UKF2MYD++9F_AM*KZ&J&.PV>QN(C>?JR=
M$8B>Q B"S>VT$=ZP>MS]1H0=;G_)G*5'+O7A8)*QF)CAJDK4.%+]H(H+BT55
M5\V?M+W(H8[H2;J?3D@B% ?9_(VB 9R9D4F3"(2_[.39//ZFR$%9RA5LM72O
M55180(N)?'@#[6",ICWY+-\VDO0S:4S?,VW+LL?7<UY*"[YC;X4 $?:G["?A
M1ND+IM?R]$K"C[S')\5'#,<M]5E1/FOKDZQ'9;L>KRNUS^.^<!--KMBVRA=N
MW!!59G.A3OJ=2D\-@<2WC<.;XNT>2F43'\U62]FP49G?8R?N+DVK5U5+@):^
MKJI_$?VP2KV].>MN8>*N/F\ME2X_&"9?K+@YX(;=S\$F:4(FHC8(30/.&F!^
MDM1HJC6\C1#U$H6N,8X$$-A2HVFV3UYE)"_[RB.JB#6 5REK9^$]=YAV=H_?
M4^)0/%C#]VXL_4,9(J_XH:?U&IJU3T(MI.BKTA3B^)KVDE:UZ>!$EX:ZH_T@
MJ;VV\@IV.M]6N^(2I3VN'<NG-\*!1/(R['3A'N-1:8@G5/F$TOU"M]'UQ?U,
MWU3WTZCD6MX2'80>*"]6.K$6:DT\)<W[Z ?R;7I^9K6<R[WFML$0UT1%B9JG
M#X#OM3N=_*!^)=H8=& UN^A9XTU?QF=5$&;LSCX\-=_'E*OU432S=J-/YQ"\
M:'BOE;ZF>F^U,)S?=WHXK28\//6.V80<@2S8,?3S B_O!2FD"BCL=]MN/P?R
M6_R48+F">MLAZ.-'4ZT%OR@4BG'6D"D-%OH4$B45O.JL(1PN+OEF2;5K^@>A
M]/^@ A%&2;>:$V(567590R;ZL:5B0&*$3AOK.AE67)!@&(*=B//!0WB<P1T3
M!QM&32,Q'!L^3W?I\D;1TYN^QOM<H701;%\)/?X-0&@%>7[ >Y#AK"K=PUF%
M]O5UY/E/A,:R#FFYIQ2;XDZK!Q4PM8EB*ETRR(UWIG:-<TT$X)U;9$N+^,+I
M..4+AI03+^O@1!>[TXEG-J!8 4!/X;#%)N?-5)87!%>3I'!J4Y.?=S9$L+J0
M6_L'C4$Y7@>+B)4]35US>9F>O^IMF=6BE=4S+$XR6E>NYFZB939ZU@P=P<O)
MWX_)5!N--Y_RT)M/YCH)0<G_7EHAD'>$]LK8X^*"''UQA<J_,6RL7_8?;4:(
MM3=)Z1NZ[+5F?^D6HG5^A*5^S=_^E?$?'4?_M(HVO":(8C#PF_VK7"O\7VP1
M>;7<)H;D/<2O#Y]<$$Z$Z(G("4\WVQ>YPB=*IK(A.2;%!,JKUYWP<<J]N($)
M9ZPR<[ 4!N9=+\.88W@U@Z>\8(07 <-X+I4R53:+S<=D5GNLZ:W^/JFE35DQ
MJEN?$=NV'+-$/IQH"VQ#[IQBE4T ;C9C9!2]^J1YB;EQ5XA?JL,>GTI6N^=;
MB@Y$MW*.+TZ?*EE);FW:\,[EDGLE,]N/RV$V!*7$%!0'Q;AX4L^J'%A<23BM
M?-]83YEGXFX4W<VZQBD>[Y;G:V-Q.6,ZA,!O'J1K1B7"'S(@XQAT3%G7T[&T
MQ_=/HVR]M@^G.#5JE'U_N8UWF)-P_95+9-BO'HO[V:>"A2?-H/F<4%I?T$P:
M'MD9M1]A^(_PEL4NWLE5TF<+HQIB=%6\?@&K@%5E7TTB:G;G2Q067:]5<A*1
M;DZV]CW<]0E)Z7@WU4=F<Y;KD_K==YPA^TGF"'[:LN2*\]8.2GLUK<PVZ\0T
M__U4=5?-DF5[:[]QTQ*03H7';@Y$]1/JDL%XSF?XWEVX8)];<JY6A1Z^)]>U
M=%/-"^+,*H?%=]\RU*".9[.<L9B6[KDE/0W A94P*AHEO@9FF5:/R')G&#7%
M89PPL:D_@QB6[*X7"4D?WKT]'C;L#F1FS/NWF. F,,TB,!Q!B(\+9.! 7$1P
MR^R)A(][@F4[1 'MP_?Q GK+ 6BP8?S_VI)3.W5(5>^B$IGUNC\1IWK[+'/<
MU":Z>N#7 >0&G3PRH%F;!I)5&<9H0ZL%.HW&6F"C1P:**%E2M"-C^G%ZZ^6R
M\O78&:&/-I'=DZXNLQOF>4O)]E<HQ[7GG89IF^J7M9@+WM @F=2N49$-86I'
M5N':._N.B(J!<=F)TBG&M84.^!0/*?$M&(?W _+#$<]'Z?)7HDAJBW<T3H6+
M=+LYZ$NFH\]<)'DY$IUW6D,$>M+DEJ#C;"%$/8.2XG [=!'?TIIDT'.O6_:7
MZDFD&=%:KU=)/?N6J]3]VXWL-5;YC?@>N?(D)NY[#LS3]V5T,C]:Q**6#$@F
M@Y$SD0$1ID!2 & 8W=%= BE"<[RXWE:#&'CMU38/ODQ%>5Z@SN6N5#2V;9HH
MG:X?%W""$NAI=<D<+LJ^)>0FW;M77*&"[>A_(Y;/G'.5G+.5=#,B%)NTQC<Q
MYI@RL!:_3=SOY-! O T"L2P)OP.>FBVE )F-QB;4CBB*]J.X#G;V]X"6F<6;
M<\!$M%!%+RE@X'3@;4/WMA6, JA*U7;QU.)]MGH&Y,&HY")!E=Q?'T/\!VGH
MC,N;B["Z#XY$KP\?(P !M"'/-LOW S<"<#LL&.LR/=WD!;V,_J(3M=K9+?*5
MQTHJXPQ6,[B']HD)M*1(WMV>N(**<@^E8B["+=%(8:NBLQ<D<I*CD"Y_8IFX
M;$;?M6:##<XJZ5_W-6QH;H%X.]/05;9LU]V'6<$O>:5&TR?MV^FA]B_52V!B
M^VV5BF>JUI9SL!'*@$XI^G*CKO5>:8WS#-YYL3IVLA!AU +"IQX=NUJ?,]-9
M02 32= T6;D8R!TY!#F/R"GJO<-(Q4D-/^2YKB@=_ZW:'\^"NKQ9YX>\-QOI
M4Q\0R#)]H[V^\'&Y],94&G$%#?&UC3VPJ1E00]U'ZOH#*.W*NI7\OUYUT_MW
M?Q YK4*;/PJD4H_\U3=V).7W:SS@6./LP>WR/>Z.A/5_Z&2Z]Y]JBOR-R<<U
MWI?+%W3 @P+<W6SM1<0/%W2Z!K$H1;(G7B@,QE=^R"L;##Z<:1@0G2(BQ0Z1
MQ5TB0WAOQ:Q0(@-IXPEH\JZ7MANK]Z7)_GGGB03F\@L2M,AX&V/F.\9_LT>4
MJ77]:"&%W8^0RS$,"HV\;A$4<Y$XK.#G//G@T/D#$^P/_TPTI'X=\N:XH( /
MDL&B_P>NO_[@&E&[8HH5&JTD3U<BJ,,'AZ,L J3*E,V_@8%">^G^3W_^KT7^
M4B=!U$=6+L][.8')($G<+0(8%X["P@G\9I*!_*$^6/'7_UC%_W@=$3;C31@J
MQ;MDP9CD\H'!J+!D76:A-"1J:'0KI=1X@YQ2_; :L-(G:C#L)A&-4!-<!?XI
M\E)+W5:E?DN!4O-2$2 2  8K\@9]!@85;OEO;E'4^5&M+8_2X+!FLNGJVM;6
M2.9$U%C]YC5S(2VP?S>7Q%#]O*^4:(&"^)C34.>YZN-IM6[>A' =,]FN)#A<
M1.U:LVA2*K@S)_B@ZG/]PJLIR/?E5S6_R_)C(YA)R*_U;C<G\%4HKH[HI^&F
M%UL,(C/\:J46WK7[9ZKJ)&'1B(_TJODI(10X092"$JR"KBB_ 5J&;+<=" I?
M?[GO@<9*YK^HJQZO$NH?,+Q;?@*1?V88!O:JV%<0009)R][_!FR-8?=0)2MI
M"2$7,\.HR8Q#";RP#)(T$OW'C=;)#Y?9\_>8U+/1I94T!V1U? -J8A,7C5?;
M*>+TE%G2*D(%'5Y.O;D5\UJ<3Z;GQ&$I #H5>H[&FAJ_ABZ(GKW.QTO/E[;,
MT@0_0Y8,4M<L=;O<;EUWW7DM'?1VIJ;D*M9NOZ+O[F0:R'&X; [PRFV4815G
MRB'\(,QE'<X-/WK;<);^LA">&[]2T..O"+Y"F<"U9[6W^M'-)3NR?IJD!5:S
M7_ )8^,N[&4]$N>[S?# 4^)G7:_'HD-DW':H=&3%^!9H[+LRWU?I\QLPNLV6
M7>(KE,?IW#&+YA2^;7'JK<^8DT>1!JRW2JR5R5^89Y:18_M9XGNA'<6F@O9!
M&X[+Z3=@C:^E]9JFTVG#/_D:K1""A.SK*56C['3:O6;I9HU9UX;+W%;!<74W
M@9"Y-_[Z8S$56YHT"UVZX5NR71L 1Q%>K-F?/'D]U'81TORKU$$[ZF=H9LYH
M<J4FW;:S[Y;(G(YKF;8M<Y57N02W\R"(5?VINH>.7UIPLB%AC=_ASA;\\#"X
MR8^/P!F\%@2GL1IW XVK&5W5G,H*56H,D#44+3^G?Q_LKKG4W^0WD_6TUVJ\
M;'?EG>TH"M*&QA_OJ?G)D%6FA&OK\N(*$#U<[<]T1+C9?GUW9IABOJA&Y!ZW
M/#75Y,F"1L0T^4<\O.Z(-2?< QHB>G3,<9FF@L#@&_2,,9UST3;F)_O);-[3
M2,/(BS$GT)_F5*Z]55DZ:-,O/J\O SL@7K[W"ZY:*O1*$YD@3;(P$'FJXUO3
M2-'X7#N<WZ"<(A(8%38.&W'9R<D8/-Z-P;AK%# @LAT@_ZTCR_R\H]_H@E1@
M:B9T363K6$H(J8X (6H?O5]?]SH^W*H-2G\?%_C!;N^\K-(NT'(T?4$IM,B+
M]W"(%36G:R_>-;G^9\>1 13D\#-&_KWW*5>B6M(I6RBM+E5C6'"C4)GOR<.F
M>+.O8'>;>.O8:-;$M!5UP\.+XA9*<U;-X,EQ=2Z)DB-P+V6,NE]\S-[0W\"2
M&9=);NEBNC59=_Y67X@C!]7 ?72JR'#YU1P2Y]QB=<K"U(FS*%R:>(B1P=X6
M8;6XSK9NM>;"SEK5'+!O&J-1KS@@)=/A#A^ZJA-$V$;:PJGN8:*)5F7+T$&6
M><3Z39)GK</83+5J0ZGD/&+*Z^!<VV2<>S6.;ZHA@=_J4R"7>U;#]#JJUU8;
M-I%68@7;%#?$9KNBM]<TG>:NSV#B,5:OMK-R94W2_V>E?#8;C9U?S;POT*))
M3T\TSFN1CT\HL"/,_!%^S^]<?E5'5FZ,,TM^1^]Y9B%N26R7PN(##F2&_9!P
MDC7/TK>.Z@Z["[L_REY$W##//T@NIM[ +KN<)2F\6+A. )Q;S/VCGL85?64P
M0:#*:XLP75,9<>TO(9M-;9Y_N[JR=G+658_(&#YFUM/F\$O '%XZY_#G6\>X
M4>@K+E-WW1ZN64\K3\V<ICV7$IOKEV>1S_((\S%"N42?\J/C1A'-?!V45F@\
MNOK+ZDD,2,Y)&9NKUR2M^=O&3XDYP2FX,KR/*UF+6.N5$*O,FNF3&?!:AKRD
M3]K*<G6_M*9!(2B% T!T=(B^5B-PP,_@\ZR_FF.XJ?VJ/N\97U("8C.XMRQB
M_Z7?O$BYR1<3*JM/%5O5H#)11XXP5+@82NF8F*@SA2NF(9Y5 A>DB2Q_LHB>
M8@#166Y=8[XEVJ!-WCAXY[0[+X*+.A8V%-</,/_T=EJ.HJ@HI?Q>L3S":!(.
MQ;?HH*O@L6I+7>_'^:/R*A9NI0@E:Y3<RC-?\PZ*-+/-$%0*K'P"\5^T W.L
MWJS3MK,<-\035[:1T 7A-KI2D GUP&!6._U0J/?Z-?#"J+KM_55]GL>^LHB6
M7-K9,4(^MW2%[L"K**J,^PM*J"?T6H.5:M$LNU!Q+!.TW2J-D\A ^!OPGR /
M('^%/$#16K21:5ZMP+0K[KQI/S0WK(6H1G5F),*B?&:/=.$D'.%2>-!VBB?#
MMD"A(RO%>C?G:*_;4JR3H$CKK]K%%H-G?KN9U_A+1_:DP_57\X[N!_B7%0'U
MR6RW0(+F9= 8!(2\E.>0O4-0PQ6 'V,$K ;9E!BJJ+0#S0XXDBV^I%%946LY
MRKF"4'[!,MVJQ7T4D4QP^21*'2Y459<IZ24VV^2[.ZU76K[C[V+\*6X]24F&
M4ZEUM:%X/:Z<_]R;5C]E=R[!87+(CQF?4,#VTG&8/3N@_4CYCR#Y,OK1?"#7
M/@V&G>+;"\U_:A8D4;DN_0W "?I7DED'O]Y!3^AO (?SJR+'FS_!3RC2R5^*
MXS#,M_XYXH#S7Q '1IS$74.UW+CR+*OU=W2&IG3-*4VU5A)=TJ[.&'[8*$B)
MU#-$KK.$:1R5RP@'H4M41:C)C95_#(=#)@!T8.E=&$]^"Z\QBU-.:X(WD0A/
M!C:B/ 501G\GPZ.A(^72DJ*&68'-CXC:\?EZVK$%[16HK>'= TNT>&L*F6<7
M0E=X]+:ZC-#L)::H<HJO6"L;3SAY&N+V#%N4M/9QP\K+)3*"$0$DL#;V:3^=
MK(H04%F5V"^#ISZSIH.S@I;[M;<;J;_[F+-?Y,/EZ1[O^?7ZY)[_!CC!8.T9
MJ^9.C:\:JC.A.[A7F9O3LZ SJTXH30X/",O_>A]051D;^RH=J[$OUVCQ1?4X
MOP+%#481((!$?X-"4SP9%ZV<IIY4I["L73:AW%,]\#XSM4)(,-5=.RG%94RV
MUKX&1R#C#"2832(E)4<=[&MV^[4UM%:DO/_T24I:'2B\Y4LT:*B.*-KY2CW@
MDM#E;*K'(<.[X!T&57] DAOS!@EX^Q'XA;"CJ5<N$].,=^G6]G%+4 EUQ\C9
MV/QH'NT=Q!TS,\42C[' 4J9BJ=5"A ;#X,"8WZ,8_6P/F;E*44RLS(I\+=()
ME'OOQTE7VAD<[0[BT7!&U1\FZFR4'$3U@XT2CGP0)?0OF('+-R'+6M2J5_AL
M:U"F36'G>0AP,873BTCX]-D")6>\'(UJ=QUBMH*CVF_NC6Q4BHD)[:6A-J<V
M7:4DQB0;9A*L(R'FB+,)Q5/J RDW!(=JC15_$BL<)S@\3Q7*Z*=>HPY6G?%S
M5]-BL6[5@ABUUNJ#A ]PF_IF3S'Y>'%2+V*3OO'ULW9F?J-B(A[!U*[<W+FX
M/1% \)CF$Q*X2$U(L!B2ERU+3A;F*^=['QL=R6]7'+I'E8D*/5[GD><$*5]]
MRI)B2) (!N#LY?J*^3M;UAFI59Q?S,9.D1/[N.N&&VV3D[DQ9:XT-%2.7BL1
MYL3D%";;IWY"XO" DL!%^YT:4]ND=E)+EY9X9B<@1X']/",E]&AW0WAFD<<4
M8'3"FL)\:)+>?J^LGS]/A>N8@0-<]9UTF>I&NL/H+^,(W;Q=&F_P?8.D6BLU
M*&S5$6[$,CMICWQXMNS0"(FO2!&$+U4]Y(CPD7)!Z=E:N0B0,=^Z,WJ.H8@C
M5 %);F/&,QUZZ/P,W'D:;6!.00E.]Q] @%>:KW6"45$X?2+]-(3D_+5XP0H*
MB2_0:U)8VBFN GWGG*SXA.ZX1UM<Z#].H"A:4QFH2"6: UL@PR?8<=1@PV$1
MEAJMA)F8*%WYIOMCK \;*I;?652:MSP7$O"!5C#VS</G\YL+#%61UK^<ENZT
MWB3 SAT88KLYKL<9E8SBIEI;@K7*O"6?FA"^+-=67K^#.)8P5Y"NKJD[K+_5
M7ZC"()94$8W3W?>W%,/2J&2(%C,4I9I[N)!;U-:C)_1BOPOK9[8T?MO()YR]
MFZV^)]Q956QJW?'M[.U$&3N:66?%Q36M@:< W2H&3(-M<3*-5+#M(1.L5E+?
M*4:Z=.@$O:>Q( :G5+,]H4*84TTE\.>\HR,8DV8M@LFZ3?3.HOY=W-F2():!
MA04MPML C0,<>3P[$?%W N1B3PTMIF7VI.YJ+3J:+7HG34+A3M_L-4&X#G<$
M0K\"+!;#Q8T?7-7MY"MK9'O.G\#KZ\':/O\ ]8*\5D=B!YI1'*(*-8B$GS:+
M&I>,-7>AC!7CA#]@[) 2BC!VX'B+64%WK]@\L09ZGMJ*XC=8QDZ\1&ZN/:T
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MST$VBC_P"WW.L+??O9U^EMD[L%QL.'(NT!/D;?2QBN!DTWOJ'([@-ZT%F3%
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M04]?NY9JEF,M+\EVO,I5UBF4J D_)GPU1 X[L-"LD6USQJI\I::FR2"\#N9
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M:1<1E?N.J\$9P)B]/#H3?3_2BKJHJSDD&K*)36BAQD%>:Y0/,[___5^!"5Y
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MGRF%TEV[-S>L,3*SY!**')ER521T+UIL*#T5XY6/$\NSWQ16BJRA.%Z 2FL
M!_(M% :&2+O1/U1R8[.[?['YU3)G@[BQAZW#3:54FWVC';IAL..%LJL1EIQJ
MS#N$B^]ZDZLAL]ER"7&P;UWE;+%DF&8340LOU]<(_U@NW]<ZYF*_E:7]&\ 6
M)1'[[\E<T#&S<ZMS=T]\+_V?F[H;E,/_4/K2UTO%W#/*L>U.&.CT%8;[3U]
MU#,G8^QJT=T5\Q_K3=ZE]>PC)SR%!EV9!BO]F23"]]PD\Y_S]"PG/L"?_VDK
ML'AMOT(Q[T5J'ZF^8^O\ZQ,E;*V*1@ROOB7>;'Z\T%0:T; Q,B?^#<AQ]D6U
M'0\Y]D)S;"HG5BMQ2GFW^/;-1?099QW43'N;TQ4GE&_VW8@+>JJ2S'$&ZODA
M/JF5+[9D6$2U,O?G>E"9$C]13L5&&08=:)6E;YZ^LDF^'YIZN0A'DT^7#PA.
M59C9-1D.TLR-67R^KO_)]QJ>:_Y6HV_!- TA4'YO\S@V?\]U/;9&?$A^?*,P
MEZ9\D11T<:;BQ>FOT,Y^TOZ9Y\ICHU/;;+=E_G#(DY%1_]2.M[((;"#PH#;T
M4SMFSD\HE/:M+43$VS0O5]U-G"AG8= #Q\<OVTIIK?D'2YK/=VPQQ<HCN=R=
M=XQ @!CFZ;%WG5^$*1^;UN:2)\$)T;!7T*'3^+(Z!(F@7(+O:2[;#=A2.G=-
M#K1+4GKLV-[X)7KLI"_T)=/J)9>?&(N/\NA&^&KW@)[>L2G9*5&^W=437#C6
M$^(HNK415-T89'FH##1T:E+X7JY;>JKBIG"N^?Q2.Y3P?_]^I!%RR5JVOIYP
MV^Q\U@GS7]!PY39)_?4&J%.=VDQ64I6_6'(NTJ@SRH1,*,Y$^N(E(B.:57N%
M/R(T/?N[OC9/O:0'B_Z+-&+JI)CD]GJ"L_5-L_L?_*J9>/S>T'WBUKI)D@M7
MHAESR($MS41!H$0A:UE13Q4"^!,@6?<VYSD[?5A:[6FX1/H7:?3ZPI'H(1=N
MOI\&4:18S)<-[MV::9SH!8! ]S*/8<7"#S1P:[W"_^I%_%>T)[5T@E.R#26O
MLSQ.Y)O23-84$_5W!3,E#'[;)@ 3TA[8M<"NUM\ ?:O7B5[R_\4'H<]1));
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M!)OARFWS'K<15IYM0>GYN:D!X1AI0C%'9(Z_Y"^*VY.4=\Q@'EWQU#^G_T4
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M+3(P,C Q,C,Q+GAS9%!+ 0(4 Q0    ( #R$4%)@BUZ:!0D  (!>   5
M          "  ;@)  !A=GAL+3(P,C Q,C,Q7V-A;"YX;6Q02P$"% ,4
M"  \A%!2&G#KX=X2  #)+0$ %0              @ 'P$@  879X;"TR,#(P
M,3(S,5]D968N>&UL4$L! A0#%     @ /(104H: AQ>!,0  7,@" !4
M         ( ! 28  &%V>&PM,C R,#$R,S%?;&%B+GAM;%!+ 0(4 Q0    (
M #R$4%)5J/R$>"   '4G @ 5              "  ;57  !A=GAL+3(P,C Q
M,C,Q7W!R92YX;6Q02P$"% ,4    "  \A%!2UZ"7@U7S  #)] @ #0
M        @ %@>   93(T,35?,3!Q+FAT;5!+ 0(4 Q0    ( #R$4%($/="&
M# <  ,XB   0              "  >!K 0!E,C0Q-5]E>#,Q+3$N:'1M4$L!
M A0#%     @ /(104E\7<U\.!P  '"0  !               ( !&G,! &4R
M-#$U7V5X,S$M,BYH=&U02P$"% ,4    "  \A%!2OFT1&Q4&  !6&@  $
M            @ %6>@$ 93(T,35?97@S,BTQ+FAT;5!+ 0(4 Q0    ( #R$
M4%)TY,]VK0H  - S   /              "  9F  0!E,C0Q-5]E>#4M,2YH
M=&U02P$"% ,4    "  \A%!22JHFW9B0 0!=P@$ #0              @ %S
MBP$ :6UA9V5?,# Q+FIP9U!+ 0(4 Q0    ( #R$4%*L#$#&H!4! &4Q 0 -
M              "  38< P!I;6%G95\P,#(N:G!G4$L%!@     ,  P \P(
'  $R!     $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
